{
  "data": [
    {
      "name": "Ace®",
      "img_id":"JkJMJW9.jpeg",
      "image": "Ace-500-Tablet-250s.jpg",
      "active_ingredients": ["Paracetamol"],
      "indication": [
        "Fever",
        "Headache",
        "Toothache",
        "Earache",
        "Bodyache",
        "Myalgia",
        "Dysmenorrhoea",
        "Neuralgia",
        "Sprains",
        "Colic pain",
        "Back pain",
        "Chronic pain of cancer",
        "Inflammatory pain",
        "Post-vaccination pain",
        "Fever of children",
        "Rheumatism",
        "Osteoarthritic pain and stiffness"
      ],
      "dosage_and_administration": {
        "Tablet": {
          "Adults": "1-2 tablets every 4 to 6 hours up to 8 tablets daily",
          "Children (6-12 years)": "1/2 to 1 tablet 3 to 4 times daily"
        },
        "XR Tablet": "2 tablets every 6 to 8 hours, max 6 tablets daily",
        "Syrup & Suspension": {
          "3 months - 1 year": "1/2 to 1 tsp 3 to 4 times daily",
          "1-5 years": "1-2 tsp 3 to 4 times daily",
          "6-12 years": "2-4 tsp 3 to 4 times daily",
          "Adults": "4-8 tsp 3 to 4 times daily"
        },
        "Paediatric Drop": {
          "Up to 3 months": "0.5 ml (40 mg)",
          "4 to 11 months": "1.0 ml (80 mg)",
          "1 to 2 years": "1.5 ml (120 mg)"
        },
        "Suppository": {
          "3 months - 1 year": "60-120 mg 4 times daily",
          "Below 5 years": "125-250 mg 4 times daily",
          "6-12 years": "250-500 mg 4 times daily",
          "Adults and above 12 years": "0.5 - 1 g 4 times daily"
        }
      },
      "contraindication_and_precaution": ["Known sensitivity to Paracetamol"],
      "side_effect": [
        "Mild side effects",
        "Hematological reactions",
        "Pancreatitis",
        "Skin rashes",
        "Allergic reactions"
      ],
      "use_in_pregnancy_and_lactation": "Safe in all stages of pregnancy and lactation",
      "preparation": [
        "500 mg Tablet",
        "XR Tablet",
        "60 ml & 100 ml Syrup",
        "60 ml Suspension",
        "30 ml Paediatric Drops",
        "125 mg, 250 mg & 500 mg Suppository"
      ]
    },
    {
      "name": "Ace® Plus",
     "img_id":"e8qjemd.jpeg",
      "image": "Ace-Plus_l.jpg",
      "active_ingredients": ["Paracetamol", "Caffeine"],
      "indication": [
        "Fever",
        "Headache",
        "Migraine",
        "Muscle ache",
        "Backache",
        "Toothache",
        "Menstrual pain"
      ],
      "dosage_and_administration": {
        "Adults": "1-2 tablets every 4-6 hours. Max 8 tablets daily",
        "Children": "Not recommended for children below 12 years"
      },
      "contraindication_and_precaution": [
        "Hypersensitivity to Paracetamol, Caffeine or any components",
        "Caution in hepatic or renal failure",
        "Avoid prolonged use without medical advice"
      ],
      "side_effect": [
        "Skin rashes",
        "Neutropenia",
        "Gastrointestinal disturbances",
        "High doses may cause hepatotoxicity"
      ],
      "use_in_pregnancy_and_lactation": "Seek medical advice before use",
      "drug_interaction": [
        "Increases effect of chloramphenicol and coumarin anticoagulants",
        "Increased hepatotoxicity risk with alcohol or anti-epileptics"
      ],
      "preparation": "Paracetamol 500 mg & Caffeine 65 mg Tablet"
    },
    {
      "name": "Ace Power",
     "img_id":"GktTQp0.jpeg",
      "image": "Ace_power_DS1-01.jpg",
      "active_ingredients": ["Paracetamol BP 1000 mg"],
      "indication": [
        "Fever",
        "Common cold and influenza",
        "Headache",
        "Toothache",
        "Earache",
        "Bodyache",
        "Myalgia",
        "Dysmenorrhoea",
        "Neuralgia",
        "Sprains",
        "Colic pain",
        "Back pain",
        "Post-operative pain",
        "Postpartum pain",
        "Chronic pain of cancer",
        "Inflammatory pain",
        "Post-vaccination pain",
        "Fever of children",
        "Rheumatism",
        "Osteoarthritic pain and stiffness"
      ],
      "dosage_and_administration": "1 tablet every 6 hours",
      "contraindication": ["Known sensitivity to Paracetamol"],
      "side_effect": [
        "Mild side effects",
        "Hematological reactions",
        "Pancreatitis",
        "Skin rashes",
        "Allergic reactions"
      ],
      "overdose": {
        "Moderate": "6-10 gm/day",
        "Excessive": "More than 10 gm/day",
        "Symptoms": [
          "Pallor",
          "Nausea",
          "Vomiting",
          "Anorexia",
          "Abdominal pain",
          "Liver damage",
          "Hepatic failure",
          "Encephalopathy",
          "Coma",
          "Death"
        ]
      },
      "preparation": "1000 mg Tablet"
    },

    {
      "name": "Acetram™",
     "img_id":"5HuPFWt.png",
      "image": "Acetram-tablet.png",
      "active_ingredients": ["Paracetamol 325 mg", "Tramadol HCl 37.5 mg"],
      "indication": [
        "Moderate to moderately severe pain in adults",
        "Short-term (five days or less) management of acute pain"
      ],
      "dosage_and_administration": {
        "Normal use": "1 or 2 tablets every 4 to 6 hours as needed, max 8 tablets/day",
        "Short-term acute pain": "2 tablets every 4 to 6 hours as needed, max 8 tablets/day"
      },
      "contraindication_and_precaution": [
        "Contraindicated where opioids are contraindicated",
        "Caution when taking tranquilizers, hypnotics, or other opioid analgesics"
      ],
      "side_effect": [
        "Asthenia",
        "Fatigue",
        "Hot flushes",
        "Dizziness",
        "Headache",
        "Tremor",
        "Abdominal pain",
        "Constipation",
        "Diarrhea",
        "Dyspepsia",
        "Flatulence",
        "Dry mouth",
        "Nausea",
        "Vomiting",
        "Anorexia",
        "Anxiety",
        "Confusion",
        "Euphoria",
        "Insomnia",
        "Nervousness",
        "Somnolence",
        "Pruritus",
        "Rash",
        "Increased sweating"
      ],
      "use_in_pregnancy_and_lactation": "Pregnancy Category C – use only if benefit outweighs risk. Safety not studied in infants/newborns.",
      "preparation": "Paracetamol 325 mg & Tramadol HCl 37.5 mg Tablet"
    },
    {
      "name": "Adryl®",
     "img_id":"DEBoTkz.jpeg",
      "image": "ADRYL-100ml.jpg",
      "active_ingredients": [
        {
          "ingredient": "Diphenhydramine",
          "dose": "10 mg/5 ml"
        }
      ],
      "indications": [
        "Allergic conditions (rhinitis, urticaria, pruritus)",
        "Anaphylaxis",
        "Motion sickness",
        "Parkinsonism",
        "Insomnia",
        "Cough & cold"
      ],
      "dosage_and_administration": {
        "adults": "25-50 mg, 3-4 times daily",
        "children_6_to_12_years": "10 mg (5 ml), 3-4 times daily",
        "children_1_to_6_years": "5 mg (2.5 ml), 3-4 times daily",
        "specific_instructions": [
          "For motion sickness, Parkinsonism, insomnia, etc."
        ]
      },
      "contraindications_and_precautions": [
        "Not for premature/newborn infants",
        "Avoid in drivers/machine operators",
        "Hypersensitivity to diphenhydramine"
      ],
      "drug_interactions": [
        "CNS depressants",
        "Alcohol",
        "MAO inhibitors",
        "Para-aminosalicylic acid (PAS)"
      ],
      "side_effects": ["Drowsiness", "Dry mouth", "Nausea", "Blurred vision"],
      "pregnancy_and_lactation": {
        "recommendation": "Use only if clearly needed",
        "lactation": "Not recommended during lactation"
      },
      "preparation": "Syrup"
    },
    {
      "name": "Afun® VT",
     "img_id":"ZgYnGrz.jpeg",
      "image": "AFUN-Cream.jpg",
      "active_ingredients": [
        {
          "ingredient": "Clotrimazole",
          "dose": "200 mg"
        }
      ],
      "indications": [
        "Vaginitis",
        "Vaginal itching, burning & discharge associated with recurrent vaginal yeast infections (vaginal candidiasis)",
        "Infections due to Candida or Trichomonas",
        "Super-infections with Clotrimazole-sensitive bacteria"
      ],
      "dosage_and_administration": {
        "recommendation": "Insert 1 vaginal tablet deeply into the vagina for 3 consecutive nights",
        "specific_instructions": [
          "It is best done while lying on one's back with knees slightly bent.",
          "Avoid treatment during menstrual periods.",
          "For prevention of reinfection, the partner should be treated locally with Clotrimazole cream."
        ]
      },
      "contraindications_and_precautions": [
        "Hypersensitivity to Clotrimazole",
        "Treatment should be timed to avoid the menstrual period."
      ],
      "side_effects": ["Local irritation", "Burning sensation"],
      "pregnancy_and_lactation": {
        "recommendation": "Should be used only if considered necessary by the physician during pregnancy"
      },
      "preparation": "200 mg Vaginal Tablet with applicator"
    },
    {
      "name": "Alacot® Eye Drops",
     "img_id":"ydtxwr8.jpeg",
      "image": "Alacot_o1.jpg",
      "active_ingredients": [
        {
          "ingredient": "Olopatadine",
          "dose": "0.1%"
        }
      ],
      "indications": [
        "Treatment of the signs & symptoms of allergic conjunctivitis"
      ],
      "dosage_and_administration": {
        "recommendation": "One drop in each affected eye, two times per day, at an interval of 6 to 8 hours"
      },
      "contraindications_and_precautions": [
        "Contraindicated in persons with a known hypersensitivity to Olopatadine Hydrochloride",
        "Should not be used to treat contact lens-related irritation",
        "Patients who wear soft contact lenses should wait at least ten minutes after instilling the drops before inserting lenses"
      ],
      "pregnancy_and_lactation": {
        "recommendation": "Use only if the potential benefit justifies the potential risk to the fetus during pregnancy. Caution should be exercised during lactation."
      },
      "side_effects": [
        "Headaches (reported in 7% of patients)",
        "Asthenia",
        "Blurred vision",
        "Burning or stinging",
        "Cold syndrome",
        "Dry eye",
        "Foreign body sensation",
        "Hyperemia",
        "Hypersensitivity",
        "Keratitis",
        "Lid edema",
        "Nausea",
        "Pharyngitis",
        "Pruritus",
        "Rhinitis",
        "Sinusitis",
        "Taste perversion"
      ],
      "preparation": "0.1% Eye Drops"
    },
    {
      "name": "Alacot® Max Eye Drops",
     "img_id":"wNo3LvW.jpeg",
      "image": "Alacot-max_l.jpg",
      "active_ingredients": [
        {
          "ingredient": "Olopatadine",
          "dose": "0.7%"
        }
      ],
      "indications": [
        "Treatment of the signs and symptoms of allergic conjunctivitis"
      ],
      "dosage_and_administration": {
        "recommendation": "One drop in the affected eye(s) once-daily"
      },
      "contraindications_and_precautions": [
        "Contraindicated in patients with known hypersensitivity to any ingredient of this formulation",
        "Patients who wear soft contact lenses should remove their lenses prior to instilling the drops and wait at least 10 minutes after instillation"
      ],
      "side_effects": [
        "Blurred vision",
        "Dry eye",
        "Superficial punctate keratitis",
        "Dysgeusia",
        "Abnormal sensation in the eye"
      ],
      "pregnancy_and_lactation": {
        "recommendation": "Use only if the potential benefit justifies the potential risk to the fetus during pregnancy. Caution should be exercised during lactation.",
        "additional_info": "Olopatadine has been identified in the milk of nursing rats following oral administration, but it's unclear if topical ocular administration can produce detectable quantities in human breast milk."
      },
      "use_in_children": "Not recommended for use in children below 2 years",
      "preparation": "5 ml solution in plastic dropper bottle"
    },
    {
      "name": "Alacot® DS Eye Drops",
      "img_id":"HGboiUd.jpeg",
      "image":"Alacot-DS1.jpg",

      "active_ingredients": [
        {
          "ingredient": "Olopatadine",
          "dose": "0.2%"
        }
      ],
      "indications": [
        "Treatment of the signs and symptoms of allergic conjunctivitis"
      ],
      "dosage_and_administration": {
        "recommendation": "One drop in the affected eye once a day"
      },
      "contraindications_and_precautions": [
        "Contraindicated in persons with a known hypersensitivity to Olopatadine Hydrochloride",
        "Should not be used to treat contact lens-related irritation",
        "Patients who wear soft contact lenses should wait at least ten minutes after instilling the solution before inserting their contact lenses"
      ],
      "side_effects": [
        "Headaches (7% incidence)",
        "Asthenia",
        "Blurred vision",
        "Burning or stinging",
        "Cold syndrome",
        "Dry eye",
        "Foreign body sensation",
        "Hyperemia",
        "Hypersensitivity",
        "Keratitis",
        "Lid edema",
        "Nausea",
        "Pharyngitis",
        "Pruritus",
        "Rhinitis",
        "Sinusitis",
        "Taste perversion"
      ],
      "pregnancy_and_lactation": {
        "recommendation": "Use only if the potential benefit justifies the potential risk to the fetus during pregnancy.",
        "additional_info": "It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Caution should be exercised during lactation."
      },
      "use_in_children": "Not recommended for use in children below 2 years",
      "preparation": "Each plastic dropper bottle contains 5 ml of Olopatadine HCl USP 0.2% sterile solution"
    },
    {
      "name": "Alarid®",
     "img_id":"YPgDyBM.jpeg",
      "image": "Alarid-Tablet_l.jpg",
      "active_ingredients": [
        {
          "ingredient": "Ketotifen",
          "dose": "1 mg"
        }
      ],
      "indications": [
        "Symptomatic treatment of allergic conditions including rhinitis & conjunctivitis",
        "Prophylactic treatment of bronchial asthma"
      ],
      "dosage_and_administration": {
        "adults": "1 mg twice daily with food. If necessary, the dose may be increased to 2 mg twice daily in severe cases.",
        "children_above_3_years": "1 mg twice daily with food",
        "sedated_patients": "0.5 to 1 mg at night for the first few days or as directed by the physician",
        "use_in_elderly": "Same as adult dose or as advised by the physician"
      },
      "contraindications_and_precautions": [
        "A reversible fall in the platelet count has been observed when Ketotifen is used concomitantly with oral antidiabetic agents, and this combination should be avoided",
        "Although there is no evidence of any teratogenic effect, recommendations for Ketotifen in pregnancy or when breastfeeding cannot be given",
        "Continue previous treatment for a minimum of two weeks after starting Ketotifen to avoid exacerbation of asthma, especially with systemic corticosteroids and ACTH due to possible adrenocortical insufficiency in steroid-dependent patients"
      ],
      "side_effects": [
        "Drowsiness",
        "Dry mouth",
        "Slight dizziness (usually disappears after a few days)"
      ],
      "preparation": ["1 mg Tablet", "1 mg/5 ml Syrup"]
    },
    {
      "name": "Alarid® Eye Drops",
     "img_id":"z4OJcQY.jpeg",
      "image": "ALADRID-eye-drop.jpg",
      "active_ingredients": [
        {
          "ingredient": "Ketotifen Fumarate",
          "dose": "0.025%"
        }
      ],
      "indications": [
        "Treatment of signs & symptoms (itchy, watery, red & swollen eyes & eyelids) of allergic conjunctivitis including vernal keratoconjunctivitis, vernal-keratitis, blepharitis, blepharo-conjunctivitis, & giant papillary conjunctivitis"
      ],
      "dosage_and_administration": {
        "adults_and_children_above_3_years": "1 drop in the affected eye(s) twice daily, every 8-12 hours, not more than twice per day"
      },
      "contraindications_and_precautions": [
        "Hypersensitivity to Ketotifen or any of the components",
        "Should not be instilled while the patient is wearing lenses"
      ],
      "side_effects": {
        "1-2%": ["Burning/stinging", "Punctate corneal epithelial erosion"],
        "<1%": [
          "Blurring of vision upon drug instillation",
          "Dry eyes",
          "Eyelid disorder",
          "Conjunctivitis",
          "Eye pain",
          "Photophobia",
          "Subconjunctival hemorrhage"
        ]
      },
      "use_in_pregnancy_and_lactation": {
        "systemic_levels": "After ocular administration, systemic levels are much lower than after oral use",
        "caution": "Should be exercised when prescribing to pregnant women"
      },
      "use_in_children": {
        "under_3_years": "Consult with a doctor"
      },
      "preparation": "0.025% Eye Drops"
    },
    {
      "name": "Alatrol®",
     "img_id":"snYOXW9.jpeg",
      "image": "Alatrol-Tablet-PRO_l.jpg",
      "active_ingredients": [
        {
          "ingredient": "Cetirizine",
          "dose": "10 mg"
        }
      ],
      "indications": [
        "Seasonal Allergic Rhinitis",
        "Perennial Allergic Rhinitis",
        "Chronic Idiopathic Urticaria",
        "Pruritus",
        "Allergen induced asthma"
      ],
      "dosage_and_administration": {
        "adults_and_children_6_years_and_older": {
          "tablet": "1 tablet daily",
          "syrup": "2 teaspoonfuls once daily or 1 teaspoonful twice daily"
        },
        "patients_with_decreased_renal_function_or_hemodialysis_or_hepatic_impairment": {
          "tablet_or_syrup": "1/2 tablet or 1 teaspoonful once daily"
        },
        "children_2_to_6_years": {
          "syrup": "1 teaspoonful once daily or 1/2 teaspoonful twice daily"
        },
        "children_6_months_to_2_years": {
          "syrup": "1/2 teaspoonful once daily",
          "maximum_dose_for_12_to_23_months": "1/2 teaspoonful every 12 hours"
        },
        "paediatric_drops_6_months_and_above": {
          "dose": "1 ml, once daily",
          "maximum_dose_for_12_to_23_months": "1 ml every 12 hours"
        }
      },
      "contraindications_and_precautions": [
        "Hypersensitivity or idiosyncrasy to cetirizine or hydroxyzine",
        "Caution should be exercised when driving a car or operating heavy machinery",
        "Concurrent use with alcohol or other CNS depressants should be avoided"
      ],
      "drug_interaction": "No clinically significant drug interactions have been found.",
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Should be used only if clearly needed.",
        "lactation": "Use in lactating mothers is not recommended."
      },
      "preparation": [
        "10 mg Tablet",
        "5 mg/5 ml Syrup",
        "2.5 mg/ml Paediatric Drops"
      ]
    },
    {
      "name": "Alenvir™",
     "img_id":"xSObjUE.jpeg",
      "image": "Alenvir_l.jpg",
      "active_ingredients": "Tenofovir Alafenamide",
      "indication": "Treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.",
      "dosage_and_administration": {
        "recommended_dosage": "25 mg (one tablet) orally once daily with food.",
        "renal_impairment": "No dosage adjustment required in patients with mild, moderate, or severe renal impairment. Not recommended in patients with end-stage renal disease (estimated creatinine clearance below 15 mL/min).",
        "hepatic_impairment": "No dosage adjustment required in patients with mild hepatic impairment (Child-Pugh A). Not recommended in patients with decompensated hepatic impairment (Child-Pugh B or C)."
      },
      "side_effects": [
        "Lactic acidosis",
        "Severe hepatomegaly with steatosis, including fatal cases",
        "Cases mostly in women"
      ],
      "precaution": [
        "Should not be used in patients with HIV infection.",
        "Discontinuation of Tenofovir Alafenamide may result in severe acute exacerbations of hepatitis B. Close monitoring with clinical and laboratory follow-up is required for several months after stopping treatment."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "It is not known whether Tenofovir Alafenamide is present in human breast milk or affects human milk production.",
        "lactation": "The developmental and health benefits of breastfeeding should be considered along with the mother's need for Tenofovir Alafenamide and any potential adverse effects on the breastfed infant."
      },
      "overdose": "If overdose occurs, monitor the patient for toxicity. General supportive measures include monitoring vital signs and observing the patient's clinical status.",
      "preparation": "25 mg Tablet"
    },
    {
      "name": "Alice™",
     "img_id":"u6aSuea.jpeg",
      "image": "Alice-loiton.jpg",
      "active_ingredients": "Ivermectin",
      "indication": "Topical treatment of head lice infestations in patients 6 months of age and older.",
      "dosage_and_administration": {
        "application": "For topical use only on scalp and scalp hair. Do not use orally, ophthalmically, or intravaginally.",
        "instructions": "Apply to dry hair to thoroughly coat the hair and scalp. Leave on for 10 minutes, then rinse with water. The tube is for single use; discard any unused portion."
      },
      "contraindications_and_precautions": [
        "To prevent ingestion, administer to pediatric patients under adult supervision.",
        "In case of accidental poisoning, provide supportive therapy including parenteral fluids, respiratory support, and pressor agents if necessary."
      ],
      "side_effects": [
        "Conjunctivitis",
        "Ocular hyperemia",
        "Eye irritation",
        "Dandruff",
        "Dry skin",
        "Skin burning sensation"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Pregnancy Category C. Should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.",
        "lactation": "Caution should be exercised when administered to nursing women."
      },
      "preparation": "60 gm lotion"
    },
    {
      "name": "Almex®",
     "img_id":"mazgrVZ.jpeg",
      "image": "Almex-Sus-6s.jpg",
      "active_ingredients": "Albendazole",
      "indication": "Single or mixed intestinal infections caused by various helminths.",
      "dosage_and_administration": {
        "12_to_24_months": "200 mg as a single dose (Half of Almex 400 tablet or 5 ml Almex suspension).",
        "adults_and_children_over_2_years": {
          "ascariasis_enterobiasis_trichuriasis_hookworm": "400 mg (One Almex 400 tablet or 10 ml Almex suspension) single dose.",
          "strogyloidiasis_taeniasis": "400 mg once daily for three consecutive days.",
          "giardiasis": "400 mg once daily for five days.",
          "hydatid_disease_echinococcosis": "400 mg twice daily for 28 days.",
          "cystic_echinococcosis": "28-days course may be repeated after 14 days without treatment to a total of three treatment cycles.",
          "alveolar_echinococcosis": "400 mg twice daily for 28 days followed by 14 days without treatment. May continue for months or years."
        }
      },
      "contraindications_and_precautions": "Should only be used in the treatment of echinococcosis if there is constant medical supervision with regular monitoring of serum transaminase concentrations, leucocyte, and platelet counts.",
      "side_effects": [
        "Epigastric pain",
        "Diarrhoea",
        "Headache",
        "Nausea",
        "Vomiting",
        "Dizziness",
        "Constipation",
        "Pruritis",
        "Dry mouth"
      ],
      "use_in_pregnancy_and_lactation": "Should not be administered during pregnancy or in women planning to be pregnant.",
      "use_in_children": "For children of 12 months and above.",
      "preparation": "400 mg Tablet & 200 mg/5 ml Suspension"
    },
    {
      "name": "Ambrox®",
     "img_id":"25vpxBN.jpeg",
      "image": "Ambrox-75- SR-Capsule.jpg",
      "active_ingredients": "Ambroxol",
      "indication": "Productive cough, acute & chronic inflammatory disorders of upper & lower respiratory tracts associated with viscid mucus, including bronchitis, laryngitis, pharyngitis, sinusitis, rhinitis, asthmatic bronchitis, bronchial asthma with thick expectoration, bronchiectasis, chronic pneumonia.",
      "dosage_and_administration": {
        "paediatric_drops": {
          "0_to_6_months": "0.5 ml, 2 times a day",
          "6_to_12_months": "1 ml, 2 times a day",
          "1_to_2_years": "1.25 ml, 2 times a day"
        },
        "syrup": {
          "2_to_5_years": "2.5 ml (1/2 teaspoonful), 2-3 times a day",
          "5_to_10_years": "5 ml (1 teaspoonful), 2-3 times a day",
          "10_years_and_adults": "10 ml (2 teaspoonful), 3 times a day"
        },
        "ambrox_75_sr_capsule": "Adults & children over 12 years old - 1 capsule, once daily."
      },
      "side_effects": [
        "Epigastric pain",
        "Stomach overfill feeling",
        "Rarely eruption",
        "Urticaria",
        "Angioneurotic edema"
      ],
      "contraindications_and_precautions": [
        "Known hypersensitivity to Ambroxol or Bromhexine.",
        "Use cautiously in patients with gastric & duodenal ulceration or convulsive disorders.",
        "Use with caution in patients with hepatic & renal insufficiency."
      ],
      "drug_interaction": "Should not be taken simultaneously with antitussives (e.g. Codeine).",
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "It is advised not to use during pregnancy, especially during the first trimester.",
        "lactation": "Safety during lactation has not been established."
      },
      "preparation": "6 mg/ml Paediatric Drops, 15 mg/5 ml Syrup, 75 mg SR Capsule"
    },
    {
      "name": "Ambrisan™",
     "img_id":"33hl1no.jpeg",
      "image": "Ambrisan-50-Tablet.jpg",
      "active_ingredients": "Ambrisentan",
      "indication": "Pulmonary Arterial Hypertension",
      "dosage_and_administration": {
        "initial_treatment": "5 mg once daily, can be increased to 10 mg once daily if 5 mg is tolerated.",
        "administration": "Tablets may be administered with or without food."
      },
      "contraindications_and_precautions": [
        "May cause fetal harm when administered to a pregnant woman.",
        "Contraindicated in women who are or may become pregnant. Pregnancy must be excluded before the initiation of treatment and prevented during treatment & for one month after stopping treatment.",
        "Contraindicated in patients with Idiopathic Pulmonary Fibrosis (IPF), including IPF patients with pulmonary hypertension (WHO Group 3)."
      ],
      "side_effects": [
        "Decreases in hemoglobin concentration and hematocrit observed in clinical studies."
      ],
      "drug_interaction": "Co-administration with Cyclosporine increases Ambrisentan exposure. Limit dose to 5 mg once daily when co-administered with Cyclosporine.",
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Pregnancy Category X. Should not be used during pregnancy.",
        "lactation": "Breastfeeding while receiving Ambrisentan is not recommended. It is not known if Ambrisentan is excreted in human milk."
      },
      "use_in_children": "Safety & effectiveness in pediatric patients have not been established.",
      "preparation": "5 mg Tablet"
    },
    {
      "name": "Amodis®",
     "img_id":"BUtvdhg.jpeg",
      "image": "AMODIS-400.jpg",
      "active_ingredients": "Metronidazole",
      "indication": [
        "All forms of amoebiasis (intestinal & extraintestinal, including liver abscess & symptomless cyst passers)",
        "Trichomoniasis",
        "Giardiasis",
        "Bacterial vaginosis",
        "Acute ulcerative gingivitis",
        "Anaerobic infections including sepsis, bacteremia, peritonitis, brain abscess, necrotising pneumonia, osteomyelitis, puerperal sepsis, pelvic abscess, pelvic cellulitis",
        "Anaerobically-infected leg ulcers & pressure sores",
        "Acute dental infections (e.g. acute pericoronitis & acute apical infections)",
        "Surgical prophylaxis (prevention of postoperative infections due to anaerobic bacteria)",
        "Chronic symptomatic peptic ulcer disease (as part of triple therapy to eradicate H. pylori)"
      ],
      "dosage_and_administration": {
        "trichomoniasis": {
          "adults_over_10_years": "200 mg t.i.d. or 400 mg b.i.d.",
          "children_7_10_years": "100 mg t.i.d.",
          "children_3_7_years": "50 mg t.i.d.",
          "children_1_3_years": "50 mg t.i.d."
        },
        "invasive_intestinal_amoebiasis": {
          "adults_over_10_years": "800 mg t.i.d.",
          "children_7_10_years": "400 mg t.i.d.",
          "children_3_7_years": "200 mg q.i.d.",
          "children_1_3_years": "200 mg t.i.d."
        },
        "extra_intestinal_amoebiasis_and_liver_abscess": {
          "adults_over_10_years": "400–800 mg t.i.d.",
          "children_7_10_years": "200–400 mg t.i.d.",
          "children_3_7_years": "100–200 mg q.i.d.",
          "children_1_3_years": "100–200 mg t.i.d."
        },
        "giardiasis": {
          "adults_over_10_years": "2.0 gm once daily",
          "children_7_10_years": "1.0 gm once daily",
          "children_3_7_years": "600-800 mg",
          "children_1_3_years": "500 mg once daily"
        },
        "acute_ulcerative_gingivitis": {
          "adults_over_10_years": "200 mg t.i.d.",
          "children_7_10_years": "100 mg t.i.d.",
          "children_3_7_years": "50 mg t.i.d.",
          "children_1_3_years": "50 mg t.i.d."
        },
        "acute_dental_infections": {
          "adults_over_10_years": "200 mg t.i.d.",
          "children_7_10_years": "100 mg t.i.d.",
          "children_3_7_years": "50 mg t.i.d.",
          "children_1_3_years": "50 mg t.i.d."
        },
        "bacterial_vaginosis": {
          "adults_over_10_years": "400–500 mg twice daily",
          "children_7_10_years": "2.0 gm as a single dose",
          "children_3_7_years": "500 mg once daily",
          "children_1_3_years": "500 mg once daily"
        },
        "leg_ulcers_and_pressure_sores": {
          "adults_over_10_years": "400 mg t.i.d.",
          "children_7_10_years": "7.5 mg/kg t.i.d.",
          "children_3_7_years": "7.5 mg/kg t.i.d.",
          "children_1_3_years": "7.5 mg/kg t.i.d."
        },
        "anaerobic_infections": {
          "adults_over_10_years": "400 mg every 8 hours",
          "children_7_10_years": "7.5 mg/kg t.i.d.",
          "children_3_7_years": "7.5 mg/kg t.i.d.",
          "children_1_3_years": "7.5 mg/kg t.i.d."
        },
        "surgical_prophylaxis": {
          "adults_over_10_years": "400–500 mg 2 hours before surgery; up to 3 further doses of 400–500 mg may be given every 8 hours for high-risk procedures.",
          "children_7_10_years": "7.5 mg/kg t.i.d.",
          "children_3_7_years": "7.5 mg/kg t.i.d.",
          "children_1_3_years": "7.5 mg/kg t.i.d."
        }
      },
      "side_effects": [
        "Metallic taste",
        "Furred tongue",
        "Nausea",
        "Vomiting",
        "Diarrhea",
        "Drowsiness",
        "Rashes",
        "Mild reversible leucopenia"
      ],
      "drug_interaction": [
        "Metronidazole interacts with Warfarin",
        "Nicoumalone",
        "Phenytoin",
        "Phenobarbitone",
        "Fluorouracil",
        "Disulfiram",
        "Lithium",
        "Cimetidine"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Not recommended during first & later trimesters. Pregnancy Category B.",
        "lactation": "Breastfeeding should be delayed until 48 hours after discontinuing metronidazole in the mother."
      },
      "preparation": ["400 mg Tablet", "200 mg/5 ml Suspension"]
    },
    {
      "name": "Amodis® 500 IV",
     "img_id":"hHzcRWf.jpeg",
      "image": "Amodis-infusion_l.jpg",
      "active_ingredients": "Metronidazole",
      "indication": [
        "Prophylaxis and treatment of infections in which anaerobic bacteria have been identified",
        "Prevention of postoperative infections due to anaerobic bacteria",
        "Treatment of septicaemia",
        "Bacteraemia",
        "Peritonitis",
        "Brain abscess",
        "Necrotizing pneumonia",
        "Osteomyelitis",
        "Puerperal sepsis",
        "Pelvic abscess",
        "Pelvic cellulitis",
        "Postoperative wound infections from which pathogenic anaerobes have been isolated"
      ],
      "dosage_and_administration": {
        "bacterial_infections": {
          "adults": "500 mg (100 ml) IV every 8 hours",
          "children": "7.5 mg/kg (1.5 ml/kg) IV every 8 hours"
        },
        "surgical_prophylaxis": {
          "adults": "500 mg (100 ml) IV shortly before operation, repeated every 8 hours",
          "children": "7.5 mg/kg (1.5 ml/kg) IV every 8 hours"
        }
      },
      "side_effects": [
        "Pain, tenderness, redness, or swelling over vein",
        "Unsteadiness",
        "Fever or chills",
        "Sore throat",
        "Headache",
        "Numbness",
        "Tingling pain or weakness in hands or feet",
        "Seizures",
        "Skin itching",
        "Unusual tiredness or weakness",
        "Vaginal irritation or discharge"
      ],
      "drug_interaction": [
        "Alcohol or alcohol-containing beverages",
        "Barbiturates",
        "Carbamazepine",
        "Cimetidine",
        "Disulfiram",
        "Fluorouracil",
        "Lithium",
        "Methadone",
        "Phenytoin",
        "Warfarin"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Not recommended during the first trimester; safety in humans not established",
        "lactation": "Not recommended as metronidazole passes into breast milk"
      },
      "precaution": [
        "Anaemia or other blood disorders",
        "Liver disease",
        "Disease of the nervous system",
        "Seizures"
      ],
      "preparation": ["500 mg/100 ml intravenous infusion"]
    },
    {
      "name": "Anadol®",
     "img_id":"9RN17ym.jpeg",
      "image": "Anadol-50_l.jpg",
      "active_ingredients": "Tramadol",
      "indication": [
        "Post-operative pain",
        "Colic and spastic pain",
        "Cancer pain",
        "Joint pain",
        "Neck and back pain",
        "Pain associated with osteoporosis"
      ],
      "dosage_and_administration": {
        "general": {
          "usual_dose": "50–100 mg every 4 to 6 hours",
          "acute_pain": "Initial dose of 100 mg"
        }
      },
      "contraindication_and_precaution": [
        "Hypersensitivity to tramadol",
        "Acute intoxication with alcohol",
        "Acute intoxication with hypnotics",
        "Acute intoxication with centrally acting analgesics",
        "Acute intoxication with opioids or psychotropic drugs",
        "Caution in patients with increased intracranial pressure or head injury",
        "Caution in patients with acute abdominal conditions"
      ],
      "side_effects": [
        "Dizziness/vertigo",
        "Nausea",
        "Constipation",
        "Headache",
        "Somnolence",
        "Vomiting",
        "Pruritus",
        "CNS stimulation",
        "Asthenia"
      ],
      "drug_interaction": [
        "Monoamine oxidase (MAO) inhibitors",
        "Carbamazepine"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Should be used only if the potential benefit justifies the risk to the fetus",
        "lactation": "Not specifically mentioned; caution is advised"
      },
      "preparation": [
        "50 mg Capsule",
        "100 mg SR Capsule",
        "100 mg/2 ml Injection",
        "100 mg Suppository"
      ]
    },
    {
      "name": "Anclog®",
     "img_id":"h47uB1a.jpeg",
      "image": "Anclog-(600x400).jpg",
      "active_ingredients": "Clopidogrel",
      "indication": [
        "Atherosclerotic disease (ischemic stroke, myocardial infarction, or established peripheral arterial disease)",
        "Prophylaxis in patients at risk of thrombo-embolic disorders such as myocardial infarction and stroke"
      ],
      "dosage_and_administration": {
        "general": "One tablet once daily"
      },
      "contraindication_and_precaution": [
        "Hypersensitivity",
        "Active pathological bleeding such as peptic ulcer or intracranial hemorrhage"
      ],
      "side_effects": [
        "Hemorrhage",
        "Abdominal discomfort",
        "Nausea",
        "Vomiting",
        "Diarrhoea",
        "Headache",
        "Dizziness",
        "Vertigo",
        "Paraesthesia",
        "Rash",
        "Pruritus",
        "Hepatic and biliary disorder",
        "Neutropenia"
      ],
      "drug_interaction": ["Aspirin", "NSAIDs (should be used with caution)"],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Should be used in pregnant women only if clearly needed",
        "lactation": "Should be used in nursing mothers only if clearly needed"
      },
      "preparation": ["75 mg Tablet"]
    },
    {
      "name": "Anclog® Plus",
     "img_id":"7EDZUvc.jpeg",
      "image": "ANCLOG-PLUS.jpg",
      "active_ingredients": "Clopidogrel + Aspirin",
      "indication": [
        "Prevention of atherosclerotic events in patients with history of symptomatic atherosclerotic diseases (ischemic stroke, myocardial infarction or acute coronary syndrome)"
      ],
      "dosage_and_administration": {
        "general": "Once daily"
      },
      "contraindication_and_precaution": [
        "Hypersensitivity to any of the components or NSAIDs",
        "Active pathological bleeding such as peptic ulcer or intracranial hemorrhage",
        "Bleeding disorders like hemophilia",
        "Recent history of gastrointestinal bleeding"
      ],
      "side_effects": [
        "Abdominal pain",
        "Nausea",
        "Vomiting",
        "Neuralgia",
        "Paraesthesia",
        "Rash",
        "Pruritis"
      ],
      "drug_interaction": [
        "This combination may enhance the effect of anticoagulants"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Should be avoided during the last three months of pregnancy",
        "lactation": "Not recommended during breastfeeding due to risk of Reye’s syndrome"
      },
      "use_in_children": "Safety and efficacy in the pediatric population have not been established",
      "preparation": ["(Clopidogrel 75 mg + Aspirin 75 mg)/Tablet"]
    },
    {
      "name": "Anema™",
     "img_id":"nWgePIu.jpeg",
      "image": "Anema_l.jpg",
      "active_ingredients": "Monobasic Sodium Phosphate and Dibasic Sodium Phosphate",
      "indication": [
        "Relief of occasional constipation",
        "Bowel cleansing before and after lower bowel surgery, delivery and post-partum",
        "Before proctoscopy, sigmoidoscopy or colonoscopy",
        "Before radiological examinations of the lower bowel"
      ],
      "dosage_and_administration": {
        "adults_and_children_over_12": "1 Anema™ (118 ml delivered dose) not more than once daily or as directed by a physician",
        "children_2_to_less_than_12": "As directed by a physician"
      },
      "contraindication": [
        "Congestive heart failure",
        "Impairment of renal function",
        "Gastrointestinal obstruction",
        "Megacolon",
        "Paralytic ileus",
        "Perforation",
        "Active inflammatory bowel disease",
        "Imperforate anus",
        "Dehydration",
        "Children under 2 years of age",
        "Hypersensitivity to active ingredients or any excipients"
      ],
      "precaution": [
        "Use with caution in patients with impaired renal function",
        "Patients with pre-existing electrolyte disturbances",
        "Patients taking diuretics affecting electrolyte levels",
        "Patients taking medications that prolong QT interval",
        "Patients with ascites or colostomy"
      ],
      "side_effects": [
        "Generally well tolerated",
        "Adverse events may occur with misuse",
        "Infrequent reports of associated adverse events"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Use only as directed by a physician at delivery or postpartum due to lack of data on fetal risk",
        "lactation": "Breast milk should be expressed and discarded for at least 24 hours after use"
      },
      "drug_interaction": [
        "Use with caution in patients taking calcium channel blockers, diuretics, or lithium",
        "Avoid concomitant use with other sodium phosphate preparations",
        "May cause hyperphosphataemia, hypocalcaemia, hypokalaemia, hypernatraemic dehydration, acidosis",
        "May reduce serum lithium levels"
      ],
      "overdose": {
        "warning": "Using more than one Anema™ in 24 hours can be harmful",
        "management": "Recovery by rehydration; may require electrolyte and fluid replacement therapy"
      },
      "preparation": ["133 ml solution"]
    },
    {
      "name": "Angilock®",
     "img_id":"tN1v5oi.jpeg",
      "image": "Angilock_l.jpg",
      "active_ingredients": "Losartan Potassium",
      "indication": [
        "Treatment of hypertension (alone or with other antihypertensive agents, including diuretics)",
        "Reduce risk of stroke in hypertensive patients with left ventricular hypertrophy",
        "Treatment of diabetic nephropathy in type 2 diabetic patients with elevated serum creatinine and proteinuria"
      ],
      "dosage_and_administration": {
        "adult_hypertensive_patients": "Starting dose is 50 mg once daily; may range from 25 mg to 100 mg daily in one or two divided doses. Use 25 mg in volume-depleted or hepatic impaired patients.",
        "pediatric_patients_6_years_and_older": "Starting dose is 0.7 mg/kg once daily (max 50 mg); adjust according to BP response. Not recommended in patients <6 years or with GFR <30 mL/min/1.73 m².",
        "left_ventricular_hypertrophy": "Start with 50 mg once daily; add Hydrochlorothiazide 12.5 mg daily or increase Angilock® to 100 mg based on response.",
        "diabetic_nephropathy": "Start with 50 mg once daily; increase to 100 mg daily based on BP response. May be used with insulin or other hypoglycemic agents."
      },
      "contraindication_and_precaution": {
        "contraindications": [
          "Hypersensitivity to any component",
          "Co-administration with aliskiren in diabetic patients",
          "Severe hepatic impairment"
        ],
        "precautions": [
          "Correct volume depletion before initiation to avoid symptomatic hypotension",
          "Use lower dose in patients with hepatic impairment",
          "Avoid with potassium-sparing diuretics"
        ]
      },
      "side_effects": [
        "Dizziness",
        "Rash",
        "Angioedema (face, lips, tongue)",
        "Serious hypotension (especially in salt-depleted patients)",
        "Renal failure (mainly in renal artery stenosis)"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Category D – Contraindicated. Discontinue as soon as pregnancy is detected.",
        "lactation": "Contraindicated in lactating mothers"
      },
      "drug_interaction": [
        "No clinically significant drug interactions identified"
      ],
      "preparation": ["25 mg Tablet", "50 mg Tablet", "100 mg Tablet"]
    },
    {
      "name": "Angilock® Plus",
     "img_id":"N5y7pDd.jpeg",
      "image": "ap_50_125.jpg",
      "active_ingredients": ["Losartan Potassium", "Hydrochlorothiazide"],
      "indications": [
        "Treatment of hypertension",
        "To reduce the risk of stroke in hypertensive patients with left ventricular hypertrophy"
      ],
      "dosage_and_administration": {
        "general": "Usual starting dose is Angilock® Plus 50/12.5 once daily. Do not exceed more than two tablets of 50/12.5 or one tablet of 100/25 daily. Maximum antihypertensive effect occurs in 3 weeks.",
        "adjustment_guidelines": [
          "Switch to Angilock® Plus 50/12.5 if monotherapy fails",
          "Increase dose after 3 weeks if blood pressure remains uncontrolled",
          "Patients not controlled with Losartan 100 mg monotherapy may switch to Angilock® Plus 100/12.5"
        ],
        "renal_impairment": "Use if creatinine clearance > 30 mL/min. Avoid in severe renal impairment.",
        "hepatic_impairment": "Not recommended due to inability to titrate Losartan 25 mg starting dose.",
        "severe_hypertension": "Start with Angilock® Plus 50/12.5. If no response after 2–4 weeks, increase to Angilock® Plus 100/25. Maximum: 100/25 once daily.",
        "left_ventricular_hypertrophy": "Start with Angilock® 50 mg. If needed, switch to Angilock® Plus 50/12.5, then 100/12.5, then 100/25.",
        "administration_notes": "Can be taken with or without food. May be combined with other antihypertensive agents."
      },
      "contraindications_and_precautions": [
        "Hypersensitivity to components",
        "Anuria",
        "Hypersensitivity to sulfonamide-derived drugs",
        "Do not use with Aliskiren in diabetic patients",
        "Monitor serum electrolytes and observe for fluid/electrolyte imbalance",
        "May cause hyperuricemia or gout",
        "Adjust diabetes medications as needed due to possible hyperglycemia"
      ],
      "side_effects": [
        "Abdominal pain",
        "Edema/swelling",
        "Palpitation",
        "Back pain",
        "Dizziness",
        "Cough",
        "Sinusitis",
        "Upper respiratory infection",
        "Rash"
      ],
      "pregnancy_and_lactation": {
        "pregnancy_category": "D",
        "notes": "Weigh risks and benefits when used in nursing mothers"
      },
      "drug_interactions": {
        "losartan_potassium": [
          "Potassium-sparing diuretics",
          "Potassium supplements",
          "Salt substitutes containing potassium"
        ],
        "hydrochlorothiazide": [
          "Alcohol, barbiturates, narcotics - may increase orthostatic hypotension",
          "Other antihypertensive drugs - additive effect",
          "Cholestyramine and colestipol resins - impair absorption"
        ]
      },
      "preparation": [
        "Tablet: Losartan potassium 50 mg & Hydrochlorothiazide 12.5 mg",
        "Tablet: Losartan potassium 100 mg & Hydrochlorothiazide 25 mg",
        "Tablet: Losartan potassium 100 mg & Hydrochlorothiazide 12.5 mg"
      ]
    },
    {
      "name": "Angivent® MR",
     "img_id":"wOnZq9l.png",
      "image": "Angivent-MR_l.png",
      "active_ingredients": "Trimetazidine Hydrochloride",
      "indication": "Long-term treatment of angina pectoris",
      "dosage_and_administration": {
        "general": "1 tablet at mealtimes in the morning and evening"
      },
      "contraindications_and_precautions": [
        "Severe depression",
        "Severe renal failure (creatinine clearance < 15 ml/min)",
        "Caution in the absence of current studies"
      ],
      "side_effects": ["Rare cases of gastrointestinal disorders"],
      "pregnancy_and_lactation": {
        "pregnancy": "Studies in animals have not demonstrated a teratogenic effect. Prescription should be avoided during pregnancy for safety reasons.",
        "breastfeeding": "Breastfeeding is not recommended during treatment due to lack of data."
      },
      "preparation": "35 mg modified release tablet"
    },
    {
      "name": "Anleptic®",
      "img_id":"JcWryys.jpeg",
      "image":"ANLEPTIC-200-CR.jpg",
      "active_ingredients": "Carbamazepine",
      "indications": [
        "Partial & secondary generalized tonic-clonic seizures",
        "Primary generalized tonic-clonic seizures",
        "Trigeminal neuralgia",
        "Prophylaxis of bipolar disorder"
      ],
      "dosage_and_administration": {
        "epilepsy": {
          "adults_and_children_over_12_years": {
            "initial": "200 mg b.i.d. for tablets & XR tablets, or 1 teaspoon q.i.d. for suspension (400 mg/day)",
            "maintenance": "800-1200 mg daily"
          },
          "children_6_12_years": {
            "initial": "100 mg b.i.d. for tablets or XR tablets, or 1/2 teaspoon q.i.d. for suspension (200 mg/day)",
            "maintenance": "400-800 mg daily"
          },
          "children_under_6_years": {
            "initial": "10-20 mg/kg/day b.i.d. or t.i.d. as tablets, or q.i.d. as suspension",
            "maintenance": "Ordinarily, optimal clinical response is achieved at daily doses below 35 mg/kg"
          },
          "combination_therapy": "Carbamazepine may be used alone or with other anticonvulsants. Gradual addition to existing therapy is recommended."
        },
        "trigeminal_neuralgia": {
          "initial": "100 mg b.i.d. for tablets or XR tablets, or 1/2 teaspoon q.i.d. for suspension (200 mg/day)",
          "maintenance": "400-800 mg daily, with a maximum of 1200 mg daily. Attempts to reduce the dose should be made every 3 months."
        }
      },
      "contraindications_and_precautions": [
        "Allergic to any ingredient in the medicine",
        "Problems with electrical message pathways in the heart (atrioventricular block)",
        "History of decreased blood cell production by the bone marrow (bone marrow depression)",
        "Hereditary blood disorders (porphyrias)",
        "Allergy to tricyclic antidepressants (e.g., amitriptyline)",
        "Recent use of monoamine-oxidase inhibitor (MAOI) antidepressants (within the last 14 days)"
      ],
      "side_effects": [
        "Dizziness",
        "Drowsiness",
        "Ataxia",
        "Dry mouth",
        "Abdominal pain",
        "Nausea",
        "Vomiting",
        "Anorexia",
        "Leucopenia",
        "Proteinuria",
        "Bradycardia",
        "Heart failure",
        "Hypotension",
        "Erythematous skin rash",
        "Aplastic anemia"
      ],
      "pregnancy_and_lactation": {
        "pregnancy": "Category D. The drug should be avoided unless absolutely necessary due to potential risks to the fetus.",
        "lactation": "Not recommended during breastfeeding due to lack of safety data."
      },
      "preparation": ["200 mg CR Tablet", "100 mg/5 ml Suspension (100 ml)"]
    },
    {
      "name": "Anril®",
     "img_id":"deEMSF7.jpeg",
      "image": "ANRIL-SPRAY.jpg",
      "active_ingredients": "Nitroglycerin",
      "indications": [
        "Acute relief of an attack of angina pectoris",
        "Acute prophylaxis of angina pectoris due to coronary artery disease"
      ],
      "dosage_and_administration": {
        "400_mcg_spray": {
          "initial_dose": "1 or 2 metered sprays under the tongue at the onset of an attack",
          "max_dose": "No more than 3 metered sprays within a 15-minute period",
          "prophylaxis": "Use 5 to 10 minutes prior to activities which might precipitate an attack"
        },
        "injection": {
          "usual_dose_range": "10 - 200 mcg/min",
          "max_dose": "Up to 400 mcg/min for some surgical procedures"
        },
        "2_6_mg_sr_tablet": {
          "adults_and_elderly": {
            "usual_dose": "1 or 2 tablets taken three times daily",
            "note": "Use the lowest effective dose"
          }
        }
      },
      "contraindications_and_precautions": [
        "Early myocardial infarction",
        "Severe anemia",
        "Increased intracranial pressure",
        "Hypersensitivity to Nitroglycerin",
        "Use with sildenafil citrate (potentiates hypotensive effects)",
        "Use with caution in volume-depleted or hypotensive patients"
      ],
      "drug_interactions": [
        "Antihypertensive drugs",
        "Beta-adrenergic blockers",
        "Phenothiazines",
        "Calcium channel blockers",
        "Alcohol",
        "Aspirin",
        "Ergotamine and related drugs"
      ],
      "side_effects": [
        "Headache",
        "Facial flushing",
        "Dizziness",
        "Nausea",
        "Vomiting",
        "Feelings of weakness",
        "Postural hypotension",
        "Reflex tachycardia"
      ],
      "pregnancy_and_lactation": {
        "pregnancy": "Category C. Should be given only if clearly needed.",
        "nursing_mothers": "Caution should be exercised when administered to a nursing woman."
      },
      "use_in_children": "Safety and effectiveness in pediatric patients have not been established.",
      "preparation": [
        "400 mcg spray",
        "5 mg/ml IV Injection",
        "2.6 mg SR (Sustained Release) Tablet"
      ]
    },
    {
      "name": "Ansulin®",
     "img_id":"KF2Skqa.jpeg",
      "image": "Ansulin-30-70-Cartridge_l.jpg",
      "active_ingredients": "Insulin Human (rDNA)",
      "indications": ["Type 1 Diabetes Mellitus", "Type 2 Diabetes Mellitus"],
      "dosage_and_administration": {
        "type_1_diabetes": {
          "daily_insulin_requirement": "0.5 to 1.0 IU/kg",
          "pre_pubertal_children": "0.7 to 1.0 IU/kg",
          "insulin_resistant_cases": "May require higher dosages during puberty or obesity"
        },
        "type_2_diabetes": {
          "initial_dosage": "0.2 to 0.6 IU/kg/day"
        }
      },
      "contraindications_and_precautions": [
        "Hypoglycemia",
        "Allergic reaction to insulin or any excipients",
        "Inadequate dosing or discontinuation, especially in type 1 diabetes, leading to hyperglycemia",
        "Hypoglycemia may occur if the dose is too high or if a meal is omitted or strenuous exercise is unplanned"
      ],
      "side_effects": [
        "Hypoglycemia (most common)",
        "Allergic reactions (e.g., red, swollen, or itching areas), typically resolves in a few days"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Can be used during pregnancy if required",
        "lactation": "Can be used during lactation if required"
      },
      "preparation": {
        "vials_10ml": [
          "Ansulin R Injection 40 IU/ml",
          "Ansulin R Injection 100 IU/ml",
          "Ansulin N Injection 100 IU/ml",
          "Ansulin 30/70 Injection 40 IU/ml",
          "Ansulin 30/70 Injection 100 IU/ml",
          "Ansulin 50/50 Injection 100 IU/ml"
        ],
        "cartridges_3ml": [
          "Ansulin R Pen Cartridge 100 IU/ml",
          "Ansulin 30/70 Pen Cartridge 100 IU/ml",
          "Ansulin 50/50 Pen Cartridge 100 IU/ml"
        ]
      }
    },
    {
      "name": "Antazol®",
     "img_id":"K7WXNVa.jpeg",
      "image": "ANTAZOL-01.jpg",
      "active_ingredients": "Xylometazoline",
      "indications": [
        "Nasal congestion",
        "Seasonal allergic rhinitis",
        "Perennial allergic rhinitis",
        "Sinusitis"
      ],
      "dosage_and_administration": {
        "adults": "2 or 3 drops of adult formula (0.1%) 2-3 times daily",
        "children_under_12": "1 or 2 drops of children's formula (0.05%) in each nostril 1-2 times daily",
        "infants": "Not to be used in infants less than 3 months"
      },
      "contraindications_and_precautions": [
        "Patients with trans-sphenoidal hypophysectomy or surgery exposing the dura mater",
        "Hypersensitivity to Xylometazoline"
      ],
      "side_effects": [
        "Burning sensation",
        "Local irritation",
        "Nausea",
        "Headache",
        "Dryness of the nasal mucosa",
        "Systemic cardiovascular effects, particularly in patients with cardiovascular disease"
      ],
      "preparation": ["0.05% Nasal Drops", "0.1% Nasal Drops"]
    },
    {
      "name": "Antazol® Plus",
     "img_id":"On4joZo.jpeg",
      "image": "ANTAZOL.PLUS.jpg",
      "active_ingredients": ["Sodium Cromoglycate", "Xylometazoline"],
      "indications": [
        "Prophylaxis and treatment of allergic rhinitis accompanied by nasal congestion"
      ],
      "dosage_and_administration": {
        "adults_and_children": "One spray to each nostril four times daily"
      },
      "contraindications_and_precautions": [
        "Known hypersensitivity to any ingredients of the preparation"
      ],
      "side_effects": [
        "No serious side effects have been reported",
        "Occasional irritation of the nasal mucosa",
        "Wheezing",
        "Tightness of the chest",
        "Xylometazoline causes mild side effects such as nasal irritation, dryness of the nose, sneezing, headache, insomnia, drowsiness, and palpitations"
      ],
      "preparation": "(2.6 mg + 0.0325 mg)/spray, Metered Dose Nasal Spray"
    },
    {
      "name": "Antista®",
     "img_id":"ObPOS6x.jpeg",
      "image": "Antista_Syrup_large.jpg",
      "active_ingredients": "Chlorpheniramine",
      "indications": [
        "Allergic conditions including urticaria",
        "Sensitivity reactions",
        "Angioneurotic oedema",
        "Hay fever",
        "Vasomotor rhinitis",
        "Cough",
        "Common cold",
        "Motion sickness"
      ],
      "dosage_and_administration": {
        "adults": "4 mg 3-4 times daily",
        "children": {
          "up_to_1_year": "1 mg twice daily",
          "1_5_years": "1 mg 3-4 times daily",
          "6_12_years": "2 mg 3-4 times daily or as directed by the physician"
        }
      },
      "side_effects": [
        "Drowsiness",
        "Dizziness",
        "Headache",
        "Psychomotor impairment",
        "Urinary retention",
        "Dry mouth",
        "Blurred vision",
        "Gastrointestinal disturbances"
      ],
      "contraindications_and_precautions": [
        "Use with caution in epilepsy",
        "Prostatic hypertrophy",
        "Glaucoma",
        "Hepatic disease",
        "Impaired ability to drive or operate machinery"
      ],
      "preparation": "2 mg/5 ml Syrup"
    },
    {
      "name": "Anzitor®",
     "img_id":"z8TCQkS.jpeg",
      "image": "Anzitor-EZ-10.jpg",
      "active_ingredients": "Atorvastatin",
      "indications": [
        "For reduction of elevated total cholesterol",
        "LDL-cholesterol",
        "Apolipoprotein B",
        "Triglycerides in patients with primary hypercholesterolemia"
      ],
      "dosage_and_administration": {
        "usual_dose": "10 mg once daily",
        "dosage_range": "10 to 80 mg once daily"
      },
      "side_effects": [
        "Mild & transient side effects",
        "Reversible myositis",
        "Headache",
        "Altered liver-function tests",
        "Gastro-intestinal effects including abdominal pain",
        "Flatulence",
        "Diarrhoea",
        "Nausea & vomiting",
        "Thrombocytopenia",
        "Rash & hypersensitivity reactions",
        "Insomnia",
        "Angioedema",
        "Anorexia",
        "Asthenia",
        "Paraesthesia",
        "Peripheral neuropathy",
        "Alopecia",
        "Pruritus",
        "Impotence",
        "Chest pain",
        "Hypoglycemia & hyperglycemia"
      ],
      "contraindications": [
        "Liver disease",
        "Myalgia",
        "Myopathy",
        "Hypersensitivity to the drug"
      ],
      "drug_interactions": [
        "Cyclosporin",
        "Fibric acid derivatives",
        "Erythromycin",
        "Azole antifungals",
        "Niacin (nicotinic acid)"
      ],
      "use_in_pregnancy_and_lactation": "Atorvastatin is contraindicated in pregnancy & while breast-feeding.",
      "preparation": "10 mg, 20 mg & 40 mg Tablet"
    },
    {
      "name": "Apsol®",
     "img_id":"ybFT9Zy.jpeg",
      "image": "Apsol-Oral-01.jpg",
      "active_ingredients": "Amlexanox",
      "indications": ["For the treatment of Aphthous ulcers"],
      "dosage_and_administration": [
        "Apply the paste as soon as possible after noticing the symptoms of an aphthous ulcer.",
        "Use the paste four times daily, preferably following oral hygiene after breakfast, lunch, dinner, & at bedtime.",
        "Dry the ulcer(s) by gently patting it with a soft, clean cloth.",
        "Wash hands before applying.",
        "Moisten the tip of the index finger.",
        "Squeeze a dab of paste approximately 1/4 inch (0.5 cm) onto a finger tip.",
        "Gently dab the paste onto the ulcer. Repeat the process if more than one ulcer.",
        "Wash hands when done applying.",
        "Wash eyes promptly if they come in contact with the paste.",
        "Use the paste until the ulcer heals. If significant healing or pain relief has not occurred in 10 days, consultation with the physician is required."
      ],
      "contraindications_and_precautions": [
        "Contraindicated in patients with known hypersensitivity to Amlexanox or other ingredients in the formulation.",
        "Wash hands immediately after applying Amlexanox oral paste, directly to ulcers with the finger tips.",
        "In the event that a rash or contact mucositis occurs, discontinue use."
      ],
      "side_effects": [
        "Transient pain, stinging, and/or burning at the site of application (1-2% of patients).",
        "Infrequent adverse reactions (<1%): contact mucositis, nausea, & diarrhea."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "US FDA pregnancy Category B. This drug should be used during pregnancy only if clearly needed.",
        "nursing_mothers": "Amlexanox was found in the milk of lactating rats; therefore, caution should be exercised when administering Amlexanox oral paste to a nursing woman."
      },
      "use_in_children": "Safety & effectiveness of Amlexanox oral paste in pediatric patients have not been established.",
      "preparation": "Tube containing 5 gm oral paste"
    },
    {
      "name": "Ariprex™",
     "img_id":"cjGL4OL.png",
      "image": "Ariprex-50ML-Oral.png",
      "active_ingredients": "Aripiprazole",
      "indications": [
        "Schizophrenia",
        "Bipolar disorder",
        "Adjunctive treatment of major depressive disorder",
        "Irritability associated with autistic disorder",
        "Agitation associated with schizophrenia or bipolar mania"
      ],
      "dosage_and_administration": {
        "schizophrenia_adults": {
          "initial_dose": "10-15 mg/day",
          "recommended_dose": "10-15 mg/day",
          "maximum_dose": "30 mg/day"
        },
        "schizophrenia_adolescents": {
          "age_range": "13-17 years",
          "initial_dose": "2 mg/day",
          "recommended_dose": "10 mg/day",
          "maximum_dose": "30 mg/day"
        },
        "bipolar_mania_adults_monotherapy": {
          "initial_dose": "15 mg/day",
          "recommended_dose": "15 mg/day",
          "maximum_dose": "30 mg/day"
        },
        "bipolar_mania_adults_adjunct": {
          "initial_dose": "10-15 mg/day",
          "recommended_dose": "15 mg/day",
          "maximum_dose": "30 mg/day"
        },
        "bipolar_mania_pediatric": {
          "age_range": "10-17 years",
          "initial_dose": "2 mg/day",
          "recommended_dose": "10 mg/day",
          "maximum_dose": "30 mg/day"
        },
        "major_depressive_disorder_adults": {
          "initial_dose": "2-5 mg/day",
          "recommended_dose": "5-10 mg/day",
          "maximum_dose": "15 mg/day"
        },
        "irritability_autistic_disorder_pediatric": {
          "age_range": "10-17 years",
          "initial_dose": "2 mg/day",
          "recommended_dose": "5-10 mg/day",
          "maximum_dose": "15 mg/day"
        },
        "oral_formulations": "Administer once daily without regard to meals."
      },
      "side_effects": [
        "Vomiting",
        "Nausea",
        "Akathisia",
        "Extrapyramidal disorder",
        "Somnolence",
        "Sedation",
        "Dizziness",
        "Insomnia",
        "Tremor",
        "Restlessness",
        "Fatigue",
        "Blurred vision",
        "Salivary hypersecretion",
        "Constipation",
        "Pyrexia",
        "Drooling",
        "Decreased appetite"
      ],
      "special_warnings_and_precautions": [
        "Increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack, including fatalities) in elderly patients with dementia-related psychosis.",
        "Increased risk of suicidality in children, adolescents, young & adults with major depressive disorder.",
        "Tardive dyskinesia: Discontinue if clinically appropriate.",
        "Atypical antipsychotic drugs have been associated with metabolic changes that include hyperglycemia/diabetes mellitus, dyslipidemia, & body weight gain.",
        "Use with caution in patients with known cardiovascular or cerebrovascular disease.",
        "Use cautiously in patients with a history of seizures."
      ],
      "contraindications_and_precautions": [
        "Known hypersensitivity to Aripiprazole.",
        "Use caution when operating machinery."
      ],
      "drug_interactions": [
        "Caution should be exercised when Aripiprazole is taken in combination with other centrally acting drugs & alcohol.",
        "Carbamazepine could cause an increase in Aripiprazole clearance & lower blood levels.",
        "Ketoconazole, quinidine, fluoxetine or paroxetine can inhibit Aripiprazole elimination & cause increased blood levels."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Pregnancy category C. It should be avoided during pregnancy.",
        "lactation": "It is recommended that women receiving Aripiprazole should not breast-feed."
      },
      "preparation": ["2 mg Tablet", "10 mg Tablet", "50 ml Oral solution"]
    },
    {
      "name": "Asynta™",
     "img_id":"2tVVbNy.png",
      "image": "Asynta-Tablet.png",
      "active_ingredients": {
        "suspension": {
          "sodium_alginate": "500 mg",
          "potassium_bicarbonate": "100 mg"
        },
        "chewable_tablet": {
          "sodium_alginate": "500 mg",
          "potassium_bicarbonate": "100 mg"
        }
      },
      "indications": [
        "Treatment of symptoms of gastroesophageal reflux such as acid regurgitation, heartburn & indigestion (related to reflux)",
        "For example, following meals, or during pregnancy, or in patients with symptoms related to reflux oesophagitis"
      ],
      "dosage_and_administration": {
        "suspension": {
          "adult_children_over_12": "1-2 teaspoonful (5-10 ml) after meals & at bedtime, daily 4 times",
          "children_2_12_years": "1/2-1 teaspoonful (2.5-5 ml) after meals & at bedtime, daily 4 times"
        },
        "chewable_tablet": {
          "adult_children_over_6": "1-2 tablets after meals & at bedtime, daily 4 times",
          "children_6_12_years": "1 tablet after meals & at bedtime, daily 4 times"
        }
      },
      "contraindications_and_precautions": [
        "This medicinal product is contraindicated in patients with known or suspected hypersensitivity to the active substances or to any of the excipients."
      ],
      "side_effects": [
        "Very rarely (<1/10,000) patients may develop allergic manifestations, such as urticaria or bronchospasm, anaphylactic or anaphylactoid reactions."
      ],
      "drug_interactions": [
        "Interaction with other medicinal products & other forms of interaction are unknown."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Asynta™ can be given in pregnant mothers.",
        "lactation": "Asynta™ can be given to lactating mothers."
      },
      "use_in_children": {
        "suspension": "Asynta™ suspension can be given to children over 2 years of age.",
        "tablet": "Asynta™ tablet can be given to children over 6 years of age."
      },
      "preparation": ["Chewable Tablet", "Suspension"]
    },
    {
      "name": "Avaspray™",
     "img_id":"pSZgYoR.jpeg",
      "image": "Avaspray.jpg",
      "active_ingredients": "Fluticasone Furoate",
      "indications": [
        "Treatment of the symptoms of seasonal and perennial allergic rhinitis in patients 2 years of age and older."
      ],
      "dosage_and_administration": {
        "adults_and_children_over_12": "2 sprays in each nostril once daily.",
        "children_2_12_years": "1 spray in each nostril once daily."
      },
      "contraindications_and_precautions": [
        "Fluticasone Furoate undergoes extensive first-pass metabolism by the liver enzyme CYP3A4, therefore the pharmacokinetics of Fluticasone Furoate in patients with severe liver disease may be altered.",
        "Coadministration with ritonavir is not recommended because of the risk of systemic effects secondary to increased exposure to Fluticasone Furoate."
      ],
      "side_effects": [
        "The most common adverse reactions (>1% incidence) included headache, epistaxis, pharyngolaryngeal pain, nasal ulceration, back pain, nasopharyngitis, upper respiratory tract infection, nausea, and cough."
      ],
      "pregnancy_and_lactation": {
        "pregnancy": "Category C. There are no adequate and well-controlled studies in pregnant women. Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."
      },
      "preparation": "120 metered sprays"
    },
    {
      "name": "B-50® Forte",
     "img_id":"d90QXun.jpeg",
      "image": "B-50-FORTE-250CAPSUL_l2.jpg",
      "active_ingredients": "Vitamin B-complex",
      "indications": [
        "Glossitis",
        "Stomatitis",
        "Cheilosis",
        "Beriberi polyneuritis"
      ],
      "dosage_and_administration": {
        "capsule": "1-2, 3 times daily or as directed by the physician.",
        "syrup": "2-3 teaspoonful daily.",
        "injection": "2 ml daily IV or IM."
      },
      "contraindications_and_precautions": [
        "Hypersensitivity to the components."
      ],
      "side_effects": ["Rarely allergic reactions."],
      "drug_interaction": ["Can decrease the efficacy of levodopa."],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "It is safe to use B-50® Forte in pregnancy.",
        "lactation": "It is safe to use B-50® Forte during lactation."
      },
      "preparation": "Capsule, 200 ml Syrup & Injection"
    },
    {
      "name": "Bactrocin®",
     "img_id":"7FKEsAT.jpeg",
      "image": "BACTROCIN.jpg",
      "active_ingredients": "Mupirocin",
      "indications": [
        "Topical treatment of impetigo due to Staphylococcus aureus & Streptococcus pyogenes"
      ],
      "dosage_and_administration": {
        "ointment": "A small amount of ointment should be applied to the affected area three times daily. The area treated may be covered with gauze dressing if desired."
      },
      "contraindications_and_precautions": [
        "In individuals with a history of hypersensitivity to any of its components.",
        "If a reaction suggesting sensitivity or chemical irritation occurs, treatment should be discontinued and appropriate alternative therapy should be instituted.",
        "Prolonged use may result in overgrowth of nonsusceptible organisms, including fungi.",
        "Care should be taken to avoid the eyes when used on the face."
      ],
      "drug_interaction": [
        "The effect of the concurrent application of Mupirocin & other drug products has not been studied."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Pregnancy Category B. The drug should be used during pregnancy only if clearly needed.",
        "lactation": "Caution should be exercised when administered to a nursing woman."
      },
      "use_in_children": "Safety & effectiveness have been established in the age range of 2 months to 16 years.",
      "side_effects": [
        "Burning",
        "Stinging",
        "Pain",
        "Itching",
        "Rash",
        "Nausea",
        "Erythema",
        "Dry skin",
        "Tenderness",
        "Swelling",
        "Contact dermatitis",
        "Increased exudate"
      ],
      "preparation": "2% Ointment"
    },
    {
      "name": "Barif™",
     "img_id":"aMIDdmC.png",
      "image": "Barif-40-Tablet.png",
      "active_ingredients": "Febuxostat",
      "indications": [
        "Chronic management of hyperuricemia in patients with gout"
      ],
      "dosage_and_administration": {
        "recommended_dose": "40 mg or 80 mg once daily.",
        "starting_dose": "40 mg once daily.",
        "dose_adjustment": "For patients who do not achieve a serum uric acid less than 6 mg/dL after 2 weeks with 40 mg, 80 mg is recommended."
      },
      "contraindications_and_precautions": [
        "Febuxostat is contraindicated in patients being treated with azathioprine, mercaptopurine, or theophylline.",
        "Gout flare: An increase in gout flares is frequently observed during initiation of antihyperuricemic agents, including Febuxostat. If a gout flare occurs during treatment, Febuxostat need not be discontinued. Prophylactic therapy may be beneficial for up to six months.",
        "Cardiovascular Events: A higher rate of cardiovascular thromboembolic events was observed in patients treated with febuxostat than allopurinol in clinical trials.",
        "Liver Enzyme Elevation: Transaminase elevations have been observed in febuxostat-treated patients."
      ],
      "side_effects": [
        "Liver function abnormalities",
        "Nausea",
        "Arthralgia",
        "Rash"
      ],
      "drug_interaction": [
        "Concomitant administration of Febuxostat with azathioprine, mercaptopurine, or theophylline could increase plasma concentrations of these drugs resulting in severe toxicity."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Pregnancy Category C: Febuxostat should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.",
        "lactation": "It is not known whether this drug is excreted in human milk. Caution should be exercised when Febuxostat is administered to a nursing woman."
      },
      "use_in_children": "The safety & efficacy of Febuxostat in children (under 18 years of age) has not been established.",
      "preparation": "40 mg Tablet"
    },
    {
      "name": "Baritor™ 2",
     "img_id":"dcnHWVq.jpeg",
      "image": "Baritor-2.jpg",
      "active_ingredients": "Baricitinib INN 2 mg",
      "indications": [
        "Treatment of adult patients with moderately to severely active Rheumatoid Arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies."
      ],
      "dosage_and_administration": {
        "recommended_dose": "2 mg once daily.",
        "monotherapy_or_combination": "It may be used as monotherapy or in combination with Methotrexate or other DMARDs.",
        "administration": "Baricitinib can be given orally with or without food."
      },
      "side_effects": [
        "Increased LDL cholesterol (33.6%)",
        "Upper respiratory tract infections (14.7%)",
        "Nausea (2.8%)"
      ],
      "precautions": [
        "Serious Infections: Avoid use in patients with an active, serious infection, including localized infections.",
        "Tuberculosis: Baricitinib should not be given to patients with active TB.",
        "Malignancy and Lymphoproliferative Disorders: Consider the risks and benefits prior to initiating therapy in patients with a known malignancy other than a successfully treated non-melanoma skin cancer (NMSC) or when considering continuing therapy in patients who develop a malignancy.",
        "Thrombosis: Use with caution in patients at increased risk of thrombosis.",
        "Gastrointestinal Perforations: Use with caution in patients at increased risk for gastrointestinal perforation.",
        "Vaccinations: Avoid use of live vaccines with Baricitinib."
      ],
      "contraindications": ["None"],
      "use_in_special_population": {
        "pregnancy": "Baricitinib is contraindicated during pregnancy.",
        "lactation": "No information is available on the presence of Baricitinib in human milk.",
        "pediatric_use": "The safety and effectiveness of Baricitinib in pediatric patients has not been established.",
        "geriatric_use": "Care should be taken in dose selection for elderly patients due to increased likelihood of decreased renal function.",
        "hepatic_impairment": "No dose adjustment is necessary in patients with mild or moderate hepatic impairment.",
        "renal_impairment": "Baricitinib is not recommended for use in patients with estimated GFR of less than 60 mL/min/1.73 m2."
      },
      "drug_interactions": [
        "Strong OAT3 Inhibitors: Baricitinib exposure is increased when co-administered with strong OAT3 inhibitors (such as probenecid).",
        "Other JAK Inhibitors or Biologic DMARDs: Baricitinib has not been studied in combination with other JAK inhibitors or biologic DMARDs."
      ],
      "preparation": "2 mg Tablet"
    },
    {
      "name": "Beclomin™ HFA Inhaler",
     "img_id":"5quwoDT.jpeg",
      "image": "BECLOMIN-250-CFC-FREE.jpg",
      "active_ingredients": "Beclometasone",
      "indications": ["Preventive treatment for asthma"],
      "dosage_and_administration": {
        "adults_and_elders": "The usual starting dose is 200 micrograms twice a day. In more severe cases, the starting dose may need to increase to 600 to 800 micrograms per day.",
        "children": "50 to 100 micrograms should be given two, three or four times daily depending on the response. Alternatively, 100 micrograms or 200 micrograms twice daily should be given. The usual starting dose is 100 micrograms twice daily."
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "There is inadequate evidence of safety in human pregnancy.",
        "lactation": "The use of Beclometasone dipropionate in mothers breastfeeding their babies requires that the therapeutic benefits of the drug be weighed against the potential hazards to the mother and baby."
      },
      "contraindications_and_precautions": [
        "Contraindicated in patients with known sensitivity.",
        "Care is necessary in patients with active or quiescent pulmonary tuberculosis."
      ],
      "side_effects": [
        "Candidiasis of the mouth and throat (thrush) occurs in some patients."
      ],
      "preparation": "HFA Inhaler: 100 or 250 mcg/puff, 200 puffs"
    },
    {
      "name": "Becospray®",
     "img_id":"V6zlk6c.jpeg",
      "image": "Becospray-200.jpg",
      "active_ingredients": "Beclomethasone",
      "indications": [
        "Seasonal & perennial allergic rhinitis including hay fever",
        "Non-allergic (vasomotor) rhinitis"
      ],
      "dosage_and_administration": {
        "adults": "2 sprays in each nostril twice daily",
        "children_6_to_12_years": "1 spray in each nostril twice daily",
        "children_under_6_years": "Not recommended"
      },
      "contraindications_and_precautions": ["History of hypersensitivity"],
      "side_effects": [
        "Rare nasal septum perforation",
        "Dryness & irritation of the nose & throat",
        "Unpleasant taste & smell",
        "Epistaxis",
        "Wheezing",
        "Cataract"
      ],
      "drug_interactions": ["None known"],
      "preparation": "50 mcg/spray, Nasal Spray"
    },
    {
      "name": "Benostar™",
     "img_id":"Y6TqbOp.jpeg",
      "image": "benostar_l.jpg",
      "active_ingredients": "Benzydamine Hydrochloride",
      "indications": [
        "Sore throat",
        "Sore tongue or gums",
        "Mouth ulcers",
        "Discomfort caused by dentures",
        "Pain after dental surgery"
      ],
      "dosage_and_administration": {
        "recommended_dosage": "15 ml of Benostar mouthwash should be rinsed or gargled every 1.5–3 hours or as required, for 20-30 seconds",
        "dilution_advice": "If stinging occurs, it can be diluted with an equal volume of water"
      },
      "contraindications": [
        "Patients allergic (hypersensitive) to Benostar™ (Benzydamine Hydrochloride) or other components of mouthwash",
        "Contact with eyes should be avoided. If accidentally gets into eyes, they should be immediately washed with cold water"
      ],
      "side_effects": [
        "Severe allergic reaction including red and lumpy skin rash, difficulty breathing, swelling of face, mouth, lips or eyelids, unexplained high temperature (fever), and feeling faint",
        "Itchy rash, sometimes with pale, raised areas of skin with red edges (urticaria)",
        "A feeling of numbness in mouth",
        "A stinging feeling in mouth (the mouthwash may be diluted with water to reduce the stinging)"
      ],
      "use_in_pregnancy_and_lactation": "The safety of Benostar™ has not been established in pregnant patients. Risk to benefit ratio should be considered if this drug is to be used in these patients.",
      "pediatric_use": "Not indicated for use below 12 years of age.",
      "storage_conditions": "Keep away from light, store in cool and dry place under 30ºC. Keep out of reach of children.",
      "preparation": "250 ml mouthwash with a measuring cup"
    },
    {
      "name": "Betameson™",
     "img_id":"LTaqclT.jpeg",
      "image": "Betameson-Ointment-20-gm_1.jpg",
      "active_ingredients": "Betamethasone Dipropionate",
      "indications": [
        "Atopic eczema",
        "Nummular eczema",
        "Contact dermatitis",
        "Neurodermatitis",
        "Anogenital & senile pruritus",
        "Lichen planus",
        "Psoriasis"
      ],
      "dosage_and_administration": {
        "recommended_dosage": "Apply a thin film once or twice daily to cover completely the affected area.",
        "pulse_dosing_regimen": "For chronic psoriasis, use three consecutive applications of up to 3.5 g each, twelve hours apart, once each week to the previously affected areas. If relapse occurs, revert to conventional dosing."
      },
      "contraindications": [
        "Hypersensitivity to Betamethasone Dipropionate or other corticosteroids",
        "Contraindicated in viral infections of the skin (e.g., vaccinia, varicella, Herpes simplex)",
        "Contraindicated in tuberculosis, acne rosacea, fungal skin infections, perioral dermatitis, and ulcerative conditions"
      ],
      "side_effects": [
        "Mild to moderate transient burning/stinging, dry skin, pruritus, irritation, folliculitis",
        "Rare effects: tingling, prickly skin, tightening or cracking of skin, warm feeling, laminar scaling, perilesional scaling, follicular rash, skin atrophy, erythema, urticaria, vesiculation, telangiectasia, acneiform papules, hyperaesthesia"
      ],
      "use_in_pregnancy_and_lactation": "This medicine should not be used during pregnancy and lactation unless considered essential by your doctor.",
      "use_in_children": "Not recommended for use under one year of age, or under the nappy, or airtight dressing for infants older than one year.",
      "preparation": "20 gm Cream & Ointment"
    },
    {
      "name": "Betameson-N®",
     "img_id":"mu342k0.jpeg",
      "image": "Betameson-N-Cream_15_gm_1.jpg",
      "active_ingredients": ["Betamethasone Dipropionate", "Neomycin Sulphate"],
      "indications": [
        "Eczema",
        "Prurigo nodularis",
        "Psoriasis",
        "Neurodermatoses",
        "Seborrhoeic dermatitis",
        "Contact sensitivity reactions",
        "Systemic steroid therapy in generalized erythroderma",
        "Secondarily infected insect bites",
        "Anal & genital intertrigo (especially when secondary bacterial infection is present)"
      ],
      "dosage_and_administration": {
        "recommended_dosage": "Apply sparingly 2-3 times daily, reducing frequency as condition responds."
      },
      "contraindications_and_precautions": [
        "Untreated bacterial, fungal, or viral skin lesions",
        "Acne and perioral dermatitis",
        "Long-term continuous topical therapy should be avoided, particularly in infants & children",
        "Care should be taken to prevent contact with eyes as it can cause glaucoma"
      ],
      "side_effects": [
        "Local atrophic changes in the skin such as thinning, striae, and dilatation of superficial blood vessels",
        "Systemic absorption can produce features of hypercorticism and suppression of the HPA axis"
      ],
      "use_in_pregnancy_and_lactation": "Topical administration of corticosteroids to pregnant animals can cause abnormalities in fetal development including cleft palate, intrauterine growth retardation, and fetal ototoxicity.",
      "preparation": "15 gm Cream"
    },
    {
      "name": "Bicozin®",
     "img_id":"elyhmhr.jpeg",
      "image": "BICOZIN-200ML.jpg",
      "active_ingredients": [
        "Thiamine",
        "Riboflavin",
        "Pyridoxine",
        "Nicotinamide",
        "Zinc"
      ],
      "indications": [
        "Treatment & prevention of B-vitamins & Zinc deficiencies"
      ],
      "dosage_and_administration": {
        "syrup": {
          "adults": "10 ml (2 teaspoonfuls) 2 to 3 times daily",
          "children": "10 ml (2 teaspoonfuls) 1 to 3 times daily",
          "infants": "5 ml (1 teaspoonful) 1 to 2 times daily"
        },
        "tablet": {
          "adults_and_children_over_30kg": "1 to 2 tablets 2 to 3 times daily"
        }
      },
      "contraindications": ["Hypersensitivity to any of the ingredients"],
      "side_effects": ["Generally well tolerated"],
      "drug_interactions": "Generally no interactions have been observed",
      "use_in_pregnancy_and_lactation": "Recommended",
      "preparation": ["100 ml Syrup", "200 ml Syrup", "Tablet"]
    },
    {
      "name": "Bicozin-I®",
     "img_id":"c3WVvcr.jpeg",
      "image": "BICOZIN---I-100ML.jpg",
      "active_ingredients": [
        "Iron (III) Hydroxide Polymaltose Complex INN",
        "Thiamine Hydrochloride BP",
        "Riboflavin-5-Phosphate Sodium BP",
        "Pyridoxine Hydrochloride BP",
        "Nicotinamide BP",
        "Zinc Sulphate Heptahydrate BP"
      ],
      "indications": [
        "Treatment and prevention of Iron, B-vitamins, and Zinc deficiencies"
      ],
      "dosage_and_administration": {
        "adults": "5 ml–10 ml (1–2 teaspoonful) 3 times daily or as recommended by the physician",
        "children": "5 ml (1 teaspoonful) 3 times daily or as recommended by the physician",
        "infants": "0.33 ml/kg body weight daily or as recommended by the physician"
      },
      "contraindications_and_precautions": [
        "Known hypersensitivity to any of the ingredients"
      ],
      "side_effects": [
        "Generally well tolerated",
        "Possible side effects of oral iron: nausea, vomiting, constipation, or diarrhoea"
      ],
      "use_in_pregnancy_and_lactation": "Recommended",
      "drug_interactions": [
        "No interactions observed",
        "Iron is complex bound, so interactions with food components (phytates, oxalates, tannin) and medications (tetracyclines, antacids) are unlikely"
      ],
      "preparation": ["100 ml Syrup"]
    },
    {
      "name": "Bimator™ Eye Drops",
     "img_id":"24WgKRB.jpeg",
      "image": "bimator.jpg",
      "active_ingredients": ["Bimatoprost", "Timolol"],
      "indications": [
        "Reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to monotherapy"
      ],
      "dosage_and_administration": {
        "recommended_dose": "One drop in the affected eye(s) once daily"
      },
      "contraindications_and_precautions": [
        "Known hypersensitivity to any ingredient of the formulation",
        "Systemic absorption may occur, leading to cardiovascular, pulmonary and other adverse effects as seen with systemic beta-blockers",
        "Caution in patients with severe or unstable and uncontrolled cardiovascular disease"
      ],
      "drug_interactions": [
        "Potential for bradycardia when used with oral calcium channel blockers, guanethidine, beta-blockers, parasympathomimetics, anti-arrhythmics, and digitalis glycosides",
        "Other ocular medications should be administered at least 5 minutes apart"
      ],
      "side_effects": [
        "Ocular hyperemia (reported in ~26% of patients)",
        "5-10% reported: decreased visual acuity, eye discomfort, foreign body sensation, pain, and pruritis"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Should not be used during pregnancy unless clearly necessary",
        "lactation": "Not recommended during breastfeeding due to excretion of Bimatoprost in rat’s milk and Timolol in human milk"
      },
      "preparation": ["3 ml Eye Drops in LDPE bottle"]
    },
    {
      "name": "Bisocam 2.5/5 Tablet",
     "img_id":"i501Ur9.jpeg",
      "image": "bisocam_large.jpg",
      "active_ingredients": ["Bisoprolol", "Amlodipine"],
      "indications": [
        "Treatment of hypertension as substitution therapy in patients adequately controlled with the individual products given concurrently at the same doses level as in the combination, but as separate tablets"
      ],
      "dosage_and_administration": {
        "recommended_dose": "Once daily with or without food"
      },
      "contraindications_and_precautions": [
        "Acute heart failure",
        "High grade aortic stenosis",
        "Cardiogenic shock",
        "Second or third degree AV block",
        "Sick sinus syndrome",
        "Slowed heart rate",
        "Symptomatic bradycardia",
        "Symptomatic hypotension",
        "Severe bronchial asthma",
        "Hypersensitivity to Bisoprolol, Amlodipine or any of the excipients"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Not recommended unless clearly necessary",
        "lactation": "Not known if Bisoprolol or Amlodipine is excreted in human milk"
      },
      "side_effects": ["Headache", "Drowsiness", "Dizziness", "Bradycardia"],
      "preparation": ["Bisocam 2.5/5 Tablet"]
    },
    {
      "name": "Bisocor",
     "img_id":"2yoK8f1.jpeg",
      "image": "BISOCOR-5_1.jpg",
      "active_ingredients": ["Bisoprolol Fumarate"],
      "indications": [
        "Management of hypertension",
        "Treatment of angina",
        "May be used alone or in combination with other antihypertensive agents"
      ],
      "dosage_and_administration": {
        "recommended_dose": "Start with 5 mg once daily; some patients may start with 2.5 mg",
        "adjustment": "Increase to 10 mg or 20 mg once daily if needed"
      },
      "contraindications_and_precautions": [
        "Cardiogenic shock",
        "Overt cardiac failure",
        "Second or third degree AV block",
        "Marked sinus bradycardia",
        "Use with caution in patients with renal or hepatic impairment",
        "May increase risk and severity of anaphylactic reactions",
        "Reduced responsiveness to epinephrine during allergic reactions"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Should not be used unless clearly necessary; monitor uteroplacental blood flow and fetal growth if used",
        "lactation": "Not recommended during breastfeeding due to unknown excretion in human milk"
      },
      "side_effects": [
        "Fatigue",
        "Dizziness",
        "Headache",
        "Nausea",
        "Vomiting",
        "Diarrhea",
        "Constipation",
        "Abdominal pain",
        "Cold or numb extremities",
        "Muscle weakness or cramps",
        "Bradycardia",
        "Worsening of heart failure",
        "Sleep disturbance",
        "Depression",
        "Bronchospasm (especially in asthma or COPD patients)"
      ],
      "preparation": ["2.5 mg tablet", "5 mg tablet"]
    },
    {
      "name": "Bisocor Plus",
     "img_id":"LxSOeo0.jpeg",
      "image": "BISOCOR-PLUS-2.5-6.25.jpg",
      "active_ingredients": [
        "Bisoprolol Fumarate USP 2.5 mg or 5 mg",
        "Hydrochlorothiazide BP 6.25 mg"
      ],
      "indications": ["Management of hypertension"],
      "dosage_and_administration": {
        "bisoprolol_dose_range": "2.5 to 40 mg once daily",
        "hydrochlorothiazide_dose_range": "12.5 to 50 mg",
        "combination_doses_tested": [
          "Bisoprolol 2.5 to 20 mg",
          "Hydrochlorothiazide 6.25 to 25 mg"
        ],
        "note": "Antihypertensive effect increases with increasing doses of either component"
      },
      "contraindications": [
        "Cardiogenic shock",
        "Overt cardiac failure",
        "Second or third degree AV block",
        "Marked sinus bradycardia",
        "Anuria",
        "Hypersensitivity to Bisoprolol, Hydrochlorothiazide, or other sulfonamide-derived drugs"
      ],
      "precautions": [
        "May precipitate hyperuricemia or acute gout",
        "Watch for fluid & electrolyte imbalance (symptoms: dry mouth, thirst, weakness, drowsiness, muscle cramps, hypotension, nausea, vomiting)",
        "Hypokalemia may occur",
        "Withdraw therapy gradually over 2 weeks with careful monitoring"
      ],
      "side_effects": [
        "Fatigue",
        "Dizziness",
        "Headache",
        "Bradycardia",
        "Arrhythmia",
        "Peripheral ischemia",
        "Chest pain",
        "Palpitations",
        "Cold extremities",
        "Claudication",
        "Orthostatic hypotension",
        "Diarrhea",
        "Constipation",
        "Nausea",
        "Dyspepsia",
        "Rhinitis",
        "Pharyngitis"
      ],
      "drug_interactions": [
        "Potentiates other antihypertensive agents",
        "Do not combine with other beta-blockers",
        "Use caution with catecholamine-depleting drugs (e.g., reserpine, guanethidine)",
        "Withdraw several days before stopping clonidine",
        "Use caution with myocardial depressants or AV conduction inhibitors (e.g., verapamil, diltiazem, disopyramide)",
        "Use caution with digitalis glycosides due to bradycardia risk"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Category C. Use only if potential benefit justifies risk to fetus",
        "lactation": "Not studied; use caution"
      },
      "preparation": [
        "Bisocor Plus 2.5/6.25 tablet",
        "Bisocor Plus 5/6.25 tablet"
      ]
    },
    {
      "name": "Bonizol™",
     "img_id":"v1Jwd4N.jpeg",
      "image": "Bonizol-IC_l.jpg",
      "active_ingredients": "Zoledronic Acid",
      "indications": [
        "Treatment of osteoporosis in postmenopausal women to reduce hip, vertebral and non-vertebral fractures",
        "Treatment of osteoporosis in men",
        "Treatment of Paget’s disease of bone",
        "Treatment and prevention of glucocorticoid-induced osteoporosis",
        "Prevention of clinical fractures after hip fracture"
      ],
      "dosage_and_administration": {
        "postmenopausal_osteoporosis": "5 mg intravenous infusion once a year with adequate Calcium and Vitamin D supplementation",
        "osteoporosis_in_men": "5 mg intravenous infusion once a year with adequate Calcium and Vitamin D supplementation",
        "glucocorticoid_induced_osteoporosis": "5 mg intravenous infusion once a year with adequate Calcium and Vitamin D supplementation",
        "pagets_disease_of_bone": "5 mg intravenous infusion once. Re-treatment may be considered after 12 months based on serum alkaline phosphatase and symptoms. Ensure Vitamin D and 1000 mg/day elemental Calcium for 10 days after infusion",
        "prevention_after_hip_fracture": "5 mg intravenous infusion once a year. Administer 2+ weeks after fracture repair. Prior to infusion, give 50,000–125,000 IU of Vitamin D orally or intramuscularly"
      },
      "special_dosage_instruction": {
        "renal_impairment": "Use contraindicated if creatinine clearance <35 mL/min",
        "hepatic_impairment": "No dose adjustment required",
        "elderly": "No dose adjustment required, but monitor renal function carefully"
      },
      "contraindications": [
        "Hypersensitivity to Zoledronic Acid, excipients, or any bisphosphonates",
        "Hypocalcaemia",
        "Renal impairment (creatinine clearance <35 mL/min)",
        "Current or recent uveitis or history of bisphosphonate-associated uveitis",
        "Pregnancy",
        "Lactation"
      ],
      "precautions": [
        "Ensure proper hydration before and after infusion",
        "Correct any pre-existing hypocalcaemia with adequate Calcium and Vitamin D",
        "Use with caution in elderly and patients on diuretics"
      ],
      "drug_interactions": [
        "Use caution with nephrotoxic drugs such as aminoglycosides and dehydrating diuretics"
      ],
      "side_effects": [
        "Fever",
        "Myalgia",
        "Flu-like symptoms",
        "Arthralgia",
        "Headache (most within 3 days post-infusion, usually mild to moderate)",
        "Rare severe bone, joint, or muscle pain"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Contraindicated",
        "lactation": "Contraindicated",
        "children": "Not recommended for use below 18 years of age"
      },
      "preparation": "5 mg/100 ml solution for infusion"
    },
    {
      "name": "Brofex®",
     "img_id":"0BWvXAY.jpeg",
      "image": "BROFEX-100ML.jpg",
      "active_ingredients": "Dextromethorphan",
      "indications": [
        "Chronic dry cough / unproductive cough",
        "Acute dry cough interfering with normal function or sleep"
      ],
      "dosage_and_administration": {
        "adults_and_children_over_12_years": "15 to 30 mg, 3-4 times per day",
        "children_6_to_12_years": "5 to 15 mg, up to 4 times per day",
        "children_2_to_6_years": "2.5 to 5 mg, up to 4 times per day"
      },
      "contraindications": ["Concomitant use with MAO inhibitors"],
      "precautions": [],
      "side_effects": [
        "Rare: nausea, dizziness",
        "Overdose: excitation, confusion, respiratory depression"
      ],
      "drug_interactions": [
        "Fatal interactions reported with phenelzine and dextromethorphan at therapeutic doses"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Use with caution; safety not established",
        "lactation": "Not recommended; unknown if secreted in breast milk"
      },
      "preparation": "10 mg/5 ml Syrup"
    },
    {
      "name": "Bromolac™",
     "img_id":"jSikaqu.jpeg",
      "image": "Bromolac_e.jpg",
      "active_ingredients": "Bromocriptine",
      "indications": [
        "Hyperprolactinemia-related dysfunctions (amenorrhea with or without galactorrhea, infertility, hypogonadism)",
        "Prolactin-secreting adenomas",
        "Acromegaly",
        "Parkinson’s Disease"
      ],
      "dosage_and_administration": {
        "general": "Take with food; monitor during dose escalation to find minimum effective dose",
        "hyperprolactinemia": "1.25 mg to 2.5 mg daily; increase by 2.5 mg every 2–7 days as tolerated",
        "acromegaly": "1.25–2.5 mg at bedtime with food for 3 days; increase by 1.25–2.5 mg every 3–7 days as tolerated",
        "parkinson_disease": "1.25 mg twice daily (half of a 2.5 mg tablet) with meals",
        "prolactinomas": "2.5 mg to 3.75 mg daily",
        "inhibition_of_lactation": "5 mg daily (2.5 mg twice daily with meals) for 14 days"
      },
      "contraindications_and_precautions": [
        "Use with caution in patients with renal or hepatic impairment",
        "Use with caution when taken with other antihypertensives"
      ],
      "side_effects": [
        "Nausea",
        "Headache",
        "Dizziness",
        "Fatigue",
        "Lightheadedness",
        "Vomiting",
        "Abdominal cramps",
        "Nasal congestion",
        "Constipation",
        "Diarrhea",
        "Drowsiness",
        "Mild hypotension"
      ],
      "drug_interactions": [
        "Reduced efficacy when used with dopamine antagonists (phenothiazines, haloperidol, metoclopramide, pimozide)",
        "Avoid use with other ergot alkaloids"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Category B",
        "lactation": "Not recommended for postpartum women"
      },
      "use_in_children": "Not established for children under 8 years",
      "preparation": "2.5 mg Tablet"
    },
    {
      "name": "Bufocort™",
     "img_id":"yxUxRDL.jpeg",
      "image": "Bufocort-200_l.jpg",
      "form": "Cozycap",
      "active_ingredients": ["Budesonide", "Formoterol Fumarate Dihydrate"],
      "indications": [
        "Regular treatment of asthma",
        "Symptomatic treatment of severe chronic obstructive pulmonary disease (COPD) with repeated exacerbations despite long-acting bronchodilators"
      ],
      "dosage_and_administration": {
        "asthma": {
          "approach": [
            {
              "type": "Maintenance Therapy",
              "adults_18+": {
                "Bufocort_200": "1–2 Cozycaps twice daily, max 4 Cozycaps twice daily",
                "Bufocort_400": "1 Cozycap twice daily, max 2 Cozycaps twice daily"
              },
              "adolescents_12_17": {
                "Bufocort_200": "1–2 Cozycaps twice daily",
                "Bufocort_400": "1 Cozycap twice daily"
              },
              "children_6_11": {
                "Bufocort_200": "1 Cozycap twice daily"
              }
            },
            {
              "type": "Single Maintenance & Reliever Therapy (SMART)",
              "applicable_form": "Bufocort 200 only",
              "instructions": [
                "Take daily maintenance dose",
                "Use 1 additional Cozycap as needed",
                "If symptoms persist, take another Cozycap",
                "Do not exceed 6 Cozycaps on a single occasion"
              ]
            }
          ]
        },
        "COPD": {
          "Bufocort_200": "2 Cozycaps twice daily"
        }
      },
      "contraindications_and_precautions": [
        "Contraindicated in hypersensitivity to any component",
        "Caution in cardiovascular disorders, arrhythmias, diabetes, untreated hypokalaemia, or thyrotoxicosis"
      ],
      "side_effects": [
        "Hoarseness",
        "Oral candidiasis",
        "Cardiac arrhythmias",
        "Muscle cramps",
        "Rash",
        "Oedema",
        "Angio-oedema",
        "Cutaneous hypersensitivity",
        "Tremor",
        "Palpitations",
        "Headache"
      ],
      "use_in_pregnancy_and_lactation": "Use only if expected benefit outweighs potential risk to fetus",
      "use_in_children": "Safety not established for children under 6 years",
      "preparation": ["200 Cozycap", "400 Cozycap"]
    },
    {
      "name": "Burna®",
     "img_id":"M6Jr4ks.jpeg",
      "image": "BURNA-CREAM.jpg",
      "active_ingredients": "Silver Sulfadiazine",
      "indication": "Topical prophylaxis against bacterial colonization and infection in burn wounds",
      "dosage_and_administration": "Apply once to twice daily to a thickness of approximately 1/16 inch (1.5 mm)",
      "contraindications": [
        "Hypersensitivity to Silver Sulfadiazine or any component of the preparation"
      ],
      "side_effects": [
        "Transient leukopenia",
        "Skin necrosis",
        "Erythema multiforme",
        "Skin discoloration",
        "Burning sensation",
        "Rashes",
        "Interstitial nephritis"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy_category": "B",
        "lactation": "Unknown if excreted in human milk"
      },
      "preparation": "1% Cream"
    },
    {
      "name": "Caberol™",
     "img_id":"0SNuZth.jpeg",
      "image": "Caberol.jpg",
      "active_ingredients": "Cabergoline",
      "indications": [
        "Treatment of hyperprolactinemic disorders (idiopathic or due to pituitary adenomas)",
        "Stopping breast milk production (lactation) soon after childbirth, stillbirth, abortion, or miscarriage",
        "Treatment of conditions caused by hormonal disturbances resulting in high levels of prolactin, including tumors of the pituitary gland in both men and women"
      ],
      "dosage_and_administration": {
        "initiation_of_therapy": "0.25 mg (1/2 of Caberol 0.5 mg tablet) twice a week. Dosage may be increased by 0.25 mg twice weekly up to 1 mg twice a week (increases not faster than every 4 weeks).",
        "maintenance": "After 6 months of normal serum prolactin level, Cabergoline may be discontinued.",
        "preventing_lactation": "1 mg (two 0.5 mg tablets) on the first day after delivery.",
        "stopping_lactation_after_breastfeeding": "0.25 mg (1/2 of Caberol 0.5 mg tablet) every 12 hours for two days.",
        "other_conditions": "Initially one 0.5 mg tablet (to be taken in two doses), up to a maximum dose of 4.5 mg or until full response to treatment."
      },
      "contraindications": [
        "Uncontrolled hypertension",
        "Known hypersensitivity",
        "History of cardiac valvular disorders or valve leaflet thickening",
        "High blood pressure during pregnancy with swelling and protein in urine",
        "History of pulmonary, pericardial, or retroperitoneal fibrotic disorders",
        "Serious mental diseases"
      ],
      "precautions": [
        "Initial doses higher than 1.0 mg may produce orthostatic hypotension",
        "Exercise caution with other medications known to lower blood pressure",
        "Care in patients with hypersensitivity, severe liver disease, or mental illness"
      ],
      "side_effects": [
        "Pathological gambling",
        "Increased libido",
        "Hypersexuality",
        "Generally reversible upon reduction of the dose or discontinuation"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy_category": "B",
        "lactation": "Unknown whether excreted in human milk"
      },
      "pediatric_use": "Safety and effectiveness in pediatric patients have not been established",
      "geriatric_use": "Start at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and other concurrent diseases",
      "hepatic_impairment": "Use with caution and monitor carefully in patients with hepatic impairment",
      "drug_interactions": [
        "D2-antagonists (e.g., Phenothiazines, Butyrophenones, Thioxanthenes, Metoclopramide, Chlorpromazine, Domperidone)",
        "Medications to lower blood pressure"
      ],
      "preparation": "Cabergoline 0.5 mg tablet"
    },
    {
      "name": "Calbo® 500",
     "img_id":"HVvCWfk.jpeg",
      "image": "Calbo-500-tab.jpg",
      "active_ingredients": "Calcium Carbonate",
      "indication": "The treatment or prevention of calcium depletion.",
      "dosage_and_administration": {
        "recommended_daily_dose": "500-1500 mg of calcium daily"
      },
      "side_effects": ["Constipation", "Hypercalcaemia"],
      "contraindications_and_precautions": [
        "Hypercalcaemia",
        "Hyperparathyroidism",
        "Hypercalciuria",
        "Nephrolithiasis",
        "Zollinger-Ellison syndrome",
        "Concomitant digoxin therapy (requires careful monitoring of serum calcium level)"
      ],
      "drug_interactions": [
        "Digoxin & other cardiac glycosides",
        "Tetracycline",
        "Vitamin D (primary phosphate binder)"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Calcium-containing drugs have been widely used in pregnancy by way of oral calcium supplementation or antacid therapy.",
        "lactation": "Calcium Carbonate can be used in lactating women."
      },
      "use_in_children": "Calcium Carbonate has been extensively studied in children and infants with chronic renal failure and is both safe and effective.",
      "use_in_elders": "Monitoring of serum calcium and phosphate is indicated for elderly patients.",
      "preparation": "Calcium 500 mg Tablet"
    },
    {
      "name": "Calbo-C®",
     "img_id":"5bCbQif.jpeg",
      "image": "Calbo-C.jpg",
      "active_ingredients": [
        "Calcium Lactate Gluconate",
        "Calcium Carbonate",
        "Ascorbic Acid (Vitamin-C)"
      ],
      "indication": [
        "Indicated in increased demand for Calcium & Vitamin-C, e.g. pregnancy, lactation, periods of rapid growth (childhood, adolescence), in old age",
        "During infectious disease & convalescence",
        "Treatment of calcium & vitamin C deficiency",
        "Osteoporosis",
        "Premenstrual syndrome",
        "Postmenopausal problems",
        "Adjuvant in colds & influenza"
      ],
      "dosage_and_administration": {
        "adults_and_children_of_school_age": "1 effervescent tablet daily",
        "children_3_to_7_years": "1/2 effervescent tablet daily",
        "infants": "As prescribed by the physician",
        "administration": "Dissolve one tablet in half glass (100 ml) of water"
      },
      "contraindications_and_precautions": [
        "Hypercalcemia",
        "Severe hypercalciuria",
        "Severe renal failure",
        "Patients with hyperoxalauria",
        "Glucose - 6 - phosphate dehydrogenase deficiency",
        "Iron overload",
        "Larger doses may lead to gastrointestinal tract upset",
        "For patients with mild hypercalciuria (exceeding 300 mg = 7.5 mmol/24 hours), with mild or moderate impairment of renal function or with a history of urinary concrements, monitoring of calcium excretion in the urine is required",
        "High doses of Vitamin-D & derivatives should be avoided unless especially indicated"
      ],
      "side_effects": [
        "In rare cases, bloating & diarrhea can occur",
        "Prolonged treatment with high doses may promote the formation of calculi in the urinary tract in predisposed patients"
      ],
      "drug_interactions": {
        "potentially_hazardous": [
          "Digoxin",
          "Tetracycline",
          "Frusemide",
          "Pentagastrin",
          "Aminophylline",
          "Erythromycin",
          "Nitrofurantoin",
          "Conjugated estrogens",
          "Chloramphenicol"
        ],
        "potentially_useful": ["Vitamin-D", "Oxytocin", "Prostaglandins"],
        "note": "Vitamin-C enhances iron absorption"
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Calcium-containing drugs have been widely used in pregnancy by way of oral calcium supplementation or antacid therapy",
        "lactation": "Calcium Carbonate can be safely used in lactating women. Vitamin-C may be taken safely during pregnancy & lactation"
      },
      "preparation": "Effervescent Tablet"
    },
    {
      "name": "Calbo-D®",
     "img_id":"Sk31Eq3.jpeg",
      "image": "Calbo-D.jpg",
      "active_ingredients": ["Calcium", "Vitamin-D"],
      "indication": [
        "Treatment of osteoporosis",
        "Osteomalacia",
        "Rickets",
        "Tetany",
        "Parathyroid disease",
        "Routine supplement & phosphate binder in chronic renal failure"
      ],
      "dosage_and_administration": {
        "adults_elderly_children": "1 tablet in the morning & 1 tablet at night"
      },
      "contraindications_and_precautions": [
        "Hypercalcemia & hyperparathyroidism",
        "Hypercalciuria & nephrolithiasis",
        "Hypersensitivity to the component of this preparation",
        "Severe renal insufficiency"
      ],
      "drug_interactions": [
        "Digoxin",
        "Antacids containing calcium, aluminum or magnesium",
        "Other calcium supplements",
        "Calcitriol or other Vitamin-D supplements",
        "Tetracycline",
        "Doxycycline",
        "Aminocycline",
        "Oxytetracycline"
      ],
      "side_effects": [
        "Allergic reactions",
        "Irregular heartbeats",
        "Nausea",
        "Vomiting",
        "Decreased appetite",
        "Dry mouth",
        "Drowsiness"
      ],
      "use_in_pregnancy_and_lactation": "Should be used as directed by the physician during pregnancy & lactation",
      "preparation": "Calcium 500 mg + Vitamin-D 200 I.U. / Tablet"
    },
    {
      "name": "Calbo-D® Vita",
     "img_id":"yfPAzNQ.jpeg",
      "image": "Calbo-D-VITA_l.jpg",
      "active_ingredients": ["Calcium", "Vitamin-D"],
      "indication": [
        "Prevention & treatment of calcium & vitamin D deficiency",
        "Calcium & vitamin D supplement as an adjunct to specific therapy in the prevention & treatment of osteoporosis for patients at risk of calcium & vitamin D deficiency"
      ],
      "dosage_and_administration": {
        "adults_adolescents": "1-2 tablets daily",
        "children": "1 tablet daily"
      },
      "contraindications_and_precautions": [
        "Hypercalcemia & hyperparathyroidism",
        "Hypercalciuria & nephrolithiasis",
        "Hypersensitivity to the component of this preparation",
        "Severe renal insufficiency"
      ],
      "drug_interactions": [
        "Digoxin",
        "Antacids containing Calcium, Aluminum or Magnesium",
        "Other Calcium supplements",
        "Calcitriol",
        "Tetracycline",
        "Doxycycline",
        "Aminocycline",
        "Oxytetracycline"
      ],
      "side_effects": [
        "GI tract irritation",
        "Constipation",
        "Hypercalcemia (rare, especially in patients with chronic renal failure)",
        "Allergic reactions",
        "Irregular heartbeats",
        "Nausea",
        "Vomiting",
        "Decreased appetite",
        "Dry mouth",
        "Drowsiness",
        "Skin rash"
      ],
      "use_in_pregnancy_and_lactation": "Calbo-D® Vita effervescent tablets can be used during pregnancy for calcium & vitamin D deficiency. For supplementation starting during the third trimester, daily intake should not exceed 1500 mg calcium & 1000 IU vitamin D. It can also be used during breastfeeding.",
      "preparation": "Calcium 600 mg + Vitamin-D 400 I.U. / Tablet"
    },
    {
      "name": "Calbo® Forte",
     "img_id":"M88b6YG.jpeg",
      "image": "calbo-forte-1000-mg-tablet.jpg",
      "active_ingredients": [
        "Calcium Lactate Gluconate",
        "Calcium Carbonate",
        "Ascorbic Acid (Vitamin-C)",
        "Vitamin-D"
      ],
      "indication": [
        "Adjunct to specific therapy for osteoporosis",
        "Increased demand for Calcium, Vitamin-C & Vitamin-D (e.g., pregnancy, lactation, rapid growth periods, old age)",
        "During infectious disease & convalescence",
        "Treatment of calcium, vitamin-C & vitamin-D deficiency",
        "Osteoporosis",
        "Premenstrual syndrome",
        "Postmenopausal problems",
        "Adjuvant in colds & influenza"
      ],
      "dosage_and_administration": {
        "adults_children_of_school_age": "1 effervescent tablet daily",
        "children_3_to_7_years": "½ effervescent tablet daily",
        "infants": "As prescribed by the physician",
        "administration_method": "Dissolve one tablet in half glass (100 ml) of water"
      },
      "contraindications_and_precautions": [
        "Hypercalcemia",
        "Severe hypercalciuria",
        "Severe renal failure",
        "Patients with hyperoxalauria",
        "Glucose-6-phosphate dehydrogenase deficiency",
        "Iron overload",
        "Larger doses may cause gastrointestinal upset, bone metastasis, sarcoidosis, primary hyperparathyroidism, vitamin-D overdosage",
        "Patients with mild hypercalciuria or mild/moderate renal impairment should monitor calcium excretion in urine",
        "Use caution in patients with severely impaired renal function receiving aluminium-containing preparations"
      ],
      "side_effects": [
        "Mild gastrointestinal disturbances (bloating, diarrhea) in rare cases",
        "Prolonged high-dose use may promote urinary tract calculi formation",
        "Occasional skin rash after vitamin-D supplements",
        "Hypercalciuria and rare hypocalcaemia in long-term high-dose vitamin-D treatment"
      ],
      "use_in_pregnancy_and_lactation": "Treatment with Calbo Forte during pregnancy & lactation should always be under a physician’s guidance. Calcium & vitamin-D requirements are increased, but supplementation should consider the availability of these agents from other sources.",
      "preparation": "Each effervescent tablet contains Calcium Lactate Gluconate 1000 mg, Calcium Carbonate BP 327 mg, Ascorbic Acid (Vitamin-C) BP 500 mg, Vitamin-D BP 400 I.U."
    },
    {
      "name": "Calbo® Jr",
     "img_id":"dUxEnho.jpeg",
      "image": "Calbo-Jr_l.jpg",
      "active_ingredients": ["Calcium Carbonate"],
      "indication": [
        "Raised calcium requirement for children & adolescents during rapid growth",
        "Inadequate intake of calcium due to malnutrition",
        "Prevention & treatment of osteoporosis",
        "Disorders of osteogenesis & tooth formation (in addition to specific treatment)",
        "Latent tetany",
        "During pregnancy & lactation"
      ],
      "dosage_and_administration": {
        "children": "1 tablet daily",
        "adolescents": "1-2 tablets daily",
        "adults": "2 tablets daily or as directed by the physician"
      },
      "contraindications_and_precautions": [
        "Hypercalcemia & hyperparathyroidism",
        "Hypercalciuria & nephrolithiasis",
        "Hypersensitivity to any component of this product",
        "Severe renal insufficiency",
        "Concomitant digoxin therapy (requires careful monitoring of serum calcium levels)",
        "Use cautiously in patients with sarcoidosis, renal or cardiac disease, & those receiving cardiac glycosides",
        "Patients with a history of stone formation should increase fluid intake",
        "High doses of Vitamin D should be avoided during calcium therapy unless specifically indicated"
      ],
      "side_effects": ["Constipation", "Hypercalcemia"],
      "drug_interaction": [
        "Tetracycline",
        "Fluoride preparations",
        "Vitamin D",
        "Verapamil",
        "Certain foods (e.g., spinach, bran, milk & milk products) may reduce intestinal calcium uptake"
      ],
      "use_in_pregnancy_and_lactation": "Calcium-containing drugs have been widely used in pregnancy. Calcium Carbonate can be safely used in lactating women.",
      "preparation": "Calcium 250 mg Chewable Tablet"
    },
    {
      "name": "Calboral-D™",
     "img_id":"dOWHNjw.png",
      "image": "Calboral-D.png",
      "active_ingredients": [
        "Calcium Carbonate USP (from coral source)",
        "Vitamin-D USP"
      ],
      "indication": [
        "Osteoporosis",
        "Osteomalacia",
        "Rickets",
        "Tetany",
        "Parathyroid disease"
      ],
      "dosage_and_administration": {
        "adults": "One tablet in the morning & one tablet at night"
      },
      "contraindications": [
        "Hypercalcemia & hyperparathyroidism",
        "Hypercalciuria & nephrolithiasis",
        "Hypersensitivity to any component of this preparation",
        "Severe renal insufficiency",
        "Concomitant digoxin therapy (requires careful monitoring of serum calcium levels)"
      ],
      "side_effects": [
        "Irritation to the GI tract",
        "Constipation",
        "Hypercalcemia (rare, may occur with large doses in chronic renal failure)",
        "Allergic reactions",
        "Irregular heartbeats",
        "Nausea",
        "Vomiting",
        "Decreased appetite",
        "Dry mouth",
        "Drowsiness",
        "Skin rash (following vitamin-D supplementation)"
      ],
      "precautions_and_warnings": [
        "Discontinuation of the drug is usually sufficient to return serum calcium concentrations to normal when hypercalcemia occurs",
        "Calcium salts should be used cautiously in patients with sarcoidosis, renal or cardiac disease, and in patients receiving cardiac glycosides",
        "Patients with a history of stone formation should increase fluid intake"
      ],
      "drug_interaction": [
        "Digoxin",
        "Antacids containing Calcium, Aluminum or Magnesium",
        "Other Calcium supplements",
        "Calcitriol",
        "Tetracycline",
        "Doxycycline",
        "Aminocycline",
        "Oxytetracycline"
      ],
      "use_in_pregnancy_and_lactation": "It should be used as directed by the physician during Pregnancy & Lactation.",
      "preparation": "500 mg (from coral source) & 200 IU Tablet"
    },
    {
      "name": "Calboral™ -DX",
     "img_id":"NfhOqtD.jpeg",
      "image": "Calboral-DX_l.jpg",
      "active_ingredients": [
        "Calcium Carbonate USP 1500 mg (from Coral source) equivalent to 600 mg of elemental Calcium",
        "Vitamin D USP 400 IU"
      ],
      "indication": [
        "Osteoporosis",
        "Osteomalacia",
        "Rickets",
        "Tetany",
        "Parathyroid disease"
      ],
      "dosage_and_administration": {
        "adults": "One tablet in the morning and one tablet at night or as directed by the Physician."
      },
      "contraindications": [
        "Hypercalcemia and hyperparathyroidism",
        "Hypercalciuria and nephrolithiasis",
        "Hypersensitivity to any component of this preparation",
        "Severe renal insufficiency",
        "Concomitant digoxin therapy (requires careful monitoring of serum calcium levels)"
      ],
      "side_effects": [
        "Irritation to the GI tract",
        "Constipation",
        "Hypercalcemia (rare, may occur with large doses in chronic renal failure)",
        "Allergic reactions",
        "Irregular heartbeats",
        "Nausea",
        "Vomiting",
        "Decreased appetite",
        "Dry mouth",
        "Drowsiness",
        "Skin rash (following vitamin D supplementation)"
      ],
      "precautions_and_warnings": [
        "Discontinuation of the drug is usually sufficient to return serum calcium concentrations to normal when hypercalcemia occurs",
        "Patients with a history of stone formation should increase fluid intake"
      ],
      "drug_interaction": [
        "Digoxin",
        "Antacids containing Calcium, Aluminum or Magnesium",
        "Other Calcium supplements",
        "Calcitriol",
        "Tetracycline",
        "Doxycycline",
        "Aminocycline",
        "Oxytetracycline"
      ],
      "overdose_symptoms": [
        "Nausea and vomiting",
        "Severe drowsiness",
        "Dry mouth",
        "Loss of appetite",
        "Metallic taste",
        "Stomach cramps",
        "Unconsciousness",
        "Diarrhea",
        "Weakness",
        "Headache",
        "Constipation",
        "Dizziness",
        "Irritability"
      ],
      "preparation": "600 mg of elemental Calcium and Vitamin D USP 400 IU"
    },
    {
      "name": "Calboplex®",
     "img_id":"uiZDKmX.jpeg",
      "image": "calboplex_1_l.jpg",
      "active_ingredients": ["Calcium", "Vitamin-D", "Multiminerals"],
      "indication": [
        "Helps maintain strong bones and teeth",
        "Supports the health of the heart, muscles, and nerves",
        "Indicated for bone development and constant regeneration of bone",
        "Prevention and treatment of osteoporosis"
      ],
      "dosage_and_administration": {
        "adults": "1 tablet twice daily, preferably 1 tablet in the morning and 1 tablet in the evening or as directed by the physician. Best taken with or just after main meals with a full glass of water."
      },
      "contraindications_and_precautions": [
        "Hypercalcemia and hyperparathyroidism",
        "Hypercalciuria and nephrolithiasis",
        "Hypersensitivity to any component of this preparation",
        "Severe renal insufficiency"
      ],
      "drug_interaction": [
        "Digoxin",
        "Antacids containing calcium, aluminum, or magnesium",
        "Other calcium supplements",
        "Calcitriol or other Vitamin-D supplements",
        "Tetracycline",
        "Doxycycline",
        "Aminocycline",
        "Oxytetracycline"
      ],
      "side_effects": [
        "GI tract irritation",
        "Constipation",
        "Hypercalcemia (rare, may occur with large doses in chronic renal failure)"
      ],
      "use_in_pregnancy_and_lactation": "Should be used as directed by the physician during pregnancy and lactation.",
      "preparation": "Calcium 600 mg, Vitamin-D 200 IU, and Multimineral Tablet"
    },
    {
      "name": "Calcitrol®",
     "img_id":"3OpYZ6E.jpeg",
      "image": "CALCITROL.jpg",
      "active_ingredients": "Calcitriol",
      "indication": [
        "Treatment of established osteoporosis",
        "Increases spine density & total body calcium",
        "Significantly increases BMD",
        "Reduces the rate of new vertebral fractures in women with post-menopausal osteoporosis",
        "Restores bone metabolism in patients with predialysis chronic renal failure",
        "Treatment of hypoparathyroidism & rickets"
      ],
      "dosage_and_administration": {
        "postmenopausal_osteoporosis": "0.25 mcg twice daily. Serum calcium & creatinine levels should be determined at 4 weeks, 3 & 6 months, and at 6 monthly intervals thereafter.",
        "renal_osteodystrophy": "0.25 mcg daily or 0.25 mcg every other day depending on serum calcium levels.",
        "hypoparathyroidism_rickets": "0.25 mcg per day in the morning. Dose may be increased if no satisfactory response is observed within 2-4 weeks."
      },
      "contraindications_and_precautions": [
        "Hypersensitivity to any of its ingredients",
        "Diseases associated with hypercalcemia",
        "Dosage should be reduced or stopped if serum calcium rises to 1 mg/100 ml above normal or serum creatinine rises above 120 micromole/L"
      ],
      "side_effects": [
        "Occasional acute symptoms: anorexia, headache, vomiting, constipation",
        "Chronic effects: dystrophy, fever with thirst"
      ],
      "drug_interaction": [
        "Uncontrolled intake of additional calcium-containing preparations",
        "Concomitant treatment with thiazide diuretics increases the risk of hypercalcemia",
        "Treatment with digitalis may precipitate cardiac arrhythmias in hypercalcemia",
        "Magnesium-containing drugs (e.g., antacids) may cause hypermagnesemia",
        "Phosphate binding agents dosage must be adjusted according to serum phosphate concentration"
      ],
      "use_in_pregnancy_and_lactation": "Calcitrol should be used during pregnancy only if the benefits outweigh the potential risks. Mothers may breastfeed while taking Calcitrol but serum calcium levels of both mother and infant should be monitored.",
      "preparation": "0.25 mcg Licap"
    },
    {
      "name": "Caloprid™",
     "img_id":"ZKzhVfu.jpeg",
      "image": "Caloprid-PIC_l.jpg",
      "active_ingredients": "Prucalopride Succinate equivalent to Prucalopride 1 mg",
      "indication": [
        "Symptomatic treatment of chronic constipation in adults when laxatives fail to provide adequate relief"
      ],
      "dosage_and_administration": {
        "chronic_constipation_adults": "2 mg once daily with or without food, at any time of the day. Exceeding 2 mg is not expected to increase efficacy.",
        "older_people": "Start with 1 mg once daily; if needed, increase to 2 mg once daily.",
        "children": "Not recommended for children and adolescents under 18 years.",
        "renal_impairment": "1 mg once daily for patients with severe renal impairment (GFR < 30 ml/min/1.73 m2). No dose adjustment for mild to moderate renal impairment.",
        "hepatic_impairment": "Start with 1 mg once daily for patients with severe hepatic impairment (Child-Pugh class C), may increase to 2 mg if necessary. No dose adjustment for mild to moderate hepatic impairment."
      },
      "contraindications": [
        "Hypersensitivity to prucalopride or any of its excipients",
        "Renal impairment requiring dialysis"
      ],
      "warnings": [
        "Renal excretion is the main route of elimination. A dose of 1 mg is recommended for severe renal impairment.",
        "Caution in prescribing for patients with severe hepatic impairment (Child-Pugh class C) due to limited data.",
        "In case of severe diarrhea, the efficacy of oral contraceptives may be reduced. An additional contraceptive method is recommended.",
        "Contains lactose. Should not be taken by patients with rare hereditary problems of galactose intolerance, lactase deficiency, or glucose-galactose malabsorption."
      ],
      "adverse_reactions": [
        "Headache (17.8%)",
        "Gastrointestinal symptoms: abdominal pain, nausea, and diarrhea",
        "Most adverse reactions occur predominantly at the start of therapy and usually disappear within a few days."
      ],
      "drug_interaction": [
        "Low interaction potential with co-medicated medicinal products",
        "Ketoconazole (200 mg b.i.d.) increases systemic exposure to prucalopride by approximately 40%, which is not clinically relevant.",
        "No clinically relevant effects on the pharmacokinetics of warfarin, digoxin, alcohol, paroxetine, or oral contraceptives."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Not recommended during pregnancy. Women of childbearing potential should use effective contraception during treatment.",
        "lactation": "Not recommended during breastfeeding due to lack of human data."
      },
      "overdosage": {
        "symptoms": "Headache, nausea, diarrhea",
        "treatment": "Symptomatic treatment with supportive measures. Electrolyte disturbances may require correction due to fluid loss from diarrhea or vomiting."
      },
      "preparation": ["1 mg Tablet", "2 mg Tablet"]
    },
    {
      "name": "Camlodin®",
     "img_id":"lbAoKNI.png",
      "image": "camlodin_large.png",
      "active_ingredients": "Amlodipine",
      "indication": ["Hypertension", "Stable angina", "Vasospastic angina"],
      "dosage_and_administration": "5-10 mg once daily.",
      "contraindications_and_precaution": ["Known hypersensitivity"],
      "side_effects": [
        "Headache",
        "Oedema",
        "Fatigue",
        "Nausea",
        "Flushing",
        "Dizziness",
        "Gum hyperplasia",
        "Erythema multiforme"
      ],
      "drug_interaction": ["Digoxin", "Warfarin", "Cimetidine"],
      "use_in_pregnancy_and_lactation": "Not recommended.",
      "preparation": "5 mg Tablet"
    },
    {
      "name": "Camlodin® Plus",
     "img_id":"AuUAvmx.jpeg",
      "image": "CAMLODIN-PIUS-25.jpg",
      "active_ingredients": ["Amlodipine", "Atenolol"],
      "indication": [
        "Hypertension not controlled by monotherapy",
        "Patients with angina pectoris & hypertension as co-existing diseases",
        "Post MI",
        "Refractory angina pectoris where nitrate therapy has failed"
      ],
      "dosage_and_administration": "Initiated with a single dose of Amlodipine 5 mg + Atenolol 50 mg. Depending upon the therapeutic response, titration of the dosage is recommended. In elderly patients, it is advisable to initiate the therapy with Amlodipine 5 mg + Atenolol 25 mg tablet.",
      "contraindications_and_precaution": [
        "Hypersensitivity to any of the components",
        "Bronchospasm: The combination should be used with caution in patients with airway obstruction",
        "Renal Impairment: Caution may be necessary if the creatinine clearance is less than 30 ml/min",
        "Hepatic impairment: Caution may be necessary in the use of the combination in patients with severe liver damage",
        "Drug withdrawal: Any discontinuation should be gradual & under observation"
      ],
      "drug_interaction": [
        "Disopyramide",
        "Ampicillin",
        "Oral antidiabetics & insulin"
      ],
      "side_effects": [
        "Fatigue",
        "Headache",
        "Edema",
        "Nausea",
        "Drowsiness",
        "Anxiety",
        "Depression"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "The combination should be used during pregnancy only if the expected benefit outweighs the potential fetal risk",
        "lactation": "Nursing mothers should not use the combination. If its use is considered necessary, breast feeding should be stopped."
      },
      "preparation": [
        "Amlodipine 5 mg + Atenolol 50 mg Tablet",
        "Amlodipine 5 mg + Atenolol 25 mg Tablet"
      ]
    },
    {
      "name": "CamlosartTM",
     "img_id":"gNMxpiv.png",
      "image": "Camlosart-01_large.png",
      "active_ingredients": ["Amlodipine", "Olmesartan"],
      "indication": [
        "Hypertension, alone or with other antihypertensive agents",
        "It can be used as initial therapy"
      ],
      "dosage_and_administration": "One tablet (5/20 mg) once daily. Maximum dose two tablets (10/40 mg) once daily. May be taken with or without food.",
      "contraindications_and_precaution": [
        "Hypersensitivity to any of the components of this combination product",
        "When pregnancy is detected, this combination drug should be discontinued as soon as possible",
        "Symptomatic hypotension may occur after initiation of therapy",
        "Exercise caution when administering this combination, particularly in patients with severe aortic stenosis",
        "Patients may develop increased frequency, duration or severity of angina or acute MI on starting calcium channel blocker therapy or at the time of dosage increase",
        "Patients with Congestive Heart Failure: Calcium channel blocker should be used with caution in patients with impaired renal function/hepatic impairment/congestive heart failure"
      ],
      "side_effects": [
        "Edema",
        "Dizziness",
        "Flushing",
        "Palpitation",
        "Vomiting",
        "Diarrhoea",
        "Rhabdomyolysis",
        "Alopecia",
        "Pruritus",
        "Urticaria"
      ],
      "drug_interaction": "No significant drug interactions have been observed when used individually or in combination.",
      "use_in_pregnancy_and_lactation": "Not recommended.",
      "use_in_children": "Safety & effectiveness have not been established.",
      "preparation": [
        "Amlodipine 5 mg + Olmesartan 20 mg Tablet",
        "Amlodipine 5 mg + Olmesartan 40 mg Tablet"
      ]
    },
    {
      "name": "CanaglifTM",
     "img_id":"2QMcwS6.jpeg",
      "image": "Canaglif.jpg",
      "active_ingredients": "Canagliflozin",
      "indication": "Canaglif is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.",
      "dosage_and_administration": "The recommended starting dose of CanaglifTM is 100 mg once daily, taken before the first meal of the day. Dose can be increased to 300 mg once daily in patients tolerating CanaglifTM 100 mg once daily who have an eGFR of 60 mL/min/1.73 m2 or greater and require additional glycemic control. If the eGFR of patients is 45 to 60 mL/min/1.73 m2, the dose of CanaglifTM should be 100 mg once daily.",
      "side_effects": [
        "Dehydration",
        "Vaginal yeast infection",
        "Yeast infection of the penis (balanitis or balanoposthitis)"
      ],
      "adverse_reactions": [
        "Hypotension",
        "Impairment in Renal Function",
        "Hyperkalemia",
        "Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues",
        "Genital Mycotic Infections",
        "Hypersensitivity Reactions",
        "Increases in Low-Density Lipoprotein (LDL-C)"
      ],
      "precautions": [
        "Hypotension: Before initiating Canagliflozin, assess volume status and correct hypovolemia in patients with renal impairment, the elderly, in patients with low systolic blood pressure, or if on diuretics, ACEi, or ARB. Monitor for signs and symptoms during therapy.",
        "Impairment in Renal Function: Monitor renal function during therapy. More frequent monitoring is recommended in patients with eGFR below 60 mL/min/1.73 m2. Do not initiate Canagliflozin if eGFR is below 45 mL/min/1.73 m2.",
        "Hyperkalemia: Monitor potassium levels in patients with impaired renal function and in patients predisposed to hyperkalemia.",
        "Hypoglycemia: Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with Canagliflozin."
      ],
      "contraindication": [
        "History of a serious hypersensitivity reaction to Canagliflozin",
        "Severe renal impairment (eGFR less than 30 mL/min/1.73 m2)",
        "End stage renal disease or patients on dialysis"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Pregnancy Category C.",
        "nursing_mothers": "It is not known if Canagliflozin passes into breast milk. Discontinue drug or nursing."
      },
      "preparation": "100 mg Tablet"
    },
    {
      "name": "Candex®",
     "img_id":"Ugs61Be.jpeg",
      "image": "candex.jpg",
      "active_ingredients": "Nystatin",
      "indication": "Oropharyngeal & Esophageal Candidiasis.",
      "dosage_and_administration": {
        "children": {
          "intestinal_and_oral_candidiasis": "1,00,000 units (1 ml) should be dropped into the mouth four times daily. The longer the suspension is kept in contact with the affected area in the mouth, before swallowing, the greater will be its effect.",
          "prophylaxis_in_newborn": "1,00,000 units (1 ml) once daily or as prescribed by the physician."
        },
        "adult": {
          "intestinal_or_esophageal_candidiasis": "5,00,000 units (5 ml) by mouth 3 or 4 times daily. The dose may be doubled, if required.",
          "prophylaxis_of_intestinal_candidiasis": "10,00,000 units (10 ml) daily.",
          "prophylaxis_to_suppress_candida_albicans": "10,00,000 units (10 ml) daily.",
          "treatment_of_dental_sores_or_oral_infection": "1,00,000 units (1 ml) suspension should be dropped into the mouth four times daily.",
          "older_people_with_intestinal_candidiasis": "5,00,000 units (5 ml) suspension four times daily if unable to swallow tablets."
        }
      },
      "contraindication_and_precaution": "Hypersensitivity.",
      "side_effects": [
        "Oral irritation or sensitization",
        "Nausea",
        "Diarrhoea",
        "Gastrointestinal distress",
        "Nausea & vomiting",
        "Rash, including urticaria (rare)"
      ],
      "drug_interaction": "Not known.",
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Nystatin should be prescribed during pregnancy only if the potential benefits to be derived outweigh the possible risks involved.",
        "nursing_mothers": "Caution should be exercised when Nystatin is prescribed for nursing women."
      },
      "preparation": "1 lac unit/1 ml Suspension"
    },
    {
      "name": "Carbizol®",
     "img_id":"WeuqZoh.jpeg",
      "image": "Carbizol-10-Tablet.jpg",
      "active_ingredients": "Carbimazole",
      "indication": "Management of hyperthyroidism, thyrotoxicosis (including thyroid storm), & also for the preparation of patients for thyroidectomy. It can also be used in combination with radioactive ablative therapy.",
      "dosage_and_administration": {
        "adults": {
          "initial_dose": "20 - 60 mg, in 2-3 divided doses until the patient is euthyroid. Daily dosage should be divided.",
          "maintenance_regimen": "Dose is gradually reduced to maintain a euthyroid state. Final dosage is usually in the range of 5 - 15 mg/day which may be taken as a single daily dose."
        },
        "neonates_and_children_below_12_years": {
          "initial_dose": "250 mcg /Kg/day in divided doses."
        },
        "duration_of_treatment": "18 to 24 months"
      },
      "contraindication_and_precaution": "Patients with known hypersensitivity to Carbimazole or other thiourea antithyroid agents.",
      "pregnancy_and_lactation": {
        "pregnancy": "Recommended but the smallest effective dose should be used. Least overdosage adversely affects the foetus.",
        "lactation": "Recommended."
      },
      "use_in_children": "Recommended.",
      "drug_interaction": "Iodine or iodine excess may decrease the response to Carbimazole.",
      "side_effects": [
        "Rash",
        "Pruritis",
        "Skin pigmentation",
        "Paraesthesias",
        "Urticaria",
        "Headache",
        "Arthralgia",
        "Gastro-intestinal disturbances"
      ],
      "preparation": "5 mg Tablet"
    },
    {
      "name": "Carva®",
     "img_id":"R7yaj4P.jpeg",
      "image": "CARVA-75.jpg",
      "active_ingredients": "Aspirin",
      "indication": "Antithrombotic action, mediated through inhibition of platelet activation, secondary prophylaxis following myocardial infarction & unstable angina or cerebral transient ischemic attacks.",
      "dosage_and_administration": {
        "initial_dose": "150 mg at diagnosis",
        "maintenance_dose": "75 mg daily thereafter"
      },
      "contraindication": [
        "Hypersensitivity to aspirin",
        "Hypoprothrombinaemia",
        "Haemophilia",
        "Peptic ulceration",
        "Asthma"
      ],
      "side_effects": [
        "Hypersensitivity",
        "Asthma",
        "Urate kidney stones",
        "Chronic gastro-intestinal blood loss",
        "Tinnitus",
        "Nausea",
        "Vomiting"
      ],
      "drug_interaction": [
        "Oral anticoagulants",
        "Oral hypoglycemic",
        "Phenytoin",
        "Probenecid",
        "Sulphonamides"
      ],
      "pregnancy_and_lactation": {
        "pregnancy": "Aspirin should be avoided during the last 3 months of pregnancy.",
        "lactation": "It should not be used by patients who are breast feeding."
      },
      "preparation": "75 mg Tablet"
    },
    {
      "name": "CavirTM",
     "img_id":"D4Bvp8v.jpeg",
      "image": "Cavir-0.5_l.jpg",
      "active_ingredients": ["Entecavir 0.5 mg", "Entecavir 1 mg"],
      "indication": "Chronic hepatitis B virus infection in adults with evidence of active viral replication & either evidence of persistent elevations in serum Aminotransferase (ALT or AST) or histologically active disease.",
      "dosage_and_administration": {
        "general_adults": {
          "nucleoside_treatment_naive": "0.5 mg once daily",
          "lamivudine_refractory": "1 mg once daily"
        },
        "pediatric_patients": {
          "nucleoside_inhibitor_treatment_naive_and_lamivudine_experienced": "Dosing is based on weight, for patients at least 2 years of age and weighing at least 10 kg.",
          "decompensated_liver_disease": "1 mg once daily"
        },
        "renal_impairment": {
          "creatinine_clearance_50": "0.5 mg every 24 hrs",
          "creatinine_clearance_30_to_50": "0.5 mg every 48 hrs",
          "creatinine_clearance_10_to_30": "0.5 mg every 72 hrs",
          "creatinine_clearance_less_than_10_hemodialysis_or_capd": "0.5 mg every 7 days"
        },
        "administration": "Cavir should be administered on an empty stomach (at least 2 hours after a meal or 2 hours before the next meal)."
      },
      "contraindication": [
        "Known hypersensitivity to Entecavir or any component of the product",
        "Lactic acidosis",
        "Severe hepatomegaly with steatosis",
        "Exacerbations of hepatitis B after discontinuation of treatment"
      ],
      "side_effects": ["Headache", "Fatigue", "Dizziness", "Nausea"],
      "drug_interaction": [
        "Coadministration with drugs that reduce renal function or compete for active tubular secretion may increase serum concentration of either Entecavir or the coadministered drug.",
        "Coadministration with Lamivudine, Adefovir Dipivoxil, or Tenofovir Disoproxil Fumatare did not result in significant drug interactions."
      ],
      "pregnancy_and_lactation": {
        "pregnancy": "USFDA pregnancy category C. There are no data on the effect of Entecavir on transmission of HBV from mother to infant. Appropriate care should be taken.",
        "lactation": "It is not known whether Entecavir is excreted in human milk. Mothers should be instructed not to breastfeed if they are taking Entecavir."
      },
      "use_in_children": "Safety & effectiveness of Entecavir in pediatric patients below the age of 2 years have not been established.",
      "preparation": ["0.5 mg Tablet", "1 mg Tablet"]
    },
    {
      "name": "Ceevit®",
     "img_id":"W32Vc1w.jpeg",
      "image": "Ceevit.jpg",
      "active_ingredients": ["Ascorbic acid", "Sodium Ascorbate"],
      "indication": [
        "Scurvy",
        "Pregnancy",
        "Lactation",
        "Infection",
        "Trauma",
        "Burns",
        "Cold exposure",
        "Following surgery",
        "Fever",
        "Stress",
        "Peptic ulcer",
        "Cancer",
        "Methaemoglobinaemia",
        "Haematuria",
        "Dental caries",
        "Pyorrhea",
        "Acne",
        "Infertility",
        "Atherosclerosis",
        "Fractures",
        "Leg ulcers",
        "Hay fever",
        "Vascular thrombosis prevention",
        "Levodopa toxicity",
        "Succinyl-choline toxicity",
        "Arsenic toxicity"
      ],
      "dosage_and_administration": "1-2 tablets daily.",
      "contraindication_and_precaution": "There is no serious contraindication to the administration of Vitamin C.",
      "side_effects": ["Diarrhoea", "Hyperoxaluria"],
      "drug_interaction": [
        "Ascorbic acid increases the apparent half-life of paracetamol",
        "Enhances iron absorption from the gastrointestinal tract."
      ],
      "pregnancy_and_lactation": {
        "pregnancy": "The drug is safe in normal doses in pregnant women, but a daily intake of 5 gm or more is reported to have caused abortion.",
        "lactation": "The drug may be taken safely during lactation."
      },
      "preparation": "250 mg Tablet"
    },
    {
      "name": "Ceevit® DS",
     "img_id":"n3zyZe5.jpeg",
      "image": "ceevit_ds_l.jpg",
      "active_ingredients": ["Ascorbic acid", "Sodium Ascorbate"],
      "indication": [
        "Prevention and treatment of scurvy",
        "Pregnancy",
        "Lactation",
        "Infection",
        "Trauma",
        "Burns",
        "Cold exposure",
        "Following surgery",
        "Fever",
        "Stress",
        "Peptic ulcer",
        "Cancer",
        "Methaemoglobinaemia",
        "Infants receiving unfortified formulas",
        "Haematuria",
        "Dental caries",
        "Pyorrhea",
        "Acne",
        "Infertility",
        "Atherosclerosis",
        "Fractures",
        "Leg ulcers",
        "Hay fever",
        "Vascular thrombosis prevention",
        "Levodopa toxicity",
        "Succinyl-choline toxicity",
        "Arsenic toxicity",
        "Reduction of risk of stroke in the elderly"
      ],
      "dosage_and_administration": {
        "scurvy": "1-2 tablets daily, but dose may be increased depending on severity.",
        "stroke_risk_in_elderly": "1-2 tablets daily.",
        "other_cases": "1 tablet daily or as directed by the physician.",
        "maximum_safe_dose": "2000 mg daily in divided doses."
      },
      "contraindication_and_precaution": "Ingestion of megadose (more than 1000 mg daily) of vitamin C during pregnancy has resulted in scurvy in neonates.",
      "side_effects": [
        "Diarrhoea",
        "Abdominal bloating",
        "Iron over-absorption"
      ],
      "drug_interaction": [
        "Ascorbic acid is incompatible in solution with aminophylline",
        "Bleomycin",
        "Erythromycin",
        "Lactobionate",
        "Nafcillin",
        "Nitrofurantoin sodium",
        "Conjugated oestrogen",
        "Sodium bicarbonate",
        "Sulphafurazole diethanolamine",
        "Chloramphenicol sodium succinate",
        "Chlorthiazide sodium",
        "Hydrocortisone"
      ],
      "pregnancy_and_lactation": {
        "pregnancy": "The drug is safe in normal doses in pregnant women, but a daily intake of 5 gm or more is reported to have caused abortion.",
        "lactation": "The drug may be taken safely during lactation."
      },
      "preparation": "500 mg tablet"
    },
    {
      "name": "Ceevit® Forte",
     "img_id":"RFhYtG7.jpeg",
      "image": "ceevit-forte-1000-mg.jpg",
      "active_ingredients": "Vitamin C (Ascorbic acid)",
      "indication": [
        "Treatment or prevention of Vitamin C Deficiency",
        "Scurvy",
        "Infection",
        "Trauma",
        "Burns",
        "Cold exposure",
        "Following Surgery",
        "Fever",
        "Stress",
        "Cancer",
        "Methaemoglobinaemia",
        "Children receiving unfortified formulas",
        "Hematuria",
        "Dental Caries",
        "Gum Diseases",
        "Pyorrhea",
        "Acne",
        "Infertility",
        "Atherosclerosis",
        "Fractures",
        "Leg ulcers",
        "Hay fever",
        "Vascular thrombosis prevention",
        "Levodopa toxicity",
        "Arsenic toxicity"
      ],
      "dosage_and_administration": {
        "general_dosage": "One tablet daily with a meal or as directed by physician.",
        "dissolving_instructions": "Dissolve one tablet in half glass (100 ml) of water & drink instantly."
      },
      "contraindication_and_precaution": "There is no serious contraindication to the administration of Vitamin C. Diabetes, patients prone to recurrent renal calculi & those on sodium restricted diets or anticoagulant therapy should not take excessive doses of ascorbic acid over an extended period of time.",
      "side_effects": [
        "Stomach upset",
        "Diarrhea",
        "Mouth sores",
        "Frequent urination"
      ],
      "drug_interaction": "Limited evidence suggests that ascorbic acid may influence the intensity & duration of action of hydroxycoumarin.",
      "pregnancy_and_lactation": "During pregnancy & lactation usual dose is safe.",
      "preparation": "Vitamin C 1000 mg Effervescent Tablet"
    },
    {
      "name": "Cef-3®",
     "img_id":"DytQSlt.jpeg",
      "image": "Cef-3-Max-P-Drop.jpg",
      "active_ingredients": "Cefixime",
      "indication": [
        "Urinary tract infections",
        "Upper & lower respiratory tract infections",
        "Acute otitis media",
        "Gonococcal urethritis",
        "Enteric fever"
      ],
      "dosage_and_administration": {
        "adults": "200-400 mg as a single dose or in 2 divided doses daily for 7-14 days.",
        "children": "8 mg/kg daily as a single dose or in two divided doses for 7-14 days."
      },
      "contraindication_and_precaution": "Known hypersensitivity to Cephalosporin group of drugs.",
      "side_effects": [
        "Diarrhoea",
        "Nausea",
        "Abdominal pain",
        "Dyspepsia",
        "Vomiting",
        "Flatulence",
        "Headache",
        "Dizziness"
      ],
      "pregnancy_and_lactation": "Pregnancy Category B. Caution should be exercised when Cefixime is administered to a nursing mother.",
      "preparation": [
        "200 mg Capsule",
        "400 mg Capsule",
        "100 mg/5 ml Suspension (30 ml, 50 ml & 75 ml)",
        "200 mg/5ml Suspension",
        "25 mg/ml Paediatric Drops"
      ]
    },
    {
      "name": "Cefopen™",
     "img_id":"OfPGAlo.jpeg",
      "image": "Cefopn_lar.jpg",
      "active_ingredients": "Cefoperazone",
      "indication": [
        "Respiratory Tract Infections",
        "Peritonitis & Other Intra-abdominal Infections",
        "Bacterial Septicemia",
        "Skin and Skin Structures Infections",
        "Pelvic Inflammatory Disease",
        "Endometritis & Other Infections of the Female Genital Tract",
        "Urinary Tract Infections",
        "Enterococcal Infections"
      ],
      "dose_and_administration": {
        "adult": "2 to 4 grams per day administered in equally divided doses every 12 hours. In severe infections or infections caused by less sensitive organisms, the total daily dose and/or frequency may be increased. Patients have been successfully treated with a total daily dosage of 6-12 grams divided into 2, 3, or 4 administrations ranging from 1.5 to 4 grams per dose. When treating infections caused by Streptococcus pyogenes, therapy should be continued for at least 10 days."
      },
      "contraindication_and_precaution": "Cefoperazone is contraindicated in patients with known allergy to the Cephalosporin-class of antibiotics. Cefoperazone is extensively excreted in bile. The serum half-life of Cefoperazone is increased 2-4 fold in patients with hepatic disease and/or biliary obstruction. In general, total daily dosage above 4 gm should not be necessary in such patients. If higher dosages are used, serum concentrations should be monitored.",
      "side_effects": [
        "Hypersensitivity: Skin reactions (1 in 45)",
        "Drug fever (1 in 260)",
        "Change in Coombs’ test (1 in 60)"
      ],
      "use_in_pregnancy_and_lactation": "Pregnancy Category B. This drug should be used during pregnancy only if clearly needed. Only low concentrations of Cefoperazone are excreted in human milk. Although Cefoperazone passes poorly into breast milk of nursing mothers, caution should be exercised when Cefoperazone is administered to a nursing woman.",
      "preparation": ["1 gm IM/IV Injection", "2 gm IM/IV Injection"]
    },
    {
      "name": "Cefotil®",
     "img_id":"9kz2wom.jpeg",
      "image": "Cefotil-250-Tablet.jpg",
      "active_ingredients": "Cefuroxime",
      "indication": [
        "Upper respiratory tract infections (ear, nose & throat infections such as otitis media, sinusitis, tonsillitis, pharyngitis)",
        "Lower respiratory tract infections (acute bronchitis, acute exacerbations of chronic bronchitis, pneumonia)",
        "Skin & soft tissue infections (furunculosis, pyoderma, impetigo)",
        "Genito-urinary tract infections (pyelonephritis, urethritis, cystitis)",
        "Gonorrhoea (acute uncomplicated gonococcal urethritis, cervicitis)",
        "Early Lyme disease & prevention of late Lyme disease"
      ],
      "dose_and_administration": {
        "adults": {
          "general": "250 mg b.i.d. to 500 mg b.i.d.",
          "urinary_tract_infections": "125 mg b.i.d.",
          "gonorrhoea": "Single dose of 1 gm",
          "parenteral": "750 mg to 1.5 g IM or IV every 8 hourly, usually 5 to 10 days"
        },
        "children": {
          "general": "125 mg b.i.d. or 10 mg/kg b.i.d. to a maximum of 250 mg daily",
          "course_of_therapy": "7-10 days",
          "parenteral": "50 to 100 mg/kg/day in equally divided doses every 6 to 8 hours"
        }
      },
      "contraindication_and_precaution": "Known allergy to Cephalosporins. Prolonged use may result in overgrowth of non-susceptible organisms (e.g., Candida, Enterococci, Clostridium difficile). Pseudomembranous colitis has been reported, consider diagnosis in patients with serious diarrhoea during or after antibiotic use.",
      "side_effects": ["Nausea", "Vomiting"],
      "use_in_pregnancy_and_lactation": "Avoid in the first trimester if possible. Cefuroxime has been safely used in later pregnancy to treat urinary and other infections. Caution should be exercised when Cefuroxime is administered to a nursing mother.",
      "preparation": [
        "250 mg Tablet",
        "500 mg Tablet",
        "125 mg/5 ml Suspension",
        "750 mg IM/IV Injection",
        "1.5 gm IV Injection"
      ]
    },
    {
      "name": "Cefotil™ Plus",
     "img_id":"6h7HYVk.jpeg",
      "image": "Cefotil-Plus-250-Tablet.jpg",
      "active_ingredients": ["Cefuroxime", "Clavulanic Acid"],
      "indication": [
        "Pharyngitis/Tonsillitis",
        "Acute Bacterial Otitis Media",
        "Acute Bacterial Maxillary Sinusitis",
        "Acute Bacterial Exacerbations of Chronic Bronchitis",
        "Secondary Bacterial Infections of Acute Bronchitis",
        "Haemophilus influenzae (beta-lactamase negative strains)",
        "Haemophilus parainfluenzae (beta-lactamase negative strains)",
        "Uncomplicated Skin & Skin-Structure Infections",
        "Uncomplicated Urinary Tract Infections",
        "Uncomplicated Gonorrhea (urethral & endocervical)",
        "Early Lyme disease (erythema migrans)",
        "Septicemia",
        "Meningitis",
        "Switch therapy (injectable to oral) after surgery when patient’s condition is improved"
      ],
      "dose_and_administration": {
        "pediatric_patients": {
          "age_range": "03 months to 12 years (who can swallow tablet whole)",
          "infections": {
            "acute_otitis_media": {
              "dosage": "250 mg b.i.d.",
              "duration": "10 days"
            },
            "acute_bacterial_maxillary_sinusitis": {
              "dosage": "250 mg b.i.d.",
              "duration": "10 days"
            }
          }
        }
      },
      "contraindication_and_precaution": "Cefuroxime-Clavulanic Acid is contraindicated in patients with known allergy to Cephalosporins & in patients with Pseudomonas Colitis.",
      "side_effects": [
        "Diarrhea",
        "Nausea",
        "Vomiting",
        "Transient elevation in AST, ALT, LDH, & eosinophilia",
        "Abdominal pain",
        "Abdominal cramps",
        "Flatulence",
        "Indigestion",
        "Headache",
        "Vaginitis",
        "Rash",
        "Itch",
        "Dysuria",
        "Sleepiness",
        "Thirst",
        "Anorexia"
      ],
      "drug_interaction": [
        "Concomitant administration of probenecid with Cefuroxime-Clavulanic Acid increases the area under the serum concentration versus time curve by 50%",
        "Drugs that reduce gastric acidity may result in a lower bioavailability of Cefuroxime & tend to cancel the effect of postprandial absorption"
      ],
      "use_in_pregnancy_and_lactation": "All antibiotics should be avoided in the first trimester if possible. However, Cefuroxime-Clavulanic Acid can be safely used in later pregnancy to treat urinary tract & other infections. It is excreted into breast milk in small quantities; caution should be exercised when it is administered to a nursing mother.",
      "preparation": [
        "Cefotil Plus 250 Tablet: Each box contains 12 tablets in blister pack",
        "Cefotil Plus 500 Tablet: Each box contains 12 tablets in blister pack",
        "Cefotil Plus Powder for Suspension (70ml): Bottle containing dry powder to reconstitute 70ml suspension"
      ]
    },
    {
      "name": "Ceftiben™",
     "img_id":"PgVZFYG.jpeg",
      "image": "ceftiben_l.jpg",
      "active_ingredients": "Ceftibuten",
      "indication": [
        "Acute Bacterial Exacerbations of Chronic Bronchitis",
        "Acute Bacterial Otitis Media",
        "Pharyngitis",
        "Tonsillitis",
        "Pneumonia",
        "Urinary Tract Infections",
        "Enteritis",
        "Gastroenteritis"
      ],
      "dose_and_administration": {
        "adults": {
          "dosage": "400 mg once daily",
          "duration": "10 days"
        },
        "paediatric_patients": {
          "age_range": "Children 6 months and above",
          "dosage": "9 mg/kg/day once daily",
          "duration": "10 days"
        }
      },
      "contraindication_and_precaution": "Ceftibuten is contraindicated in patients with known allergy to the Cephalosporin group of antibiotics.",
      "side_effects": [
        "Nausea",
        "Vomiting",
        "Diarrhea",
        "Stomach upset",
        "Headache"
      ],
      "use_in_pregnancy_and_lactation": "Pregnancy category B. It is not known whether Ceftibuten (at recommended dose) is excreted in human milk. Caution should be exercised when Ceftibuten is administered in a nursing mother.",
      "preparation": ["400 mg Capsule", "60 ml PFS"]
    },
    {
      "name": "Ceftron®",
     "img_id":"l65v2VV.jpeg",
      "image": "ceftron-1-gm-injection.jpg",
      "active_ingredients": "Ceftriaxone",
      "indication": [
        "Renal & urinary tract infections",
        "Lower respiratory tract infections, particularly pneumonia",
        "Gonococcal infections",
        "Skin & soft tissue, bone & joint infections",
        "Bacterial meningitis",
        "Serious bacterial infections e.g. septicemia",
        "ENT infections",
        "Infections in cancer patients",
        "Prevention of postoperative infection",
        "Perioperative prophylaxis of infections associated with surgery",
        "Typhoid fever"
      ],
      "dose_and_administration": {
        "adults_and_children_over_12": {
          "dosage": "1 gm once daily",
          "severe_infections": "2-4 gm daily, normally as a single dose every 24 hours"
        },
        "children_under_12": {
          "dosage": "20-50 mg/kg/day",
          "severe_infections": "up to 80 mg/kg/day"
        }
      },
      "contraindication_and_precaution": [
        "Hypersensitivity to Cephalosporin antibiotics",
        "Contraindicated in premature infants during the first 6 weeks of life",
        "Safety in pregnancy not established, should only be used if absolutely necessary",
        "Mothers receiving Ceftriaxone should not breast-feed",
        "Dosage reduction required in severe renal impairment with hepatic insufficiency"
      ],
      "side_effects": [
        "Diarrhea",
        "Nausea & vomiting",
        "Stomatitis & glossitis",
        "Rash",
        "Pruritus",
        "Urticaria",
        "Edema & erythema multiforme",
        "Eosinophilia",
        "Thrombocytopenia",
        "Leukopenia & neutropenia",
        "Elevations of SGOT or SGPT",
        "Bilirubinemia",
        "Headache",
        "Hyperactivity",
        "Nervousness",
        "Sleep disturbances",
        "Confusion",
        "Hypertonia & dizziness"
      ],
      "drug_interaction": "A possible disulfiram-like reaction may occur with alcohol.",
      "preparation": [
        "250 mg IV",
        "250 mg IM",
        "500 mg IV",
        "500 mg IM",
        "1 gm IV",
        "1 gm IM",
        "2 gm IV Injection"
      ]
    },
    {
      "name": "Cerevas™",
     "img_id":"eIBNgZM.jpeg",
      "image": "Cerevas-Tablet.jpg",
      "active_ingredients": "Vinpocetine",
      "indication": [
        "Acute Cerebro-Vascular Accidents (Stroke): Ischemic stroke due to cerebral thrombosis, cerebral embolism, acute circulatory disorder, hypertensive crisis, reversible ischemic neurological deficit (RIND), complete stroke (CS), multi-infarct dementia, cerebral arteriosclerosis, hypertensive encephalopathy, post-apoplectic conditions with the background of hemorrhagic strokes.",
        "Geriatrics: For relief of psychosomatic symptoms in the elderly due to cerebral insufficiency e.g. forgetfulness, memory disturbances, slow thinking, lack of concentration, dizziness, mood instability, aphasia, sleep disturbances, vasovegetative symptoms of menopausal syndrome.",
        "Ophthalmology: Vascular disorder of the choroid & retina due to arteriosclerosis, vasospasm, macula degenerations, arterial or venous thrombosis or embolism, or glaucoma secondary to above mentioned disorders.",
        "Otology: For the treatment of impaired hearing of vascular toxic (iatrogenic) origin, presbyacusis, Meniere’s disease, cochleovestibular neuritis, tinnitus & dizziness of labyrinth origin."
      ],
      "dose_and_administration": {
        "recommended_dosage": "1-2 tablets thrice daily",
        "maintenance_dosage": "1 tablet thrice daily"
      },
      "contraindication_and_precaution": [
        "Contraindicated to pregnant & breastfeeding women",
        "Caution in patients with a history of high blood pressure & heart disease"
      ],
      "drug_interaction": "Individuals using blood-thinning medications, including aspirin, should not use Vinpocetine.",
      "side_effects": ["Transient hypotension", "Tachycardia"],
      "use_in_children": "No proven safety.",
      "preparation": ["5 mg tablet"]
    },
    {
      "name": "Cilosta®",
     "img_id":"SknVBGX.jpeg",
      "image": "Cilosta.jpg",
      "active_ingredients": "Cilostazol",
      "indication": "Cilosta is indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance.",
      "dose_and_administration": {
        "recommended_dosage": "100 mg bid, taken at least half an hour before or two hours after breakfast & dinner",
        "alternative_dosage": "50 mg bid during coadministration of Ketoconazole, Itraconazole, Erythromycin, & Diltiazem"
      },
      "contraindication_and_precaution": [
        "Contraindicated in patients with congestive heart failure of any severity",
        "Contraindicated in patients with known or suspected hypersensitivity to any of its components",
        "No information on the concurrent use of Cilostazol & Clopidogrel"
      ],
      "drug_interaction": [
        "Omeprazole & Erythromycin significantly increased the systemic exposure of Cilostazol and/or its major metabolites",
        "Higher concentrations of Cilostazol in patients concurrently treated with Diltiazem"
      ],
      "side_effects": [
        "Headache",
        "Diarrhoea",
        "Vomiting",
        "Leg cramps",
        "Rash"
      ],
      "less_frequent_side_effects": ["Anorexia", "Oedema"],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "There are no adequate & well-controlled studies in pregnant women.",
        "lactation": "Transfer of Cilostazol into milk has been reported in experimental animals. Due to the potential risk to nursing infants, a decision should be made to discontinue nursing or discontinue Cilostazol."
      },
      "preparation": "100 mg Tablet"
    },
    {
      "name": "Cinaron®",
     "img_id":"gt4Da9J.jpeg",
      "image": "Cinaron.jpg",
      "active_ingredients": "Cinnarizine",
      "indication": [
        "Cerebral circulatory disorders: Prophylaxis & maintenance therapy for symptoms of cerebral vascular spasms & arteriosclerosis",
        "Sequelae of cerebral & cranial trauma",
        "Postapoplectic disorders",
        "Migraine",
        "Peripheral circulatory disorders: Prophylaxis & maintenance therapy for symptoms of vascular spasms & arteriosclerosis such as obliterating arteritis, thromboangiitis, Raynaud’s disease, diabetes, acrocyanosis pernio, etc.",
        "Symptoms such as intermittent claudication, trophic disturbances, pregangrene, trophic & varicose ulcers, paresthesia, nocturnal cramps, cold extremities",
        "Disorders of balance"
      ],
      "dose_and_administration": "15 to 30 mg three times daily",
      "side_effects": ["Somnolence", "Gastrointestinal disturbances"],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "The safety of Cinnarizine in human pregnancy has not been established. Studies in animals have not demonstrated teratogenic effects. Therefore, it is not advisable to administer Cinnarizine in pregnancy."
      },
      "preparation": "15 mg Tablet"
    },
    {
      "name": "Cinaron® Plus",
     "img_id":"8E2Ixh1.jpeg",
      "image": "Cinaron-Plus.jpg",
      "active_ingredients": "Cinnarizine + Dimenhydrinate",
      "indication": ["Vertigo", "Peripheral arterial disorders"],
      "dose_and_administration": "1 tablet thrice daily",
      "side_effects": ["Somnolence", "GI disturbance"],
      "contraindication_and_precaution": "Not known",
      "drug_interaction": "Not known",
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Risk benefit ratio is considered"
      },
      "use_in_children": "Not established",
      "preparation": "Tablet"
    },
    {
      "name": "Ciprocin®",
     "img_id":"mf2hUXx.jpeg",
      "image": "Ciprocin-250.jpg",
      "active_ingredients": "Ciprofloxacin",
      "indication": [
        "Urinary tract infections",
        "Lower respiratory tract infections",
        "Skin & soft tissue infections",
        "Bone & joint infections",
        "G.I. tract infections",
        "Uncomplicated gonorrhoea",
        "Pseudomonal infections of lower respiratory tract",
        "Surgical prophylaxis"
      ],
      "dose_and_administration": {
        "urinary_tract_infection": {
          "acute_uncomplicated": "100 mg or 250 mg b.i.d. for 3 days",
          "mild_moderate_severe_complicated": "500 mg b.i.d. for 7 to 14 days",
          "severe_complicated": "750 mg b.i.d. for 7 to 14 days"
        },
        "lower_respiratory_tract_infection": {
          "mild_moderate": "500 mg b.i.d.",
          "severe_complicated": "750 mg b.i.d. for 7 to 14 days"
        },
        "acute_sinusitis": "500 mg b.i.d.",
        "infectious_diarrhea": "500 mg b.i.d.",
        "typhoid_fever": "500 mg b.i.d.",
        "pediatric_dosage": "10 mg/kg to 20 mg/kg b.i.d. (maximum 750 mg per dose) for 10 to 21 days"
      },
      "precaution_and_warning": "Should be used with caution in patients with suspected or known CNS disorders such as arteriosclerosis or epilepsy, or other factors that predispose to seizures & convulsions. Do not split, crush, or chew the tablet.",
      "side_effects": [
        "Nausea",
        "Other gastrointestinal disturbances",
        "Headache",
        "Dizziness",
        "Skin rashes",
        "Crystalluria"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "The safety & effectiveness of ciprofloxacin in pregnant women have not been established.",
        "lactation": "The safety & effectiveness of ciprofloxacin in lactating women have not been established."
      },
      "use_in_children": "From 1 year & above",
      "contraindication": "Patients with a history of hypersensitivity to Ciprofloxacin or to other quinolones",
      "preparation": [
        "Ciprocin 250 mg tablet",
        "Ciprocin 500 mg tablet",
        "Ciprocin 750 mg tablet",
        "Ciprocin 250 mg powder for suspension"
      ]
    },
    {
      "name": "Ciprocin® Eye/Ear Drops",
     "img_id":"U5eByU2.jpeg",
      "image": "Ciprocin_l.jpg",
      "active_ingredients": "Ciprofloxacin",
      "indication": {
        "eye": ["Corneal ulcer", "Bacterial conjunctivitis"],
        "ear": [
          "Otitis externa",
          "Acute otitis media",
          "Chronic suppurative otitis media"
        ]
      },
      "dose_and_administration": {
        "eye": {
          "first_6_hours": "Two drops into the affected eye every 15 minutes",
          "remainder_of_first_day": "Two drops into the affected eye every 30 minutes",
          "second_day": "Instill 2 drops in the affected eye hourly",
          "third_to_fourteenth_day": "Place two drops in the affected eye every four hours",
          "after_fourteenth_day": "Treatment may be continued if corneal re-epithelization has not occurred"
        },
        "ear": {
          "all_infections": "2 - 3 drops every 2 - 3 hours initially"
        }
      },
      "contraindication_and_precaution": [
        "Hypersensitivity",
        "Overgrowth of non-susceptible organisms"
      ],
      "side_effects": [
        "Local burning or discomfort",
        "Crusting",
        "Crystals/scales",
        "Foreign body sensation",
        "Itching",
        "Conjunctival hyperemia",
        "Bad taste"
      ],
      "drug_interaction": "Specific drug interaction studies have not been conducted with ophthalmic Ciprofloxacin.",
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."
      },
      "preparation": "0.3% Eye/Ear Drops"
    },
    {
      "name": "Ciprocin® 200 IV",
     "img_id":"lRwMEkm.jpeg",
      "image": "Ciprocin-Infusion_l.jpg",
      "active_ingredients": "Ciprofloxacin",
      "indication": [
        "Urinary Tract Infection",
        "Lower Respiratory Tract Infection",
        "Nosocomial Pneumonia",
        "Skin & Skin Structure Infection",
        "Bone & Joint Infection",
        "Complicated Intra-Abdominal Infection",
        "Acute Sinusitis",
        "Chronic Bacterial Prostatitis",
        "Infectious diarrhea",
        "Inhalational Anthrax"
      ],
      "dose_and_administration": {
        "Urinary Tract Infection": {
          "mild_to_moderate": "200 mg q12h for 7-14 days",
          "severe_or_complicated": "400 mg q12h for 7-14 days"
        },
        "Lower Respiratory Infection": {
          "mild_to_moderate": "400 mg q12h for 7-14 days",
          "severe_or_complicated": "400 mg q8h for 7-14 days"
        },
        "Nosocomial Pneumonia": {
          "all_severity": "400 mg q8h for 10-14 days"
        },
        "Skin & Skin Structure Infection": {
          "mild_to_moderate": "400 mg q12h for 7-14 days",
          "severe_or_complicated": "400 mg q8h for 7-14 days"
        },
        "Bone & Joint Infection": {
          "mild_to_moderate": "400 mg q12h for ≥4-6 weeks",
          "severe_or_complicated": "400 mg q8h for ≥4-6 weeks"
        },
        "Intra-Abdominal Infection": {
          "complicated": "400 mg q12h for 7-14 days"
        },
        "Acute Sinusitis": {
          "mild_to_moderate": "400 mg q12h for 10 days"
        },
        "Chronic Bacterial Prostatitis": {
          "mild_to_moderate": "400 mg q12h for 28 days"
        }
      },
      "contraindication_and_precaution": [
        "Hypersensitivity to Ciprofloxacin or any quinolone class",
        "Concomitant administration with tizanidine",
        "Administer by slow infusion over 60 minutes"
      ],
      "drug_interaction": [
        "Concurrent administration with theophylline may elevate serum concentrations and prolong elimination half-life, increasing the risk of adverse reactions.",
        "Probenecid interferes with renal tubular secretion of ciprofloxacin and increases serum levels."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "The safety and effectiveness in pregnant women have not been established.",
        "lactation": "Excreted in human milk."
      },
      "use_in_children": "Usually not recommended for children. If needed, dosage is 5-10 mg/kg/day in two divided doses based on infection severity.",
      "preparation": "200 mg/100 ml intravenous infusion"
    },
    {
      "name": "CitivasTM",
     "img_id":"JvDO6KN.jpeg",
      "image": "citivas-tm.jpg",
      "active_ingredients": "Citicoline 500 mg Caplet",
      "indication": [
        "Cerebrovascular disease (e.g., ischemia due to stroke)",
        "Cerebral insufficiency (e.g., dizziness, memory loss, poor concentration, disorientation)",
        "Cognitive dysfunction due to degenerative disease (e.g., Alzheimer's disease)",
        "Parkinson’s disease (co-therapy)"
      ],
      "dosage_and_administration": {
        "ischemic_stroke": "500-2000 mg per day, start within 24 hours of stroke",
        "thinking_skills_decline_due_to_stroke": "1000-2000 mg per day",
        "chronic_cerebrovascular_disease": "1000 mg daily in divided doses with or between meals"
      },
      "side_effect": [
        "Occasionally exerts stimulating action on the parasympathetic system",
        "Fleeting and discrete hypotensive effect"
      ],
      "precaution": "In case of persistent intracranial hemorrhage, do not exceed 1000 mg daily.",
      "contraindication": "Patients with hypertonic parasympathetic nervous system",
      "drug_interaction": [
        "May enhance the effects of levodopa, carbidopa, and entacapone",
        "Must not be administered with products containing meclophenoxate"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "No adequate and well-controlled studies. Should only be used if potential benefits justify risks.",
        "lactation": "Should only be used if potential benefits justify risks."
      },
      "geriatric_use": "No dosage adjustment required. Usual dose can be administered.",
      "preparation": "500 mg caplet (capsule-shaped tablet)"
    },
    {
      "name": "ClimycinTM",
     "img_id":"0sQAqIz.jpeg",
      "image": "Climycin-300-Cap.jpg",
      "active_ingredients": "Clindamycin",
      "indication": [
        "Upper respiratory tract infections",
        "Lower respiratory tract infections",
        "Skin & soft tissue infections",
        "Bone & joint infections",
        "Pelvic infections",
        "Intra-abdominal infections",
        "Septicemia & endocarditis",
        "Dental infections",
        "Alternative therapy for multi-drug resistant Plasmodium falciparum infection when combined with quinine or amodiaquine"
      ],
      "dosage_and_administration": {
        "adults_serious_infections": "150 mg - 300 mg every six hours",
        "adults_more_severe_infections": "300 mg - 450 mg every six hours",
        "pediatric_serious_infections": "8 - 16 mg/kg/day divided into three or four equal doses",
        "pediatric_more_severe_infections": "16 - 20 mg/kg/day divided into three or four equal doses"
      },
      "contraindication_and_precaution": "Clindamycin is contraindicated in patients previously found to be sensitive to Clindamycin, lincomycin, or any of the ingredients of this medicine.",
      "side_effect": [
        "Abdominal pain",
        "Oesophagitis & oesophageal ulcer",
        "Nausea",
        "Vomiting",
        "Diarrhoea",
        "Pruritus",
        "Skin rashes",
        "Urticaria"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Pregnancy Category B. Should be used in pregnancy only if clearly needed.",
        "lactation": "Clindamycin has been reported to appear in breast milk. Not recommended for nursing mothers unless clearly needed."
      },
      "use_in_children": "When administered to newborns & infants (birth to 16 years), appropriate monitoring of organ system functions is desirable.",
      "preparation": "300 mg Capsule"
    },
    {
      "name": "Clinface® Gel",
     "img_id":"ixzZblc.jpeg",
      "image": "CLINFACE-GEL-15GM.jpg",
      "active_ingredients": ["Clindamycin Phosphate", "Tretinoin"],
      "indication": "Topical treatment of Acne vulgaris",
      "dosage_and_administration": {
        "before_sleep": [
          "Wash the face gently with a mild soap and water, then pat the skin dry.",
          "Apply the Gel with fingertips gently on the face."
        ],
        "in_the_morning": [
          "Apply a sunscreen after the application of the Gel.",
          "Do not wash your face more than 2 or 3 times a day. Apply the sunscreen cream as needed."
        ]
      },
      "contraindication_and_precaution": "Clinface® Gel should not be administered to individuals who are hypersensitive to Clindamycin, Tretinoin, or any other component of the Gel. It should not be applied to eyes, nose, ear, lips, cuts, burns, and other infections. After application, keep away from sunlight.",
      "side_effect": [
        "Erythema",
        "Scaling",
        "Nasopharyngitis",
        "Dry skin",
        "Cough",
        "Sinusitis",
        "Diarrhea"
      ],
      "use_in_pregnancy_and_lactation": "It is not known whether Clindamycin or Tretinoin is excreted in human milk. Exercise special caution while applying Clindamycin or Tretinoin to a nursing mother.",
      "preparation": "15 gm Gel"
    },
    {
      "name": "Clofenac®",
     "img_id":"GTv7mNJ.jpeg",
      "image": "Clofenac.jpg",
      "active_ingredients": "Diclofenac",
      "indication": [
        "Arthritic conditions: Rheumatoid Arthritis",
        "Osteoarthritis",
        "Ankylosing spondylitis",
        "Acute gout",
        "Acute musculoskeletal disorders such as periarthritis (e.g., frozen shoulder), tendinitis, tenosynovitis, bursitis",
        "Other painful conditions resulting from trauma, including fracture, low back pain, sprains, strains, dislocations",
        "Orthopaedic, dental & other minor surgery"
      ],
      "dosage_and_administration": {
        "tablets": {
          "adults": "75 - 150 mg daily in 2 to 3 divided doses, preferably after food. The recommended maximum daily dose of diclofenac is 150 mg.",
          "children": "In juvenile chronic arthritis, 1-3 mg of diclofenac/kg body wt. daily in divided doses.",
          "elderly": "In elderly or debilitated patients, the lowest effective dosage is recommended."
        },
        "gel": "Should be rubbed gently into the skin. Depending on the size of the affected site, 2-4 gm gel should be applied 3-4 times daily & rubbed in lightly.",
        "suppository": {
          "adults": "50 mg suppository only: 75-150 mg daily, in divided doses.",
          "children": "12.5 mg or 25 mg suppository only: 1-3 mg/kg daily, in divided doses."
        }
      },
      "contraindication_and_precaution": [
        "Diclofenac is contraindicated for those patients who are hypersensitive to diclofenac.",
        "In patients with active or suspected peptic ulcer or gastrointestinal bleeding.",
        "For those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibiting activity."
      ],
      "side_effect": [
        "Epigastric pain",
        "Nausea",
        "Vomiting",
        "Diarrhoea",
        "Abdominal cramps",
        "Dyspepsia",
        "Flatulence",
        "Anorexia",
        "Rare: gastro-intestinal bleeding",
        "Peptic ulcer (with or without bleeding or perforation)",
        "Bloody diarrhoea",
        "In isolated cases: lower gut disorders (e.g., non-specific haemorrhagic colitis & exacerbations of ulcerative colitis or Crohn’s proctocolitis)",
        "Pancreatitis",
        "Glossitis",
        "Constipation"
      ],
      "drug_interaction": [
        "Lithium & digoxin",
        "Anticoagulants",
        "Antidiabetic agents",
        "Cyclosporin",
        "Methotrexate",
        "Quinolone antimicrobials",
        "Diuretics"
      ],
      "use_in_pregnancy_and_lactation": "Diclofenac tablets & injection should not be prescribed during pregnancy. Very small quantities may be detected in breast milk, but no undesirable effects on the infant are expected.",
      "preparation": [
        "50 mg tablet",
        "50 mg DT (Dispersible Tablet)",
        "100 mg SR tablet",
        "100 mg TR capsule",
        "1% Gel",
        "12.5 mg, 25 mg, 50 mg, Plus Inj"
      ]
    },
    {
      "name": "Clopirox™ 1% Cream",
     "img_id":"k9VptXa.jpeg",
      "image": "Clopirox.jpg",
      "active_ingredients": "Ciclopirox Olamine",
      "indication": [
        "Dermal infections: Tinea pedis",
        "Tinea cruris",
        "Tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum & Microsporum canis",
        "Candidiasis (moniliasis) due to Candida albicans",
        "Tinea (pityriasis) versicolor due to Malassezia furfur",
        "Effective against some gram negative & some gram positive bacteria",
        "Anti-inflammatory effects make it effective for mild to moderate inflammatory fungal infections"
      ],
      "dosage_and_administration": {
        "general": "Should be gently massaged onto the affected & surrounding skin areas twice daily for four weeks. Clinical improvement with relief of pruritus & other symptoms usually occurs within the first week of treatment. If no clinical improvement after four weeks, the diagnosis should be redetermined.",
        "tinea_versicolor": "Clinical & mycological clearing usually occurs after two weeks of treatment."
      },
      "contraindication_and_precaution": [
        "Contraindicated in individuals who have shown hypersensitivity to any of its components."
      ],
      "side_effect": [
        "Well tolerated with a low incidence of adverse reactions reported in clinical trials."
      ],
      "use_in_pregnancy_and_lactation": "Pregnancy category B. It is not known whether this drug is excreted in human milk. Caution should be exercised when administered to nursing women.",
      "use_in_children": "Safety & effectiveness in children below the age of 10 years have not been established.",
      "preparation": ["15 gm Cream"]
    },
    {
      "name": "Clopirox™ Shampoo",
     "img_id":"XrQb4qm.jpeg",
      "image": "Clopirox-Shampoo_l.jpg",
      "active_ingredients": "Ciclopirox Olamine USP 10 mg",
      "indication": [
        "Seborrheic dermatitis",
        "Dandruff",
        "Inflammation and swelling of the scalp"
      ],
      "dosage_and_administration": {
        "general": "Wet hair and apply approximately 1 teaspoon (5 ml) of Clopirox™ Shampoo to the scalp. Up to 2 teaspoons (10 ml) may be used for long hair. Lather and leave on hair and scalp for 3 minutes. A timer may be used.",
        "frequency": "Treatment should be repeated twice per week for 4 weeks, with a minimum of 3 days between applications.",
        "precaution": "Avoid contact with eyes."
      },
      "contraindication": "This Shampoo is contraindicated in individuals who have shown hypersensitivity to any of its components.",
      "side_effect": "Well tolerated with a low incidence of adverse reactions reported in clinical trials.",
      "precaution": "Not for ophthalmic, oral, or intravaginal use.",
      "use_in_pregnancy": "Pregnancy category B.",
      "use_in_nursing_mother": "It is not known whether this drug is excreted in human milk. Caution should be exercised when administered to nursing women.",
      "use_in_children": "No clinical trials have been conducted in subjects younger than 16 years.",
      "preparation": ["100 ml Shampoo"]
    },
    {
      "name": "Clotinex™",
     "img_id":"2mHhy0X.jpeg",
      "image": "Clotinex-40.jpg",
      "active_ingredients": "Enoxaparin",
      "indication": [
        "Treatment of deep vein thrombosis",
        "Unstable angina, myocardial infarction",
        "Prophylaxis of venous thromboembolic disease"
      ],
      "dosage_and_administration": {
        "deep_vein_thrombosis": {
          "dosage_1": "Subcutaneously 100 anti-Xa IU/kg twice daily for 10 days",
          "dosage_2": "Subcutaneously 150 anti-Xa IU/kg once daily for 10 days"
        },
        "unstable_angina_mi": {
          "dosage": "Subcutaneously 100 anti-Xa IU/kg twice daily for 2 - 8 days",
          "additional_instruction": "Administer concurrently with oral aspirin (100 to 325 mg once daily) for a minimum of 2 days until clinical stabilization."
        },
        "hemodialysis": {
          "dosage": "100 anti-Xa IU/kg, reduced to 50 or 75 anti-Xa IU/kg for high hemorrhage risk"
        },
        "surgical_patients": {
          "general_surgery": "Subcutaneously 2000 anti-Xa IU (0.2 ml) or 4000 anti-Xa IU (0.4 ml) once daily for 7 to 10 days, first injection 2 hours before surgery.",
          "orthopedic_surgery": "Subcutaneously 4000 anti-Xa IU (0.4 ml) once daily for 7 to 10 days, first injection 2 hours before surgery."
        },
        "medical_patients": "Subcutaneously 4000 anti-Xa IU (0.4 ml) once daily for 6 - 14 days",
        "elderly_patients": "No dosage adjustment necessary unless kidney function impaired.",
        "renal_impairment": {
          "moderate_mild": "No adjustment recommended.",
          "severe": {
            "prophylactic": "2000 anti-Xa IU once daily",
            "therapeutic": "100 anti-Xa IU/kg once daily"
          }
        },
        "hepatic_impairment": "Caution should be used."
      },
      "contraindication_and_precaution": {
        "contraindication": [
          "Known hypersensitivity to Enoxaparin Sodium, heparin, or other low molecular weight heparins",
          "Active major bleeding",
          "Conditions with high risk of uncontrolled hemorrhage (e.g., recent hemorrhagic stroke)"
        ],
        "precaution": [
          "Inject by deep subcutaneous route in prophylactic & curative treatment",
          "Do not administer intramuscularly",
          "Use with caution in conditions with increased potential for bleeding",
          "Regular platelet count monitoring recommended"
        ]
      },
      "side_effect": [
        "Hemorrhage (bleeding)",
        "Thrombocytopenia",
        "Elevations of serum amino transferase",
        "Pain, bluish marks at injection site",
        "Skin rash at injection site",
        "Neuraxial hematomas with concurrent use of enoxaparin & spinal/epidural anesthesia or spinal puncture"
      ],
      "drug_interaction": [
        "Acetylsalicylic acid and derivatives",
        "NSAIDs (including ketorolac)",
        "Ticlopidine",
        "Clopidogrel",
        "Dextran 40",
        "Glucocorticoids",
        "Thrombolytics",
        "Anticoagulants",
        "Other anti-platelet aggregation agents including glycoprotein IIb/IIIa antagonists"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy_category": "B",
        "recommendation": "Use only if clearly needed."
      },
      "use_in_children": "Safety and effectiveness not established.",
      "preparation": [
        "40 mg (4000 anti-Xa IU/0.4 ml) pre-filled syringe injection",
        "60 mg (6000 anti-Xa IU/0.6 ml) pre-filled syringe injection"
      ]
    },
    {
      "name": "Comet®",
     "img_id":"PA0TETu.jpeg",
      "image": "Comet-500.jpg",
      "active_ingredients": "Metformin HCI",
      "indication": ["Management of type 2 diabetes mellitus"],
      "dosage_and_administration": {
        "adults": {
          "starting_dose": "500 mg twice a day or 850 mg once a day, given with meals.",
          "dosage_increase": "Increase in increments of 500 mg weekly or 850 mg every 2 weeks, up to 2000 mg per day in divided doses.",
          "comet_xr": "Starting dose of Comet XR (Metformin Hydrochloride extended release tablet) is 500 mg once daily with evening meal. Increase in increments of 500 mg weekly, up to a maximum of 2000 mg once daily. If glycemic control is not achieved with 2000 mg once daily, consider trial of 1000 mg twice daily."
        },
        "pediatrics": {
          "starting_dose": "500 mg twice a day, given with meals.",
          "dosage_increase": "Increase in increments of 500 mg weekly up to a maximum of 2000 mg per day, given in divided doses."
        }
      },
      "contraindication_and_precaution": {
        "contraindication": [
          "Renal disease or renal dysfunction (serum creatinine levels > 1.5 mg/dL for males, > 1.4 mg/dL for females, or abnormal creatinine clearance)",
          "Congestive heart failure requiring pharmacologic treatment",
          "Known hypersensitivity to metformin hydrochloride",
          "Acute or chronic metabolic acidosis, including diabetic ketoacidosis with or without coma"
        ],
        "pregnancy": "Pregnancy Category B. Should not be used during pregnancy unless clearly needed.",
        "lactation": "Caution should be exercised, as hypoglycemia in nursing infants may exist. Decision should be made whether to discontinue nursing or the drug."
      },
      "side_effect": [
        "Diarrhea",
        "Nausea",
        "Vomiting",
        "Flatulence",
        "Asthenia",
        "Indigestion",
        "Abdominal discomfort",
        "Headache"
      ],
      "drug_interaction": [
        "Furosemide",
        "Nifedipine",
        "Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, vancomycin)"
      ],
      "preparation": ["500 mg & 850 mg Tablet", "XR 500 mg & XR 1 gm tablet"]
    },
    {
      "name": "Colicon®",
     "img_id":"WDuzgOh.jpeg",
      "image": "COLICON-50ML.jpg",
      "active_ingredients": "Dicycloverine HCl",
      "indication": [
        "Irritable bowel syndrome",
        "Infantile colic",
        "GIT spasm",
        "Diverticulitis",
        "Abdominal colic",
        "Diarrhoea",
        "Dysentery"
      ],
      "dosage_and_administration": {
        "adults": {
          "dose_range": "10 to 20 mg three to four times a day",
          "maximum_dose": "160 mg daily in divided dose"
        },
        "children": {
          "age_over_6_months": "5 to 10 mg three times a day"
        }
      },
      "contraindication_and_precaution": {
        "contraindication": [
          "Obstructive uropathy",
          "Obstruction disorder in GIT",
          "Severe ulcerative colitis",
          "Unstable cardiovascular status in acute hemorrhage",
          "Glaucoma",
          "Myasthenia gravis",
          "Hypersensitivity to dicycloverine hydrochloride"
        ]
      },
      "side_effect": [
        "Insomnia",
        "Headache",
        "Weakness",
        "Confusion",
        "Increased ocular tension",
        "Urinary hesitancy",
        "Palpitations"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Pregnancy Category B. Should be used during pregnancy only if clearly needed.",
        "lactation": "Should not be used in lactating mothers."
      },
      "drug_interaction": [
        "Antiarrhythmic agents",
        "Antihistamines",
        "Antipsychotic agents",
        "Benzodiazepines",
        "MAO inhibitors",
        "Narcotic analgesics",
        "Nitrates & nitrites",
        "Sympathomimetic agents",
        "Tricyclic antidepressants",
        "Other drugs having anticholinergic activity"
      ],
      "preparation": ["10 mg Tablet", "10 mg/5 ml Syrup (50 ml)"]
    },

    {
      "name": "Colimax™",
     "img_id":"igKkJD7.jpeg",
      "image": "Colimax.jpg",
      "active_ingredients": "Colchicine USP 0.6 mg",
      "indication": "Colchicine is approved by US FDA for the prevention & treatment of acute gout attack.",
      "dosage_and_administration": {
        "prophylaxis_of_gout_flare": {
          "dose": "0.6 mg (1 tablet) once or twice daily in adults & adolescents older than 16 years of age",
          "maximum_dose": "1.2 mg/day (2 tablets)"
        },
        "treatment_of_acute_gout_attack": {
          "initial_dose": "1.2 mg (2 tablets) at first sign of a gout flare followed by 0.6 mg (1 tablet) one hour later",
          "maximum_recommended_dose": "1.8 mg over a 1 hour period",
          "maintenance_dose": "Prophylactic dose should be resumed after 12 hours of the acute treatment course"
        }
      },
      "contraindication": [
        "Patients with renal or hepatic impairment",
        "Patients given in conjunction with permeable glycoprotein or strong CYP3A4 inhibitors (e.g., Clarithromycin or Cyclosporine)"
      ],
      "side_effect": [
        "Myelosuppression",
        "Leucopenia",
        "Granulocytopenia",
        "Thrombocytopenia",
        "Aplastic anemia",
        "Diarrhea",
        "Pharyngolaryngeal pain"
      ],
      "drug_interaction": [
        "Co-administration of permeable glycoprotein (P-gp) and/or CYP3A4 inhibitors (e.g., clarithromycin or cyclosporine)"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Pregnancy Category C. There are no adequate & well-controlled studies in pregnant women.",
        "lactation": "Colchicine is excreted into human milk. Caution should be exercised when administered to a nursing woman."
      },
      "use_in_children": "Gout is rare in pediatric patients. Safety & effectiveness of Colchicine in pediatric patients have not been established. Not recommended for patients under 16 years of age.",
      "preparation": "0.6 mg Tablet"
    },
    {
      "name": "Comprid®",
     "img_id":"b3A0vxD.jpeg",
      "image": "Comprid_80.jpg",
      "active_ingredients": "Gliclazide",
      "indication": "Indicated for the treatment of type 2 diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.",
      "dosage_and_administration": {
        "initial_dose": "40 to 80 mg daily, gradually increased up to 320 mg daily until adequate control is achieved. A single dose should not exceed 160 mg.",
        "higher_doses": "Should be taken twice daily, according to the main meals of the day.",
        "extended_release_tablet": {
          "initial_dose": "30 mg daily, even in elderly patients (>65 years)",
          "dose_range": "30 to 120 mg daily, taken orally once daily",
          "with_food": "Should be taken with food to reduce risk of hypoglycemia if a meal is taken late.",
          "dose_titration": "Dose titration should be in steps of 30 mg, based on fasting blood glucose response, with each step lasting at least two weeks.",
          "tablet_instruction": "Should not be broken or chewed."
        },
        "elderly": "Plasma clearance of Gliclazide is not altered in the elderly. It is effective & well tolerated in elderly patients.",
        "missed_dose": "If a dose is forgotten, the dose on the next day should not be increased.",
        "replacement_for_80_mg_tablets": "Comprid® XR 30 can replace Gliclazide 80 mg tablets, tablet for tablet, for doses of 1 to 4 tablets per day."
      },
      "contraindication_and_precaution": [
        "Juvenile onset diabetes",
        "Diabetes complicated by ketosis & acidosis",
        "Diabetes undergoing surgery, after severe trauma or during infections",
        "Hypersensitivity to other sulfonylureas & related drugs",
        "Diabetic pre-coma & coma",
        "Severe renal or hepatic insufficiency",
        "Combination with miconazole tablets"
      ],
      "precaution": "Care should be exercised with patients having hepatic & renal impairment. A small starting dose should be used with careful monitoring.",
      "side_effect": [
        "Hypoglycemia (in conditions such as hepatic & renal diseases, alcohol intoxication & adrenal & pituitary insufficiency)",
        "Mild gastrointestinal disturbances (nausea, dyspepsia, diarrhea, constipation)",
        "Allergic dermatological reactions (rash, pruritus, erythema, bullous eruption)"
      ],
      "drug_interaction": [
        "The hypoglycemic effect may be potentiated by NSAIDs (especially aspirin), phenylbutazone, sulfonamides, coumarin derivatives, MAOIs, beta-adrenergic blockers, tetracyclines, chloramphenicol, clofibrate, cimetidine, and miconazole tablets.",
        "Ingestion of alcohol may increase the hypoglycemic effect.",
        "Some drugs may reduce its activity, such as barbiturates, corticosteroids, thiazide diuretics, thyroid hormones, laxatives, and oral contraceptives."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Gliclazide should not be used in pregnancy.",
        "lactation": "No study has reported its presence in human breast milk. However, other sulfonylureas have been found in milk, and there is no evidence to suggest that gliclazide differs in this respect."
      },
      "use_in_children": "Should not be used below 18 years.",
      "preparation": {
        "comprid_tablet": "Each box containing 60 tablets in blister pack.",
        "comprid_xr_30_tablet": "Each box containing 30 tablets in blister pack.",
        "comprid_xr_60_tablet": "Each box containing 30 tablets in blister pack."
      }
    },
    {
      "name": "Contilex®",
     "img_id":"3YnZiQY.jpeg",
      "image": "Contilex.jpg",
      "active_ingredients": "Glucosamine + Chondroitin",
      "indication": "Treatment of osteoarthritis of fingers, shoulder joints & weight bearing joints of the body. As a dietary supplement to prevent Osteoarthritis.",
      "dosage_and_administration": {
        "initial_dose": "1 - 2 tablets, three times daily.",
        "tapered_dose": "Doses can be tapered after 60 days as per requirement."
      },
      "contraindication_and_precaution": [
        "Proven hypersensitivity to these ingredients."
      ],
      "side_effect": [
        "No demonstrable side effects.",
        "Mild & reversible intestinal flatulence occurs rarely."
      ],
      "preparation": "Each tablet contains Glucosamine Sulfate 250 mg + Chondroitin Sulfate 200 mg."
    },
    {
      "name": "Cotrim®",
     "img_id":"3xKQivo.jpeg",
      "image": "cotrim-400-mg-tablet.jpg",
      "active_ingredients": "Sulphamethoxazole & Trimethoprim",
      "indication": "Respiratory tract infections, genito-urinary tract infections, skin infections, acute & chronic osteomyelitis, acute brucellosis, septicaemia, nocardiosis & other infections caused by susceptible organisms.",
      "dosage_and_administration": {
        "tablet": "2 tablets twice daily. In severe cases, 3 times/day.",
        "ds_tablet": "1 tablet twice daily.",
        "suspension": "1-2 teaspoonful twice daily."
      },
      "contraindication_and_precaution": [
        "Hepatic & renal insufficiency",
        "Blood dyscrasias",
        "Sulphonamides sensitivity",
        "Megaloblastic anaemia",
        "Pregnancy & during nursing"
      ],
      "side_effect": [
        "Exfoliative dermatitis",
        "Stevens-Johnson syndrome",
        "Toxic epidermal necrolysis (Lyell’s syndrome) are rare",
        "Nausea & vomiting",
        "Diarrhoea",
        "Glossitis",
        "Stomatitis",
        "Anemia",
        "Granulocytopenia",
        "Purpura",
        "Agranulocytosis"
      ],
      "preparation": [
        "(400 mg + 80 mg)/Tablet",
        "(800 mg + 160 mg)/DS Tablet",
        "(200 mg + 40 mg)/5 ml Suspension"
      ]
    },
    {
      "name": "CozycolTM 800",
     "img_id":"OBCSLVh.jpeg",
      "image": "Cozycol-800_l.jpg",
      "active_ingredients": "Mesalamine",
      "indication": [
        "Treatment of mild to moderately active Ulcerative Colitis",
        "Maintenance of remission of Ulcerative Colitis",
        "Maintenance of remission of Crohn’s disease"
      ],
      "dosage_and_administration": {
        "acute_disease": "3-6 delayed release tablets (2400-4800 mg) daily in divided doses for 6 weeks.",
        "maintenance_therapy": "3 delayed release tablets (2400 mg) daily in divided doses.",
        "maintenance_of_remission_of_crohns_disease": "3 delayed release tablets (2400 mg) daily in divided doses.",
        "paediatric": "Safety and effectiveness has not been established.",
        "elderly": "Because elderly patients are more likely to have decreased renal function, care should be taken when prescribing this drug therapy. It is recommended that all patients have an evaluation of renal function prior to initiation of Mesalamine tablets. Monitor blood cell counts during drug therapy."
      },
      "contraindication_and_precaution": [
        "Hypersensitivity to salicylates or to any other component of the formulation"
      ],
      "side_effect": [
        "Headache",
        "Nausea",
        "Dizziness",
        "Asthenia",
        "Dyspepsia",
        "Vomiting",
        "Pruritus"
      ],
      "drug_interaction": [
        "Concurrent use of other known nephrotoxic agents such as NSAIDs and Azathioprine may increase the risk of renal reactions."
      ],
      "use_in_special_population": {
        "pregnant_women": "It should be given in pregnancy only if the potential benefit justifies the potential risk to the fetus.",
        "lactating_mother": "Caution is advised when it is administered to a nursing mother.",
        "geriatrics": "Patients who are 65 years or older, caution should be taken to closely monitor blood cell counts during Mesalamine therapy."
      },
      "preparation": "800 mg"
    },

    {
      "name": "DaizyTM",
     "img_id":"ljADflN.jpeg",
      "image": "Daizy_large.jpg",
      "active_ingredients": "Dienogest 2 mg Tablet",
      "indication": "Endometriosis",
      "dosage_and_administration": {
        "initial_dosage": "Once daily for 3 months initially"
      },
      "contraindication": [
        "Known or suspected pregnancy",
        "Lactation",
        "Active Venous Thromboembolic disorder",
        "Arterial and Cardiovascular disease",
        "Diabetes mellitus with vascular involvement",
        "Presence or history of severe hepatic disease as long as liver function values have not returned to normal",
        "Presence or history of liver tumors (benign or malignant)",
        "Known or suspected sex hormone-dependent malignancies",
        "Undiagnosed abnormal vaginal bleeding",
        "Any ocular lesion arising from ophthalmic vascular disease such as partial or complete loss of vision or defect in visual fields",
        "Current or history of migraine with focal aura",
        "Hypersensitivity to Dienogest or to any ingredient in the formulation"
      ],
      "adverse_effects": [
        "Headache",
        "Breast discomfort",
        "Depressed mood",
        "Acne",
        "Irregular endometrial breakthrough bleeding",
        "Spotting",
        "Irregular bleeding",
        "Amenorrhea"
      ],
      "pregnancy_and_breastfeeding": {
        "pregnancy": "Contraindicated",
        "breastfeeding": "Not recommended for breastfeeding mother"
      },
      "preparation": "2 mg Tablet"
    },
    {
      "name": "D-balanceTM",
     "img_id":"0YVUHFq.jpeg",
      "image": "D-balance-2000.jpg",
      "active_ingredients": "Cholecalciferol",
      "indication_and_usage": [
        "Prevention & treatment of Vitamin D3 deficiency and associated diseases such as Osteomalacia, Rickets, Fractures, Preeclampsia, Eclampsia during pregnancy.",
        "Management of Cardiovascular & Diabetic profile."
      ],
      "dosage_and_administration": {
        "adults": {
          "treatment_of_vitamin_d_deficiency": "50,000 IU once a week for 6-10 weeks, followed by maintenance therapy (800-2000 IU/day). Follow-up 25 (OH) D measurements should be made approximately 3 to 4 months after initiating maintenance therapy.",
          "treatment_of_vitamin_d_deficiency_alternate": "40,000 IU/week for 7 weeks, followed by maintenance therapy (1400-2000 IU/day). Follow-up 25 (OH) D measurements should be made approximately 3 to 4 months after initiating maintenance therapy.",
          "prevention_of_vitamin_d_deficiency": "20,000 IU/month."
        },
        "children": {
          "treatment_of_vitamin_d_deficiency_12_18_years": "20,000 IU once every 2 weeks for 6 weeks.",
          "prevention_of_vitamin_d_deficiency_12_18_years": "20,000 IU once every 6 weeks."
        }
      },
      "contraindications": [
        "Hypersensitivity to Cholecalciferol (Vitamin D3) or any of the excipients in the product.",
        "Hypervitaminosis D",
        "Nephrolithiasis",
        "Diseases or conditions resulting in hypercalcemia and/or hypercalciuria",
        "Severe renal impairment"
      ],
      "drug_interactions": [
        "Carbamazepine",
        "Dactinomycin",
        "Diuretics",
        "Fosphenytoin",
        "Miconazole",
        "Phenobarbital",
        "Phenytoin",
        "Primidone"
      ],
      "adverse_effects": {
        "metabolism_and_nutrition_disorders": "Uncommon (1/1000 to <1/100): Hypercalcemia and hypercalciuria.",
        "gastrointestinal_disorders": "Rare (1/10,000 to <1/1000): Constipation, flatulence, bloating, abdominal distension, nausea, abdominal pain, and diarrhea.",
        "skin_and_subcutaneous_tissue_disorders": "Rare (1/10,000 to <1/1000): Pruritus, rash, and urticaria."
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Studies show safe use of doses up to 4000 IU during pregnancy. Recommended daily intake is 400 IU, but higher doses may be required for deficient women. Consult a medical practitioner for dosage adjustments based on severity and response to treatment.",
        "lactation": "Cholecalciferol and its metabolites are excreted in breast milk. Overdose in infants induced by nursing mothers has not been observed. However, when prescribing additional Cholecalciferol to a breastfed child, the dose given to the mother should be considered."
      },
      "preparation": [
        "50000 IU Licap",
        "40000 IU Licap",
        "20000 IU Licap",
        "2000 IU Licap"
      ]
    },
    {
      "name": "Defiron®",
     "img_id":"0FIQeDv.jpeg",
      "image": "Defiron.jpg",
      "active_ingredients": "Iron Sucrose Injection",
      "indication_and_usage": [
        "Treatment of Iron deficiency in patients who require rapid iron supply.",
        "For patients who cannot tolerate oral iron therapy or are non-compliant.",
        "In active inflammatory bowel disease where oral iron preparations are ineffective.",
        "Non-dialysis dependent-chronic kidney disease (NDD-CKD) patients receiving erythropoietin.",
        "Non-dialysis dependent-chronic kidney disease (NDD-CKD) patients not receiving erythropoietin.",
        "Hemodialysis dependent-chronic kidney disease (HDD-CKD) patients receiving erythropoietin.",
        "Peritoneal dialysis dependent-chronic kidney disease (PDD-CKD) patients receiving erythropoietin.",
        "Treatment of Iron deficiency anaemia in patients undergoing surgical procedures, patients donating blood, postpartum patients."
      ],
      "dosage_and_administration": {
        "adults_and_elderly": "5-10 ml Defiron (100-200 mg Iron) once to three times a week depending on the hemoglobin level.",
        "children": "Recommended not to exceed 0.15 ml Defiron (3 mg Iron) per kg body weight once to three times per week depending on the hemoglobin level, with limited data available on children under study conditions.",
        "administration": "Defiron is to be administered intravenously by drip infusion, slow injection, or directly into the venous limb of the dialyser. It is not suitable for intramuscular use or total dose infusion (TDI). A test dose should be given before the first therapeutic dose. Therapy should be stopped immediately if allergic reactions or intolerance occur."
      },
      "contraindications_and_precautions": [
        "Contraindicated in patients with evidence of iron overload.",
        "Contraindicated in patients with known hypersensitivity to Iron Sucrose or any of its inactive components.",
        "Contraindicated in patients with anaemia not caused by iron deficiency.",
        "Contraindicated in patients with history of allergic disorders including asthma, eczema, and anaphylaxis.",
        "Contraindicated in patients with liver disease and infections."
      ],
      "side_effects": [
        "Hypotension",
        "Cramps/Leg cramps",
        "Nausea",
        "Headache",
        "Vomiting",
        "Diarrhea",
        "Some of these symptoms may be seen in patients with chronic renal failure or on hemodialysis not receiving intravenous iron."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Category B. Should be used during pregnancy only if clearly needed.",
        "lactation": "It is not known whether this drug is excreted in human milk. Caution should be exercised when administered to a nursing woman."
      },
      "preparation": "Iron 20 mg/ml IV Injection (5 ml)"
    },
    {
      "name": "Deflacort™",
     "img_id":"tnQJF9P.jpeg",
      "image": "Deflacort-6.jpg",
      "active_ingredients": "Deflazacort",
      "indication_and_usage": [
        "Anaphylaxis, asthma, severe hypersensitivity reactions",
        "Rheumatoid arthritis, juvenile chronic arthritis, polymyalgia rheumatica",
        "Systemic lupus erythematosus, dermatomyositis, mixed connective tissue disease (other than systemic sclerosis), polyarteritis nodosa, sarcoidosis",
        "Pemphigus, bullous pemphigoid, pyoderma gangrenosum",
        "Minimal change nephrotic syndrome, acute interstitial nephritis",
        "Rheumatic carditis",
        "Ulcerative colitis, Crohn’s disease",
        "Uveitis, optic neuritis",
        "Autoimmune haemolytic anaemia, idiopathic thrombocytopenic purpura",
        "Acute & lymphatic leukaemia, malignant lymphoma, multiple myeloma",
        "Immune suppression in transplantation"
      ],
      "dosage_and_administration": {
        "adults": {
          "acute_disorders": "Up to 120 mg/day may be needed initially.",
          "maintenance_doses": "3 - 18 mg/day depending on the condition.",
          "rheumatoid_arthritis": "3 - 18 mg/day, smallest effective dose should be used.",
          "bronchial_asthma": {
            "acute_attack": "48-72 mg/day depending on severity.",
            "chronic_asthma": "Titrate to the lowest dose that controls symptoms."
          },
          "other_conditions": "Dose titrated to the lowest effective dose for maintenance."
        },
        "hepatic_impairment": "Carefully monitor and adjust to the minimum effective dose.",
        "renal_impairment": "No special precautions other than those generally adopted in glucocorticoid therapy.",
        "elderly": "No special precautions other than those generally adopted in glucocorticoid therapy.",
        "children": {
          "general_guidance": "0.25 - 1.5 mg/kg/day, use the lowest effective dosage.",
          "juvenile_chronic_arthritis": "0.25 - 1.0 mg/kg/day.",
          "nephrotic_syndrome": "1.5 mg/kg/day followed by down titration.",
          "bronchial_asthma": "0.25 - 1.0 mg/kg on alternate days."
        }
      },
      "contraindications_and_precautions": [
        "Hypersensitivity to Deflazacort or any of its ingredients.",
        "Patients receiving live virus immunisation.",
        "Cardiac disease or congestive heart failure (except in the presence of active rheumatic carditis).",
        "Hypertension, thromboembolic disorders, gastritis, oesophagitis, ulcerative colitis.",
        "Diabetes mellitus, osteoporosis, renal insufficiency, emotional instability, or psychotic tendency.",
        "Liver failure, ocular herpes simplex, hypothyroidism, and cirrhosis."
      ],
      "side_effects": [
        "Musculoskeletal issues such as osteoporosis.",
        "Fluid & electrolyte disturbances such as oedema & heart failure.",
        "Ophthalmic issues such as glaucoma, papilloedema.",
        "Gastrointestinal issues such as dyspepsia, peptic ulceration.",
        "General reactions such as anaphylaxis & benign intracranial hypertension.",
        "Withdrawal symptoms such as acute adrenal insufficiency, hypotension, and death."
      ],
      "drug_interactions": [
        "Rifampicin, rifabutin, carbamazepine, phenobarbital, phenytoin, primidone, aminoglutethimide.",
        "Ketoconazole, insulin, acetazolamide, carbenoxolone.",
        "Estrogens, hypoglycaemics, antihypertensives, diuretics, coumarin anticoagulants.",
        "Non-depolarising muscle relaxants, salicylates, antacids, oral contraceptives, vaccines.",
        "Liver enzyme inducers, liver enzyme inhibitors, beta-agonists, and xanthines."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Deflazacort crosses the placenta. Should only be used when the benefits to the mother & child outweigh the risks.",
        "lactation": "Corticosteroids are excreted in breast milk. Up to 50 mg daily is unlikely to cause systemic effects in the infant. Higher doses may cause adrenal suppression, but the benefits of breastfeeding outweigh the risk."
      },
      "use_in_children": "Corticosteroids can cause dose-related growth retardation in infancy, childhood, and adolescence, which may be irreversible.",
      "preparation": [
        "6 mg tablet",
        "24 mg tablet",
        "30 mg tablet",
        "60 ml suspension"
      ]
    },
    {
      "name": "Depram®",
     "img_id":"FUYR82l.jpeg",
      "image": "Depram-2.jpg",
      "active_ingredients": "Imipramine",
      "indication_and_usage": ["Depression", "Nocturnal enuresis"],
      "dosage_and_administration": {
        "depression": "1 tab 3 times daily.",
        "nocturnal_enuresis": "1 tab/day for children ≥ 6 years of age, before bedtime."
      },
      "contraindications_and_precautions": [
        "Recent myocardial infarction",
        "Arrhythmias (particularly heart block)",
        "Not indicated in manic phase",
        "Severe liver disease"
      ],
      "side_effects": [
        "Dry mouth",
        "Less sedation",
        "Blurred vision",
        "Constipation",
        "Nausea",
        "Difficulty with micturition",
        "Cardiovascular side effects",
        "Sweating",
        "Tremors",
        "Interference with sexual function",
        "Blood sugar changes"
      ],
      "drug_interactions": [
        "Monoamine Oxidase Inhibitors (MAOI)",
        "Anticholinergic agents",
        "Antihypertensive agents",
        "Methylphenidate",
        "Levodopa",
        "Antipsychotic drugs",
        "Cimetidine",
        "Barbiturates",
        "TCA"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Treatment with Imipramine should be avoided during pregnancy, unless the anticipated benefits justify the potential risk to the fetus.",
        "lactation": "Consult a doctor before using during lactation."
      },
      "preparation": ["25 mg Tablet"]
    },
    {
      "name": "Deprex™",
     "img_id":"4f0Jv5Q.jpeg",
      "image": "Deprex_5_l.jpg",
      "active_ingredients": "Olanzapine",
      "indication_and_usage": [
        "Acute & maintenance treatment of schizophrenia & related psychoses where positive symptoms (e.g. delusions, hallucinations, disordered thinking, hostility & suspiciousness)",
        "Acute manic or mixed episodes in bipolar disorder"
      ],
      "dosage_and_administration": {
        "recommended_starting_dose": "10 mg/day, administered as a single daily dose without regard to meals"
      },
      "contraindications_and_precautions": [
        "Hypersensitivity",
        "Narrow-angle glaucoma",
        "Prostatic hypertrophy",
        "Paralytic ileus & related conditions",
        "Neuroleptic Malignant Syndrome (NMS): unexplained high fever without additional clinical manifestations of NMS, all antipsychotic medicines, including olanzapine, must be discontinued",
        "History of seizures or conditions associated with seizures"
      ],
      "side_effects": {
        "frequent": ["Somnolence", "Weight gain"],
        "occasional": [
          "Dizziness",
          "Asthenia",
          "Akathisia",
          "Increased appetite",
          "Peripheral oedema",
          "Orthostatic hypotension",
          "Mild, transient anticholinergic effects including constipation & dry mouth",
          "Transient, asymptomatic elevations of hepatic transaminases (ALT, AST)"
        ]
      },
      "preparation": ["5 mg Tablet", "10 mg Tablet"]
    },
    {
      "name": "De-rash®",
     "img_id":"LxIN02j.jpeg",
      "image": "De-rash.jpg",
      "active_ingredients": "Zinc Oxide",
      "indication_and_usage": [
        "Helps treat & prevent diaper rash while it moisturizes & nourishes the skin",
        "Provides a protective barrier on the skin against natural causes of irritation",
        "Spreads smoothly onto the skin and can be wiped off easily without causing irritation"
      ],
      "dosage_and_administration": {
        "steps": [
          "Change wet & soiled diapers promptly",
          "Cleanse the diaper area and allow drying",
          "Apply ointment liberally as often as necessary, especially at bedtime or anytime exposure to wet diapers may be prolonged"
        ]
      },
      "contraindications_and_precautions": [
        "For external use only",
        "Avoid contact with eyes",
        "Stop use and ask a doctor if the condition worsens or does not improve within 7 days",
        "If swallowed, get medical help immediately",
        "Keep out of reach of children"
      ],
      "side_effects": "Not known",
      "use_in_children": "Recommended",
      "preparation": "25 gm ointment"
    },
    {
      "name": "Dermasol®",
     "img_id":"o6KQJYX.jpeg",
      "image": "Dermasol-0.5-Ointment.jpg",
      "active_ingredients": "Clobetasol Propionate",
      "indication_and_usage": [
        "Eczema",
        "Psoriasis",
        "Hypertrophic lichen planus",
        "Localized bullous disorders",
        "Keloid scarring",
        "Pretibial myxoedema",
        "Vitiligo",
        "Suppression of reaction after cryotherapy"
      ],
      "dosage_and_administration": {
        "steps": [
          "Apply once or twice daily until improvement occurs",
          "Should not be continued for more than four weeks"
        ]
      },
      "contraindications_and_precautions": [
        "Impetigo",
        "Tinea corporis",
        "Herpes simplex",
        "Scabies",
        "Acne vulgaris",
        "Rosacea",
        "Gravitational ulceration"
      ],
      "side_effects": [
        "Adrenal suppression",
        "Prolonged & intensive treatment with a highly active corticosteroid may cause atrophic changes like thinning, striae, and dilatation of the superficial blood vessels"
      ],
      "use_in_pregnancy_and_lactation": "Clobetasol Propionate should be avoided during pregnancy",
      "use_in_children": "Should not be used in children below the age of 12 years",
      "preparation": "20 gm cream & ointment"
    },
    {
      "name": "Dermasol-N®",
     "img_id":"W6DJDx1.jpeg",
      "image": "Dermasol-N.jpg",
      "active_ingredients": [
        "Clobetasol Propionate BP",
        "Neomycin Sulphate BP",
        "Nystatin BP"
      ],
      "indication_and_usage": [
        "Short courses treatment of eczemas infection or fungal infection is present, suspected or likely to occur",
        "Neurodermatoses",
        "Psoriasis (excluding widespread plaque psoriasis) where secondary bacterial infection or fungal infection is present, suspected or likely to occur",
        "Other inflammatory conditions which do not respond satisfactorily to less active steroids"
      ],
      "dosage_and_administration": {
        "adults": "Apply sparingly to the affected area once or twice daily until improvement occurs",
        "resistant_lesions": "For very resistant lesions, especially with hyperkeratosis, the anti-inflammatory effect can be enhanced by occluding the treatment area with polythene if necessary",
        "treatment_duration": "Treatment should not be continued for more than 7 days without medical supervision. If a longer course is necessary, treatment should not exceed 4 weeks without review of the patient’s condition",
        "elderly": "Dermasol-N is suitable for use in elderly, but caution should be exercised in cases of decreased renal function due to possible systemic absorption of Neomycin Sulphate",
        "children": "Suitable for children (2 years and over) at the same dose as adults. Not recommended for use in neonates and infants (younger than 2 years)"
      },
      "contraindications_and_precautions": [
        "Rosacea",
        "Acne vulgaris",
        "Perioral dermatitis",
        "Primary cutaneous viral infections (e.g., Herpes simplex, chicken pox)",
        "Hypersensitivity to the preparation"
      ],
      "side_effects": [
        "Prolonged use of large amounts or treatment of extensive areas can lead to systemic absorption resulting in features of hypercortisolism",
        "Higher risk of hypercortisolism in infants, children, and with occlusive dressings",
        "Prolonged treatment may cause local atrophic changes in the skin such as thinning, striae, and dilatation of superficial blood vessels",
        "Pigmentation changes and hypertrichosis have been reported with topical steroids"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Not recommended due to the potential risk of fetal toxicity from Neomycin in the maternal blood crossing the placenta",
        "lactation": "The safety of Clobetasol Propionate in lactating mothers has not been established"
      },
      "preparation": "15 gm Cream & Ointment"
    },
    {
      "name": "Dermasol®-S",
     "img_id":"5G76uHP.png",
      "image": "Dermasol_s.png",
      "active_ingredients": "Clobetasol Propionate",
      "indication_and_usage": [
        "Topical therapy of recalcitrant corticosteroid-responsive dermatitis of the scalp",
        "Recalcitrant cases of psoriasis and seborrheic dermatitis"
      ],
      "dosage_and_administration": {
        "application": "Apply required quantity of spray once or twice daily to the affected areas of the scalp and gently rub in"
      },
      "contraindications_and_precautions": [
        "Infections of the scalp",
        "Hypersensitivity to the preparation",
        "Use is not indicated in dermatitis in children under one year of age",
        "Care must be taken to avoid contact with eyes",
        "Long-term continuous therapy should be avoided, particularly in infants and children due to risk of adrenal suppression",
        "Topical corticosteroids may cause rebound relapses, tolerance, risk of generalized pustular psoriasis, and systemic toxicity in psoriasis",
        "Appropriate antimicrobial therapy should be used when treating infected lesions. Any spread of infection requires withdrawal of corticosteroid therapy and systemic antimicrobial treatment"
      ],
      "side_effects": [
        "Prolonged use of large amounts or treatment of extensive areas can result in systemic absorption leading to hypercortisolism",
        "This effect is more likely in infants, children, and with occlusive dressings",
        "Local atrophy may occur after prolonged treatment",
        "In rare instances, corticosteroids (or their withdrawal) may provoke pustular psoriasis"
      ],
      "drug_interactions": [
        "Potential interactions with other corticosteroid-containing preparations"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Topical corticosteroids may cause fetal abnormalities in animal studies, but relevance to humans is not established. Use should be limited during pregnancy, especially in large amounts or prolonged periods",
        "lactation": "The safety of Clobetasol Propionate during lactation has not been established"
      },
      "use_in_children": "Not recommended for use in children under one year of age",
      "preparation": "Each container contains 25 ml Solution"
    },
    {
      "name": "Dexonex®",
     "img_id":"cLMT0dr.jpeg",
      "image": "DEXONEX-5MG.jpg",
      "active_ingredients": "Dexamethasone",
      "indication_and_usage": [
        "Various types of dermatological disorders",
        "Allergic disorders",
        "Severe respiratory disorders like severe bronchial asthma and non-specific chronic obstructive lung disease",
        "Primary/secondary adrenocortical insufficiency",
        "Ocular inflammatory conditions unresponsive to topical corticosteroids",
        "Adjunctive therapy for various rheumatic disorders",
        "Other indications requiring glucocorticoid therapy"
      ],
      "dosage_and_administration": {
        "adults": "Daily oral dosages vary from 1 to 10 mg, depending on individual response",
        "children": "Daily oral dosages vary from 0.03 to 0.20 mg/kg body weight, depending on individual response"
      },
      "contraindications_and_precautions": [
        "Contraindicated in patients with gastric & duodenal ulcers, systemic & ophthalmic fungal infections, viral infections (e.g., varicella, herpes genitalis, viral infections of the eye), glaucoma, and hypersensitivity to corticosteroids",
        "Use the lowest possible dose for the condition under treatment and reduce gradually",
        "Use with caution in patients with osteoporosis, cardiomyopathy, hypertension, renal insufficiency, and latent tuberculosis"
      ],
      "side_effects": [
        "Endocrine & metabolic disturbances",
        "Fluid & electrolyte disturbances",
        "Musculoskeletal effects",
        "Gastrointestinal effects",
        "Dermatological effects",
        "Ophthalmic effects",
        "CNS effects",
        "Immunosuppressive effects (especially with prolonged systemic glucocorticoid therapy)"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "US FDA pregnancy category C. Glucocorticoids appear in breast milk. High dosages should not be used during pregnancy",
        "lactation": "Mothers taking high dosages of corticosteroids should be advised not to breast-feed"
      },
      "use_in_children": "In pediatric patients, titrate to the lowest effective dose to minimize potential growth effects",
      "preparation": "0.5 mg Tablet & 5 mg/ml IV or IM Injection"
    },
    {
      "name": "Dexonex-CTM",
     "img_id":"SI10h5o.jpeg",
      "image": "dexonex-05-mg-tablet.jpg",
      "form": "Eye/Ear Drops",
      "active_ingredients": ["Dexamethasone Phosphate", "Chloramphenicol"],
      "indication_and_usage": {
        "eye": [
          "Steroid-responsive inflammatory ocular conditions where a corticosteroid is indicated and where bacterial infection or risk of bacterial ocular infection exists",
          "Chronic anterior uveitis",
          "Corneal injury from chemical, radiation, or thermal burns, or foreign body penetration",
          "Postoperative inflammation",
          "Other ocular inflammation associated with infection"
        ],
        "ear": [
          "Otitis externa",
          "Otitis media",
          "Chronic suppurative otitis media"
        ]
      },
      "dosage_and_administration": {
        "eye": {
          "bacterial_conjunctivitis": "One or two drops instilled into the conjunctival sac(s) every two hours while awake for two days, then every four hours for the next five days"
        },
        "ear": "Two to three drops every two to three hours initially. Frequency should be decreased gradually as clinical signs improve, but therapy should not be discontinued prematurely"
      },
      "contraindications_and_precautions": [
        "Epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and other viral diseases of the conjunctiva and cornea",
        "Mycobacterial infections of the eye",
        "Fungal diseases of ocular structures",
        "Hypersensitivity to any component of the medication",
        "Possibility of persistent fungal infections of the cornea after prolonged corticosteroid dosing"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "US FDA Pregnancy category C. Should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus",
        "lactation": "Caution should be exercised when administering Dexamethasone ophthalmic solution to a nursing woman"
      },
      "use_in_children": "Safety and efficacy in pediatric patients have not been established",
      "side_effects": [
        "Transient ocular burning or discomfort",
        "Other reactions include stinging, redness, itching, conjunctivitis/keratitis, periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain"
      ],
      "preparation": "(Dexamethasone Sodium Phosphate 1 mg & Chloramphenicol 5 mg)/ml sterile solution"
    },
    {
      "name": "Dibenol®",
     "img_id":"MTaSMfN.jpeg",
      "image": "DIBENOL.jpg",
      "active_ingredients": "Glibenclamide",
      "indication_and_usage": "For the management of Diabetes Mellitus.",
      "dosage_and_administration": {
        "recommended_dose": "Half tablet (2.5 mg) to 3 tablets daily, as directed by the physician and depending on blood sugar level"
      },
      "contraindications_and_precautions": [
        "Known hypersensitivity to the drug or any of its excipients",
        "Type 1 diabetes or diabetic ketoacidosis, with or without coma (this should be treated with insulin)"
      ],
      "side_effects": [
        "Nausea",
        "Vomiting",
        "Epigastric pain",
        "Dizziness",
        "Weakness",
        "Paraesthesia",
        "Headache",
        "Allergic skin reactions",
        "Haemopoietic reactions (leukopenia, thrombocytopenia, etc.)"
      ],
      "drug_interactions": [
        "Alcohol",
        "Cyclophosphamide",
        "Dicoumarol",
        "Monoamino oxidase inhibitors",
        "Phenylbutazone",
        "Propranolol",
        "Other beta-adrenergic blocking agents"
      ],
      "use_in_pregnancy_and_lactation": "No information is available on the use of glibenclamide in human pregnancy.",
      "preparation": "5 mg Tablet"
    },
    {
      "name": "Diliner® DR",
     "img_id":"1GFTwj4.jpeg",
      "image": "Diliner-DR.jpg",
      "active_ingredients": "Duloxetine",
      "indication_and_usage": [
        "Depression",
        "Anxiety",
        "Diabetic Peripheral Neuropathic Pain",
        "Osteoarthritis pain",
        "Fibromyalgia"
      ],
      "dosage_and_administration": {
        "recommended_dose": "30-60 mg/day (given either once a day or as 30 mg BID) without regard to meals"
      },
      "contraindications_and_precautions": [
        "Known hypersensitivity to Duloxetine",
        "Concomitant use in patients taking Monoamine Oxidase Inhibitors (MAOIs)",
        "Avoid use in patients with uncontrolled narrow-angle glaucoma"
      ],
      "side_effects": {
        "MDD_patients": [
          "Nausea",
          "Dry mouth",
          "Constipation",
          "Decreased appetite",
          "Fatigue",
          "Somnolence",
          "Increased sweating"
        ],
        "DPN_patients": [
          "Nausea",
          "Somnolence",
          "Dizziness",
          "Constipation",
          "Dry mouth",
          "Decreased appetite",
          "Asthenia"
        ]
      },
      "drug_interactions": [
        "Inhibitors of CYP1A2 (e.g., Fluvoxamine, quinolone antibiotics)",
        "CYP2D6 inhibitors (e.g., Paroxetine, fluoxetine, quinidine)",
        "Thioridazine",
        "Alcohol",
        "Other CNS acting drugs"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Use only when potential benefits justify possible risk to the fetus",
        "lactation": "Women receiving the drug should not breastfeed their infants"
      },
      "preparation": [
        "30 mg DR (Delayed Release) Capsule",
        "60 mg DR (Delayed Release) Capsule"
      ]
    },
    {
      "name": "Diltizem® SR",
     "img_id":"MBZiaHP.jpeg",
      "image": "DILTIZEM-SR90.jpg",
      "active_ingredients": "Diltiazem",
      "indication_and_usage": [
        "Angina pectoris",
        "Hypertension with tachycardia"
      ],
      "dosage_and_administration": {
        "recommended_dose": "90 - 120 mg twice daily",
        "maximum_dose": "up to 240 mg"
      },
      "contraindications_and_precautions": [
        "Known hypersensitivity",
        "Sick sinus syndrome",
        "Second or third degree AV block",
        "Severe hypertension",
        "Acute myocardial infarction & pulmonary congestion"
      ],
      "side_effects": [
        "Bradycardia",
        "Sino-atrial block",
        "Atrioventricular block",
        "Hypertension",
        "Malaise",
        "Headache",
        "Hot flushes",
        "GIT disturbances",
        "Oedema",
        "Hepatitis",
        "Depression reported"
      ],
      "drug_interactions": [
        "Caution & careful dosage titration when administered concomitantly with other drugs that can affect cardiac contractility and/or conduction"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Use only when potential benefits justify possible risk to the fetus",
        "lactation": "Women receiving the drug should not breastfeed their infants"
      },
      "preparation": "90 mg SR Tablet"
    },
    {
      "name": "Dormitol®",
     "img_id":"NEh6WDV.jpeg",
      "image": "DORMITOL.jpg",
      "active_ingredients": "Midazolam",
      "indication_and_usage": [
        "Short term management of insomnia (Hypnotic)",
        "Relieves anxiety, tension & fear (Sedative)",
        "Pre-anaesthetics",
        "Anticonvulsants"
      ],
      "dosage_and_administration": {
        "duration": "Should not exceed 2 weeks, extension may be necessary in certain cases",
        "insomnia": {
          "adults": "7.5 mg to 15 mg daily",
          "elderly": "7.5 mg daily"
        },
        "premedication": {
          "dose": "7.5 mg to 15 mg",
          "timing": "30-60 minutes before the procedure"
        },
        "endoscopic_or_cardiovascular_procedures": {
          "adults": "Initial dose 2.5 mg (IV)",
          "elderly_and_debilitated": "1-1.5 mg (IV)"
        },
        "induction_of_anesthesia": {
          "adults": "10-15 mg (IV) or 0.07-0.1 mg/kg body weight, usually 5 mg (IM)",
          "children": "0.15-0.20 mg/kg (IM)",
          "elderly_and_debilitated": "0.025-0.05 mg/kg (IM)"
        },
        "rectal_administration_in_children": {
          "purpose": "Preoperative sedation",
          "dose": "0.35-0.45 mg/kg",
          "timing": "20-30 min before induction of general anesthesia"
        }
      },
      "contraindications_and_precautions": [
        "Known hypersensitivity to Midazolam or other benzodiazepines",
        "Severe respiratory insufficiency",
        "Severe hepatic insufficiency",
        "Sleep apnea syndrome",
        "Myasthenia gravis",
        "Patients with a history of alcohol or drug abuse",
        "Children",
        "Concomitant use with CNS depressants, erythromycin, azole type antimycotics, or cimetidine may interfere with metabolism",
        "Long-term use may increase dependency",
        "Avoid before driving or performing skilled tasks due to strong sedative effects"
      ],
      "side_effects": [
        "Drowsiness (most common)",
        "CNS depression",
        "Ataxia",
        "Confusion",
        "Tiredness",
        "Muscle weakness",
        "Fatigue",
        "Headache",
        "Dizziness",
        "Double vision"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Category D, use only when potential benefits justify possible risk to the fetus",
        "lactation": "Breastfeeding is not recommended during treatment"
      },
      "preparation": ["7.5 mg tablet", "15 mg/3ml injection"]
    },
    {
      "name": "Doxacil",
     "img_id":"HPaz2bk.jpeg",
      "image": "Doxacil.jpg",
      "active_ingredients": "Doxycycline",
      "indication_and_usage": [
        "Respiratory tract infections (e.g., pneumonia, influenza, pharyngitis, tonsillitis, bronchitis, sinusitis, otitis media, streptococcal and staphylococcal infections where tetracycline resistance is not a problem)",
        "Genitourinary tract infections (e.g., pyelonephritis, cystitis, urethritis, gonorrhea, epididymitis, syphilis, chancroid, granuloma inguinale)",
        "Chlamydia (e.g., lymphogranuloma venereum, psittacosis, trachoma)",
        "Intestinal diseases (e.g., Whipple's disease, tropical sprue, blind loop syndrome, acute intestinal amoebiasis as an adjunct to amoebicides)",
        "Bacillary infections (e.g., brucellosis, tularemia, cholera, traveler’s diarrhea)",
        "Acne (e.g., acne vulgaris, acne conglobata, other forms of acne)",
        "Other infections (e.g., actinomycosis, yaws, relapsing fever, leptospirosis, typhus, rickettsial pox, Q fever, cellulitis, furunculosis, abscess, infections caused by Mycobacterium marinum, Bordetella pertussis, Bacillus anthracis)"
      ],
      "dosage_and_administration": {
        "adults": {
          "initial_dose": "Two capsules at a time or one capsule every 12 hours for the first day",
          "maintenance_dose": "One capsule per day",
          "severe_infections": "Dosage may be doubled based on severity"
        },
        "children": {
          "age_and_weight": "Over 8 years or weighing 45 kg or less",
          "initial_dose": "4.4 mg/kg on the first day",
          "maintenance_dose": "2.2 mg/kg daily"
        },
        "acute_gonococcal_urethritis": {
          "male": "1 capsule twice daily for 2 to 4 days",
          "female": "1 capsule twice daily until cure is obtained"
        },
        "chlamydial_infections": "1 capsule twice daily for 7 days",
        "syphilis": "3 capsules in divided doses for 10 days"
      },
      "contraindications_and_precautions": [
        "Known hypersensitivity to any Tetracyclines",
        "Severe hepatic disorder",
        "Systemic lupus erythematosus",
        "Concomitant intake of alkalis, antacids, and iron may interfere with absorption",
        "Avoid use with penicillin",
        "Not recommended in pregnant women unless essential for patient welfare",
        "Use during tooth development (last half of pregnancy, infancy, childhood up to 12 years) may cause permanent tooth discoloration",
        "Not recommended in children under 12 years unless other drugs are ineffective or contraindicated"
      ],
      "side_effects": [
        "Gastrointestinal irritation (e.g., epigastric distress, abdominal discomfort, nausea, vomiting)",
        "Hematological changes (with long-term therapy)",
        "Skin reactions (e.g., rashes, urticaria, exfoliative dermatitis, rare)"
      ],
      "drug_interactions": ["Alkalis", "Antacids", "Iron", "Penicillin"],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Not recommended unless essential for patient welfare due to risk of tooth discoloration and other effects",
        "lactation": "No specific information provided, but use with caution"
      },
      "preparation": "100 mg Capsule"
    },
    {
      "name": "Duolax™",
     "img_id":"2eoshkn.jpeg",
      "image": "Duolax.jpg",
      "active_ingredients": ["Magnesium Hydroxide", "Liquid Paraffin"],
      "indication_and_usage": [
        "Constipation",
        "Hyperacidity with constipation",
        "Anorectal disorder",
        "Post-operative constipation",
        "Constipation associated with chronic cholecystitis",
        "Hernia"
      ],
      "dosage_and_administration": {
        "adults": "15-30 ml before breakfast or at bedtime",
        "children": {
          "over_7_years": "7.5-15 ml at bedtime",
          "3_to_7_years": "5-10 ml at bedtime"
        },
        "administration_note": "The dose may be mixed with milk or half a glass of water if desired"
      },
      "contraindications_and_precautions": [
        "Acute GI conditions like abdominal pain"
      ],
      "side_effects": [
        "Rectal irritation",
        "Potassium loss (thirst, weakness, nausea, diarrhea)"
      ],
      "drug_interactions": [
        "Cimetidine",
        "Diuretics",
        "Famotidine",
        "Ranitidine"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Can be given to pregnant women only if physician recommends",
        "lactation": "Can be given to lactating mothers only if physician recommends"
      },
      "use_in_children": {
        "general": "Safe for children over 03 years",
        "under_3_years": "Can be given if physician recommends"
      },
      "preparation": "Each 5 ml oral emulsion contains 300 mg Magnesium Hydroxide USP & 1.25 ml Liquid Paraffin BP"
    },
    {
      "name": "Durol®",
     "img_id":"y9cxzNR.png",
      "image": "Durol.png",
      "active_ingredients": "Carvedilol",
      "indication_and_usage": [
        "Congestive Heart Failure: Treatment of mild or moderate heart failure of ischemic or cardiomyopathic origin, in conjunction with digitalis, diuretics, and ACE inhibitors to reduce disease progression",
        "Hypertension: Management of essential hypertension, used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics"
      ],
      "dosage_and_administration": {
        "hypertension": {
          "initial_dose": "12.5 mg once daily",
          "usual_dose": "Increased after 2 days to 25 mg once daily",
          "maximum_dose": "May be increased at intervals of at least 2 weeks to max 50 mg daily in single or divided doses",
          "elderly": "12.5 mg daily may provide satisfactory control"
        },
        "angina": {
          "initial_dose": "12.5 mg twice daily",
          "usual_dose": "Increased after 2 days to 25 mg twice daily"
        },
        "heart_failure": {
          "administration_note": "Under special supervision, with food",
          "initial_dose": "3.125 mg twice daily",
          "dose_escalation": "Increased at intervals of at least 2 weeks to 6.25 mg twice daily, then 12.5 mg twice daily, then 25 mg twice daily",
          "maximum_dose": "25 mg twice daily for severe heart failure or body weight less than 85 kg; 50 mg twice daily for patients over 85 kg"
        }
      },
      "contraindications_and_precautions": [
        "Severe chronic cardiac failure requiring intravenous inotropic therapy",
        "Bronchial asthma or related bronchospastic conditions",
        "Second or third-degree AV block",
        "Sick sinus syndrome (unless a permanent pacemaker is in place)",
        "Cardiogenic shock",
        "Severe bradycardia",
        "Clinically manifested hepatic impairment",
        "Hypersensitivity to the drug"
      ],
      "side_effects": [
        "Postural hypotension",
        "Dizziness",
        "Headache",
        "Fatigue",
        "Gastro-intestinal disturbances",
        "Bradycardia",
        "Diminished peripheral circulation",
        "Peripheral oedema",
        "Painful extremities",
        "Dry mouth",
        "Dry eyes",
        "Eye irritation or disturbed vision",
        "Impotence",
        "Disturbances of micturition",
        "Influenza-like symptoms",
        "Angina (rarely)",
        "AV block",
        "Exacerbation of intermittent claudication or Raynaud’s phenomenon",
        "Allergic skin reactions",
        "Exacerbation of psoriasis",
        "Nasal stuffiness",
        "Wheezing",
        "Depressed mood",
        "Sleep disturbances",
        "Paraesthesia",
        "Heart failure",
        "Changes in liver enzymes",
        "Thrombocytopenia",
        "Leucopenia"
      ],
      "drug_interactions": [
        "Digoxin (increased bioavailability, not clinically significant)",
        "No significant interactions with hydrochlorothiazide, cimetidine, torsemide, or warfarin"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Not recommended due to potential alpha and beta blockade effects on the fetus; embryotoxicity observed in animal studies at large doses",
        "lactation": "Not recommended as carvedilol is excreted in breast milk"
      },
      "use_in_children": "Safety and efficacy not established in pediatric patients",
      "preparation": "6.25 mg tablet"
    },
    {
      "name": "Dyvon™",
     "img_id":"vpRPg7u.jpeg",
      "image": "Dyvon-Oint-20gm.jpg",
      "active_ingredients": "Calcipotriol",
      "indication_and_usage": [
        "Topical treatment of chronic stable plaque type psoriasis vulgaris in adult patients"
      ],
      "dosage_and_administration": {
        "adults": {
          "application": "Apply topically to the affected area twice daily (morning and evening)",
          "adjustment": "Less frequent application may be indicated after initial treatment period",
          "discontinuation": "Discontinue after satisfactory improvement; reinstitute if recurrence occurs",
          "duration_note": "Experience lacking for use beyond 1 year"
        }
      },
      "contraindications_and_precautions": [
        "History of hypersensitivity to any components of the preparation",
        "Known disorders of calcium metabolism",
        "Severe renal insufficiency",
        "Severe hepatic disorders",
        "Avoid application or accidental transfer to scalp, face, mouth, or eyes",
        "Not recommended for use on the face due to risk of itching and erythema",
        "Avoid treatment of more than 30% of body surface",
        "Instruct patients to wash hands after use to avoid inadvertent transfer to face"
      ],
      "drug_interactions": [
        "No experience with concomitant therapy of other antipsoriatic drugs applied to the same skin area"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Safety not established; use only if benefits clearly outweigh risks",
        "lactation": "Unknown if excreted in breast milk; use only if benefits outweigh risks, avoid application to chest area to prevent ingestion by infants"
      },
      "use_in_children": "Not recommended due to inadequate experience",
      "preparation": "20 gm Ointment"
    },
    {
      "name": "Dyvon™ Plus",
     "img_id":"3Ui21ez.jpeg",
      "image": "dyvon-pluse.jpg",
      "active_ingredients": ["Betamethasone Dipropionate", "Calcipotriol"],
      "indication_and_usage": [
        "Topical treatment of plaque type psoriasis of the scalp & body"
      ],
      "dosage_and_administration": {
        "application": "Apply required quantity of Ointment & Topical Suspension once daily to affected areas, gently rub in using fingertips",
        "duration": "Continue for up to 8 weeks; may discontinue earlier if symptoms clear",
        "maximum_dose": "Maximum weekly dose should not exceed 100 gm",
        "administration_note": "Shake before use; not for oral, ophthalmic, or intravaginal use"
      },
      "contraindications_and_precautions": [
        "History of hypersensitivity to any components of the preparation",
        "Known disorders of calcium metabolism",
        "Severe renal insufficiency",
        "Severe hepatic disorders",
        "Risk of hypercalcemia and hypercalciuria; discontinue if either occurs until calcium metabolism normalizes",
        "Topical corticosteroids may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing’s syndrome, or unmask latent diabetes",
        "Increased risk of adrenal suppression with prolonged treatment duration",
        "Systemic absorption may require evaluation for HPA axis suppression; modify use if suppression develops",
        "Potent corticosteroids, large area use, prolonged use, or occlusive use may increase systemic absorption",
        "Local adverse reactions include atrophy, striae, irritation, acneiform eruptions, hypopigmentation, allergic contact dermatitis; more likely with occlusive use or potent corticosteroids",
        "Not recommended for use on face, axillae, groin, or areas with atrophy",
        "Children may be more susceptible to systemic toxicity from topical corticosteroids"
      ],
      "side_effects": ["Folliculitis", "Burning sensation of skin"],
      "drug_interactions": [],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "No adequate studies; use only if potential benefit justifies potential risk to the fetus",
        "lactation": "Unknown if sufficient systemic absorption produces detectable quantities in human milk; caution advised as systemically administered corticosteroids may suppress growth, interfere with endogenous corticosteroid production, or cause other effects"
      },
      "use_in_children": "Not recommended for children and adolescents below 18 years",
      "preparation": ["20 gm Ointment", "25 ml Topical Suspension"]
    },
    {
      "name": "Efaxim™",
     "img_id":"0QiNhDD.jpeg",
      "image": "efaxim-200.jpg",
      "active_ingredients": "Rifaximin",
      "indication_and_usage": [
        "Treatment of traveler’s diarrhea by noninvasive strains of E. coli",
        "Reduction in risk of hepatic encephalopathy",
        "Bacterial overgrowth of irritable bowel syndrome"
      ],
      "dosage_and_administration": {
        "traveler’s_diarrhea": {
          "age": ">12 years",
          "dose": "200 mg 3 times daily for 3 days"
        },
        "hepatic_encephalopathy": {
          "age": ">18 years",
          "dose": "550 mg 2 times daily"
        },
        "bacterial_overgrowth_irritable_bowel_syndrome": {
          "dose": "400 mg 3 times daily for 10 days or 550 mg 3 times daily for 14 days"
        },
        "administration_note": "Can be taken with or without food"
      },
      "contraindications_and_precautions": [
        "Hypersensitivity to Rifaximin, any rifamycin antimicrobial agents, or any components of the product",
        "Not effective for diarrhea complicated by fever and/or blood in stools",
        "Discontinue if diarrhea symptoms worsen or persist for more than 24-48 hours; consider alternative antibiotic therapy",
        "Consider pseudomembranous colitis in patients presenting with diarrhea after antibacterial agent use"
      ],
      "side_effects": [
        "Flatulence",
        "Headache",
        "Abdominal pain",
        "Rectal tenesmus",
        "Defecation urgency",
        "Nausea",
        "Constipation",
        "Pyrexia",
        "Vomiting"
      ],
      "drug_interactions": [
        "In vitro study suggests Rifaximin induces CYP3A4, but not expected to induce CYP3A4 in patients with normal liver function at recommended dosing"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Category C; use only if potential benefit justifies potential risk to the fetus",
        "lactation": "Unknown if excreted in breast milk; use with caution"
      },
      "preparation": [
        "Efaxim™ 200 tablet: Each box contains 10 tablets in alu-alu blister",
        "Efaxim™ 550 tablet: Each box contains 10 tablets in alu-alu blister"
      ]
    },
    {
      "name": "Elorim™ Cream",
     "img_id":"haJRoBc.jpeg",
      "image": "Elorim_l.jpg",
      "active_ingredients": "Eflornithine Hydrochloride 13.9%",
      "composition": "Each gm cream contains Eflornithine Hydrochloride 139 mg as Eflornithine Hydrochloride Monohydrate INN",
      "indication_and_usage": "Reduction of unwanted facial hair in women",
      "dosage_and_administration": {
        "application": "Apply a thin layer to affected areas of the face and adjacent involved areas under the chin, rub in thoroughly",
        "frequency": "Use twice daily, at least 8 hours apart, or as directed by a physician",
        "post_application": "Do not wash treated area for at least 4 hours"
      },
      "contraindications_and_precautions": [
        "History of sensitivity to any components of the preparation",
        "For external use only",
        "Transient stinging or burning may occur when applied to abraded or broken skin"
      ],
      "side_effects": [
        "Acne",
        "Headache",
        "Dry skin",
        "Itching",
        "Rash",
        "Folliculitis"
      ],
      "drug_interactions": [
        "No known interactions with other topically applied drug products"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Category C; use only if potential benefit justifies potential risk to the fetus",
        "lactation": "Unknown if excreted in human milk; caution advised when administered to a nursing woman"
      },
      "use_in_children": "Safety and effectiveness not established in pediatric patients less than 12 years of age",
      "preparation": "30 gm Cream"
    },
    {
      "name": "Emcil®",
     "img_id":"VjaWLsw.jpeg",
      "image": "emcil-200-mg.jpg",
      "active_ingredients": "Pivmecillinam",
      "indication_and_usage": [
        "Acute cystitis",
        "Complicated urinary tract infections",
        "Salmonellosis",
        "Shigellosis",
        "Enteropathic E.coli diarrhoea",
        "Gram-negative septicaemia",
        "Biliary infections"
      ],
      "dosage_and_administration": {
        "adults": "1-2 tablets 3 times daily, depending on severity of infection",
        "children": {
          "less_than_20kg": "20-60 mg/kg divided into 3-4 daily doses",
          "more_than_20kg": "Normal adult dose"
        },
        "administration_note": "Take with at least 50-100 ml fluid"
      },
      "contraindications_and_precautions": [
        "No reported allergy to Pivmecillinam in patients with hypersensitivity to penicillins or cephalosporins"
      ],
      "side_effects": [
        "Gastrointestinal disturbances (nausea, vomiting, diarrhoea, indigestion) when taken on an empty stomach",
        "Skin rashes (in some cases)"
      ],
      "drug_interactions": [],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Use when expected benefits outweigh potential risks",
        "lactation": "Mecillinam is not excreted into breast milk"
      },
      "preparation": "200 mg Tablet"
    },
    {
      "name": "Emolent™ Cream & Lotion",
     "img_id":"ymWsxeS.jpeg",
      "image": "emolent_large_lotion.jpg",
      "active_ingredients": ["Light Liquid Paraffin", "White Soft Paraffin"],
      "indication_and_usage": ["Treatment of dry skin conditions"],
      "dosage_and_administration": {
        "application": "Apply to the affected area and rub in well when required",
        "note": "Especially effective after washing when sebum content of the stratum corneum may be depleted, resulting in excessive moisture loss"
      },
      "contraindications_and_precautions": [
        "Hypersensitivity to any of the ingredients of the cream or lotion"
      ],
      "side_effects": ["No remarkable adverse effects reported"],
      "drug_interactions": [],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "No restrictions on use",
        "lactation": "No restrictions on use"
      },
      "preparation": ["25 gm Cream", "120 ml Lotion"]
    },
    {
      "name": "Entacyd®",
     "img_id":"4bAWj5n.jpeg",
      "image": "Entacyd.jpg",
      "active_ingredients": ["Aluminum Hydroxide", "Magnesium Hydroxide"],
      "indication_and_usage": [
        "Hyperacidity",
        "Peptic ulcer",
        "Gastritis",
        "Heartburn",
        "Sour stomach",
        "Dyspepsia"
      ],
      "dosage_and_administration": {
        "dose": "Two tablets or two teaspoonfuls of suspension",
        "timing": "1-3 hours after meals and at bedtime"
      },
      "contraindications_and_precautions": [
        "Hypophosphatemia",
        "Hypermagnesemia"
      ],
      "side_effects": ["Long term use may cause alkaluria", "Nephrolithiasis"],
      "drug_interactions": [],
      "use_in_pregnancy_and_lactation": {},
      "preparation": ["Chewable tablet", "Suspension"]
    },
    {
      "name": "Entacyd® Plus",
     "img_id":"AuT1LLB.jpeg",
      "image": "ENTACYD-PLUS.jpg",
      "active_ingredients": [
        "Aluminum Hydroxide",
        "Magnesium Hydroxide",
        "Simethicone"
      ],
      "indication_and_usage": [
        "Hyperacidity",
        "Peptic ulcer",
        "Gastritis",
        "Peptic oesophagitis",
        "Gastric hyperacidity",
        "Heartburn",
        "Sour stomach",
        "Hiatus hernia"
      ],
      "dosage_and_administration": {
        "dose": "1-2 tablets or 1-2 teaspoonfuls of suspension",
        "timing": "1-3 hours after meals and at bedtime"
      },
      "contraindications_and_precautions": [
        "Renal failure",
        "Hypophosphatemia",
        "Alkalosis",
        "Hypermagnesemia"
      ],
      "side_effects": ["Diarrhea", "Constipation", "Regurgitation"],
      "drug_interactions": [],
      "use_in_pregnancy_and_lactation": {},
      "preparation": ["Chewable Tablet", "Suspension"]
    },
    {
      "name": "Epitra®",
     "img_id":"XJU7DcV.png",
      "image": "Epitra_0.5.png",
      "active_ingredients": "Clonazepam",
      "indication_and_usage": [
        "Anxiety and panic disorder, with or without agoraphobia",
        "Epilepsy and other seizure disorders, alone or as an adjunct in the management of myoclonic and akinetic seizures and petit mal variant (Lennox-Gastaut syndrome)"
      ],
      "dosage_and_administration": {
        "children": {
          "age_and_weight": "Infants and children up to 10 years or 30 kg",
          "initial_dose": "0.01-0.03 mg/kg/day, not exceeding 0.05 mg/kg/day, given in 2 or 3 divided doses",
          "dose_adjustment": "Increase by 0.25-0.50 mg every third day until maintenance dose of 0.1-0.2 mg/kg is reached, unless seizures are controlled or side effects preclude further increase"
        },
        "adults": {
          "initial_dose": "Not exceeding 1.5 mg/day, divided into three doses",
          "dose_adjustment": "Increase by 0.5-1 mg every three days until seizures are controlled",
          "maintenance_dose": "8-10 mg/day in three divided doses"
        }
      },
      "contraindications_and_precautions": [
        "Significant liver disease",
        "Narrow angle glaucoma",
        "Sensitivity to benzodiazepines",
        "Gradual withdrawal required when discontinuing",
        "May increase incidence or precipitate generalized tonic-clonic seizures in patients with multiple seizure types"
      ],
      "side_effects": [
        "Drowsiness",
        "Ataxia",
        "Behaviour problems",
        "Increased salivation"
      ],
      "drug_interactions": [
        "Alcohol",
        "Narcotics",
        "Barbiturates",
        "Nonbarbiturate hypnotics",
        "Antianxiety agents",
        "Phenothiazines",
        "Anticonvulsant drugs",
        "Monoamine oxidase inhibitors",
        "Tricyclic antidepressants"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Use only if potential benefit justifies potential risk to the fetus",
        "lactation": "Use only if potential benefit justifies potential risk"
      },
      "preparation": ["0.5 mg Tablet", "1 mg Tablet", "2 mg Tablet"]
    },
    {
      "name": "Eporen™",
     "img_id":"1E6kJx4.jpeg",
      "image": "Eporen.jpg",
      "active_ingredients": "Erythropoietin BP",
      "indication_and_usage": [
        "Anemia associated with Chronic Kidney Disease",
        "Anemia associated with chemotherapy in non-myeloid malignancy",
        "Anemic patients scheduled to undergo elective, noncardiac, nonvascular surgery",
        "Anemia associated with Zidovudine therapy in HIV patients"
      ],
      "dosage_and_administration": {
        "anemia_in_chronic_renal_failure": {
          "starting_dose": {
            "adult": "50-100 IU/kg thrice weekly by IV or SC route",
            "pediatric": "50 IU/kg thrice weekly by IV or SC route"
          },
          "dose_adjustment": "Increase if hematocrit does not rise by 5-6 points after 8 weeks and is below target range; reduce when hematocrit approaches 36% or increases >4 points in any 2-week period",
          "maintenance_dose": {
            "dialysis_patients": "Median 75 IU/kg thrice weekly, range 12.5-525 IU/kg thrice weekly",
            "non_dialysis_patients": "75-150 IU/kg/week"
          }
        },
        "anemia_in_cancer_patients_on_chemotherapy": {
          "starting_dose": {
            "adult": "150 IU/kg thrice weekly by SC route or 40,000 IU weekly by SC route",
            "pediatric": "25-300 IU/kg 3-7 times per week by SC or IV route"
          },
          "dose_adjustment": "Increase to 300 IU/kg thrice weekly if response is unsatisfactory; withhold if hematocrit exceeds 40% until it falls to 36%, then reduce by 25% and titrate"
        },
        "zidovudine_treated_hiv_patients": {
          "starting_dose": {
            "adult": "100 IU/kg thrice weekly by IV or SC route for 8 weeks",
            "pediatric": "50-400 IU/kg 2-3 times per week by SC or IV route"
          },
          "dose_adjustment": "Increase by 50-100 IU/kg thrice weekly if response is unsatisfactory; evaluate every 4-8 weeks and adjust by 50-100 IU/kg increments",
          "maintenance_dose": "Titrate to maintain hematocrit between 33-36%"
        },
        "surgery_patients": {
          "dose_schedule_1": "300 IU/kg/day by SC route for 10 days before surgery, on the day of surgery, and for 4 days after surgery",
          "dose_schedule_2": "600 IU/kg by SC route once weekly (21, 14, and 7 days before surgery) and a fourth dose on the day of surgery"
        },
        "administration_notes": [
          "Do not shake to avoid denaturing the glycoprotein",
          "Inspect for particulate matter and discoloration before administration",
          "IV injection over 1-2 minutes; for dialysis patients, inject post-dialysis",
          "Slow IV injection over 5 minutes may reduce flu-like symptoms",
          "Do not administer by IV infusion or with other drug solutions",
          "SC route: Maximum 1 mL per injection site; use multiple sites for larger volumes"
        ]
      },
      "contraindications_and_precautions": [
        "Uncontrolled hypertension",
        "Known hypersensitivity to mammalian cell-derived products",
        "History of hypersensitivity to Erythropoietin or any component of the preparation",
        "Use with caution in patients with controlled hypertension, ischaemic vascular disease, history of seizures, or suspected allergy",
        "Evaluate iron stores (transferrin saturation ≥20%, ferritin ≥100 ng/mL) before and during therapy; supplemental iron usually required"
      ],
      "side_effects": [
        "Headache",
        "Dizziness",
        "Fever",
        "Malaise",
        "Arthralgia",
        "Hyperkalemia (occasionally)",
        "Hypertension",
        "Palpitations",
        "Nausea",
        "Vomiting",
        "Anorexia",
        "Diarrhea",
        "Allergic reactions"
      ],
      "drug_interactions": [],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Category C; use only if clearly needed due to lack of controlled studies",
        "lactation": "Unknown if excreted in human milk; exercise caution when administering to nursing women"
      },
      "preparation": [
        "Eporen™ 3000 IU: 1 Pre-filled syringe containing 3000 IU of Recombinant Human Erythropoietin Alpha in Alu-PVC blister pack",
        "Eporen™ 5000 IU: 1 Pre-filled syringe containing 5000 IU of Recombinant Human Erythropoietin Alpha in Alu-PVC blister pack"
      ]
    },
    {
      "name": "Equra®",
     "img_id":"V4kHEcY.jpeg",
      "image": "EQURA-CREAM.jpg",
      "active_ingredients": "Urea",
      "indications": [
        "Ichthyosis & dry skin conditions",
        "eczemas",
        "psoriasis"
      ],
      "dosage_and_administration": "Twice daily",
      "side_effects": "Burning & irritation, if applied to inflamed, broken or exudative skin eruptions",
      "use_in_pregnancy_lactation": "Equra cream can be used during pregnancy & lactation. Equra can be used in all age groups.",
      "contraindications_precautions": [
        "Local irritation & edema, when applied to sensitive skin",
        "If the condition is aggravated or there is no improvement the doctor should be consulted"
      ],
      "preparation": "10% Cream"
    },
    {
      "name": "Erian®",
     "img_id":"qMwAPha.jpeg",
      "image": "Erian.jpg",
      "active_ingredients": [
        "Cinchocaine Hydrochloride",
        "Hydrocortisone",
        "Framycetin Sulphate",
        "Esculin"
      ],
      "indications": [
        "Internal & external haemorrhoids",
        "Haemorrhoids post-partum",
        "Anal pruritus, peri-anal eczema, anal fissures & proctitis",
        "Post-haemorrhoidectomy application to relieve pain & discomfort"
      ],
      "dosage_and_administration": {
        "ointment": "Apply a small quantity with the finger on the affected area, morning & evening and after each defecation. For deep application, use the supplied applicator/cannula.",
        "suppository": "One suppository in the morning, one in the evening, and after each defecation."
      },
      "contraindications": [
        "Hypersensitivity to any ingredient",
        "Pregnancy",
        "Herpes simplex, vaccinia, or varicella infections",
        "Tuberculous infection of the anal region"
      ],
      "precautions": [
        "Discontinue if sensitization occurs",
        "Prolonged use may cause systemic corticosteroid effects (rare)"
      ],
      "side_effects": "Long-term use may cause skin atrophy, thinning, loss of elasticity, telangiectasia, and ecchymoses.",
      "use_in_pregnancy_lactation": "Avoid unnecessary use during pregnancy (not recommended for extended areas, large amounts, or prolonged periods).",
      "use_in_children": "Not recommended.",
      "drug_interactions": "No proper data available.",
      "preparation": "Ointment"
    },
    {
      "name": "Eromycin®",
     "img_id":"LHp6I3Z.jpeg",
      "image": "EROMYCIN-100ML.jpg",
      "active_ingredients": "Erythromycin",
      "indications": [
        "Alternative to penicillin in penicillin-sensitive patients",
        "Penicillin-resistant staphylococcal infections",
        "Alternative to tetracycline in mycoplasma pneumonia",
        "Pertussis (whooping cough)",
        "Diphtheria (especially carrier state treatment)",
        "Rheumatic fever prophylaxis",
        "Chronic bronchitis",
        "Otitis media",
        "Chronic prostatitis"
      ],
      "dosage_and_administration": {
        "adults": "1-2 g daily in divided doses",
        "children": "30-50 mg/kg/day"
      },
      "contraindications": [
        "Hypersensitivity to erythromycin",
        "Impaired hepatic function"
      ],
      "side_effects": "Nausea, gastrointestinal disturbances, and allergy (most common, occurring in 0.5-5% of cases)",
      "drug_interactions": [
        "Theophylline",
        "Carbamazepine",
        "Digoxin",
        "Warfarin",
        "Ergotamine"
      ],
      "use_in_pregnancy_lactation": "No known hazards in pregnancy, but crosses the placental barrier.",
      "preparations": [
        "500 mg Tablet",
        "125 mg/5 ml Dry Powder for Syrup",
        "200 mg/5 ml Paediatric Drops"
      ]
    },
    {
      "name": "Eromycin® Lotion",
     "img_id":"R9iZQpS.jpeg",
      "image": "EROMYCIN-LOTION.jpg",
      "active_ingredients": "Erythromycin",
      "indications": [
        "Acne",
        "Pimples",
        "Bacterial skin infections susceptible to Erythromycin"
      ],
      "dosage_and_administration": "Apply in morning & evening to the affected areas.",
      "contraindications": "Hypersensitivity to any of its ingredients.",
      "side_effects": [
        "Erythema",
        "Desquamation",
        "Burning sensation",
        "Eye irritation",
        "Tenderness",
        "Dryness or oily skin"
      ],
      "drug_interactions": "Clindamycin interacts with Erythromycin.",
      "use_in_pregnancy_lactation": "Use with caution.",
      "preparation": "25 ml Lotion"
    },
    {
      "name": "Esloric®",
     "img_id":"3zi8Igu.jpeg",
      "image": "Esloric.jpg",
      "active_ingredients": "Allopurinol",
      "indications": ["Primary gout", "Secondary gout"],
      "dosage_and_administration": {
        "general_guidelines": {
          "initial_dosage": "100 mg/day (to reduce adverse reactions)",
          "titration": "Increase only if serum urate response is unsatisfactory",
          "renal_caution": "Extra caution required in poor renal function"
        },
        "specific_dosages": {
          "adults": {
            "mild_conditions": "100-200 mg daily",
            "moderately_severe": "300-600 mg daily",
            "severe_conditions": "700-900 mg daily",
            "weight_based": "2-10 mg/kg body weight per day (if required)"
          },
          "children": {
            "under_15_years": "10-20 mg/kg/day (max 400 mg daily)"
          },
          "elderly": "Lowest effective dose for urate reduction",
          "renal_impairment": {
            "severe": "<100 mg/day or 100 mg at intervals >24h"
          }
        }
      },
      "contraindications": "Not explicitly stated (but implied: hypersensitivity to allopurinol)",
      "side_effects": [
        "Pruritic maculopapular skin eruptions",
        "Fever",
        "Chills",
        "Arthralgias",
        "Cholestatic jaundice",
        "Eosinophilia",
        "Mild leukocytosis/leukopenia"
      ],
      "drug_interactions": ["Anticoagulants", "Diuretics", "Cytotoxic agents"],
      "use_in_pregnancy_lactation": {
        "pregnancy": "Use only if clearly needed",
        "lactation": "Exercise caution"
      },
      "preparation": "100 mg Tablet"
    },
    {
      "name": "Evit®",
     "img_id":"ev3lV1l.jpeg",
      "image": "Evit-Soft-400_l.jpg",
      "active_ingredients": "α-Tocopheryl Acetate (Vitamin E)",
      "indications": {
        "primary": "Vitamin E deficiency",
        "secondary": [
          "Cardiovascular health (400-800 mg/day)",
          "Thalassemia (800 mg/day)",
          "Sickle-cell anemia (400 mg/day)",
          "Skin & Hair improvement (400 mg/day)",
          "Topical use for beautification"
        ]
      },
      "dosage_and_administration": {
        "cardiovascular_health": "400-800 mg/day",
        "deficiency_syndrome": "400 mg/day (adults)",
        "thalassemia": "800 mg/day",
        "sickle-cell_anemia": "400 mg/day",
        "dermatological_use": "400 mg/day (oral) + topical application"
      },
      "contraindications": "No absolute contraindication",
      "side_effects": ["Fatigue", "Diarrhea", "Myopathy"],
      "drug_interactions": ["Vitamin A", "Vitamin K", "Warfarin"],
      "use_in_pregnancy_lactation": {
        "safety": "Safe at recommended doses",
        "caution": "Higher doses not established"
      },
      "preparations": ["400 mg Licap", "200 mg Licap"]
    },
    {
      "name": "Eyevi®",
     "img_id":"rbwzKF6.jpeg",
      "image": "EYEVI.jpg",
      "active_ingredients": [
        "Vitamin C",
        "Vitamin E",
        "Zinc",
        "Copper",
        "Lutein"
      ],
      "indications": "Age-related Eye Disease",
      "dosage_and_administration": "1 capsule 1-2 times daily or as directed by physician",
      "contraindications": [
        "Hyperoxaluria",
        "Use with anticoagulants",
        "Use with estrogens",
        "Use with vitamin-K"
      ],
      "side_effects": [
        "Diarrhea",
        "Abdominal pain",
        "Other gastrointestinal disturbances",
        "Fatigue",
        "Weakness"
      ],
      "preparation": "Capsule",
      "additional_notes": {
        "drug_interactions": "Potential interactions with anticoagulants, estrogens and vitamin-K as per contraindications",
        "pregnancy_lactation": "Not specified in provided information",
        "special_populations": "No specific dosage adjustments mentioned"
      }
    },
    {
      "name": "Ezex®",
     "img_id":"lpXCbSM.jpeg",
      "image": "EZEX.jpg",
      "active_ingredients": "Clobetasone Butyrate",
      "indications": ["Eczema", "Dermatitis", "Otitis externa"],
      "dosage_and_administration": "Apply up to 4 times daily",
      "contraindications": {
        "infectious_lesions": [
          "Viral infections (Herpes Simplex, chicken pox)",
          "Fungal infections (candidiasis, tinea)",
          "Bacterial infections (impetigo)"
        ],
        "hypersensitivity": "Hypersensitivity to the preparation",
        "ocular_precaution": "Avoid eye contact (risk of glaucoma if applied to eyelids)"
      },
      "side_effects": [
        "Hypersensitivity reactions",
        "Transient adrenal suppression",
        "Local atopic changes",
        "Hypertrichosis",
        "Possible exacerbation of symptoms"
      ],
      "use_in_pregnancy_lactation": "Inadequate evidence of safety in human pregnancy and lactation",
      "preparations": ["25 gm Cream", "25 gm Ointment"],
      "warnings": {
        "application_site": "Avoid use on infected skin lesions",
        "ocular_warning": "Special care required when applying near eyes"
      }
    },
    {
      "name": "Facticin™",
     "img_id":"5lenapO.jpeg",
      "image": "FACTICIN.jpg",
      "active_ingredients": {
        "name": "Gemifloxacin",
        "strength": "320 mg"
      },
      "indications": [
        "Acute exacerbations of chronic bronchitis (AECB)",
        "Community-acquired pneumonia (CAP)"
      ],
      "dosage_and_administration": {
        "AECB": "Once daily for 5 days",
        "CAP": {
          "mild_to_moderate": "Once daily for 5 days",
          "severe": "Once daily for 7 days"
        }
      },
      "contraindications": [
        "Hypersensitivity to gemifloxacin or other quinolones",
        "History of tendon damage with fluoroquinolones"
      ],
      "precautions": [
        "Maintain adequate hydration to prevent crystalluria",
        "Avoid in patients with QT prolongation",
        "Caution in patients with CNS disorders"
      ],
      "side_effects": [
        "Abdominal pain",
        "Diarrhea",
        "Headache",
        "Nausea",
        "Rash",
        "Vomiting"
      ],
      "drug_interactions": {
        "antacids": {
          "aluminum_magnesium": "Take 2 hours before or 3 hours after",
          "sucralfate": "Take at least 2 hours before"
        },
        "iron_salts": "Take 2 hours before or 3 hours after"
      },
      "special_populations": {
        "pregnancy_lactation": {
          "status": "Contraindicated",
          "reason": "Safety and efficacy not established"
        },
        "pediatric_use": {
          "status": "Not recommended",
          "age_range": "Below 18 years"
        }
      },
      "pharmaceutical_form": {
        "type": "Tablet",
        "packaging": "Box containing 1x6's Alu-Alu blister packs"
      },
      "administration_notes": [
        "Take with a full glass of water",
        "Maintain adequate fluid intake"
      ]
    },
    {
      "name": "Famotack®",
     "img_id":"7jWvl0Q.png",
      "image": "Famotack-20.png",
      "active_ingredients": {
        "name": "Famotidine",
        "strength": "20 mg"
      },
      "indications": [
        "Duodenal ulcer",
        "Gastric ulcer",
        "Gastro-oesophageal reflux disease (GERD)",
        "Zollinger-Ellison syndrome",
        "Gastritis"
      ],
      "dosage_and_administration": {
        "treatment_dosage": ["20 mg twice daily", "40 mg at night"],
        "maintenance_therapy": "20 mg tablet at night"
      },
      "contraindications": [
        "Hypersensitivity to famotidine or other H2 antagonists"
      ],
      "side_effects": [
        "Headache",
        "Dizziness",
        "Constipation",
        "Diarrhoea",
        "Nausea/vomiting",
        "Abdominal discomfort/distention",
        "Anorexia",
        "Fatigue",
        "Rash"
      ],
      "use_in_special_populations": {
        "pregnancy": "Should be prescribed only if clearly needed",
        "lactation": "Best avoided by nursing mothers"
      },
      "preparation": {
        "form": "Tablet",
        "strength": "20 mg"
      },
      "pharmacological_class": "H2-receptor antagonist",
      "administration_notes": [
        "May be taken with or without food",
        "For maintenance therapy, take at bedtime"
      ]
    },
    {
      "name": "Favinil™",
     "img_id":"Rp1tru3.jpeg",
      "image": "Favinil-Tablet_l.jpg",
      "active_ingredients": {
        "name": "Favipiravir INN",
        "strength": "200 mg"
      },
      "indications": "Treatment of novel or re-emerging pandemic influenza virus infections",
      "dosage_and_administration": {
        "adult_dosage": {
          "day_1": "1600 mg twice daily",
          "days_2_to_5": "600 mg twice daily",
          "total_duration": "5 days"
        },
        "administration_route": "Oral"
      },
      "side_effects": ["Diarrhea", "Increased blood uric acid levels"],
      "precautions": [
        "Confirm non-pregnancy in women of childbearing potential before use",
        "Require contraception during treatment and for 7 days after treatment",
        "Use with caution in hepatic and renal impairment",
        "Must be used under direction of registered physician"
      ],
      "contraindications": ["Pregnancy", "Women who may possibly be pregnant"],
      "use_in_special_populations": {
        "pregnancy": {
          "risk": "May cause delayed development or death of embryos",
          "recommendation": "Contraindicated"
        },
        "lactation": "Not specified (assume contraindicated due to pregnancy risk)"
      },
      "preparation": {
        "form": "Tablet",
        "strength": "200 mg"
      },
      "important_note": "This antiviral medication has specific use restrictions for pandemic influenza only"
    },
    {
      "name": "Femastin™",
     "img_id":"DX0hd8O.jpeg",
      "image": "Femastin-2-cream_l2.jpg",
      "active_ingredients": {
        "name": "Estriol",
        "concentration": "0.1%"
      },
      "indications": [
        "Vaginal atrophy",
        "Pre- and post-operative therapy in postmenopausal women undergoing vaginal surgery",
        "Labial adhesions",
        "Estrogen deficiency symptoms (vaginal dryness, itching, hot flashes, osteoporosis, vaginal discharge)"
      ],
      "dosage_and_administration": {
        "vaginal_atrophy": "Once daily for 2 months",
        "pre_post_operative": {
          "pre_surgery": "Once daily for 2 weeks before surgery",
          "post_surgery": "Twice weekly for 2 weeks after surgery"
        },
        "labial_adhesions": "1-2 times daily for two months"
      },
      "contraindications": [
        "Pregnancy",
        "Known or suspected estrogen-dependent tumors",
        "Undiagnosed vaginal bleeding",
        "Untreated endometrial hyperplasia",
        "Known or suspected breast cancer"
      ],
      "side_effects": {
        "common": [
          "Breast tension/pain",
          "Nausea",
          "Spotting",
          "Fluid retention",
          "Cervical hypersecretion"
        ],
        "rare": [
          "Headache",
          "Hypertension",
          "Leg cramps",
          "Vision disturbances"
        ],
        "note": "Most adverse reactions disappear after the 1st week of treatment"
      },
      "drug_interactions": {
        "increased_effects": ["Corticosteroids (may require dose reduction)"],
        "decreased_effects": [
          "Activated charcoal",
          "Barbiturates",
          "Hydantoins",
          "Rifampicin"
        ]
      },
      "use_in_special_populations": {
        "pregnancy": "Contraindicated",
        "lactation": {
          "safety": "Use only if really needed",
          "risk": "Excreted in milk; may decrease milk production quality/quantity"
        }
      },
      "preparation": {
        "form": "Cream",
        "strength": "0.1%"
      },
      "application_notes": "For vaginal use only"
    },
    {
      "name": "Fentizol™ VT 600",
     "img_id":"Iwcqvgw.jpeg",
      "image": "fentizol_large.jpg",
      "active_ingredients": {
        "name": "Fenticonazole Nitrate",
        "strength": "600 mg"
      },
      "indications": [
        "Genital candidiasis (vulvovaginitis, colpitis, infectious fluor)",
        "Trichomoniasis",
        "Mixed vaginal infections (Trichomonas vaginalis & Candida albicans)"
      ],
      "dosage_and_administration": {
        "trichomonas_or_mixed_infections": {
          "primary_dose": "1 vaginal tablet",
          "follow_up": "Second administration after 24 hours if necessary"
        },
        "candida_albicans_infections": {
          "primary_dose": "1 vaginal tablet in the evening",
          "follow_up": "Second administration after 3 days if symptoms persist"
        },
        "administration_instructions": [
          "Introduce deep into vagina and push well up to the fornix",
          "Partner should undergo concurrent treatment with azole cream"
        ]
      },
      "contraindications": [
        "Hypersensitivity to fenticonazole",
        "Hypersensitivity to other imidazoles"
      ],
      "precautions": {
        "overdose_management": [
          "For accidental ingestion: induce emesis or perform gastric lavage",
          "Administer activated charcoal with water/lemon juice",
          "Give laxative after vomiting"
        ],
        "treatment_monitoring": [
          "Discontinue if persistent irritation occurs",
          "Consult doctor if resistant microorganisms develop"
        ]
      },
      "side_effects": [
        "Transient burning sensation (usually resolves quickly)",
        "Possible sensitization reactions with prolonged use",
        "Mild erythematous reactions (rare)",
        "Local irritation (discontinue if persistent)"
      ],
      "use_in_special_populations": {
        "pregnancy": "Not recommended",
        "lactation": "Safety not established",
        "pediatric_use": "Not recommended for children"
      },
      "preparation": {
        "form": "Vaginal tablet",
        "strength": "600 mg",
        "packaging": "1 tablet in Alu-Alu blister with applicator"
      },
      "pharmacokinetics": "Very low systemic absorption",
      "partner_treatment": "Recommended concurrent treatment with azole cream"
    },

    {
      "name": "Fexo™",
     "img_id":"9ggoYPG.jpeg",
      "image": "Fexo-60-Tab-PRO_l.jpg",
      "active_ingredients": "Fexofenadine",
      "indications": [
        "Seasonal allergic rhinitis",
        "Perennial allergic rhinitis",
        "Chronic idiopathic urticaria"
      ],
      "dosage_and_administration": {
        "adults_and_children_12_years_plus": {
          "tablet": [
            "60 mg twice daily",
            "120 mg once daily",
            "180 mg once daily"
          ],
          "renal_impairment": "60 mg once daily (starting dose)"
        },
        "children_6_to_11_years": {
          "tablet": ["30 mg twice daily", "60 mg once daily"],
          "suspension": "30 mg (5 ml) twice daily",
          "starting_dose": "30 mg (5 ml) once daily"
        },
        "children_2_to_5_years": {
          "suspension": "30 mg (5 ml) twice daily",
          "starting_dose": "30 mg (5 ml) once daily"
        },
        "children_6_months_to_2_years": {
          "suspension": "15 mg (2.5 ml) twice daily",
          "starting_dose": "15 mg (2.5 ml) once daily"
        }
      },
      "contraindications": "Hypersensitivity to any ingredient",
      "side_effects": "Generally well tolerated",
      "use_in_special_populations": {
        "pregnancy": {
          "status": "Use only if potential benefit justifies risk",
          "note": "No adequate studies in pregnant women"
        },
        "lactation": {
          "status": "Caution advised",
          "note": "Excretion in human milk unknown"
        },
        "renal_impairment": {
          "recommendation": "Dose adjustment needed",
          "monitoring": "Renal function monitoring may be useful"
        }
      },
      "preparations": [
        {
          "form": "Tablet",
          "strengths": ["60 mg", "120 mg", "180 mg"]
        },
        {
          "form": "Oral suspension",
          "strength": "30 mg/5 ml"
        }
      ],
      "pharmacological_class": "Second-generation antihistamine",
      "administration_notes": {
        "food_interaction": "Avoid with fruit juices (orange, apple, grapefruit)",
        "timing": "May be taken with or without food"
      }
    },
    {
      "name": "Filfresh®",
     "img_id":"tkOPhEe.jpeg",
      "image": "Filfresh.jpg",
      "active_ingredients": {
        "name": "Melatonin INN",
        "strength": "3 mg"
      },
      "indications": {
        "primary": [
          "Short-term regulation of sleep patterns",
          "Jet lag",
          "Insomnia (circadian rhythm disorders)"
        ],
        "secondary": [
          "Osteoporosis (stimulates osteoblasts)",
          "Menopause-related sleep regulation",
          "Eating disorders (anorexia)",
          "Sarcoidosis",
          "ADHD-related sleep disturbances"
        ],
        "special_populations": [
          "Elderly with low melatonin levels",
          "Individuals with schizophrenia",
          "Children with learning disabilities and insomnia"
        ]
      },
      "dosage_and_administration": {
        "adults": {
          "insomnia": "3-6 mg one hour before bedtime",
          "jet_lag": {
            "standard": "0.5-5 mg one hour before bedtime at destination",
            "alternative": "1-5 mg 1 hour before bedtime for 2 days before departure and 2-3 days after arrival",
            "eastbound_travel": "Preflight early evening dose + bedtime dose for 4 days after arrival",
            "westbound_travel": "Bedtime dose for 4 days in new time zone"
          },
          "sarcoidosis": "20 mg/day for 4-12 months",
          "depression": "0.125 mg twice in late afternoon (4 hours apart)",
          "sleep_initiation": "5 mg 3-4 hours before imposed sleep for 4 weeks"
        },
        "pediatric": {
          "sleep_disorders": "0.30 mg/day (6 months to 14 years)"
        }
      },
      "contraindications": ["Autoimmune diseases"],
      "precautions": {
        "drug_interactions": {
          "increased_effect": ["Caffeine", "Fluvoxamine"],
          "decreased_effect": ["Nifedipine (reduced antihypertensive effect)"]
        },
        "activities": "May impair driving skills for 1 hour after administration"
      },
      "side_effects": [
        "Headache",
        "Depression",
        "Drowsiness (peaks at 30-60 minutes post-dose)"
      ],
      "overdose": "No evidence of major toxicities even at high doses",
      "pregnancy_lactation": "Safety and efficacy not established",
      "preparation": {
        "form": "Tablet",
        "strengths": ["3 mg"]
      },
      "pharmacological_class": "Endogenous hormone (pineal gland secretion)"
    },
    {
      "name": "Filwel™ Gold",
     "img_id":"5Lwodoj.jpeg",
      "image": "filwel-gold_n.jpg",
      "active_ingredients": {
        "vitamins": [
          "Vitamin A",
          "Vitamin C",
          "Vitamin D",
          "Vitamin E",
          "Vitamin K",
          "Thiamine (B1)",
          "Riboflavin (B2)",
          "Niacin (B3)",
          "Vitamin B6",
          "Folic Acid",
          "Vitamin B12",
          "Biotin",
          "Pantothenic acid"
        ],
        "minerals": [
          "Calcium",
          "Iron",
          "Phosphorus",
          "Iodine",
          "Magnesium",
          "Zinc",
          "Selenium",
          "Copper",
          "Manganese",
          "Chromium",
          "Molybdenum",
          "Chloride",
          "Potassium",
          "Boron",
          "Nickel",
          "Silicon",
          "Tin",
          "Vanadium"
        ],
        "other": ["Lutein"]
      },
      "indication": "Treatment of vitamin and mineral deficiencies",
      "dosage_and_administration": "One tablet daily with food",
      "contraindications": [
        "Known hypersensitivity to any component",
        "High risk of osteoporosis (vitamin A caution)"
      ],
      "side_effects": [
        "Diarrhea",
        "Yellow skin discoloration",
        "Other gastrointestinal disturbances"
      ],
      "use_in_special_populations": {
        "pregnancy_lactation": "Physician consultation recommended"
      },
      "preparation": {
        "form": "Tablet",
        "note": "Comprehensive multivitamin/mineral formulation"
      },
      "important_notes": [
        "Contains both water- and fat-soluble vitamins",
        "Includes trace minerals and antioxidants",
        "Take with food for optimal absorption"
      ]
    },
    {
      "name": "Filwel™ Kids",
     "img_id":"rP2ol3e.jpeg",
      "image": "Filwel-kids-100ml.jpg",
      "active_ingredients": [
        "Cod Liver Oil",
        "Vitamin A",
        "Vitamin D",
        "Vitamin C",
        "Vitamin B1 (Thiamine)",
        "Vitamin B2 (Riboflavin)",
        "Vitamin B6",
        "Vitamin E",
        "Nicotinamide"
      ],
      "indications": {
        "primary": "Prevention of vitamin deficiencies in children and adults",
        "benefits": [
          "Stimulates appetite and improves digestion",
          "Supports vision, bone and teeth health",
          "Boosts immunity against respiratory infections",
          "Maintains healthy muscles and nervous system",
          "Supports brain development"
        ]
      },
      "dosage_and_administration": {
        "infants_under_1": "0.5 teaspoon (2.5ml) daily",
        "children_1_to_4": "1 teaspoon (5ml) daily",
        "children_over_4": "1.5 teaspoons (7.5ml) daily",
        "administration_note": "Can be taken with water or milk"
      },
      "contraindications": [
        "Hypersensitivity to any ingredient",
        "Long-term use may cause hypervitaminosis of fat-soluble vitamins"
      ],
      "precautions": [
        "Avoid overdose",
        "Continuous use only under medical supervision",
        "Monitor for vitamin accumulation with prolonged use"
      ],
      "side_effects": "Generally well tolerated",
      "use_in_special_populations": {
        "pregnancy_lactation": "Recommended",
        "pediatric_use": "Recommended for all ages"
      },
      "preparation": {
        "form": "Syrup",
        "volume": "100ml",
        "key_components": {
          "omega_3_source": "Cod Liver Oil",
          "fat_soluble_vitamins": ["A", "D", "E"],
          "water_soluble_vitamins": ["C", "B1", "B2", "B6", "Nicotinamide"]
        }
      },
      "important_notes": [
        "Contains both fat- and water-soluble vitamins",
        "Specifically formulated for pediatric use",
        "Sweetened formulation for easier administration"
      ]
    },
    {
      "name": "Filwel™ Silver",
     "img_id":"yVhQOnD.jpeg",
      "image": "filwel-silver_n.jpg",
      "target_population": "Adults above 45 years",
      "active_ingredients": {
        "vitamins": [
          "Vitamin A",
          "Vitamin C",
          "Vitamin D",
          "Vitamin E",
          "Vitamin K",
          "Thiamine (B1)",
          "Riboflavin (B2)",
          "Niacin (B3)",
          "Vitamin B6",
          "Folic Acid",
          "Vitamin B12",
          "Biotin",
          "Pantothenic Acid"
        ],
        "minerals": [
          "Calcium",
          "Phosphorus",
          "Iodine",
          "Magnesium",
          "Zinc",
          "Selenium",
          "Copper",
          "Manganese",
          "Chromium",
          "Molybdenum",
          "Chloride",
          "Potassium",
          "Boron",
          "Nickel",
          "Silicon",
          "Vanadium"
        ],
        "other": ["Lutein"]
      },
      "indications": "Treatment of vitamin and mineral deficiencies in adults 45+",
      "dosage": "1 tablet daily with food",
      "contraindications": [
        "Hypersensitivity to ingredients",
        "Postmenopausal women at risk for osteoporosis (vitamin A caution)"
      ],
      "side_effects": [
        "Diarrhea",
        "Mild yellow skin discoloration",
        "GI disturbances"
      ],
      "pregnancy_lactation": "Physician consultation recommended",
      "drug_interactions": "None reported",
      "preparation": "Tablet",
      "key_features": [
        "Geriatric-focused formulation",
        "Contains bone-supporting minerals (Calcium, Magnesium, Vitamin D)",
        "Includes antioxidants (Vitamins C/E, Selenium, Lutein)"
      ]
    },
    {
      "name": "Filwel™ Teen",
     "img_id":"t21xZux.png",
      "image": "Filwel-Teen-hm.png",
      "target_population": "Teenage boys (13-19 years)",
      "active_ingredients": {
        "vitamins": [
          { "Vitamin A": "2500 IU" },
          { "Vitamin C": "120 mg" },
          { "Vitamin D": "400 IU" },
          { "Vitamin E": "30 IU" },
          { "Vitamin K": "25 mcg" },
          { "Thiamine (B1)": "3.75 mg" },
          { "Riboflavin (B2)": "4.25 mg" },
          { "Niacin": "30 mg" },
          { "Vitamin B6": "5 mg" },
          { "Folic Acid": "400 mcg" },
          { "Vitamin B12": "15 mcg" },
          { "Biotin": "300 mcg" },
          { "Pantothenic Acid": "10 mg" }
        ],
        "minerals": [
          { "Calcium": "200 mg" },
          { "Iron": "9 mg" },
          { "Magnesium": "100 mg" },
          { "Zinc": "15 mg" },
          { "Selenium": "20 mcg" },
          { "Copper": "2 mg" },
          { "Manganese": "2 mg" },
          { "Chromium": "120 mcg" }
        ]
      },
      "indications": {
        "primary": "Comprehensive nutritional supplementation for teen boys",
        "benefits": [
          "Immune support (Vitamins C/E, Zinc, Iron, Selenium)",
          "Physical/mental growth acceleration",
          "Bone and teeth development",
          "Muscle function (Magnesium)",
          "Mood regulation",
          "Energy metabolism (B vitamins)"
        ]
      },
      "dosage": "1 tablet daily with food",
      "side_effects": [
        "Constipation",
        "Diarrhea",
        "Upset stomach (usually temporary)"
      ],
      "contraindications": [
        "Hypersensitivity to ingredients",
        "Not for pernicious anemia treatment (folic acid limitation)"
      ],
      "drug_interactions": "None reported",
      "preparation": "Film-coated tablet",
      "key_features": [
        "Teen-specific nutrient ratios",
        "Higher B-vitamin content for energy",
        "Growth-supporting minerals (Zinc, Magnesium)",
        "Iron inclusion for growth spurts"
      ]
    },
    {
      "name": "Filwel™ Teen hr",
     "img_id":"dF46a2S.png",
      "image": "Filwel-Teen-hr.png",
      "target_population": "Teenage girls (13-19 years)",
      "active_ingredients": {
        "vitamins": [
          { "Vitamin A": "2500 IU" },
          { "Vitamin C": "120 mg" },
          { "Vitamin D": "800 IU" },
          { "Vitamin E": "30 IU" },
          { "Vitamin K": "25 mcg" },
          { "Thiamine (B1)": "2.3 mg" },
          { "Riboflavin (B2)": "2.6 mg" },
          { "Niacin": "30 mg" },
          { "Vitamin B6": "3 mg" },
          { "Folic Acid": "400 mcg" },
          { "Vitamin B12": "9 mcg" },
          { "Biotin": "300 mcg" },
          { "Pantothenic Acid": "10 mg" }
        ],
        "minerals": [
          { "Calcium (elemental)": "300 mg" },
          { "Iron": "18 mg" },
          { "Magnesium": "50 mg" },
          { "Zinc": "15 mg" },
          { "Selenium": "20 mcg" },
          { "Copper": "2 mg" },
          { "Manganese": "2 mg" },
          { "Chromium": "120 mcg" }
        ]
      },
      "indications": {
        "primary": "Comprehensive nutritional supplementation for teen girls",
        "benefits": [
          "Bone and teeth development (Higher Vitamin D & Calcium vs boys)",
          "Immune support",
          "Energy metabolism (B vitamins)",
          "Skin health (Collagen synthesis, acne prevention)",
          "Hormonal balance",
          "Mental health (Anxiety/depression reduction)"
        ]
      },
      "dosage": "1 tablet daily with food",
      "side_effects": ["Constipation", "Diarrhea", "Upset stomach (temporary)"],
      "contraindications": [
        "Hypersensitivity to ingredients",
        "Pernicious anemia (B12 deficiency)"
      ],
      "pregnancy_lactation": "Contraindicated",
      "drug_interactions": "None reported",
      "preparation": "Film-coated tablet",
      "key_differences_vs_boys": [
        "Higher Iron (18mg vs 9mg) for menstrual needs",
        "Higher Vitamin D (800IU vs 400IU) for bone health",
        "Lower B1/B2/B6 for female metabolic needs",
        "Skin/hormone-focused benefits"
      ]
    },
    {
      "name": "Flacol®",
     "img_id":"as8hE9e.jpeg",
      "image": "flacol_1.jpg",
      "active_ingredients": {
        "name": "Simethicone",
        "strengths": [
          { "Paediatric Drops": "67 mg/ml" },
          { "Chewable Tablet": "40 mg" }
        ]
      },
      "indications": [
        "Flatulence",
        "Abdominal distention",
        "Gas colic",
        "Bowel preparation"
      ],
      "dosage": {
        "paediatric_drops": {
          "<2 years": "20 mg (0.3 ml) 4 times daily",
          "2-12 years": "40 mg (0.6 ml) 4 times daily"
        },
        "chewable_tablets": {
          "adults": "40-80 mg (1-2 tablets) 4 times daily",
          "administration": "Chew after meals and at bedtime"
        },
        "max_daily_dose": "Do not exceed 12 doses/day without medical advice"
      },
      "contraindications": "None (physically inert)",
      "side_effects": "None reported",
      "preparation": ["67 mg/ml Paediatric Drops", "40 mg Chewable Tablet"],
      "mechanism": "Defoaming agent that disperses gas bubbles",
      "safety_notes": [
        "Non-systemic action (not absorbed)",
        "Safe for all ages including infants"
      ]
    },
    {
      "name": "Flexi®",
     "img_id":"qLKGBUL.jpeg",
      "image": "Flexi.jpg",
      "active_ingredients": "Aceclofenac",
      "indications": [
        "Osteoarthritis",
        "Rheumatoid Arthritis",
        "Ankylosing Spondylitis"
      ],
      "dosage": {
        "standard": "100 mg twice daily",
        "sustained_release": "200 mg SR tablet once daily"
      },
      "contraindications": [
        "Peptic ulcer/GI bleeding",
        "Moderate-severe renal impairment",
        "Severe hepatic impairment",
        "Pregnancy (unless compelling reasons)"
      ],
      "side_effects": [
        "GI: Dyspepsia, abdominal pain, nausea, diarrhea",
        "CNS: Dizziness",
        "Dermatological: Pruritus, rash",
        "Hepatic: Elevated enzymes",
        "Renal: Increased serum creatinine"
      ],
      "drug_interactions": [
        "Lithium",
        "Digoxin",
        "Diuretics",
        "Anticoagulants",
        "Methotrexate"
      ],
      "pregnancy_lactation": {
        "risk": "May increase uterine tone in 3rd trimester",
        "recommendation": "Avoid unless benefits outweigh risks"
      },
      "pediatric_use": "No clinical data available",
      "preparations": ["100 mg Tablet", "200 mg SR Tablet"]
    },
    {
      "name": "Flexilax®",
     "img_id":"icdpkUc.jpeg",
      "image": "Flexilax-5_l.jpg",
      "active_ingredients": "Baclofen",
      "indications": [
        "Muscle spasm/contraction",
        "Spasticity (MS, spinal cord injuries)",
        "Cerebral palsy",
        "Tension-type headache"
      ],
      "dosage": {
        "adults": "Start 5 mg TID, max 20 mg TID",
        "children": "QID dosing (specific dose not stated)"
      },
      "contraindications": "Hypersensitivity to components",
      "side_effects": [
        "Drowsiness",
        "Daytime sedation",
        "Dizziness",
        "Weakness",
        "Fatigue"
      ],
      "pregnancy_lactation": {
        "category": "B",
        "breastfeeding": "Minimal excretion in milk"
      },
      "preparation": ["5 mg Tablet", "10 mg Tablet"]
    },
    {
      "name": "Flindof™",
     "img_id":"8Iz11hW.jpeg",
      "image": "Flindof-200_l.jpg",
      "active_ingredients": "Doxofylline",
      "indications": [
        "Bronchial asthma",
        "COPD",
        "Pulmonary diseases with bronchospasm"
      ],
      "dosage": {
        "adults": "400 mg 2-3 times daily",
        "elderly": "200 mg 2-3 times daily",
        "children": "6-9 mg/kg BID",
        "max_daily": "1200 mg"
      },
      "side_effects": [
        "GI: Nausea, vomiting, epigastric pain",
        "CNS: Headache, irritability, insomnia",
        "CV: Tachycardia, arrhythmias",
        "Metabolic: Hyperglycemia",
        "Renal: Albuminuria"
      ],
      "contraindications": [
        "Hypersensitivity",
        "Acute MI",
        "Hypotension",
        "Arrhythmia",
        "Duodenal ulcer",
        "Epilepsy"
      ],
      "drug_interactions": [
        "Other xanthines/caffeine",
        "Ephedrine (toxic synergy)",
        "Macrolides, clindamycin",
        "Allopurinol",
        "Cimetidine",
        "Propranolol",
        "Anti-flu vaccine"
      ],
      "pregnancy_lactation": {
        "pregnancy": "Use only if clearly needed",
        "lactation": "Contraindicated"
      },
      "preparation": ["200 mg Tablet", "400 mg Tablet"]
    },
    {
      "name": "Flonasin™",
     "img_id":"V98zmp8.jpeg",
      "image": "flonacin_l.jpg",
      "active_ingredients": [
        {
          "name": "Azelastine Hydrochloride",
          "dose": "137 mcg/spray"
        },
        {
          "name": "Fluticasone Propionate",
          "dose": "50 mcg/spray"
        }
      ],
      "indication": "Seasonal allergic rhinitis (≥12 years)",
      "dosage": "1 spray/nostril BID",
      "contraindications": [
        "Concurrent CNS depressants/alcohol",
        "Driving/operating machinery"
      ],
      "side_effects": ["Dysgeusia", "Epistaxis", "Headache"],
      "pregnancy_lactation": {
        "category": "C",
        "recommendation": "Benefit must outweigh risk"
      },
      "pediatric_use": "Not recommended <12 years",
      "overdose": {
        "azelastine": "Increased somnolence",
        "fluticasone": "Hypercorticism with chronic OD"
      },
      "preparation": "120 sprays (50 mcg fluticasone + 137 mcg azelastine per spray)"
    },
    {
      "name": "Flonaspray®",
     "img_id":"BLVgAqx.jpeg",
      "image": "FLONASPRAY-NASAL-SPRAY.jpg",
      "active_ingredients": {
        "name": "Fluticasone Propionate",
        "strength": "50 mcg/spray"
      },
      "indication": "Allergic rhinitis (prophylaxis & treatment)",
      "dosage": {
        "adults": "2 sprays/nostril once daily (morning)",
        "children": "1 spray/nostril once daily (4-11 yrs)"
      },
      "contraindications": [
        "Hypersensitivity",
        "Impaired adrenal function (when switching from systemic steroids)"
      ],
      "side_effects": [
        "Common: Nasal irritation, stinging",
        "Rare: Septal perforation, epistaxis, dry nose/throat"
      ],
      "drug_interactions": "None known",
      "preparation": ["Nasal spray (50 mcg/spray)"]
    },
    {
      "name": "Flugal®",
     "img_id":"ygXiVWs.jpeg",
      "image": "Flugal-50_l.jpg",
      "active_ingredients": "Fluconazole",
      "indications": [
        "Candidiasis",
        "Cryptococcal infections (including meningitis)",
        "Tinea pedis",
        "Tinea corporis",
        "Tinea cruris",
        "Tinea versicolor",
        "Dermal candidiasis"
      ],
      "dosage_and_administration": {
        "acute_or_recurrent_vaginal_candidiasis": "150 mg as a single dose",
        "mucosal_candidiasis": {
          "general": "50 mg daily",
          "difficult_infections": "100 mg daily",
          "duration": {
            "oropharyngeal_candidiasis": "7-14 days",
            "other_mucosal_infections": "14-30 days"
          }
        },
        "systemic_candidiasis_and_cryptococcal_infections": {
          "initial_dose": "400 mg",
          "maintenance_dose": "200 mg daily",
          "max_dose": "400 mg daily if necessary"
        },
        "children_over_1_year": {
          "superficial_candidal_infections": "1-2 mg/kg daily",
          "systemic_candidiasis_and_cryptococcal_infections": {
            "general": "3-6 mg/kg daily",
            "serious_infections": "up to 12 mg/kg daily (max 400 mg daily for ages 5-13)"
          }
        }
      },
      "contraindications_and_precautions": [
        "Hypersensitivity",
        "Advanced liver disease",
        "Renal impairment",
        "Children below the age of one year"
      ],
      "side_effects": [
        "Nausea",
        "Abdominal discomfort",
        "Diarrhoea",
        "Flatulence",
        "Occasional abnormalities of liver enzyme",
        "Rarely rash",
        "Angioedema",
        "Anaphylaxis"
      ],
      "drug_interactions": ["Rifampicin", "Warfarin", "Phenytoin"],
      "use_in_pregnancy_and_lactation": "Caution should be taken.",
      "preparation": [
        "200 mg capsule",
        "150 mg capsule",
        "50 mg capsule",
        "50 mg/5 ml suspension",
        "2 mg/ml IV infusion"
      ]
    },
    {
      "name": "Flurizin®",
     "img_id":"ta0B5ZJ.jpeg",
      "image": "Flurizin-5.jpg",
      "active_ingredients": "Flunarizine",
      "indications": [
        "Prophylaxis of classic (with aura) or common (without aura) migraine",
        "Symptomatic treatment of vestibular vertigo",
        "Peripheral Vascular Disease (PVD)",
        "Motion sickness"
      ],
      "dosage_and_administration": {
        "migraine_prophylaxis": {
          "starting_dose": {
            "less_than_65_years": "10 mg at night",
            "greater_than_65_years": "5 mg daily"
          },
          "maintenance_treatment": {
            "description": "If responding satisfactorily, decrease to 5 days treatment at the same daily dose with two successive medicine-free days every week.",
            "interruption": "Should be interrupted after 6 months and reinitiated only if the patient relapses."
          }
        },
        "peripheral_vascular_disease": "10 mg twice daily, up to 30 mg per day if required.",
        "vertigo_and_motion_sickness": {
          "adults": "10-20 mg daily",
          "children": "5 mg daily for children (> 40 kg)"
        }
      },
      "contraindications_and_precautions": [
        "Hypersensitivity to Flunarizine",
        "History of depressive illness",
        "Pre-existing symptoms of Parkinson’s disease or other extrapyramidal disorders",
        "May lead to drowsiness, aggravated by alcohol or other CNS depressants",
        "Caution against driving or hazardous tasks"
      ],
      "side_effects": [
        "Drowsiness and/or fatigue",
        "Weight gain and/or increased appetite",
        "Infrequently reported: heartburn, nausea, gastralgia, insomnia, anxiety, galactorrhoea, dry mouth, muscle ache, skin rash"
      ],
      "use_in_pregnancy_and_lactation": "Safety in pregnancy & lactation has not been established.",
      "preparations": ["5 mg tablet", "10 mg tablet"]
    },
    {
      "name": "FodexilTM",
     "img_id":"Xxy0fbl.jpeg",
      "image": "Fodexil_1.jpg",
      "active_ingredients": "Cefadroxil",
      "preparations": [
        {
          "form": "Capsule",
          "strength": "500 mg",
          "packaging": "Each box contains 18 capsules in blister pack."
        },
        {
          "form": "Tablet",
          "strength": "1 gm",
          "packaging": "Each box contains 12 tablets in blister pack."
        }
      ],
      "indications": [
        "Upper respiratory tract infections caused by Streptococcus pyogenes (Group A beta-hemolytic Streptococci) & Streptococcus pneumoniae",
        "Urinary tract infections caused by E. coli, Proteus mirabilis, & Klebsiella species",
        "Skin & soft tissue infections caused by Staphylococci (including penicillinase producing strains) & Streptococci"
      ],
      "dosage_and_administration": {
        "upper_respiratory_tract_infections": {
          "adults": "1 g/day in single or divided doses for 10 days",
          "children": "30 mg/kg/day in equally divided doses every 12 hours for at least 10 days"
        },
        "uncomplicated_lower_urinary_tract_infections": {
          "adults": "1-2 g daily as a single or 2 divided doses",
          "children": {
            "greater_than_6_years": "500 mg bid",
            "1_to_6_years": "250 mg bid",
            "less_than_1_year": "25 mg/kg daily in divided doses"
          }
        },
        "skin_and_soft_tissue_infections": {
          "adults": "1 g/day in single or divided doses",
          "children": "30 mg/kg/day in equally divided doses every 12 hours"
        }
      },
      "contraindications_and_precautions": [
        "History of hypersensitivity to any of the ingredients",
        "Caution in patients with markedly impaired renal function (creatinine clearance rate of less than 50 ml/min)",
        "Cefadroxil can be excreted by hemodialysis",
        "Prolonged use may result in overgrowth of nonsusceptible organisms",
        "Caution in individuals with a history of gastrointestinal disease, particularly colitis"
      ],
      "side_effects": [
        "Gastrointestinal disturbances",
        "Hypersensitivity phenomena",
        "Nausea",
        "Vomiting",
        "Diarrhoea",
        "Dyspepsia",
        "Abdominal discomfort",
        "Fever",
        "Dizziness",
        "Headache",
        "Arthralgia"
      ],
      "drug_interactions": [
        "Prolonged prothrombin time and bleeding with anticoagulants",
        "Decreased elimination with probenecid"
      ],
      "use_in_pregnancy_and_lactation": "Pregnancy category B; use only if clearly needed. Caution in nursing mothers."
    },
    {
      "name": "Fona®",
     "img_id":"A470MZh.jpeg",
      "image": "fona_small_1.jpg",
      "active_ingredients": "Adapalene",
      "indications": ["Acne"],
      "dosage_and_administration": {
        "cream": {
          "strength": "0.1%",
          "application": "Once daily at night-time"
        },
        "gel": {
          "strength": "0.3%",
          "application": "Once daily in the evening"
        }
      },
      "contraindications_and_precautions": [
        "Hypersensitivity to Adapalene",
        "Should not be applied to cuts, abrasions, eczematous or sunburned skin"
      ],
      "side_effects": [
        "Erythema",
        "Scaling",
        "Dryness",
        "Pruritus",
        "Burning sensation",
        "Skin irritation",
        "Stinging",
        "Sunburn",
        "Acne flares"
      ],
      "drug_interactions": [
        "Caution with other potentially irritating topical products"
      ],
      "use_in_pregnancy_and_lactation": "Use only if potential benefit justifies potential risk to the fetus; caution in nursing mothers.",
      "use_in_children": "Safety and effectiveness in children below 12 years have not been established.",
      "preparation": ["10 gm Cream", "10 gm Gel"]
    },
    {
      "name": "FonaTM Plus Gel",
     "img_id":"qmy7dxg.jpeg",
      "image": "Fona-plus-gel_e.jpg",
      "active_ingredients": "Adapalene & Benzoyl Peroxide",
      "indications": [
        "Topical treatment of acne vulgaris in patients 12 years of age and older"
      ],
      "dosage_and_administration": {
        "application": "Apply a thin film to affected areas of the face and/or trunk once daily after washing.",
        "amount": "Use a pea-sized amount for each area of the face (e.g., forehead, chin, each cheek).",
        "precautions": "Avoid the eyes, lips, and mucous membranes. Not for oral, ophthalmic, or intravaginal use."
      },
      "contraindications_and_precautions": [
        "Should not be administered to individuals who are hypersensitive to any of its components.",
        "Avoid exposure to sunlight and sunlamps.",
        "Wear sunscreen when sun exposure cannot be avoided."
      ],
      "side_effects": [
        "Erythema",
        "Scaling",
        "Dryness",
        "Stinging/Burning",
        "Dry skin",
        "Contact dermatitis",
        "Application site burning",
        "Application site irritation",
        "Skin irritation"
      ],
      "use_in_pregnancy_and_lactation": "There are no well-controlled trials in pregnant women treated with Adapalene and Benzoyl peroxide. Caution should be exercised when administered to a nursing woman.",
      "preparation": {
        "form": "Gel",
        "strength": "10 gm"
      }
    },
    {
      "name": "FosfomaxTM",
     "img_id":"mfNDEL2.jpeg",
      "image": "FOSFOMAX_l.jpg",
      "active_ingredients": "Fosfomycin Trometamol EP granules for oral solution equivalent to 3 g Fosfomycin",
      "indications": [
        "Treatment of acute cystitis (uncomplicated urinary tract infection) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis"
      ],
      "dosage_and_administration": {
        "recommended_dosage": "One sachet for women 18 years of age and older with or without food",
        "preparation": "Pour the entire content of the Fosfomax sachet into half a glass of water, stir gently to dissolve. Hot water should not be used. Take immediately after dissolving."
      },
      "contraindications": [
        "Known hypersensitivity to the drug",
        "Severe renal insufficiency",
        "Patients undergoing hemodialysis"
      ],
      "precautions": [
        "Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Fosfomycin.",
        "Do not use more than one single dose of Fosfomycin to treat a single episode of acute cystitis.",
        "Repeated daily doses did not improve clinical success or microbiological eradication rates compared to single dose therapy, but increased the incidence of adverse events."
      ],
      "adverse_effects": {
        "frequent": [
          { "event": "Diarrhea", "rate": "10.4%" },
          { "event": "Headache", "rate": "10.3%" },
          { "event": "Vaginitis", "rate": "7.6%" },
          { "event": "Nausea", "rate": "5.2%" },
          { "event": "Rhinitis", "rate": "4.5%" },
          { "event": "Back pain", "rate": "3.0%" },
          { "event": "Dysmenorrhea", "rate": "2.6%" },
          { "event": "Pharyngitis", "rate": "2.5%" },
          { "event": "Dizziness", "rate": "2.3%" },
          { "event": "Abdominal pain", "rate": "2.2%" },
          { "event": "Pain", "rate": "2.2%" },
          { "event": "Dyspepsia", "rate": "1.8%" },
          { "event": "Asthenia", "rate": "1.7%" },
          { "event": "Rash", "rate": "1.4%" }
        ],
        "less_frequent": [
          "Abnormal stools",
          "Anorexia",
          "Constipation",
          "Dry mouth",
          "Dysuria",
          "Ear disorder",
          "Fever",
          "Flatulence",
          "Flu syndrome",
          "Hematuria",
          "Infection",
          "Insomnia",
          "Lymphadenopathy",
          "Menstrual disorder",
          "Migraine",
          "Myalgia",
          "Nervousness",
          "Paresthesia",
          "Pruritus",
          "SGPT increased",
          "Skin disorder",
          "Somnolence",
          "Vomiting"
        ]
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy_category": "B",
        "recommendation": "Should not be used during pregnancy unless the benefit outweighs the risk. A decision should be made to discontinue breastfeeding or not administer the drug, considering the importance of the drug to the mother."
      },
      "drug_interactions": [
        {
          "drug": "Metoclopramide",
          "effect": "Lowers serum concentration and urinary excretion of Fosfomycin when co-administered."
        },
        "Other drugs that increase gastrointestinal motility may produce similar effects."
      ],
      "preparation": {
        "packaging": "Box containing 1 sachet of Fosfomycin Trometamol EP granules for oral solution equivalent to 3 g Fosfomycin."
      }
    },
    {
      "name": "Frabex®",
     "img_id":"b5c3O7q.jpeg",
      "image": "Frabex500.jpg",
      "active_ingredients": "Tranexamic Acid",
      "indications": [
        "Short term use for haemorrhage or risk of haemorrhage in those with increased fibrinolysis or fibrinogenolysis",
        "Local fibrinolysis in conditions such as:",
        "Prostatectomy and bladder surgery",
        "Menorrhagia",
        "Epistaxis",
        "Conisation of the cervix",
        "Traumatic hyphaema",
        "Management of dental extraction in haemophiliacs",
        "Hereditary angioneurotic oedema"
      ],
      "dosage_and_administration": {
        "adults": {
          "local_fibrinolysis": "15-25 mg/kg body weight two to three times daily",
          "prostatectomy": "1 gm three to four times daily until macroscopic haematuria is no longer present",
          "menorrhagia": "1 gm three times daily for up to 4 days, with a maximum of 4g daily",
          "epistaxis": "1 gm three times daily for 7 days when repeated bleeding is anticipated",
          "cervix_conisation": "1.5 gm three times daily",
          "traumatic_hyphaema": "1-1.5 gm three times daily",
          "haemophilia": "1-1.5 gm every eight hours for dental extractions",
          "hereditary_angioneurotic_oedema": "1-1.5 gm two to three times daily intermittently or continuously"
        },
        "paediatric_population": "Approximately 20 mg/kg/day, but data on efficacy, posology, and safety are limited."
      },
      "contraindications": ["History of thromboembolic disease"],
      "drug_interactions": [
        "Clinically important interactions have not been observed with tranexamic acid tablets.",
        "Simultaneous treatment with anticoagulants must be under strict supervision of an experienced physician."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy_category": "B",
        "breast_milk": "Tranexamic acid passes into breast milk at approximately one hundredth of the concentration in maternal blood; antifibrinolytic effect in the infant is unlikely."
      },
      "side_effects": ["Diarrhoea", "Eyesight problems"],
      "preparations": [
        {
          "form": "Capsule",
          "strength": "500 mg"
        },
        {
          "form": "IV Injection",
          "strength": "500 mg/5 ml"
        }
      ]
    },

    {
      "name": "Fungidal-HC®",
     "img_id":"b5c3O7q.jpeg",
      "image": "Fungidal-HC.jpg",
      "active_ingredients": "Miconazole Nitrate & Hydrocortisone",
      "indications": [
        "Inflamed dermatoses such as intertrigo",
        "Infected eczema",
        "Primary irritant or contact allergic eczema",
        "Seborrheic eczema including that associated with acne",
        "Perianal & genital dermatitis"
      ],
      "dosage_and_administration": {
        "application": "Two or three times daily"
      },
      "contraindications_and_precautions": [
        "Hypersensitivity",
        "Use with caution on extensive surface areas or under occlusive dressings including baby napkins"
      ],
      "side_effects": [
        "Local sensitivity may occur",
        "Corticosteroids can be absorbed in sufficient amounts to produce systemic effects"
      ],
      "drug_interactions": [
        "Amphotericin antagonizes the effect of Miconazole"
      ],
      "use_in_pregnancy_and_lactation": "Topical steroids should not be extensively used in pregnancy.",
      "preparation": {
        "form": "Cream",
        "strength": "10 gm"
      }
    },
    {
      "name": "Fusid®",
     "img_id":"DOEucpU.png",
      "image": "fusid_1.png",
      "active_ingredients": "Furosemide",
      "indications": [
        "Cardiac oedema",
        "Pulmonary oedema",
        "Hepatic oedema",
        "Renal oedema",
        "Peripheral oedema",
        "Hypertension"
      ],
      "dosage_and_administration": {
        "tablet": {
          "mild_cases": "20 mg daily or 40 mg on alternate days",
          "resistant_cases": "80 mg/day",
          "children": "1 to 3 mg/kg/day, max. 40 mg/day"
        },
        "injection": {
          "dosage": "20-50 mg/day IM/IV",
          "children": "0.5-1.5 mg/kg/day, max. 20 mg/day"
        }
      },
      "contraindications_and_precautions": [
        "Anuria",
        "Electrolyte deficiency",
        "Precomatose states associated with liver cirrhosis",
        "Hypersensitivity to furosemide or sulphonamides"
      ],
      "side_effects": [
        "Alkalosis",
        "Uric acid retention",
        "May rarely produce acute gout",
        "May provoke hyperglycemia and glycosuria"
      ],
      "drug_interactions": [
        "ACE inhibitors",
        "Lithium",
        "Toxic effects of nephrotoxic antibiotics may be increased by concomitant administration of potent diuretics such as furosemide"
      ],
      "use_in_pregnancy_and_lactation": {
        "caution": "Should be cautiously used in cardiogenic shock complicated by pulmonary oedema and in the first trimester of pregnancy",
        "monitoring": "Blood pressure and pulse during rapid diuresis should be monitored",
        "lactation": "Should be used with caution during lactation"
      },
      "preparation": [
        {
          "form": "Tablet",
          "strength": "40 mg"
        },
        {
          "form": "Injection",
          "strength": "20 mg/2 ml"
        }
      ]
    },

    {
      "name": "Fusid® Plus",
     "img_id":"Lo86ZQb.jpeg",
      "image": "Fusid-Plus.jpg",
      "active_ingredients": "Spironolactone + Furosemide",
      "indications": [
        "Essential hypertension",
        "Chronic congestive heart failure",
        "Hepatic cirrhosis with ascites",
        "Swelling due to excess fluid retention (edema)",
        "Hyperaldosteronism",
        "Resistant edema associated with secondary hyperaldosteronism"
      ],
      "dosage_and_administration": {
        "fusid_plus": "1 to 4 tablets daily",
        "fusid_40_plus": "One to two tablets daily"
      },
      "contraindications_and_precautions": [
        "Anuria",
        "Acute renal insufficiency",
        "Rapidly deteriorating or severe impairment of renal function (creatinine clearance: < 30 ml/min)",
        "Hyperkalaemia",
        "Addison’s disease",
        "Hypersensitivity to spironolactone, furosemide, or sulphonamides",
        "Caution in patients liable to electrolyte deficiency",
        "Used with caution in diabetes, enlarged prostate, hypotension, and hypovolemia"
      ],
      "side_effects": [
        "Headache",
        "Drowsiness",
        "Gastrointestinal distress including cramp and diarrhoea",
        "Ataxia",
        "Mental confusion",
        "Skin rashes",
        "Gynaecomastia",
        "Hirsutism",
        "Deepening of the voice",
        "Menstrual irregularities",
        "Impotence",
        "Hyponatremia",
        "Hyperkalemia",
        "Dehydration",
        "Reduction in blood volume with circulatory collapse",
        "Cardiac arrhythmias"
      ],
      "drug_interactions": [
        "ACE inhibitors",
        "Potassium salts",
        "Cardiac glycosides",
        "Corticosteroids",
        "Indomethacin and other non-steroidal anti-inflammatory drugs (NSAIDs)",
        "Aminoglycoside antibiotics",
        "Sucralfate"
      ],
      "use_in_pregnancy": {
        "recommendation": "Furosemide should only be used in women of childbearing age when appropriate contraceptive measures are taken or if the potential benefits justify the potential risks to the fetus."
      },
      "use_in_lactation": {
        "recommendation": "If use of Spironolactone is considered essential, an alternative method of infant feeding should be instituted. Furosemide is excreted in breast milk and breastfeeding should be discontinued if treatment is essential."
      },
      "preparations": [
        {
          "form": "Tablet",
          "composition": "Spironolactone 50 mg & Furosemide 20 mg"
        },
        {
          "form": "Tablet",
          "composition": "Spironolactone 50 mg & Furosemide 40 mg"
        }
      ]
    },

    {
      "name": "Gabastar®",
     "img_id":"NnTMeg7.jpeg",
      "image": "GABASTAR-100.jpg",
      "active_ingredients": "Gabapentin",
      "indications": [
        "Neuropathic Pain",
        "Adjunctive therapy in partial seizure",
        "Adjunctive therapy in secondary generalized seizure"
      ],
      "dosage_and_administration": {
        "neuropathic_pain": {
          "initial_dose": [
            "300 mg once on Day 1",
            "300 mg twice on Day 2",
            "300 mg three times on Day 3"
          ],
          "maintenance_dose": "Up to 1800 mg/day divided into three doses (TID)"
        },
        "epilepsy": {
          "patients_over_12": {
            "starting_dose": "300 mg three times a day",
            "effective_dose": "900 to 1800 mg/day in three divided doses"
          },
          "paediatric_3_to_12_years": {
            "starting_dose": "10-15 mg/kg/day in 3 divided doses",
            "titration": "Effective dose reached by upward titration over approximately 3 days"
          }
        },
        "renal_impairment": "Gabapentin doses must be reduced",
        "administration": "Can be taken orally with or without food"
      },
      "contraindication_and_precaution": {
        "contraindications": ["Known hypersensitivity to Gabapentin"],
        "precautions": [
          "Avoid driving or operating heavy machinery until effects are known",
          "Caution in renal impaired patients"
        ]
      },
      "side_effects": [
        "Fatigue",
        "Dizziness",
        "Ataxia",
        "Weight gain",
        "Peripheral edema",
        "Dry mouth",
        "Somnolence"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Category C. Use only if potential benefits justify potential risks.",
        "lactation": "May be secreted in breast milk. Use with caution if necessary."
      },
      "preparation": ["100 mg Tablet", "300 mg Tablet"]
    },
    {
      "name": "Gelora®",
     "img_id":"Z0Zx8NG.jpeg",
      "image": "GELORA-GEL.jpg",
      "active_ingredients": "Miconazole",
      "indications": [
        "Treatment and prevention of fungal infections of the oropharynx and gastrointestinal tract",
        "Treatment of superinfections due to Gram-positive bacteria"
      ],
      "dosage_and_administration": {
        "adults": "1–2 teaspoonfuls of gel four times daily",
        "children_6_years_and_over": "1 teaspoonful of gel four times daily",
        "children_2_to_6_years": "1 teaspoonful of gel twice daily",
        "infants_under_2_years": "½ teaspoonful of gel twice daily"
      },
      "side_effects": ["Nausea", "Vomiting", "Diarrhoea", "Allergic reactions"],
      "contraindication_and_precaution": {
        "contraindications": ["Known hypersensitivity to Miconazole"],
        "precautions": [
          "Monitor anticoagulant effects when used with anticoagulants",
          "Monitor Miconazole and Phenytoin levels if used together",
          "Caution in infants and young children to avoid throat obstruction"
        ]
      },
      "drug_interactions": [
        "Terfenadine",
        "Astemizole",
        "Mizolastine",
        "Cisapride",
        "Triazolam",
        "Oral Midazolam",
        "Dofetilide",
        "Quinidine",
        "Pimozide",
        "Simvastatin",
        "Lovastatin"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Avoid if possible; use only if benefits outweigh risks",
        "lactation": "Use with caution in nursing mothers"
      },
      "preparation": ["20 mg/gm Oral Gel"]
    },
    {
      "name": "Genacyn® Ointment",
     "img_id":"vq1y8FX.jpeg",
      "image": "GENACYN-OINTMENT.jpg",
      "active_ingredients": "Gentamicin",
      "indications": [
        "Burns",
        "Eczema",
        "Seborrheic dermatitis",
        "Ecthyma",
        "Excoriation",
        "Folliculitis",
        "Furunculosis",
        "Insect bites and stings",
        "Lacerations and abrasions",
        "Paronychia",
        "Pyoderma gangrenosum",
        "Skin cysts and abscesses",
        "Stasis ulcers and infected skin ulcers",
        "Bacterial, fungal, or viral superinfection",
        "Sycosis barbae",
        "Minor surgical wounds",
        "Infected contact dermatitis caused by susceptible organisms"
      ],
      "dosage_and_administration": {
        "application": "Apply 3–4 times daily",
        "instructions": [
          "Wash area with soap and water before application",
          "Dry thoroughly",
          "Remove crusts if present to maximize contact",
          "Area may be covered with gauze dressing if desired"
        ]
      },
      "precaution": [
        "Should not be used in patients with hypersensitivity to Gentamicin"
      ],
      "side_effects": [
        "Itching",
        "Redness",
        "Swelling",
        "Other signs of irritation"
      ],
      "preparation": ["0.1% Ointment"]
    },
    {
      "name": "Germicord™",
     "img_id":"hS40Qor.jpeg",
      "image": "Germicord_l.jpg",
      "active_ingredients": "Chlorhexidine Gluconate 7.1% w/v (equivalent to 35.52 ml Chlorhexidine Gluconate Solution BP or 4% w/v Chlorhexidine Solution)",
      "indication": [
        "Prophylaxis of omphalitis (infection of the umbilical cord) in newborns"
      ],
      "dosage_and_administration": {
        "application": "Immediately after cutting the cord, apply to the tip of the cord, the stump, and around the base of the stump"
      },
      "use_in_pregnancy_and_lactation": "Not applicable for the intended patient population",
      "precaution": [
        "For external use only",
        "Do not inject or swallow",
        "Avoid contact with eyes and ears",
        "Do not use over large areas of the body",
        "If contact with eyes occurs, rinse thoroughly with water",
        "Discontinue use and seek medical help if signs of allergic reaction appear (e.g., hypersensitivity, skin irritation, anaphylactic shock)",
        "Seek prompt medical advice if skin irritation or redness occurs"
      ],
      "preparation": ["10 ml solution in HDPE container"]
    },

    {
      "name": "Geston®",
     "img_id":"bkzFPa2.jpeg",
      "image": "GESTON.jpg",
      "active_ingredients": "Allylestrenol",
      "indications": [
        "Threatened abortion",
        "Habitual abortion",
        "Threatened premature delivery",
        "IUGR (Intrauterine Growth Retardation)"
      ],
      "dosage_and_administration": {
        "threatened_abortion": "1 tablet three times daily until symptoms disappear.",
        "habitual_abortion": "1-2 tablets daily as soon as pregnancy is diagnosed. Continue for at least one month after the end of the critical period.",
        "threatened_premature_delivery": "Dosage must be determined individually. High dosages (up to 40mg daily) have been used.",
        "iugr": "1 tablet three times daily for at least two months. Dose can be reduced if symptoms improve.",
        "missed_dose": "Take the missed dose as soon as the patient remembers and continue the regular dosing schedule. A double dose is not recommended."
      },
      "contraindications_and_precautions": [
        "Hypersensitivity",
        "Thrombophlebitis",
        "Undiagnosed vaginal bleeding",
        "Incomplete abortion",
        "Hormone-dependent carcinoma",
        "Cerebral apoplexy",
        "Used as a diagnostic test for pregnancy",
        "Severe hepatic impairment"
      ],
      "side_effects": [
        "Gastrointestinal complaints such as vomiting, nausea, and sometimes epigastric discomfort"
      ],
      "use_in_pregnancy_and_lactation": "Specially designed for pregnancy. Should not be used during lactation.",
      "use_in_children": "Not for children younger than 16 years old.",
      "preparation": "5 mg tablet"
    },
    {
      "name": "Glysup® Suppository",
     "img_id":"Du8tsfK.jpeg",
      "image": "Glysup.jpg",
      "active_ingredients": "Glycerin",
      "indications": ["For the relief of occasional constipation"],
      "dosage_and_administration": {
        "children_under_2_years": "Consult with a physician.",
        "children_2_to_6_years": "Only 1 Glysup 1.15 suppository per 24 hours or as directed by the physician.",
        "adults_and_children_from_6_years": "Only 1 Glysup 2.30 suppository per 24 hours or as directed by the physician. Insert suppository well up into rectum. Suppository needs to melt completely to produce laxative action."
      },
      "contraindications_and_precautions": [
        "Sensitivity to the ingredients",
        "Do not use unless the patient needs to be treated (when constipated)"
      ],
      "side_effects": [
        "Rectal discomfort or a burning sensation when used rectally"
      ],
      "use_in_pregnancy_and_lactation": "There are no controlled data in human pregnancy.",
      "preparation": "1.15 gm & 2.30 gm Suppository"
    },
    {
      "name": "Gol™",
     "img_id":"iK8rsLX.jpeg",
      "image": "gol_l.jpg",
      "active_ingredients": "Macrogol & Electrolytes",
      "pharmacology": "Macrogol (3350) exerts an osmotic action in the gut, which induces a laxative effect. Macrogol (3350) increases the stool volume, which triggers colon motility via neuromuscular pathways. The physiological consequence is an improved propulsive colonic transportation of the softened stools and a facilitation of defecation. Electrolytes combined with Macrogol (3350) are exchanged across the intestinal barrier with serum electrolytes and excreted without net gain or loss of sodium, potassium, and water. Macrogol (3350) is unchanged along the gut and is virtually unabsorbed from the gastrointestinal tract.",
      "indications": [
        "Effective relief from constipation",
        "Treatment of chronic constipation",
        "Effective in resolving faecal impaction (refractory constipation with faecal loading of the rectum and colon)"
      ],
      "dosage_and_administration": {
        "adults": {
          "constipation": "25 mL of GOL™ oral solution added to 100 mL of water once daily (to make a total volume of 125 mL). This may be increased to 2 – 3 doses of 25 mL daily if required according to individual response.",
          "fecal_impaction": "8 doses of 25 mL daily (each 25 mL dose added to 100 mL of water). A course of treatment for faecal impaction does not normally exceed 3 days."
        },
        "children_12_18_years": "25 mL of GOL™ oral solution added to 100 mL of water once daily.",
        "preparation_instructions": "Measure 25 mL of GOL™ oral solution with the measuring cup provided, then add this to 100 mL of water. Any unused diluted solution should be discarded within 24 hours."
      },
      "contraindications": [
        "Intestinal perforation or obstruction due to structural or functional disorder of the gut wall",
        "Ileus",
        "Severe inflammatory conditions of the intestinal tract (e.g. Crohn’s disease, ulcerative colitis, toxic megacolon)",
        "Hypersensitivity to the active substances"
      ],
      "precautions": [
        "This medicinal product contains 8.125 mmol of sodium in each dose of 25 mL. The sodium content should be considered when administering to patients on a controlled sodium diet."
      ],
      "side_effects": [
        "Diarrhoea or loose stools (usually responds to a reduction in dose)",
        "Abdominal distension",
        "Anorectal discomfort",
        "Mild vomiting (may resolve with dose reduction or delay)"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Clinically, no effects during pregnancy are anticipated, since systemic exposure to Macrogol (3350) is negligible. GOL™ oral solution can be used during pregnancy.",
        "lactation": "No effects on the breastfed newborn/infant are anticipated since systemic exposure to Macrogol (3350) is negligible. GOL™ oral solution can be used during breastfeeding."
      },
      "drug_interaction": "There is a possibility that the absorption of other medicinal products could be transiently reduced during use with GOL™ oral solution. Isolated reports of decreased efficacy with some concomitantly administered medicinal products, e.g. anti-epileptics.",
      "overdose": "Extensive fluid loss by diarrhea or vomiting may require correction of electrolyte disturbances.",
      "preparation": "100 ml solution"
    },
    {
      "name": "Grastim™",
     "img_id":"OHB7Ocd.jpeg",
      "image": "grastim_l.jpg",
      "active_ingredients": "Filgrastim Concentrated Solution",
      "indications": [
        "Cancer patients receiving myelosuppressive chemotherapy",
        "Patients with Acute Myeloid Leukemia receiving Induction or consolidation chemotherapy",
        "Cancer patients receiving bone marrow transplant",
        "Patients undergoing peripheral blood progenitor cell collection and therapy",
        "Patients with severe chronic neutropenia"
      ],
      "side_effects": [
        "Neutropenia",
        "Vomiting",
        "Leukopenia",
        "Anaemia",
        "Thrombocytopenia",
        "Pyrexia",
        "Back pain",
        "Abdominal pain",
        "Diarrhoea",
        "Cough",
        "Pain",
        "Nausea",
        "Pain in extremity",
        "Headache",
        "Constipation",
        "Stomatitis",
        "Asthenia",
        "Mucosal inflammation",
        "Alopecia"
      ],
      "contraindications": [
        "Hypersensitivity to the drug",
        "Hypersensitivity to any ingredient in the formulation",
        "Hypersensitivity to proteins derived from Escherichia coli"
      ],
      "pediatric_precautions": "Filgrastim has been used in children aged 3 months to 18 years without unusual adverse effects. However, safety and efficacy in neonates or patients with autoimmune neutropenia of infancy have not been established.",
      "use_in_pregnancy_and_lactation": {
        "pregnancy_category": "C",
        "description": "Although there are no adequate and controlled studies in humans, Filgrastim has been shown to adversely affect pregnancy and the fetus in animals. Filgrastim should be used during pregnancy only when the potential benefits justify the possible risks to the fetus.",
        "lactation": "It is not known whether Filgrastim is distributed into milk. Because many drugs are distributed into milk, Filgrastim should be used with caution in nursing women."
      },
      "drug_interaction": "The safety and efficacy of concomitant administration of doses of Filgrastim with doses of myelosuppressive antineoplastic agents have not been established. Due to transient decreases in platelet counts reported in some patients, it is recommended that Filgrastim be used with caution in patients receiving other drugs known to decrease platelet count.",
      "dosage_and_administration": "As directed by the physician.",
      "preparation": "Each 0.5 ml pre-filled syringe contains sterile Filgrastim Concentrated Solution BP (GCSF) 300 mcg (30 MU)."
    },
    {
      "name": "Gutfix™",
     "img_id":"T9gKHIw.jpeg",
      "image": "Gutfix_l.jpg",
      "active_ingredients": "Lubiprostone INN",
      "indications": [
        "Irritable Bowel Syndrome with Constipation (IBS-C)",
        "Chronic Idiopathic Constipation (CIC) in adults",
        "Opioid-Induced Constipation (OIC) in adult patients with chronic, non-cancer pain"
      ],
      "dosage_and_administration": {
        "IBS_C": "The recommended dose is 8 mcg twice daily orally with food and water.",
        "CIC_OIC": "The recommended dose is 24 mcg twice daily orally with food and water."
      },
      "contraindications": [
        "Lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction."
      ],
      "side_effects": [
        "Diarrhea",
        "Full or bloated feeling or pressure in the stomach",
        "Nausea",
        "Stomach pain",
        "Swelling of abdominal or stomach area",
        "Dyspnea"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "May be used in pregnancy only if it is clearly needed, based on the assessment of the risk-benefit ratio.",
        "lactation": "Caution should be exercised when Lubiprostone is administered to a nursing woman."
      },
      "drug_interaction": "There is a possibility of a dose-dependent decrease in the efficacy of Lubiprostone in patients using diphenylheptane opioids.",
      "preparation": "8 mcg and 24 mcg Capsule"
    },
    {
      "name": "Gynepro®",
     "img_id":"4RMmy9H.jpeg",
      "image": "Gynepro.jpg",
      "active_ingredients": [
        "Metronidazole",
        "Neomycin Sulphate",
        "Polymyxin B Sulphate",
        "Nystatin"
      ],
      "indications": [
        "Vaginal trichomoniasis",
        "Vaginal leucorrhoeas",
        "Mixed vaginal infections (Fungal or Bacterial)"
      ],
      "dosage_and_administration": {
        "general": "One suppository in vagina at bedtime for 12 days, or as directed by the physician."
      },
      "contraindications_and_precautions": [
        "Contraindicated to the patients who are hypersensitive to Metronidazole, Neomycin Sulphate, Polymyxin B Sulphate & Nystatin.",
        "Caution should be taken in case of renal impairment."
      ],
      "side_effects": ["Skin rash", "Urticaria (may occur rarely)"],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Caution should be practiced in pregnancy.",
        "lactation": "Caution should be practiced during lactation."
      },
      "preparation": "Each box contains 2 x 6's vaginal suppositories."
    },
    {
      "name": "Halobet™",
     "img_id":"/MgcKwHk.jpeg",
      "image": "halo_05_l_20.jpg",
      "active_ingredients": "Halobetasol Propionate",
      "indications": [
        "Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatitis"
      ],
      "dosage_and_administration": {
        "general": "Apply a thin layer to the affected skin once or twice daily, as directed by your physician. Rub in gently and completely. Discontinue treatment once control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. Halobet should not be used with occlusive dressings."
      },
      "contraindications_and_precautions": [
        "Contraindicated in patients with a history of hypersensitivity to any components of the preparations.",
        "Systemic absorption of topical corticosteroids can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria.",
        "Conditions that increase systemic absorption include application of potent steroids, use over large surface areas, prolonged use, or occlusive dressings. Evaluation of HPA axis function may be necessary for patients receiving large doses or applying it over large areas.",
        "If HPA axis suppression occurs, consider reducing dose or frequency, or substituting a less potent steroid."
      ],
      "side_effects": [
        "Stinging, burning, or itching (4.4% of patients)",
        "Dry skin, erythema, skin atrophy, leukoderma, vesicles, rash",
        "Folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, striae, miliaria"
      ],
      "drug_interactions": "No known reports of drug interactions.",
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Topical corticosteroids should be used during pregnancy only if the potential benefits justify the potential risks to the fetus. They should not be used extensively on pregnant patients, in large amounts, or for prolonged periods.",
        "lactation": "It is not known if topical corticosteroids are secreted into breast milk. Caution should be exercised when administering topical corticosteroids to a nursing woman."
      },
      "use_in_children": "Not recommended for use in children.",
      "preparation": "Halobet 0.05% Cream - Each pack contains the cream."
    },
    {
      "name": "Hemorif®",
     "img_id":"ZqEe0LW.jpeg",
      "image": "HEMORIF.jpg",
      "active_ingredients": "Micronised Diosmin & Hesperidin",
      "indications": [
        "Acute hemorrhoidal attacks",
        "Chronic hemorrhoidal disease",
        "Organic & functional chronic venous insufficiency of the lower limbs with symptoms like heavy legs, pain, and nocturnal cramps"
      ],
      "dosage_and_administration": {
        "acute_hemorrhoidal_attacks": "3 tablets twice daily for 4 days, then 2 tablets twice daily for three days. If required, 1 tablet twice daily.",
        "chronic_hemorrhoids": "1 tablet twice daily",
        "chronic_venous_insufficiency": "1 tablet twice daily initially for seven days. Duration may be increased depending on severity."
      },
      "side_effects": [
        "Gastric disorders",
        "Neurovegetative disorders (feeling of discomfort)"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Experimental studies in animals have not demonstrated any teratogenic effects, and no harmful effects have been reported in women to date.",
        "lactation": "Breastfeeding is not recommended during treatment."
      },
      "preparation": "(Diosmin 450 mg + Hesperidin 50 mg)/Tablet"
    },
    {
      "name": "Hemorif® DS",
     "img_id":"h1SUPN8.jpeg",
      "image": "Hemorif-DS.jpg",
      "active_ingredients": "Diosmin BP 900 mg & Hesperidin USP 100 mg",
      "indications": [
        "Poor circulation in the legs (Chronic Venous Insufficiency, CVI)",
        "Hemorrhoids",
        "Leg ulcers from poor circulation (venous stasis ulcers)",
        "Treatment of bleeding gums",
        "Treatment of bleeding/hemorrhage in the eye",
        "Preventing liver damage",
        "Varicose veins"
      ],
      "dosage_and_administration": {
        "acute_hemorrhoid": "1 tablet thrice daily for first 4 days, followed by 1 tablet twice daily for 3 days, and then 1 tablet once daily as maintenance dose.",
        "relapse_of_internal_hemorrhoid_and_chronic_hemorrhoid": "1 tablet once daily for 3 months.",
        "cvi": "1 tablet once daily for 2-6 months.",
        "leg_wounds": "1 tablet once daily for 2 months."
      },
      "contraindications": [
        "CVI and its complications should be diagnosed and managed by a physician.",
        "Contraindicated in patients with hypersensitivity to any ingredient in the product."
      ],
      "adverse_effects": [
        "Gastrointestinal disturbances",
        "Headache",
        "Rash",
        "Cramps in lower limb",
        "Phlebitis",
        "Venous thrombosis"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnant_women": "Experimental studies have not shown any teratogenic effect in animals. In human beings, no harmful effect has been reported.",
        "nursing_women": "In the absence of data concerning excretion into breast milk, breastfeeding is not recommended during treatment."
      },
      "preparation": "30 tablets"
    },
    {
      "name": "HemosolTM -A",
     "img_id":"7mVZceR.jpeg",
      "image": "Hemosol-A_l1.jpg",
      "active_ingredients": "Bicarbonate Hemodialysis Solution (Acidic Component)",
      "indications": [
        "Acute & Chronic renal failure",
        "To correct electrolyte and acid-base imbalance",
        "In the treatment of poisoning"
      ],
      "dosage_and_administration": {
        "dilution_ratio": "HemosolTM-A (Acidic Solution): Hemosol™-B (Basic Solution): Purified Water BP = 1:1.83:34",
        "hemodialysis_frequency": "2-3 times a week",
        "session_duration": "Each session lasts for 3-6 hours"
      },
      "preparation": "10 Liter Solution"
    },
    {
      "name": "Heplol TM",
     "img_id":"hIKlRDC.jpeg",
      "image": "Heplol-Tablet.jpg",
      "active_ingredients": "L-Ornithine L-Aspartate",
      "active_ingredients_amount": "150 mg per tablet",
      "indications": [
        "Treatment of hyperammonemia due to acute and chronic liver diseases such as liver cirrhosis, fatty liver, hepatitis",
        "Treatment of incipient disturbances of consciousness (pre-coma) or neurological complications (hepatic encephalopathy)",
        "Treatment of concomitant diseases and sequelae of acute and chronic liver diseases (e.g. liver cirrhosis) with latent and manifest hepatic encephalopathy symptoms"
      ],
      "dosage_and_administration": {
        "adults_and_children_over_7_years": "150 mg-300 mg (1 to 2 tablets) 3 times a day with a small amount of water",
        "treatment_duration": "Course determined individually"
      },
      "side_effects": [
        "Nausea",
        "Vomiting",
        "Stomachache",
        "Flatulence",
        "Diarrhea"
      ],
      "use_in_pregnancy_and_lactation": "Caution needed during pregnancy and breastfeeding due to unknown effects",
      "contraindications": [
        "Hypersensitivity to L-Ornithine L-Aspartate or any excipients",
        "Severe renal insufficiency (serum creatinine > 3 mg/100 ml)"
      ],
      "drug_interaction": "Not known",
      "preparation": "150 mg tablet"
    },

    {
      "name": "Imotil®",
     "img_id":"hMmuM6q.jpeg",
      "image": "Imotil.jpg",
      "active_ingredients": "Loperamide",
      "indications": [
        "Acute diarrhoea",
        "Chronic diarrhoea",
        "IBS (Diarrhoea predominant)"
      ],
      "dosage_and_administration": {
        "acute_diarrhoea": {
          "adults": "2 capsules initially, then 1 capsule for each subsequent loose stool. Maximum 8 capsules per day.",
          "children_over_8": "1 capsule initially, then 1 capsule for each subsequent loose stool. Maximum 6 capsules per day, based on age."
        },
        "chronic_diarrhoea": {
          "adults": "2 capsules daily",
          "children_over_8": "1 capsule daily"
        }
      },
      "contraindication_and_precaution": {
        "contraindication": "Should not be used in children under 4 years of age",
        "precaution": "Use with caution during pregnancy and lactation"
      },
      "side_effects": [
        "Paralytic ileus",
        "Abdominal cramps & bloating",
        "Urticaria",
        "Nausea",
        "Vomiting",
        "Constipation",
        "Tiredness",
        "Drowsiness",
        "Dizziness",
        "Dry mouth"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Should not be administered during pregnancy, despite no teratogenic effect observed in animals.",
        "lactation": "Low fraction secreted in breast milk, use with caution during lactation."
      },
      "preparation": "2 mg Capsule"
    },
    {
      "name": "Infudex™",
     "img_id":"FIcUggG.jpeg",
      "image": "int_l1.jpg",
      "active_ingredients": "Dextrose Anhydrous",
      "indications": [
        "Simple dehydration",
        "Carbohydrate depletion",
        "Hypoglycemic coma",
        "General weakness"
      ],
      "dosage_and_administration": {
        "dose": "Variable, depending on clinical condition, age, and body surface area of the patient."
      },
      "preparation": [
        {
          "product": "Infudex 5 IV Infusion",
          "volume": "500 ml",
          "concentration": "Each 100 ml solution contains 5 gm Dextrose Anhydrous USP"
        },
        {
          "product": "Infudex 5 IV Infusion",
          "volume": "1000 ml",
          "concentration": "Each 100 ml solution contains 5 gm Dextrose Anhydrous USP"
        },
        {
          "product": "Infudex 10 IV Infusion",
          "volume": "500 ml",
          "concentration": "Each 100 ml solution contains 10 gm Dextrose Anhydrous USP"
        },
        {
          "product": "Infudex 10 IV Infusion",
          "volume": "1000 ml",
          "concentration": "Each 100 ml solution contains 10 gm Dextrose Anhydrous USP"
        }
      ]
    },
    {
      "name": "Intimate™",
     "img_id":"gk02hw8.png",
      "image": "Intimate.png",
      "active_ingredients": "Tadalafil",
      "indications": [
        "Erectile Dysfunction (ED)",
        "Signs & symptoms of Benign Prostatic Hyperplasia (BPH)"
      ],
      "dosage_and_administration": {
        "erectile_dysfunction": {
          "use_as_needed": {
            "recommended_starting_dose": "10 mg",
            "dose_adjustment": "Increase to 20 mg or decrease to 5 mg based on efficacy and tolerability.",
            "max_dosing_frequency": "Once per day"
          },
          "once_daily_use": {
            "recommended_starting_dose": "2.5 mg",
            "dose_adjustment": "Increase to 5 mg based on efficacy and tolerability."
          }
        },
        "food": "Tadalafil can be taken without regard to food.",
        "dose_adjustment_in_renal_impairment": {
          "mild": "No dose adjustment required.",
          "moderate": "Starting dose of 5 mg, max 10 mg once every 48 hours.",
          "severe": "Max dose of 5 mg once every 72 hours."
        },
        "dose_adjustment_in_hepatic_impairment": {
          "mild_or_moderate": "Dose should not exceed 10 mg once per day.",
          "severe": "Not recommended."
        },
        "geriatric_use": "No dose adjustment required in patients >65 years of age."
      },
      "contraindications": [
        "Nitrates",
        "Hypersensitivity reactions to tadalafil"
      ],
      "side_effects": {
        "general": [
          "Hypersensitivity reactions including rash, urticaria, facial edema, Stevens-Johnson syndrome, exfoliative dermatitis."
        ],
        "cardiovascular_and_cerebrovascular": [
          "Myocardial infarction",
          "Sudden cardiac death",
          "Unstable angina pectoris",
          "Ventricular arrhythmia",
          "Stroke",
          "Transient ischemic attacks",
          "Chest pain",
          "Palpitations",
          "Tachycardia",
          "Hypotension (more common with antihypertensive agents)",
          "Hypertension",
          "Syncope"
        ],
        "skin_and_subcutaneous_tissues": ["Hyperhidrosis (sweating)"],
        "gastrointestinal": ["Abdominal pain", "Gastroesophageal reflux"],
        "nervous_system": ["Migraine", "Transient global amnesia"],
        "respiratory_system": ["Epistaxis (nosebleed)"],
        "special_senses": [
          "Blurred vision",
          "Non-arteritic anterior ischemic optic neuropathy",
          "Retinal vein occlusion",
          "Visual field defect"
        ],
        "otologic": ["Sudden decrease or loss of hearing"]
      },
      "pregnancy_and_lactation": "Not indicated for use in newborns, children, or women.",
      "precautions": [
        "Evaluation of erectile dysfunction & BPH should include a proper medical assessment.",
        "Consider cardiovascular status, interaction with other medicines (e.g., nitrates, alpha-blockers, anti-hypertensive agents, potent inhibitors of CYP3A4), alcohol consumption, and conditions like renal insufficiency and hepatic impairment."
      ],
      "overdosage": "Adverse events are similar to those seen at lower doses. Standard supportive measures should be taken. Hemodialysis contributes negligibly to tadalafil elimination.",
      "preparation": ["5 mg Tablet", "10 mg Tablet", "20 mg Tablet"]
    },
    {
      "name": "Iprex™",
     "img_id":"us6fzjE.jpeg",
      "image": "IPREX-20ML.jpg",
      "active_ingredients": "Ipratropium Bromide",
      "indications": [
        "Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD)",
        "Chronic bronchitis",
        "Emphysema"
      ],
      "dosage_and_administration": {
        "adults": {
          "dose": "0.4-2 ml (100-500 mcg) of Ipratropium bromide",
          "dilution": "Diluted to a final volume of 2.0-4.0 ml with normal saline (0.9%)",
          "frequency": "Administered four times daily"
        },
        "children": {
          "age_group": "Over 3 years",
          "dose": "0.4-2 ml of the prepared solution",
          "frequency": "Administered three times daily"
        }
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "History of hypersensitivity to soya lecithin or related food products such as soybean & peanut",
          "Known or suspected hypersensitivity to ipratropium bromide, atropine, and its derivatives"
        ],
        "precautions": [
          "Use with caution in patients with narrow-angle glaucoma",
          "Prostatic hypertrophy",
          "Bladder-neck obstruction"
        ]
      },
      "side_effects": {
        "general": [
          "Dry mouth",
          "Dryness of the oropharynx",
          "Cough",
          "Exacerbation of symptoms",
          "Irritation from aerosol"
        ],
        "nervous_system": [
          "Headache",
          "Dizziness",
          "Blurred vision/difficulty in accommodation",
          "Tachycardia",
          "Nervousness",
          "Paresthesias",
          "Drowsiness",
          "Coordination difficulty"
        ],
        "skin_and_subcutaneous_tissues": [
          "Itching",
          "Hives",
          "Flushing",
          "Alopecia"
        ],
        "gastrointestinal": ["Constipation"],
        "other": [
          "Tremor",
          "Mucosal ulceration",
          "Worsening of narrow-angle glaucoma",
          "Acute eye pain",
          "Hypotension",
          "Allergic-type reactions (skin rash, angio-oedema, urticaria)",
          "Laryngospasm",
          "Anaphylactic reaction"
        ]
      },
      "drug_interaction": "No studies fully evaluating the interaction effects of Ipratropium.",
      "use_in_pregnancy_and_lactation": {
        "pregnancy_category": "B",
        "precaution": "Should be used during pregnancy only if clearly needed",
        "lactation": "It is not known whether ipratropium bromide is excreted in human milk"
      },
      "preparation": "250 mcg/ml Respirator Solution"
    },
    {
      "name": "Iracet™",
     "img_id":"rUne0a9.png",
      "image": "iracet-250_f1.png",
      "active_ingredients": "Levetiracetam",
      "indications": [
        "Adjunctive therapy for Partial Onset Seizures",
        "Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy",
        "Primary Generalized Tonic-Clonic Seizures"
      ],
      "dosage_and_administration": {
        "oral_and_tablet_solution": {
          "initial_dose": "1000 mg/day, given as twice-daily dosing (500 mg twice daily)",
          "dose_increments": "1000 mg/day additional every 2 weeks",
          "max_daily_dose": "3000 mg"
        },
        "pediatric_dosing": {
          "1_month_to_6_months": {
            "initial_dose": "7 mg/kg twice daily",
            "incremental_dose": "21 mg/kg twice daily"
          },
          "6_months_to_4_years": {
            "initial_dose": "10 mg/kg twice daily",
            "incremental_dose": "25 mg/kg twice daily"
          },
          "4_years_to_16_years": {
            "initial_dose": "10 mg/kg twice daily",
            "incremental_dose": "30 mg/kg twice daily"
          },
          "adolescent_20_40_kg": {
            "initial_dose": "250 mg twice daily",
            "incremental_dose": "750 mg twice daily"
          }
        },
        "injection": {
          "dose": "500 mg/5 mL",
          "dilution": "Dilute in 100 mL of compatible diluent",
          "infusion_time": "15-minute IV infusion"
        },
        "dosing_instructions": [
          {
            "dose": "500 mg",
            "withdraw_volume": "5 ml",
            "diluent_volume": "100 ml",
            "infusion_time": "15 minutes"
          },
          {
            "dose": "1000 mg",
            "withdraw_volume": "10 ml",
            "diluent_volume": "100 ml",
            "infusion_time": "15 minutes"
          },
          {
            "dose": "1500 mg",
            "withdraw_volume": "15 ml",
            "diluent_volume": "100 ml",
            "infusion_time": "15 minutes"
          }
        ]
      },
      "compatibility_and_stability": {
        "diluents": [
          "Sodium chloride (0.9%) injection, USP",
          "Lactated Ringer’s injection",
          "Dextrose 5% injection, USP"
        ],
        "other_antiepileptic_drugs": [
          "Lorazepam",
          "Diazepam",
          "Valproate sodium"
        ]
      },
      "contraindications_and_precautions": {
        "contraindications": "None",
        "precautions": "None"
      },
      "side_effects": [
        "Dizziness",
        "Drowsiness",
        "Irritability",
        "Sore throat",
        "Tiredness",
        "Weakness",
        "Severe allergic reaction (rare)"
      ],
      "drug_interaction": "No potential drug interaction has been reported.",
      "use_in_pregnancy_and_lactation": {
        "pregnancy_category": "C",
        "lactation": "Levetiracetam is contraindicated during breast-feeding due to secretion into milk"
      },
      "use_in_children": {
        "age_group": "1 month to 16 years",
        "effectiveness": "Established for adjunctive treatment of partial onset seizures in pediatric patients with epilepsy"
      },
      "preparation": [
        "250 mg & 500 mg tablets",
        "500 mg XR Tablet",
        "Injection: 50 ml oral solution"
      ]
    },
    {
      "name": "Isodex™ IV",
     "img_id":"eb2BhuV.jpeg",
      "image": "Isode.jpeg",
      "active_ingredients": [
        {
          "name": "Dextrose Anhydrous USP",
          "concentration": "4.30% w/v"
        },
        {
          "name": "Sodium Chloride BP",
          "concentration": "0.18% w/v"
        }
      ],
      "indications": [
        "Water and sodium depletion",
        "Provides Dextrose as a nutrient in a suitable medium of Sodium Chloride",
        "Source of Sodium Chloride",
        "Maintenance and replacement of fluid, electrolyte, and carbohydrate in patients on nothing by mouth regimen during pre & post-operative stages"
      ],
      "dosage_and_administration": {
        "guidelines": "The volume and rate of infusion depend on clinical condition, age, body surface area of the patient, and judgment of the physician."
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "Hypernatremia",
          "Acidosis",
          "Hypokalemia",
          "Fluid overload"
        ],
        "precautions": "Use with caution in patients with any of the above conditions."
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "It is not known whether Dextrose and Sodium Chloride Infusion can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.",
        "lactation": "It is not known whether this drug is excreted in human milk. Caution should be exercised when administered to a nursing woman."
      },
      "preparation": {
        "product_format": "Isodex™ IV, 1000 ml",
        "contents_per_bottle": "Each 1000 ml PP bottle contains Sodium Chloride BP 0.18% w/v and Dextrose Anhydrous USP 4.30% w/v solution."
      }
    },
    {
      "name": "Isovent®",
     "img_id":"Ecaeq1v.jpeg",
      "image": "ISOVENT-200.jpg",
      "active_ingredients": "Misoprostol",
      "indications": [
        "Labor induction (in unfavorable cervical conditions)",
        "Prevention & treatment of Postpartum Hemorrhage (PPH)"
      ],
      "dosage_and_administration": {
        "induction_of_labor": [
          "25 mcg vaginally every 6 hours",
          "50 mcg orally every 4 hours"
        ],
        "postpartum_hemorrhage_prophylaxis": "400 mcg to 600 mcg orally or rectally immediately following delivery of the child.",
        "postpartum_hemorrhage_treatment": [
          "1000 mcg rectally",
          "200 mcg orally with 400 mcg sublingually"
        ]
      },
      "side_effects": [
        "Spotting",
        "Cramps",
        "Hypermenorrhea",
        "Menstrual disorder",
        "Dysmenorrhea",
        "Postmenopausal vaginal bleeding may be related to Misoprostol administration"
      ],
      "contraindications_and_precautions": {
        "contraindications": "Misoprostol is contraindicated in pregnant women due to its abortifacient properties.",
        "precautions": "Precaution should be taken in conditions where hypertension might precipitate severe complications (e.g., Cerebrovascular & cardiovascular disease)."
      },
      "drug_interactions": {
        "interactions": "No evidence of clinically significant interaction between Misoprostol & cardiac, pulmonary, CNS drugs & NSAIDs. Bioavailability of Misoprostol is decreased with high doses of antacid."
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Due to the abortifacient property, Misoprostol is contraindicated in women who are pregnant.",
        "lactation": "Caution should be exercised, but specific information on lactation is not provided."
      },
      "preparation": {
        "product_formats": ["200 mcg Tablet", "600 mcg Tablet"]
      }
    },
    {
      "name": "Itra®",
     "img_id":"BHa24tt.jpeg",
      "image": "Itra.jpg",
      "active_ingredients": "Itraconazole",
      "indications": [
        "Candidiasis",
        "Pityriasis Versicolor",
        "Tinea",
        "Histoplasmosis",
        "Systemic candidiasis",
        "Aspergillosis",
        "Cryptococcosis",
        "Prevention of relapse of underlying fungal infections in AIDS patients",
        "Prevention of fungal infection during prolonged neutropenia"
      ],
      "dosage_and_administration": "100 mg - 200 mg daily.",
      "side_effects": [
        "Nausea",
        "Abdominal pain",
        "Dyspepsia",
        "Constipation",
        "Headache",
        "Dizziness",
        "Raised liver enzymes",
        "Menstrual disorders",
        "Allergic reactions (including pruritus, rash, urticaria & angioedema)",
        "Hepatitis & cholestatic jaundice",
        "Peripheral neuropathy",
        "Stevens-Johnson syndrome",
        "Hypokalemia",
        "Oedema",
        "Hair loss (with prolonged use)"
      ],
      "contraindications_and_precautions": {
        "contraindications": "Known hypersensitivity, severe hepatic disease.",
        "precautions": "Use with caution in patients with hepatic disorders."
      },
      "drug_interactions": {
        "interactions": [
          "Terfenadine",
          "Astemizole",
          "Cisapride",
          "HMG-CoA reductase inhibitors such as simvastatin",
          "Oral midazolam or triazolam",
          "Rifampin",
          "Phenytoin",
          "Phenobarbital",
          "Digoxin",
          "Calcium channel blockers"
        ]
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Itraconazole is contraindicated in pregnancy.",
        "lactation": "Breastfeeding while receiving Itraconazole is not recommended."
      },
      "preparation": {
        "product_format": "100 mg Capsule"
      }
    },
    {
      "name": "Ivanor™",
     "img_id":"VcxfJ1z.png",
      "image": "ivanor_5_l.png",
      "active_ingredients": "Ivabradine Hydrochloride",
      "indications": [
        "Symptomatic treatment of chronic stable angina pectoris in coronary artery disease patients with normal sinus rhythm",
        "In patients unable to tolerate or with a contraindication to the use of beta-blockers",
        "In combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose & whose heart rate is > 60 bpm"
      ],
      "dosage_and_administration": {
        "starting_dose": "5 mg twice daily",
        "increase_after_3_4_weeks": "7.5 mg twice daily depending on therapeutic response",
        "administration": "1 tablet in the morning and 1 tablet in the evening during meals"
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "History of hypersensitivity to Ivabradine or any of the excipients",
          "Resting heart rate below 60 bpm before treatment",
          "Cardiogenic shock",
          "Acute myocardial infarction",
          "Severe hypotension (<90/50 mmHg)",
          "Severe hepatic insufficiency",
          "Sick sinus syndrome",
          "Sino-atrial block",
          "Heart failure",
          "Pacemaker dependent",
          "Unstable angina",
          "3rd degree AV block",
          "Combination with strong cytochrome P450 3A4 inhibitors (such as azole antifungals, macrolide antibiotics, HIV protease inhibitors)"
        ],
        "precautions": [
          "Mild to moderate hypotension",
          "Atrial fibrillation",
          "Patients with congenital QT syndrome or treated with QT wave prolonging medicinal products",
          "Moderate hepatic insufficiency",
          "Severe renal insufficiency"
        ]
      },
      "side_effects": [
        "Visual symptoms",
        "Blurred vision",
        "Bradycardia",
        "1st degree AV block",
        "Ventricular extrasystoles",
        "Headaches",
        "Dizziness"
      ],
      "drug_interactions": {
        "contraindicated_interactions": [
          "QT wave prolonging medicinal products (e.g., quinidine, disopyramide, bepridil, sotalol, ibutilide, amiodarone)",
          "Non-cardiovascular QT wave prolonging medicinal products (e.g., pimozide, ziprasidone, sertindole, mefloquine, halofantrine, pentamidine, cisapride, intravenous erythromycin)"
        ],
        "caution": "The concomitant use of cardiovascular and non-cardiovascular QT wave prolonging medicinal products with Ivabradine should be avoided since QT wave prolongation may be exacerbated by heart rate reduction. If the combination appears necessary, close cardiac monitoring is needed."
      },
      "use_in_pregnancy_and_lactation": {
        "fertility": "Studies in rats have shown no effect on fertility in males and females",
        "pregnancy": "Ivabradine is contraindicated during pregnancy due to limited data",
        "breastfeeding": "Ivabradine is contraindicated during breastfeeding as it is excreted in milk"
      },
      "use_in_children": "Not recommended",
      "preparation": {
        "product_formats": ["5 mg Tablet", "7.5 mg Tablet"]
      }
    },
    {
      "name": "Iventi®",
     "img_id":"UpRowHc.jpeg",
      "image": "Iventi.jpg",
      "formulation": "Eye Drops",
      "active_ingredients": "Moxifloxacin",
      "indication": "Bacterial conjunctivitis",
      "dosage_and_administration": {
        "recommended_dosage": "One drop in the affected eye 3 times a day for 7 days"
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "History of hypersensitivity to Moxifloxacin, other quinolones, or any of the components in this medication"
        ],
        "precautions": [
          "Prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use & institute alternative therapy",
          "Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis"
        ]
      },
      "drug_interactions": {
        "interaction_studies": "Drug-drug interaction studies have not been conducted with Moxifloxacin Hydrochloride ophthalmic solution"
      },
      "side_effects": {
        "ocular_side_effects": [
          "Conjunctivitis",
          "Decreased visual acuity",
          "Dry eye",
          "Keratitis",
          "Ocular discomfort",
          "Ocular hyperemia",
          "Ocular pain",
          "Ocular pruritus",
          "Subconjunctival hemorrhage",
          "Tearing"
        ],
        "non_ocular_side_effects": [
          "Fever",
          "Increased cough",
          "Infection",
          "Otitis media",
          "Pharyngitis",
          "Rash",
          "Rhinitis"
        ]
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Moxifloxacin Hydrochloride ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus",
        "lactation": "Caution should be exercised when Moxifloxacin Hydrochloride ophthalmic solution is administered to a nursing mother"
      },
      "preparation": {
        "product_format": "0.5% Eye Drops"
      }
    },
    {
      "name": "Iventi-DTM",
     "img_id":"2e5jTeX.jpeg",
      "image": "Iventi-D.jpg",
      "formulation": "Eye Drops",
      "active_ingredients": ["Moxifloxacin", "Dexamethasone"],
      "indication": [
        "Steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists",
        "Postoperative inflammation and other ocular inflammation associated with infection"
      ],
      "dosage_and_administration": {
        "general_dosage": "One or two drops instilled into the conjunctival sac(s), every 4 to 6 hours",
        "initial_24_to_48_hours": "Increase dosage to 1 or 2 drops every two hours during the initial 24 to 48 hours. Gradually decrease frequency as clinical improvement occurs",
        "post_surgery_inflammation_infection_prevention": "Instill 1 drop, 4 times/day in the eye to be operated, starting 1 day before the surgery and during 15 days after the surgery",
        "ocular_infections_treatment": "Instill 1 drop 4 times/day during 7 days or as directed by the doctor",
        "cataract_surgery": "Instill the solution immediately after the surgery",
        "refractive_surgery_by_lasik": "Instill the solution within 15 minutes after the surgery"
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "Epithelial herpes simplex keratitis (Dendritic keratitis)",
          "Vaccinia",
          "Varicella",
          "Mycobacterial infection of the eye",
          "Fungal diseases of ocular structures",
          "Hypersensitivity to any of the components of the medication"
        ],
        "precautions": [
          "Prolonged use of steroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation"
        ]
      },
      "side_effects": {
        "common_side_effects": [
          "Conjunctival irritation",
          "Increased lacrimation",
          "Keratitis",
          "Papillary conjunctivitis"
        ]
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "There are no adequate and well-controlled studies in pregnant women. This drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus",
        "lactation": "Caution should be exercised when Dexamethasone ophthalmic solution is administered to a nursing woman"
      },
      "preparation": {
        "product_format": "5 ml bottle containing 0.5% Moxifloxacin and 0.1% Dexamethasone Phosphate sterile solution"
      }
    },
    {
      "name": "Iventi® 400 IV",
     "img_id":"cKg0gNz.jpeg",
      "image": "Iventi-Infusion_l.jpg",
      "formulation": "Intravenous Infusion",
      "active_ingredients": "Moxifloxacin 0.16% w/v",
      "indication": [
        "Acute Bacterial Sinusitis",
        "Acute Bacterial Exacerbation of Chronic Community Acquired Pneumonia",
        "Uncomplicated Skin & Skin Structure Infection"
      ],
      "dosage_and_administration": {
        "acute_bacterial_sinusitis": {
          "dose": "400 mg",
          "frequency": "OD",
          "duration": "10 days"
        },
        "acute_bacterial_exacerbation_of_chronic_bronchitis": {
          "dose": "400 mg",
          "frequency": "OD",
          "duration": "5 days"
        },
        "community_acquired_pneumonia": {
          "dose": "400 mg",
          "frequency": "OD",
          "duration": "10 days"
        },
        "uncomplicated_skin_and_skin_structure_infection": {
          "dose": "400 mg",
          "frequency": "OD",
          "duration": "7 days"
        }
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "History of hypersensitivity to Moxifloxacin or any member of the quinolone class of antimicrobial agents"
        ]
      },
      "side_effects": {
        "common_side_effects": [
          "Nausea",
          "Vomiting",
          "Stomach pain",
          "Diarrhea",
          "Dizziness",
          "Headache"
        ],
        "precautions": "Careful about driving or operating machinery until you are sure Iventi is not causing dizziness."
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "The safety & effectiveness of Moxifloxacin in pregnant women have not been established",
        "lactation": "The safety & effectiveness of Moxifloxacin in lactating women have not been established"
      },
      "preparation": {
        "product_format": "250 ml intravenous infusion"
      }
    },
    {
      "name": "Iventi® Tablet",
     "img_id":"FQTuepa.jpeg",
      "image": "iventi_large.jpg",
      "formulation": "Tablet",
      "active_ingredients": "Moxifloxacin",
      "indication": [
        "Acute Bacterial Sinusitis",
        "Acute Bacterial Exacerbation of Chronic Bronchitis",
        "Community Acquired Pneumonia",
        "Uncomplicated & Complicated Skin and Skin Structure Infections",
        "Complicated Intra-Abdominal Infections"
      ],
      "dosage_and_administration": {
        "acute_bacterial_sinusitis": {
          "dose": "400 mg",
          "frequency": "Once Daily",
          "duration": "10 days"
        },
        "acute_bacterial_exacerbation_of_chronic_bronchitis": {
          "dose": "400 mg",
          "frequency": "Once Daily",
          "duration": "5 days"
        },
        "community_acquired_pneumonia": {
          "dose": "400 mg",
          "frequency": "Once Daily",
          "duration": "7-14 days"
        },
        "uncomplicated_skin_and_skin_structure_infections": {
          "dose": "400 mg",
          "frequency": "Once Daily",
          "duration": "7 days"
        },
        "complicated_skin_and_skin_structure_infections": {
          "dose": "400 mg",
          "frequency": "Once Daily",
          "duration": "7-21 days"
        },
        "complicated_intra_abdominal_infections": {
          "dose": "400 mg",
          "frequency": "Once Daily",
          "duration": "5-14 days"
        }
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "Known hypersensitivity to moxifloxacin or any member of the quinolone class of antimicrobial agents"
        ],
        "precautions": [
          "Discontinue if pain or inflammation in a tendon occurs",
          "Monitor for hypersensitivity reactions",
          "Observe for QT prolongation"
        ]
      },
      "side_effects": {
        "common_side_effects": [
          "Nausea",
          "Vomiting",
          "Diarrhea",
          "Dizziness",
          "Headache"
        ]
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Moxifloxacin is a pregnancy category C drug and should only be used if the potential benefit justifies the potential risk.",
        "lactation": "Moxifloxacin may be excreted in human milk."
      },
      "drug_interactions": [
        "Administer at least 4 hours before or 8 hours after products containing magnesium, aluminum, iron or zinc, including antacids, sucralfate, multivitamins.",
        "NSAIDs may increase the risk of CNS stimulation.",
        "Warfarin may increase the risk of bleeding."
      ],
      "preparation": {
        "product_format": "400 mg tablet"
      }
    },
    {
      "name": "Ketoral®",
     "img_id":"GSsxXuT.jpeg",
      "image": "KETORAL-200MG.jpg",
      "formulation": "Tablet",
      "active_ingredients": "Ketoconazole",
      "indication": ["Superficial Mycoses", "Deep Mycoses"],
      "dosage_and_administration": {
        "dose": "200 mg",
        "frequency": "Once Daily"
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "Pregnancy",
          "Patients with acute liver pathology"
        ],
        "precautions": [
          "Monitor liver enzyme levels in patients with a previous history of liver disease"
        ]
      },
      "side_effects": {
        "common_side_effects": [
          "Nausea",
          "Itching",
          "Idiosyncratic liver reaction (incidence 1:10,000)"
        ]
      },
      "drug_interactions": [
        "Acyclovir has shown dose-dependent, synergistic, antiviral activity against herpes simplex virus type 1 & 2 in in-vitro replication studies.",
        "Ketoconazole & Vidarabine showed interference, indifference, or antagonism in vitro against these viruses."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Ketoconazole is contraindicated in pregnancy.",
        "lactation": "Breast-feeding is contraindicated in patients taking this drug."
      },
      "preparation": {
        "product_format": "200 mg tablet"
      }
    },
    {
      "name": "K-one® MM",
     "img_id":"kfiSWJP.jpeg",
      "image": "K-ONE.jpg",
      "active_ingredients": "Phytomenadione",
      "indication": [
        "Prophylaxis & treatment of haemorrhagic disease in the newborn.",
        "Haemorrhage or risk of haemorrhage due to severe hypoprothrombinemia (deficiency of clotting factors II, VII, IX, & X) from various etiologies, including overdose of coumarin-type anticoagulants, combination with phenylbutazone, hypovitaminosis K (e.g., obstructive jaundice, liver & intestinal disorders, prolonged treatment with antibiotics, sulphonamides, or salicylates).",
        "Prevention & treatment of bleeding due to vitamin K deficiency."
      ],
      "dosage_and_administration": {
        "prophylaxis": {
          "neonates": "2 mg orally at or just after birth, 2 mg on 4th-5th day, and 2 mg on 28th-30th day.",
          "alternative_route": "If oral route is unsuitable, 2 mg IM or IV.",
          "children_over_1_year": "5-10 mg orally.",
          "children_not_assured_of_second_dose": "1 mg IM for children not assured of receiving a second oral dose."
        },
        "therapy": {
          "initial_dose": "1 mg IV injection.",
          "further_doses": "Based on clinical picture and coagulation status.",
          "neonates_with_special_risk_factors": "1 mg IM or IV at birth if oral route is unsuitable, with doses based on coagulation status."
        },
        "maximum_doses": {
          "premature_infants": "0.4 mg/kg in premature infants weighing less than 2.5 kg."
        }
      },
      "side_effects": [
        "Isolated unconfirmed reports of anaphylactoid reactions.",
        "Venous irritation or phlebitis after parenteral use."
      ],
      "precautions_and_contraindications": {
        "precautions": [
          "Monitor coagulation parameters in patients with severely impaired liver function."
        ],
        "contraindications": ["Hypersensitivity to any of the constituents."]
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Not recommended for prophylaxis of hemorrhagic disease in the newborn. Should be given only if the benefit to the mother outweighs the risk to the fetus.",
        "lactation": "A small fraction enters breast milk, but caution is advised."
      },
      "preparation": {
        "product_format": "2 mg / 0.2 ml Oral / IM / IV"
      }
    },
    {
      "name": "KopTM",
     "img_id":"8MQQ5z2.jpeg",
      "image": "KOP-100SR.jpg",
      "active_ingredients": "Ketoprofen",
      "indication": [
        "Ankylosing Spondylitis",
        "Osteoarthritis",
        "Rheumatoid Arthritis",
        "Bursitis & Tendinitis",
        "Dysmenorrhoea",
        "Postoperative pain",
        "Acute gout",
        "Soft-tissue disorders"
      ],
      "dosage_and_administration": {
        "sr_capsule": "100-200 mg once daily.",
        "elderly": "Begin therapy at the lower end of the dose range."
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "Known hypersensitivity to the drug.",
          "Asthma, urticaria, or other sensitivity reactions precipitated by aspirin or other NSAIDs."
        ],
        "precautions": [
          "Consider adverse GI effects in patients receiving Ketoprofen."
        ]
      },
      "side_effects": [
        "Dyspepsia",
        "Nausea",
        "Abdominal pain",
        "Diarrhoea",
        "Constipation",
        "Flatulence",
        "Anorexia",
        "Vomiting",
        "Stomatitis",
        "Headache",
        "Dizziness",
        "Malaise",
        "Depression",
        "Nervousness",
        "Dreams",
        "Tinnitus",
        "Visual disturbance",
        "Rash",
        "Impairment of renal function",
        "Signs or symptoms of urinary-tract irritation"
      ],
      "drug_interactions": [
        "Anticoagulant or thrombolytic agent",
        "Hydrochlorothiazide",
        "Salicylates",
        "Methotrexate"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Avoid medication during pregnancy.",
        "lactation": "Should not be used during breastfeeding unless unavoidable."
      },
      "preparation": {
        "product_format": "100 mg SR Tablet"
      }
    },
    {
      "name": "LactoringTM IV",
     "img_id":"tgirXlv.jpeg",
      "image": "Lactoring-IV-500-ml_l.jpg",
      "active_ingredients": "Hartmann’s solution",
      "indication": [
        "Hypovolemia caused by surgery",
        "Hemorrhage and trauma",
        "Excessive sweating",
        "Severe diarrhea or vomiting",
        "Excess loss of fluid by nephritic kidneys",
        "Inadequate intake of fluid and electrolytes",
        "Typical hypovolemic shock",
        "Severe plasma loss caused by intestinal obstruction",
        "Burns or other denuding conditions of the skin"
      ],
      "dosage_and_administration": {
        "infusion_rate": "The volume and rate of infusion depend on patient requirements and physician judgment. The recommended flow rate is up to 100 drops/minute/70 kg body weight."
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "Concomitant administration of Ceftriaxone and Compound Sodium Lactate solution in newborns (≤28 days of age), even if separate infusion lines are used (risk of fatal Ceftriaxone-calcium salt precipitation).",
          "Known hypersensitivity to sodium lactate.",
          "Extracellular hyperhydration or hypervolemia.",
          "Severe renal insufficiency.",
          "Hyperkalemia.",
          "Hypercalcaemia.",
          "Metabolic alkalosis.",
          "Severe metabolic acidosis.",
          "Conditions associated with increased lactate levels (hyperlactatemia) including lactic acidosis."
        ]
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Can be used safely during pregnancy as long as electrolyte and fluid balance is controlled.",
        "lactation": "Can be used safely during lactation. Calcium crosses the placenta and is distributed into breast milk."
      },
      "preparation": [
        {
          "volume": "500 ml",
          "composition": {
            "Sodium Chloride": "0.6% w/v",
            "Potassium Chloride": "0.04% w/v",
            "Calcium Chloride": "0.027% w/v",
            "Sodium Lactate": "0.32% w/v"
          }
        },
        {
          "volume": "1000 ml",
          "composition": {
            "Sodium Chloride": "0.6% w/v",
            "Potassium Chloride": "0.04% w/v",
            "Calcium Chloride": "0.027% w/v",
            "Sodium Lactate": "0.32% w/v"
          }
        }
      ]
    },
    { 
      "name": "LamicetTM",
     "img_id":"1X96N3q.png",
      "image": "lem_h.png",
      "active_ingredients": "Lamotrigine",
      "indications_and_usage": {
        "epilepsy_monotherapy": "Monotherapy in patients aged 16 years and older.",
        "epilepsy_adjunctive_therapy": {
          "partial_onset_seizures": "For patients aged 2 years and older.",
          "primary_generalized_tonic_clonic_seizures": "For patients aged 2 years and older.",
          "generalized_seizures_of_lennox_gastaut_syndrome": "For patients aged 2 years and older."
        },
        "bipolar_disorder": "For patients aged 18 years and older."
      },
      "pharmacology": "Lamotrigine controls epileptic seizures by inhibiting voltage-sensitive sodium channels, stabilizing neuronal membranes and inhibiting presynaptic excitatory neurotransmitter release (e.g., glutamate and aspartate).",
      "dosage_and_administration": {
        "monotherapy_for_seizures": {
          "adults_and_children_over_16": "Initially 25 mg once daily for 14 days, then 50 mg once daily for further 14 days, increased by maximum 50 mg/day every 7-14 days; usual maintenance dose 225-375 mg/day in 1-2 divided doses."
        },
        "adjunctive_therapy_with_valproate": {
          "adults_and_children_over_12": "Initially 25 mg on alternate days for 14 days, then 25 mg once daily for further 14 days, increased by maximum 25-50 mg/day every 7-14 days; usual maintenance 100-200 mg/day in 1-2 divided doses.",
          "children_2_12_years": "Initially 150 micrograms/kg/day in 1-2 divided doses for 14 days, increased to 300 micrograms/kg/day for 14 days, thereafter increased by maximum 300 micrograms/kg/day every 7-14 days; usual maintenance 1-3 mg/kg/day."
        },
        "adjunctive_therapy_without_valproate": {
          "adults_and_children_over_12": "Initially 50 mg once daily for 14 days, then 50 mg twice daily for further 14 days, increased by maximum 100 mg/day every 7-14 days; usual maintenance 300-500 mg/day in 2 divided doses.",
          "children_2_12_years": "Initially 600 micrograms/kg/day in 2 divided doses for 14 days, increased to 1.2 mg/kg/day for further 14 days, thereafter increased by maximum 1.2 mg/kg/day every 7-14 days; usual maintenance 5-15 mg/kg/day."
        },
        "bipolar_disorder_monotherapy": {
          "adults_over_18": "Initially 25 mg once daily for 14 days, then 50 mg once daily for further 14 days, then 100 mg once daily for further 7 days; usual maintenance dose 200 mg once daily."
        },
        "bipolar_disorder_adjunctive_therapy_with_valproate": {
          "adults_over_18": "Initially 25 mg on alternate days for 14 days, then 25 mg once daily for further 14 days, then 50 mg once daily for further 7 days; usual maintenance dose 100 mg daily."
        },
        "bipolar_disorder_adjunctive_therapy_without_valproate": {
          "adults_over_18": "Initially 50 mg once daily for 14 days, then 50 mg twice daily for further 14 days, then 100 mg twice daily for further 7 days, then 150 mg twice daily for further 7 days; usual maintenance 200 mg twice daily."
        }
      },
      "adverse_reactions": {
        "adults": [
          "Dizziness",
          "Headache",
          "Diplopia",
          "Ataxia",
          "Nausea",
          "Blurred vision",
          "Somnolence",
          "Rhinitis",
          "Sharyngitis",
          "Rash"
        ],
        "children": [
          "Vomiting",
          "Diarrhea",
          "Infection",
          "Fever",
          "Abdominal pain",
          "Tremor"
        ]
      },
      "special_warnings_and_precautions": [
        "Discontinue at the first sign of rash.",
        "Monitor for blood dyscrasias (e.g., neutropenia, thrombocytopenia, pancytopenia).",
        "Monitor for suicidal thoughts or behaviors.",
        "Monitor for signs of aseptic meningitis."
      ],
      "contraindications": [
        "Hypersensitivity (e.g., rash, angioedema, acute urticaria, extensive pruritus, mucosal ulceration) to the drug or its ingredients."
      ],
      "drug_interactions": [
        "Valproate increases lamotrigine concentrations more than 2-fold.",
        "Carbamazepine, phenytoin, phenobarbital, primidone, and rifampin decrease lamotrigine concentrations by approximately 40%.",
        "Estrogen-containing oral contraceptives decrease lamotrigine concentrations by approximately 50%.",
        "Protease inhibitors lopinavir/ritonavir and atazanavir/ lopinavir decrease lamotrigine exposure by approximately 50% and 32%, respectively."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Pregnancy category C.",
        "nursing_mothers": "Lamotrigine is present in milk from lactating women taking Lamotrigine."
      },
      "hepatic_renal_impairement": {
        "hepatic_impairement": "Dosage adjustments required in patients with moderate and severe liver impairment.",
        "renal_impairement": "Reduced maintenance doses may be effective for patients with significant renal impairment."
      },
      "preparation": "20 tablets in blister pack"
    },
    {
      "name": "Lanso®",
     "img_id":"XZsOpeg.jpeg",
      "image": "LANSO-30.jpg",
      "active_ingredients": "Lansoprazole",
      "indications_and_usage": [
        "Duodenal ulcer",
        "Gastric ulcers",
        "Erosive esophagitis",
        "Zollinger-Ellison Syndrome",
        "H. pylori eradication"
      ],
      "dosage_and_administration": {
        "recommended_dose": "30 mg daily"
      },
      "contraindications_and_precautions": ["Known hypersensitivity"],
      "side_effects": [
        "Gastrointestinal disturbances",
        "Headache",
        "Dizziness",
        "Malaise",
        "Dry or sour mouth or throat"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "USFDA Pregnancy category B"
      },
      "preparation": "30 mg Capsule"
    },
    {
      "name": "Lanso DTM", 
      "img_id":"4K1cL2V.jpeg",
      "image":"lanso-d-30.jpg",
      "active_ingredients": "Dexlansoprazole",
      "indications_and_usage": [
        "Relief of heartburn",
        "Healing of all grades of Erosive Esophagitis",
        "Maintenance of healed Erosive Esophagitis",
        "Treatment of non-erosive GERD"
      ],
      "dosage_and_administration": {
        "relief_of_heartburn": {
          "dose": "30 mg once daily",
          "duration": "Up to 6 months"
        },
        "healing_of_erosive_esophagitis": {
          "dose": "60 mg once daily",
          "duration": "Up to 8 weeks"
        },
        "maintenance_of_healed_erosive_esophagitis": {
          "dose": "30 mg once daily",
          "duration": "Up to 6 months"
        },
        "symptomatic_non_erosive_gerd": {
          "dose": "30 mg once daily",
          "duration": "4 weeks"
        }
      },
      "side_effects": [
        "Diarrhea",
        "Abdominal pain",
        "Nausea",
        "Vomiting",
        "Flatulence"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "There are no studies with dexlansoprazole use in pregnant women to inform a drug-associated risk"
      },
      "contraindications": [
        "Known hypersensitivity to any component of the formulation"
      ],
      "drug_interactions": [
        "Dexlansoprazole may interfere with the absorption of drugs for which gastric pH is important for bioavailability (e.g., Ampicillin esters, Digoxin, Iron salts, Ketoconazole)"
      ],
      "overdose": "No reports of significant overdose. Multiple doses of 120 mg and single doses of 300 mg did not result in severe adverse events.",
      "preparation": ["30 mg Capsule", "60 mg Capsule"]
    },
    {
      "name": "LarsulinTM",
     "img_id":"OZEBxPr.png",
      "image": "Larsulin.png",
      "active_ingredients": "Insulin Glargine (rDNA)",
      "indications_and_usage": [
        "Improves glycemic control in adults and children with type 1 diabetes mellitus",
        "Improves glycemic control in adults with type 2 diabetes mellitus"
      ],
      "dosage_and_administration": {
        "general_info": "Larsulin™ exhibits a relatively constant glucose-lowering profile over 24 hours and is recommended for once-daily subcutaneous administration.",
        "type_1_diabetes_starting_dose": "One-third of the total daily insulin requirements. Short-acting, premeal insulin should satisfy the remainder of the daily insulin requirements.",
        "type_2_diabetes_starting_dose": "10 units (or 0.2 Units/kg) once daily, which should be adjusted to the patient’s needs.",
        "conversion_from_other_insulin_therapies": {
          "from_once_daily_nph": "The initial Larsulin™ dose is the same as the dose of NPH being discontinued.",
          "from_twice_daily_nph": "The initial Larsulin™ dose is 80% of the total NPH dose being discontinued."
        },
        "precautions": "Larsulin™ is not recommended for intravenous administration."
      },
      "side_effects": [
        "Hypoglycemia",
        "Allergic reactions",
        "Injection site reactions",
        "Lipodystrophy",
        "Pruritus",
        "Rash"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Category C. Use only if the potential benefit justifies the potential risk to the fetus.",
        "lactation": "It is unknown whether insulin glargine is excreted in human milk. Caution should be exercised when administered to a nursing woman. Dose adjustments may be required for lactating women."
      },
      "precautions": [
        "Blood glucose should be monitored in all patients treated with insulin.",
        "Insulin regimens should be modified cautiously and under medical supervision.",
        "Larsulin™ must not be diluted or mixed with any other insulin or solution.",
        "Should not be administered subcutaneously via an insulin pump or intravenously.",
        "Renal or hepatic impairment may require a reduction in the insulin glargine dose."
      ],
      "contraindications": [
        "Hypersensitivity to Insulin glargine or one of its excipients."
      ],
      "storage": {
        "refrigerated_storage": "Store at 2°C to 8°C in a refrigerator. Do not freeze.",
        "use_in_refrigeration": "For insulin in use, it need not be refrigerated but should be kept in a cool place and away from heat and light. Can be kept at room temperature for one month."
      },
      "preparation": [
        "Larsulin™ Injection: Each vial contains 3 ml solution.",
        "Larsulin™ Pen Cartridge: Each cartridge contains 3 ml solution."
      ]
    },
    {
      "name": "Laxyl®",
      "img_id":"6HDJWmP.jpeg",
      "image":"Laxyl.jpg",
      "active_ingredients": "Bromazepam",
      "indications_and_usage": [
        "Treatment of anxiety and anxiety-related disorders",
        "Emotional disturbance",
        "Functional disturbance in the gastrointestinal system",
        "Functional disturbance in the genitourinary system",
        "Psychosomatic disorders"
      ],
      "dosage_and_administration": {
        "dose_range": "3 mg to 18 mg daily in divided doses"
      },
      "contraindications_and_precautions": [
        "Hypersensitivity to benzodiazepines",
        "Acute pulmonary insufficiency",
        "Respiratory depression",
        "Phobic or obsessional states",
        "Chronic psychosis",
        "Chronic pulmonary insufficiency",
        "Chronic renal or hepatic disease (dosage may need to be reduced)"
      ],
      "use_in_pregnancy_and_lactation": "Not recommended.",
      "side_effects": ["Drowsiness", "Sedation", "Unsteadiness", "Ataxia"],
      "preparation": ["3 mg Tablet"]
    },
    {
      "name": "Lebac®",
     "img_id":"SihrOwk.jpeg",
      "image": "Lebac-250-Capsule.jpg",
      "active_ingredients": "Cephradine",
      "indications_and_usage": [
        "Pharyngitis",
        "Sinusitis",
        "Otitis media",
        "Tonsilitis",
        "Laryngotracheo-bronchitis",
        "Acute & chronic bronchitis",
        "Lobar & bronchopneumonia",
        "Cystitis",
        "Urethritis",
        "Pyelonephritis",
        "Abscess",
        "Cellulitis",
        "Furunculosis",
        "Impetigo",
        "Bacillary dysentery",
        "Enteritis",
        "Peritonitis",
        "Bone & joint infection",
        "Surgical prophylaxis"
      ],
      "dosage_and_administration": {
        "dose_range": "1-2 gm daily in 2 to 4 divided doses"
      },
      "contraindications_and_precautions": [
        "Hypersensitivity to any Cephalosporin antibiotic"
      ],
      "side_effects": [
        "Nausea",
        "Vomiting",
        "Diarrhoea",
        "Abdominal discomfort",
        "Allergic reactions",
        "Skin rashes",
        "Urticaria",
        "Eosinophilia",
        "Angioedema",
        "Anaphylaxis",
        "Elevation of hepatic enzyme values",
        "Neutropenia",
        "Super-infection with resistant microorganisms, particularly candida",
        "Pseudomembranous colitis",
        "Thrombophlebitis"
      ],
      "use_in_pregnancy_and_lactation": "The drug should be used during pregnancy only when clearly indicated, the drug should be used with caution in nursing mother.",
      "preparation": [
        "250 mg & 500 mg Capsule",
        "125 mg/5 ml Powder for Suspension",
        "250 mg/5 ml Forte Powder for Suspension",
        "125 mg/1.25 ml Powder for Paediatric Drops",
        "500 mg IM/IV Injection"
      ]
    },
    {
      "name": "Lerozol®",
     "img_id":"F6DqUJb.png",
      "image": "Lerozol.png",
      "active_ingredients": "Letrozole",
      "indications_and_usage": ["Infertility", "ER positive breast cancer"],
      "dosage_and_administration": {
        "ER_positive_breast_cancer": "The recommended dose is one 2.5 mg tablet administered once a day, regardless of meals",
        "infertility": "1 tablet daily from 3 to 7 days of menstrual cycle"
      },
      "precautions": [
        "Fatigue and dizziness have been observed with the use of letrozole; caution is advised when driving or using machinery",
        "Somnolence was uncommonly reported"
      ],
      "drug_interactions": [
        "Co-administration of letrozole and tamoxifen 20 mg daily results in reduction of plasma levels of Letrozole"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy_category": "D",
        "caution": "Caution should be exercised when letrozole is administered to a nursing woman"
      },
      "pediatric_use": "Not recommended",
      "preparation": ["2.5 mg Tablet"]
    },
    {
      "name": "Levocar®",
     "img_id":"pbKnUuZ.jpeg",
      "image": "LEVOCAR-TABLET.jpg",
      "active_ingredients": "Levocarnitine",
      "indications_and_usage": [
        "Heart Diseases",
        "Congestive Heart Failure",
        "Kidney Disease",
        "Chronic Fatigue Syndrome",
        "High Cholesterol",
        "Intermittent Claudication",
        "Dementia & memory impairment",
        "Down Syndrome",
        "Male infertility",
        "Hyperthyroidism"
      ],
      "dosage_and_administration": {
        "adults": "1 to 2 gm per day in divided doses",
        "infants_and_children": "Between 50 & 100 mg/kg/day in divided doses, with a maximum of 3 g/day. Dosage should begin at 50 mg/kg/day. The exact dosage will depend on clinical response."
      },
      "contraindications_and_precautions": "No known contraindication.",
      "side_effects": "Generally well tolerated.",
      "use_in_pregnancy_and_lactation": {
        "pregnancy_category": "B",
        "lactation": "It is not known whether Levocarnitine is excreted in human milk. Supplemental Levocarnitine is not advised for nursing mothers."
      },
      "preparation": ["330 mg Tablet"]
    },
    {
      "name": "Levostar™",
     "img_id":"5Bjb9Sj.jpeg",
      "image": "Levostar-1-Tab.jpg",
      "active_ingredients": "Levosalbutamol",
      "indications_and_usage": [
        "Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease"
      ],
      "dosage_and_administration": {
        "tablet": {
          "adults_and_adolescents_above_12_years": "1-2 mg three times daily",
          "children_up_to_11_years": "1 mg three times daily"
        },
        "syrup": {
          "adults": "5-10 ml three times daily",
          "children_up_to_11_years": "5 ml three times daily"
        }
      },
      "contraindications_and_precautions": [
        "Hypersensitivity to any components of the formulation",
        "Risk of hypokalemia, especially in acute severe asthma",
        "Caution in patients with cardiovascular disorders including coronary insufficiency, cardiac arrhythmias, or hypertension"
      ],
      "drug_interactions": [
        "Short-acting sympathomimetic bronchodilators or epinephrine",
        "Use caution with additional adrenergic drugs to avoid cardiovascular effects"
      ],
      "side_effects": [
        "Hypokalaemia",
        "Palpitation",
        "Fine tremors of the skeletal muscle (particularly the hand)",
        "Muscle cramps",
        "Nausea",
        "Vomiting",
        "Burning substernal or epigastric pain",
        "Diarrhoea",
        "Nervousness",
        "Headache",
        "Dizziness",
        "Fatigue",
        "Sleeplessness"
      ],
      "use_in_pregnancy_and_lactation": "Use only if expected benefit to mother outweighs possible risk to fetus or infant.",
      "preparation": ["1 mg Tablet", "2 mg Tablet"]
    },
    {
      "name": "Liglimet™",
     "img_id":"j0AWTe0.jpeg",
      "image": "Liglimet.jpg",
      "active_ingredients": "Linagliptin and Metformin Hydrochloride",
      "indications_and_usage": [
        "Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Linagliptin and Metformin is appropriate"
      ],
      "dosage_and_administration": {
        "general_guidelines": "Dose should be individualized based on patient’s current regimen, effectiveness, and tolerability, without exceeding 2.5 mg Linagliptin and 1000 mg Metformin twice daily",
        "administration": "Administer twice daily with meals with gradual dose escalation to reduce GI side effects due to Metformin",
        "starting_dose": {
          "patients_not_treated_with_metformin": "2.5 mg Linagliptin/500 mg Metformin twice daily",
          "patients_already_treated_with_metformin": "2.5 mg Linagliptin with current Metformin dose twice daily",
          "patients_already_on_both_components": "Switch to Liglimet with equivalent doses of Linagliptin and Metformin"
        }
      },
      "contraindications_and_precautions": [
        "Severe renal impairment (eGFR < 30 mL/min/1.73 m²)",
        "Acute or chronic metabolic acidosis, including diabetic ketoacidosis",
        "History of hypersensitivity reaction to Linagliptin or Metformin"
      ],
      "side_effects": [
        "Nasopharyngitis",
        "Diarrhea",
        "Hypoglycemia (especially when used with sulfonylureas)"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Category B",
        "lactation": "Unknown if Linagliptin is excreted in human milk; use caution"
      },
      "preparation": ["2.5/500 mg Tablet", "2.5/850 mg Tablet"]
    },
    {
      "name": "Linita™",
     "img_id":"pyctiWD.jpeg",
      "image": "Linita_l2.jpg",
      "active_ingredients": "Linagliptin INN",
      "indications_and_usage": [
        "Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus"
      ],
      "dosage_and_administration": {
        "recommended_dose": "5 mg once daily",
        "special_populations": "No dosage adjustment required for hepatic or kidney impaired patients"
      },
      "contraindications_and_precautions": [
        "History of serious hypersensitivity reaction to Linagliptin (e.g., anaphylaxis or angioedema)",
        "Consider lowering dose of insulin secretagogue (e.g., sulfonylurea) to reduce risk of hypoglycemia"
      ],
      "side_effects": [
        "Hypoglycemia",
        "Headache",
        "Drowsiness",
        "Weakness",
        "Dizziness",
        "Confusion",
        "Irritability",
        "Hunger",
        "Fast heartbeat",
        "Sweating",
        "Stuffy or runny nose",
        "Sore throat"
      ],
      "drug_interaction": [
        "P-glycoprotein/CYP3A4 inducers (e.g., rifampin) may reduce Linagliptin efficacy; alternative treatments strongly recommended"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Category B. Use only if clearly needed",
        "lactation": "Unknown if excreted in breast milk; use with caution"
      },
      "use_in_children": "Safety and effectiveness not established for patients under 18 years of age",
      "preparation": ["5 mg Tablet"]
    },
    {
      "name": "Lipired™",
     "img_id":"S1Mq7BP.jpeg",
      "image": "Lipired.jpg",
      "active_ingredients": "Fenofibrate",
      "indications_and_usage": ["Hyperlipidemia"],
      "dosage_and_administration": {
        "recommended_dose": "One 200 mg capsule daily"
      },
      "contraindications": [
        "Hepatic or severe renal dysfunction",
        "Primary biliary cirrhosis",
        "Unexplained persistent liver function abnormality",
        "Preexisting gallbladder disease",
        "Hypersensitivity to fenofibrate"
      ],
      "side_effects": [
        "Hepatitis",
        "Cholelithiasis",
        "Cholecystitis",
        "Hepatomegaly",
        "Myalgia",
        "Myasthenia",
        "Rhabdomyolysis",
        "Photosensitivity",
        "Eczema",
        "Peripheral edema",
        "Angina",
        "Palpitations",
        "Tachycardia",
        "Migraine"
      ],
      "drug_interaction": ["Oral Anticoagulants", "Resins", "Cyclosporine"],
      "preparation": ["200 mg Capsule"]
    },
    {
      "name": "Lipired™",
     "img_id":"NRoK18l.jpeg",
      "image": "Lipired_f.jpg",
      "active_ingredients": "Fenofibrate",
      "indications": ["Hyperlipidemia"],
      "dosage_and_administration": {
        "adults": "One 200 mg capsule daily"
      },
      "contraindications": [
        "Hepatic or severe renal dysfunction",
        "Primary biliary cirrhosis",
        "Unexplained persistent liver function abnormality",
        "Preexisting gallbladder disease",
        "Hypersensitivity to fenofibrate"
      ],
      "side_effects": [
        "Hepatitis",
        "Cholelithiasis",
        "Cholecystitis",
        "Hepatomegaly",
        "Myalgia",
        "Myasthenia",
        "Rhabdomyolysis",
        "Photosensitivity",
        "Eczema",
        "Peripheral edema",
        "Angina",
        "Palpitations",
        "Tachycardia",
        "Migraine"
      ],
      "drug_interactions": ["Oral Anticoagulants", "Resins", "Cyclosporine"],
      "preparation": ["200 mg Capsule"]
    },
    {
      "name": "Livwel®",
     "img_id":"AGMBk2U.jpeg",
      "image": "Livwel-100.jpg",
      "active_ingredients": [
        "Vitamin A (as Retinol Palmitate & Beta Carotene)",
        "Vitamin C",
        "Vitamin D3",
        "Vitamin E",
        "Vitamin B1",
        "Vitamin B6",
        "Vitamin B12",
        "Riboflavin",
        "Niacin",
        "Folic Acid",
        "Biotin",
        "Pantothenic Acid",
        "Calcium",
        "Iodine",
        "Magnesium",
        "Zinc",
        "Selenium",
        "Manganese",
        "Chromium",
        "Potassium",
        "Para-Amino Benzoic Acid",
        "Inositol",
        "Choline"
      ],
      "indications": [
        "Multivitamin & multimineral deficiencies in adults, children of all ages, and infants",
        "Especially for those who cannot take solid dosage forms or have GI side effects from solid forms"
      ],
      "dosage_and_administration": {
        "adults": "3 - 4 teaspoonful daily",
        "children_4_to_12_years": "2 - 3 teaspoonful daily",
        "children_1_to_4_years": "1 - 2 teaspoonful daily",
        "infants_up_to_1_year": "1 teaspoonful daily or as directed by the physician"
      },
      "contraindications_and_precautions": [
        "Should not be used in over dosage",
        "Should not be used for long periods without physician recommendation"
      ],
      "side_effects": ["Generally well tolerated"],
      "use_in_pregnancy_and_lactation": ["Specific information not available"],
      "preparation": ["100 ml Syrup", "200 ml Syrup"]
    },
    {
      "name": "LNCTM",
     "img_id":"eGsiGpz.jpeg",
      "image": "LNC_5.jpg",
      "active_ingredients": "Cilnidipine",
      "indications": ["Hypertension"],
      "dosage_and_administration": {
        "adults": "5-10 mg once daily after breakfast",
        "maximum_dose": "20 mg once daily",
        "pediatric_use": "Safety not established",
        "elderly": "Initiate with lowest possible dose (5 mg) due to susceptibility to hypotension"
      },
      "contraindications_and_precautions": [
        "Known sensitivity to Cilnidipine or any excipients",
        "Cardiogenic shock",
        "Recent myocardial infarction",
        "Acute unstable angina",
        "Severe aortic stenosis",
        "Caution in patients with serious hepatic dysfunction",
        "Caution in patients with history of serious adverse reactions to calcium antagonists",
        "Dosage should be tapered gradually during discontinuation under observation"
      ],
      "side_effects": [
        "Dizziness",
        "Flushing",
        "Headache",
        "Hypotension",
        "Peripheral edema",
        "Palpitation",
        "GI disturbances",
        "Increased micturition frequency",
        "Lethargy",
        "Eye pain",
        "Depression"
      ],
      "use_in_pregnancy_and_lactation": [
        "Should not be administered in pregnant women or those who may be pregnant",
        "Avoid use in nursing mothers; if necessary, discontinue lactation"
      ],
      "preparation": ["5 mg Tablet", "10 mg Tablet"]
    },
    {
      "name": "Loracef®",
     "img_id":"dlQdl7s.jpeg",
      "image": "Loracef_PD.jpg",
      "active_ingredients": "Cefaclor",
      "indications": [
        "Pneumonia",
        "Bronchitis",
        "Pharyngitis",
        "Tonsillitis",
        "Sinusitis",
        "Otitis media",
        "Skin and soft tissue infections",
        "Urinary tract infections including pyelonephritis and cystitis"
      ],
      "dosage_and_administration": {
        "adults": "250 mg every 8 hours",
        "children": "20 mg/kg/day in divided doses every 8 hours"
      },
      "contraindications_and_precautions": [
        "Hypersensitivity",
        "Use with caution in patients with markedly impaired renal function",
        "Risk of overgrowth of non-susceptible organisms"
      ],
      "side_effects": [
        "Diarrhea",
        "Nausea and vomiting",
        "Skin eruptions",
        "Pruritus and urticaria",
        "Serum sickness",
        "Eosinophilia",
        "Thrombocytopenia",
        "Transient lymphocytosis and leucopenia",
        "Transient hepatitis and cholestatic jaundice",
        "Slight elevation in AST, ALT or alkaline phosphatase",
        "Reversible interstitial nephritis",
        "Reversible hyperactivity",
        "Nervousness",
        "Confusion",
        "Hypertonia",
        "Dizziness",
        "Hallucinations",
        "Somnolence (rare)"
      ],
      "drug_interactions": [
        "Nephrotoxicity of aminoglycosides (e.g., gentamicin and tobramycin) may be enhanced by cephalosporins"
      ],
      "use_in_pregnancy_and_lactation": [
        "Caution recommended during early pregnancy",
        "Caution should be exercised when used in nursing women"
      ],
      "preparation": [
        "125 mg/5 ml Suspension",
        "125 mg/1.25 ml Paediatric Drops"
      ]
    },
    {
      "name": "Loratin®",
     "img_id":"Jg1WbLk.jpeg",
      "image": "Loratin-Tab-PRO_l.jpg",
      "active_ingredients": "Loratadine",
      "indications": [
        "Allergic rhinitis",
        "Skin allergies including Chronic Idiopathic Urticaria (CIU)"
      ],
      "dosage_and_administration": {
        "adults_and_children_over_6_years": "One 10 mg tablet or two teaspoonful (10 ml) suspension once daily",
        "children_2_to_5_years": "One teaspoonful (5 ml or 5 mg) suspension once daily",
        "children_under_2_years": "Not recommended"
      },
      "contraindications": [
        "Hypersensitivity to Loratadine or its ingredients",
        "Idiosyncrasy"
      ],
      "side_effects": [
        "Anticholinergic effects",
        "Fatigue",
        "Nausea",
        "Headache",
        "Tachycardia",
        "Syncope"
      ],
      "use_in_pregnancy_and_lactation": [
        "Use during pregnancy only if clearly needed",
        "Not recommended during lactation"
      ],
      "preparation": ["10 mg Tablet", "5 mg/5 ml Suspension"]
    },
    {
      "name": "Lubgel™ Eye Drops",
     "img_id":"VLYEjvz.jpeg",
      "image": "Lubgel-lg1.jpg",
      "active_ingredients": "Carboxymethylcellulose Sodium 1%",
      "indications": [
        "Long-lasting relief of burning, irritation, and discomfort due to dryness of the eye",
        "Relief from exposure to wind or sun"
      ],
      "dosage_and_administration": "Instill 1 or 2 drops in the affected eye(s) as needed or as directed by physician",
      "drug_interaction": "Concomitant ocular medications should be administered at least 5 minutes apart to avoid washout effects",
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "No human data available; animal studies show no harmful effects",
        "lactation": "Not absorbed systemically; no known risk of excretion in breast milk"
      },
      "pediatric_use": "Safety and effectiveness in pediatric patients have not been established",
      "geriatric_use": "No overall differences in safety or effectiveness between elderly and other adult patients",
      "side_effects": [
        "Visual disturbances",
        "Ocular discharge",
        "Eye pruritus",
        "Conjunctival hyperaemia (rare)",
        "Eyelid edema (rare)"
      ],
      "preparation": "10 ml eye drops"
    },
    {
      "name": "Lubtear® Eye Drops",
     "img_id":"sWN5qPZ.jpeg",
      "image": "Lubtear_l.jpg",
      "active_ingredients": ["Dextran 70", "Hypromellose"],
      "indications": [
        "Lubricant and artificial tear in dry eye and ocular irritation syndromes associated with deficient tear or mucous secretion",
        "Prevents corneal damage in patients with keratoconjunctivitis",
        "Ocular lubrication",
        "Temporary relief of burning and irritation due to dryness of the eye",
        "Protectant against further irritation"
      ],
      "dosage_and_administration": "Adults and children: One or two drops three times daily or as directed by the physician",
      "contraindication_and_precaution": "Contains Benzalkonium Chloride BP; should not be used when soft contact lenses are worn",
      "side_effects": [
        "No known side effects; consult a doctor if any reactions occur in the eye or other body parts"
      ],
      "use_in_pregnancy_and_lactation": "Insufficient evidence on safety in pregnancy and lactation; should only be used if considered essential by the physician",
      "preparation": "Each LDPE container contains 10 ml of Dextran 70 0.1% & Hypromellose 0.3%"
    },
    {
      "name": "Lumertam®",
     "img_id":"QC8bG23.jpeg",
      "image": "lumertam-20-mg-tablet.jpg",
      "active_ingredients": ["Artemether", "Lumefantrine"],
      "indications": [
        "Treatment and standby emergency treatment of acute uncomplicated Plasmodium falciparum malaria",
        "Includes mixed P. falciparum infection in adults, children, and infants weighing 5 kg and above"
      ],
      "dosage_and_administration": {
        "5-15_kg": {
          "Day_1": ["1 Tablet (0 hour)", "1 Tablet (8 hours later)"],
          "Day_2": ["1 Tablet (Morning)", "1 Tablet (Evening)"],
          "Day_3": ["1 Tablet (Morning)", "1 Tablet (Evening)"]
        },
        "15-25_kg": {
          "Day_1": ["2 Tablets (0 hour)", "2 Tablets (8 hours later)"],
          "Day_2": ["2 Tablets (Morning)", "2 Tablets (Evening)"],
          "Day_3": ["2 Tablets (Morning)", "2 Tablets (Evening)"]
        },
        "20-35_kg": {
          "Day_1": ["3 Tablets (0 hour)", "3 Tablets (8 hours later)"],
          "Day_2": ["3 Tablets (Morning)", "3 Tablets (Evening)"],
          "Day_3": ["3 Tablets (Morning)", "3 Tablets (Evening)"]
        },
        "35_kg_and_above": {
          "Day_1": ["4 Tablets (0 hour)", "4 Tablets (8 hours later)"],
          "Day_2": ["4 Tablets (Morning)", "4 Tablets (Evening)"],
          "Day_3": ["4 Tablets (Morning)", "4 Tablets (Evening)"]
        }
      },
      "contraindication_and_precaution": [
        "Hypersensitivity to any of the ingredients",
        "Patients with family history of bradycardia or severe cardiac disease",
        "Patients with known electrolyte imbalance",
        "Not evaluated for prophylaxis of malaria, cerebral malaria, or severe malaria conditions such as pulmonary edema or renal failure"
      ],
      "side_effects": "Generally well tolerated, most side effects are of mild to moderate severity and duration",
      "use_in_pregnancy_and_lactation": "Not recommended",
      "preparation": "(Artemether 20 mg + Lumefantrine 120 mg)/Tablet"
    },
    {
      "name": "LuraprexTM",
     "img_id":"ihIHW01.jpeg",
      "image": "Luraprex.jpg",
      "active_ingredients": "Lurasidone hydrochloride",
      "indications": ["Schizophrenia", "Bipolar disorder"],
      "dosage_and_administration": {
        "schizophrenia": {
          "starting_dose": "40 mg per day",
          "recommended_dose": "40 mg to 160 mg per day"
        },
        "bipolar_depression": {
          "starting_dose": "20 mg per day",
          "recommended_dose": "20 mg to 120 mg per day"
        }
      },
      "side_effects": [
        "Somnolence",
        "Akathisia",
        "Extrapyramidal symptoms",
        "Nausea"
      ],
      "drug_interaction": {
        "moderate_CYP3A4_inhibitors": "Reduce Lurasidone dose to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 (e.g., diltiazem, atazanavir, erythromycin, fluconazole, verapamil, etc.)",
        "CYP3A4_inducers": "Increase Lurasidone dose when used concomitantly with a moderate CYP3A4 inducer"
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Category B. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.",
        "lactation": "Advise against breastfeeding while taking Lurasidone."
      },
      "preparation": ["20 mg tablet", "40 mg tablet"]
    },
    {
      "name": "LysivinTM",
     "img_id":"n0HQaYg.jpeg",
      "image": "lysivin_l.jpg",
      "active_ingredients": "Multivitamin with L-Lysine",
      "indications": [
        "Improves appetite",
        "Promotes growth in height & weight",
        "Helps in building of muscle protein",
        "Helps to absorb Calcium",
        "Ensures energy production"
      ],
      "dosage_and_administration": {
        "adult": "03 Tablets daily",
        "children": "1-3 Tablets daily depending on the age & physical condition (from 01 year of age)"
      },
      "pregnancy_and_lactation": "The specific information is not available in this respect.",
      "contraindication": "Contraindicated in patients with a known hypersensitivity to any of the active ingredients of the product.",
      "side_effects": "The product is usually well tolerated and exerts no untoward effects if taken in the dosage recommended.",
      "preparation": "30 tablets"
    },
    {
      "name": "MagantaTM Plus",
     "img_id":"dBpQrq5.jpeg",
      "image": "Magantaplus.jpg",
      "active_ingredients": ["Magaldrate", "Simethicone"],
      "indications": [
        "Hyperacidity",
        "Gastric & duodenal ulcer",
        "Gastritis",
        "Heartburn",
        "Dyspepsia",
        "Gastroesophageal reflux",
        "Relief of flatulence",
        "Abdominal distention",
        "Windy colic"
      ],
      "dosage_and_administration": {
        "chewable_tablet": "1-4 chewable tablets, 20 to 60 minutes after meals & at bedtime, or as directed by the physician.",
        "suspension": "2-4 teaspoonfuls (10-20 ml) of suspension, 20 to 60 minutes after meals & at bedtime, or as directed by the physician."
      },
      "contraindication_and_precaution": [
        "Intestinal obstruction",
        "Renal function impairment",
        "Appendicitis",
        "Chronic diarrhea",
        "Sensitivity to aluminium, magnesium & simethicone",
        "Allergic to any ingredient of Magaldrate & Simethicone",
        "History of kidney problems",
        "Taking citrate salts (found in some calcium supplements, antacids & laxatives)",
        "Do not take with tetracycline antibiotics",
        "Antacids can interfere with the absorption of iron preparations"
      ],
      "side_effects": ["Constipation", "Diarrhea", "Intestinal pain"],
      "use_in_pregnancy_and_lactation": "Thought to be safe antacid during pregnancy & lactation.",
      "preparation": {
        "chewable_tablet": "Each chewable tablet contains Magaldrate USP 480 mg & Simethicone USP 20 mg.",
        "suspension": "Each 5 ml contains Magaldrate USP 480 mg & Simethicone USP 20 mg."
      }
    },
    {
      "name": "MaxbonTM",
     "img_id":"hMImmNT.jpeg",
      "image": "Maxbone-large.jpg",
      "active_ingredients": "Ibandronic acid",
      "indications": [
        "Treatment and prevention of postmenopausal osteoporosis in women",
        "Treatment and prevention of osteoporosis in men"
      ],
      "dosage_and_administration": {
        "recommended_dose": "150 mg tablet once in a month on the same date each month.",
        "how_to_take": [
          "Take the tablet exactly as prescribed by your healthcare provider.",
          "Take the tablet in the morning before you eat or drink anything except plain water.",
          "Take the tablet while you are sitting up or standing.",
          "Swallow the whole tablet. Do not chew or keep it in your mouth to melt or dissolve.",
          "After taking the tablet, wait at least 60 minutes before lying down.",
          "You may sit, stand, or do normal activities.",
          "Take vitamins, calcium, or antacids after 60 minutes of taking the tablet.",
          "Keep taking Maxbon tablet as long as your healthcare provider advises."
        ]
      },
      "drug_interaction": [
        "Tell your doctor if you are taking or have recently taken any other medicines, including over-the-counter medicines.",
        "Aspirin or other NSAIDs may interact with Ibandronic acid.",
        "Antacids, supplements, or medicines containing aluminum, calcium, magnesium, or other minerals can interfere with the absorption of Ibandronate sodium. Do not take these medicines for at least 60 minutes after taking Ibandronic Acid."
      ],
      "contraindications": {
        "pregnancy": "Ibandronic acid is contraindicated during pregnancy.",
        "lactation": "Ibandronic acid is contraindicated during lactation."
      },
      "special_dosage_instructions": [
        "No dose adjustment is necessary for patients with mild or moderate renal impairment (creatinine clearance ≥30 ml/min).",
        "No dose adjustment is required for patients with hepatic impairment."
      ],
      "preparation": "150 mg Tablet"
    },
    {
      "name": "MaxbonTM Kit",
     "img_id":"Z2MKLRS.jpeg",
      "image": "Maxbon-Kit_HDR_l.jpg",
      "active_ingredients": [
        {
          "name": "Ibandronic Acid",
          "dosage_form": "150 mg tablet"
        },
        {
          "name": "Calcium Orotate",
          "dosage_form": "400 mg tablet"
        }
      ],
      "indications": [
        "Treatment and prevention of osteoporosis in women after menopause",
        "Increases bone mineral density (BMD) and reduces the incidence of vertebral fractures"
      ],
      "dosage_and_administration": {
        "ibandronic_acid_dose": "150 mg tablet once monthly on the same date each month",
        "calcium_orotate_dose": "Two tablets of Calcium Orotate 400 mg per day in divided dosages",
        "dosing_instructions": [
          "Ibandronic Acid tablet should be taken at least 60 minutes before the first food or drink (other than water) of the day or before taking any oral medications or supplements.",
          "Ibandronic Acid tablet should be swallowed whole with a full glass of plain water (250 ml) while standing or sitting upright.",
          "Do not lie down for 60 minutes after taking Ibandronic Acid tablet.",
          "Do not eat, drink anything except water, or take other medications for at least 60 minutes after taking Ibandronic Acid tablet.",
          "Take only plain water with Ibandronic Acid tablet. Some mineral waters may contain higher concentrations of calcium and should not be used.",
          "Do not chew, crush, or let the tablet dissolve in your mouth to avoid oropharyngeal irritation.",
          "Ibandronic Acid tablet should be taken on the same date each month.",
          "Do not take two Ibandronic Acid tablets within the same week.",
          "If a dose is missed and the next dose is more than 7 days away, take the missed dose in the morning and then resume the monthly schedule.",
          "If a dose is missed and the next dose is only 1-7 days away, wait until the next month's scheduled dose to take it.",
          "Start taking Calcium Orotate tablets the day after Ibandronic Acid day (from Day 2 onward)."
        ]
      },
      "contraindications": {
        "ibandronic_acid": [
          "Abnormalities of the esophagus that delay esophageal emptying (e.g., stricture, achalasia)",
          "Inability to stand or sit upright for at least 60 minutes",
          "Hypocalcemia",
          "Hypersensitivity to Ibandronic Acid"
        ],
        "calcium_orotate": [
          "Incomplete or infrequent bowel movements",
          "Kidney stone or kidney disease",
          "Sarcoidosis",
          "Increased activity of the parathyroid gland",
          "Extreme loss of body water"
        ]
      },
      "precautions": [
        "Low blood calcium levels (hypocalcemia)",
        "Inability to sit or stand for 60 minutes",
        "Allergy to Ibandronate Sodium",
        "Pregnancy or breastfeeding",
        "Adequate intake of Calcium and Vitamin D is important for all patients",
        "Follow dosing instructions to minimize gastrointestinal side effects"
      ],
      "drug_interactions": {
        "ibandronic_acid": [
          "Calcium supplements or antacids",
          "Medications containing calcium, magnesium, aluminum, iron",
          "Take Ibandronic Acid at least 60 minutes before any oral medications or supplements"
        ],
        "calcium_orotate": [
          "Bisphosphonates (e.g., alendronate)",
          "Quinolone antibiotics (e.g., ciprofloxacin)",
          "Tetracycline antibiotics (e.g., doxycycline)",
          "Levothyroxine, phenytoin, Tiludronate disodium",
          "Thiazide diuretics, mineral oil, stimulant laxatives, glucocorticoids, oral contraceptives, NSAIDs, corticosteroids, and anti-inflammatories"
        ]
      },
      "side_effects": {
        "ibandronic_acid": [
          "Hypertension",
          "Dyspepsia",
          "Nausea",
          "Diarrhea",
          "Abdominal pain",
          "Arthralgia",
          "Back pain",
          "Localized osteoarthritis",
          "Myalgia",
          "Muscle cramps",
          "Influenza",
          "Nasopharyngitis",
          "Bronchitis",
          "Urinary tract infection",
          "Upper respiratory tract infection",
          "Headache",
          "Dizziness",
          "Skin rash",
          "Insomnia"
        ],
        "calcium_orotate": [
          "Bloating",
          "Swelling in the abdomen",
          "Loss of appetite",
          "Upset stomach",
          "Constipation",
          "Nausea",
          "Vomiting",
          "Unusual weight loss",
          "Mood changes",
          "Bone/muscle pain",
          "Increased thirst/urination",
          "Weakness",
          "Unusual tiredness",
          "Formation of kidney stones (infrequent)"
        ]
      },
      "use_in_specific_population": {
        "pregnancy": "Should be used only if the potential benefit justifies the potential risk to the mother and fetus. Pregnancy Category: C.",
        "nursing_mothers": "Caution should be exercised as it is not known whether the combination is excreted in human milk.",
        "pediatric_use": "Safety and effectiveness have not been established in patients under 18 years of age."
      },
      "preparation": {
        "contents": [
          "1 film-coated tablet of Ibandronic Acid 150 mg",
          "60 film-coated tablets of Calcium Orotate 400 mg"
        ],
        "packaging": "One calendar strip"
      }
    },
    {
      "name": "Maxcef®",
     "img_id":"G8DwquX.jpeg",
      "image": "Maxcef_250_mg.jpg",
      "active_ingredients": "Cefotaxime",
      "indications": [
        "Acute or chronic bronchitis",
        "Bacterial pneumonia",
        "Infected bronchiectasis",
        "Lung abscess & post-operative chest infections",
        "Acute & chronic pyelonephritis, cystitis & asymptomatic bacteriuria",
        "Cellulitis, peritonitis & wound infections",
        "Osteomyelitis, septic arthritis",
        "Pelvic inflammatory disease, gonorrhoea",
        "Meningitis & other sensitive infections suitable for parenteral antibiotic therapy"
      ],
      "prophylaxis": "Reduces the incidence of post-operative infections in patients undergoing surgical procedures.",
      "dosage_and_administration": {
        "adults": "1 gm every 12 hours. For severe infections, the dosage may be increased up to 12 gm daily, given in 3-4 divided doses.",
        "children": "100-150 mg/kg/day in 2-4 divided doses. In very severe infections, doses up to 200 mg/kg/day may be required.",
        "neonates": "50 mg/kg/day in 2-4 divided doses. For severe infections, doses of 150-200 mg/kg/day in divided doses."
      },
      "contraindications_and_precautions": [
        "Hypersensitivity to Cefotaxime",
        "Renal insufficiency"
      ],
      "side_effects": [
        "Mild & transient candidiasis",
        "Rashes, fever",
        "Transient rises in liver transaminase and/or alkaline phosphatase",
        "Diarrhoea, pseudomembranous colitis",
        "Changes in renal function",
        "Skin rashes, drug fever",
        "Very rarely anaphylaxis",
        "Encephalopathy (especially with high doses and renal insufficiency)"
      ],
      "drug_interactions": [
        "Increased nephrotoxicity when administered with aminoglycoside antibiotics"
      ],
      "pregnancy_and_lactation": {
        "pregnancy_category": "B",
        "lactation": "Cefotaxime is excreted in breast milk. Caution is advised when administering to nursing mothers."
      },
      "preparation": "250 mg IM/IV Injection"
    },
    {
      "name": "Maxpime®",
     "img_id":"VrPuw8m.jpeg",
      "image": "Maxpime_1gm.jpg",
      "active_ingredients": "Cefepime",
      "indications_and_dosage": {
        "moderate_to_severe_pneumonia": {
          "dose": "1-2 gm",
          "route": "IV",
          "frequency": "Every 12 hours",
          "duration": "10 days"
        },
        "mild_to_moderate_uncomplicated_or_complicated_urinary_tract_infections": {
          "dose": "0.5-1 gm",
          "route": "IV/IM",
          "frequency": "Every 12 hours",
          "duration": "7-10 days"
        },
        "severe_uncomplicated_or_complicated_urinary_tract_infections": {
          "dose": "2 gm",
          "route": "IV",
          "frequency": "Every 12 hours",
          "duration": "10 days"
        },
        "moderate_to_severe_uncomplicated_skin_and_skin_structure_infections": {
          "dose": "2 gm",
          "route": "IV",
          "frequency": "Every 12 hours",
          "duration": "10 days"
        },
        "complicated_intra_abdominal_infections": {
          "dose": "2 gm",
          "route": "IV",
          "frequency": "Every 12 hours",
          "duration": "7-10 days"
        },
        "pediatric_dosage": {
          "dose_for_infections": "50 mg/kg/dose",
          "frequency": "Every 12 hours (Every 8 hours for febrile neutropenic patients)",
          "maximum_dose": "Adult dose limit"
        }
      },
      "contraindications_and_precautions": [
        "Immediate hypersensitivity reactions to Cefepime, cephalosporins, penicillins, or other beta-lactam antibiotics"
      ],
      "side_effects": [
        "Encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma)",
        "Myoclonus",
        "Seizures"
      ],
      "drug_interactions": [
        "Renal function should be monitored if high doses of aminoglycosides are administered with Cefepime due to increased potential of nephrotoxicity and ototoxicity",
        "Nephrotoxicity reported when Cefepime is used with potent diuretics like furosemide"
      ],
      "pregnancy_and_lactation": {
        "pregnancy_category": "B",
        "lactation": "Excreted in breast milk at low concentrations (0.5 µg/mL). Caution is advised when administering to nursing mothers."
      },
      "preparation": "1 gm IM/IV injection"
    },
    {
      "name": "Maxrin™",
     "img_id":"SDq1sow.jpeg",
      "image": "maxrin.jpg",
      "active_ingredients": "Tamsulosin Hydrochloride",
      "indications": [
        "Treatment of LUTS in men and women",
        "Treatment of the signs and symptoms of Benign Prostatic Hyperplasia (BPH) in men",
        "Treatment for ureteral stone expulsion"
      ],
      "dosage_and_administration": {
        "dose": "1 capsule",
        "frequency": "Once daily after meal"
      },
      "contraindications_and_precautions": [
        "Patients with risk of hypersensitivity",
        "Orthostatic hypotension",
        "Severe hepatic insufficiency",
        "Syncope",
        "Severely renal impaired patients should be approached with caution"
      ],
      "side_effects": [
        "Dizziness",
        "Abnormal ejaculation",
        "Headache (less frequently)",
        "Asthenia",
        "Postural hypotension",
        "Palpitations",
        "Rhinitis",
        "Nausea",
        "Vomiting",
        "Diarrhea",
        "Constipation",
        "Hypersensitivity reactions such as rash, pruritus, urticaria",
        "Drowsiness",
        "Blurred vision",
        "Dry mouth",
        "Edema",
        "Syncope",
        "Angioedema",
        "Priapism"
      ],
      "drug_interactions": [
        "Atenolol",
        "Enalapril",
        "Nifedipine",
        "Theophylline",
        "Cimetidine",
        "Frusemide"
      ],
      "use_in_pregnancy_and_children": {
        "pregnancy": "Not indicated for use in pregnant women",
        "children": "Not indicated for use in children"
      },
      "preparation": "0.4 mg Capsule"
    },
    {
      "name": "Maxrin™ D",
     "img_id":"mTWVV4i.jpeg",
      "image": "Maxrin-D_l.jpg",
      "active_ingredients": ["Tamsulosin Hydrochloride", "Dutasteride"],
      "indication": "Combination of Tamsulosin Hydrochloride & Dutasteride capsules are indicated for the treatment of moderate to severe symptomatic Benign Prostatic Hyperplasia (BPH) in men with enlarged prostates.",
      "dosage_and_administration": {
        "adult_males": "The recommended dose of combination is one capsule daily taken orally approximately 30 minutes after the same meal.",
        "response_time": "An improvement in symptoms may be observed after 3 months in some patients, but it can take up to 6 months before a response to the treatment can be achieved.",
        "missed_dose": "If a dose is missed, it can be taken later in the same day. Extra capsules taken for missed doses are not necessary. Do not take two doses in the same day."
      },
      "contraindications": [
        "Combination of Tamsulosin & Dutasteride is contraindicated for use in women and children.",
        "Contraindicated in patients with known hypersensitivity to Tamsulosin Hydrochloride (including Tamsulosin induced angioedema), Dutasteride (including other 5 alpha-reductase inhibitors), or to any ingredient in the formulation."
      ],
      "warning": [
        "Combination of Tamsulosin & Dutasteride is for use in men only.",
        "Women who are pregnant, or who may become pregnant, should not handle the combination as it may pass through the skin and affect the development of male genital organs in a male baby.",
        "A reduction in blood pressure can occur in individual cases, which may lead to syncope. At the first signs of orthostatic hypotension (dizziness, weakness), the patient should sit or lie down until the symptoms have disappeared.",
        "Do not use the combination with other alpha adrenergic antagonists, as this may increase the risk of hypotension."
      ],
      "drug_interactions": [
        "Ketoconazole",
        "Erythromycin",
        "Paroxetine",
        "Terbinafine",
        "Cimetidine",
        "Other alpha-adrenergic antagonists",
        "Phosphodiesterase-5 Inhibitors",
        "Warfarin"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Contraindicated for use in women. There are no adequate and well-controlled studies in pregnant women of this combination or its individual components. The potential risk from the use of Tamsulosin during pregnancy in humans is unknown. Dutasteride may inhibit the development of external genital organs in a male fetus.",
        "lactating_mother": "Contraindicated for use in women. It is not known whether Tamsulosin or Dutasteride are excreted in breast milk."
      },
      "pediatric_use": "Contraindicated for use in children. Safety and effectiveness of Tamsulosin or Dutasteride in children have not been established.",
      "preparation": "Box contains 20 capsules in blister pack."
    },
    {
      "name": "Melano™",
     "img_id":"Geepswv.jpeg",
      "image": "melano.jpg",
      "active_ingredients": [
        "Fluocinolone Acetonide USP 0.1 mg",
        "Tretinoin USP 0.5 mg",
        "Hydroquinone USP 40 mg"
      ],
      "indication": "The Cream is indicated for the short-term treatment of moderate to severe melasma of the face (in the presence of measures for sun avoidance, including the use of sunscreens).",
      "dosage_and_administration": {
        "application": "Apply a thin film of Melano™ Cream to the affected area once daily, at least 30 minutes before bedtime.",
        "preparation": "Gently wash the face and neck with a mild cleanser. Rinse and pat the skin dry."
      },
      "contraindication": "This product is contraindicated in individuals with a history of hypersensitivity, allergy, or intolerance to this product or any of its components.",
      "precaution": [
        "This product contains Hydroquinone and Tretinoin that may cause mild to moderate irritation. Local irritation, such as skin reddening, peeling, mild burning sensation, dryness, and pruritus may be expected at the site of application.",
        "If a reaction suggests hypersensitivity or chemical irritation, the use of the medication should be discontinued.",
        "It also contains the corticosteroid Fluocinolone Acetonide. Systemic absorption of topical corticosteroids can produce reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. If HPA axis suppression is noted, the use of this product should be discontinued."
      ],
      "side_effect": [
        "A very few patients may get severe allergic reactions from this product. They may have trouble breathing or severe asthma attacks.",
        "While patients use this product, skin may develop mild to moderate redness, peeling, burning, dryness, or itching."
      ],
      "drug_interactions": [
        "Avoid use of medicated or abrasive soaps, cleansers, soaps, cosmetics with drying effects, products with high concentration of alcohol, astringent & other irritants or keratolytic drugs.",
        "Also avoid concomitant use of medications with photosensitizing effects."
      ],
      "pregnancy_and_lactation": {
        "pregnancy": "Pregnancy Category C. Melano™ Cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.",
        "lactation": "Caution should be exercised when this product is administered to nursing women."
      },
      "pediatric_use": "Safety and effectiveness of this Cream have not been established in pediatric patients.",
      "preparation": "Each pack has a laminated tube containing 30 gm Cream."
    },
    {
      "name": "Methigic™",
     "img_id":"5hW6rc7.jpeg",
      "image": "maget_2_l.jpg",
      "active_ingredients": "Methylprednisolone",
      "indication": [
        "Endocrine Disorders: Primary or Secondary Adrenocortical Insufficiency, Congenital Adrenal Hyperplasia, Nonsuppurative Thyroiditis, Hypercalcemia associated with Cancer",
        "Rheumatic Disorders: Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Ankylosing Spondylitis, Acute and Subacute Bursitis, Synovitis of Osteoarthritis, Acute nonspecific Tenosynovitis, Post-traumatic Osteoarthritis, Psoriatic Arthritis, Epicondylitis, Acute Gouty Arthritis",
        "Collagen Diseases: Systemic Lupus Erythematosus, Systemic Dermatomyositis",
        "Acute Rheumatic Carditis",
        "Dermatologic Diseases: Bullous Dermatitis Herpetiformis, Severe Erythema Multiforme (Stevens-Johnson syndrome), Severe Seborrheic Dermatitis, Exfoliative Dermatitis, Mycosis Fungoides, Pemphigus, Severe Psoriasis",
        "Allergy: Seasonal or Perennial Allergic Rhinitis, Drug hypersensitivity reactions, Serum Sickness, Contact Dermatitis, Bronchial Asthma, and Atopic Dermatitis",
        "Ophthalmic Diseases: Allergic Corneal Ulcers, Herpes Zoster Ophthalmicus, Anterior segment inflammation, Sympathetic Ophthalmia, Keratitis, Optic Neuritis, Allergic Conjunctivitis, Chorioretinitis, Iritis and Iridocyclitis",
        "Respiratory Diseases: Symptomatic sarcoidosis, Loeffler’s syndrome not manageable by other means, Berylliosis, Aspiration Pneumonitis",
        "Hematological Disorders: Idiopathic Thrombocytopenic Purpura in adults, Secondary Thrombocytopenia in adults, Acquired (Autoimmune) Hemolytic Anemia, Erythroblastopenia, Congenital (Erythroid) Hypoplastic Anemia",
        "Neoplastic Diseases: For palliative management of Leukemias and Lymphomas in adults, Acute Leukemia of childhood",
        "Edematous states: To induce a Diuresis or remission of Proteinuria in the Nephrotic Syndrome without Uremia, of the idiopathic type or that due to Lupus Erythematosus",
        "Gastrointestinal Diseases: To tide the patient over a critical period of the disease in Ulcerative Colitis & Regional Enteritis",
        "CNS Diseases: Acute Exacerbations of Multiple Sclerosis"
      ],
      "dosage_and_administration": {
        "initial_dosage": "The initial dosage of Methylprednisolone tablets may vary from 2 mg to 48 mg per day depending on the specific disease entity being treated.",
        "anti_inflammatory_dosage": "As anti-inflammatory/immunosuppressive, the initial dosage of Methylprednisolone tablets may vary from 4-48 mg per day depending on the specific disease entity being treated.",
        "maintenance_dosage": "The proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached.",
        "long_term_therapy": "It is recommended that the drug be gradually withdrawn rather than abruptly if long-term therapy is discontinued."
      },
      "contraindication": "Systemic fungal infections and known hypersensitivity to components.",
      "precaution": [
        "Adrenocortical Insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted.",
        "Corticosteroids should be used cautiously in patients with ocular herpes simplex due to the risk of corneal perforation.",
        "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.",
        "Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed."
      ],
      "pregnancy_and_lactation": {
        "pregnancy": "Pregnancy Category C. Drug should be given only if the potential benefit justifies the potential risk to the fetus.",
        "lactation": "Methylprednisolone has not been adequately evaluated in nursing mothers."
      },
      "drug_interactions": [
        "Erythromycin, Clarithromycin, Phenobarbital, Phenytoin, Rifampin, and Ketoconazole inhibit the metabolism of Methylprednisolone.",
        "Estrogens, including birth control pills, can increase the effect of corticosteroids by 50%.",
        "Cyclosporin reduces the metabolism of Methylprednisolone while Methylprednisolone reduces the metabolism of Cyclosporin.",
        "Methylprednisolone may increase or decrease the effect of blood thinners (e.g., Warfarin)."
      ],
      "adverse_effects": [
        "Fluid retention",
        "Weight gain",
        "High blood pressure",
        "Potassium loss",
        "Headache",
        "Muscle weakness",
        "Hair growth on the face",
        "Glaucoma",
        "Cataracts",
        "Peptic ulceration",
        "Growth retardation in children",
        "Convulsions",
        "Psychic disturbances (including depression, euphoria, insomnia)",
        "Corticosteroid insufficiency with symptoms like nausea, vomiting, and shock if abruptly stopped"
      ],
      "preparation": [
        "2 mg Tablet",
        "4 mg Tablet",
        "8 mg Tablet",
        "16 mg Tablet"
      ]
    },
    {
      "name": "Melixol®",
     "img_id":"I3yM1K4.jpeg",
      "image": "Melixol.jpg",
      "active_ingredients": ["Flupenthixol", "Melitracen"],
      "indication": ["Anxiety along with depression"],
      "dosage_and_administration": [
        "2 tablets per day, 1 in the morning and 1 at midday"
      ],
      "contraindication": [
        "Hypersensitivity to Melitracen & Flupenthixol",
        "Depression of the CNS (e.g., acute intoxication with alcohol, barbiturates, or opiates)",
        "State of coma",
        "Pheochromocytoma",
        "Blood dyscrasy",
        "Immediately consecutive recovery from myocardial infarction",
        "Cardiac block of any rank",
        "Disorders of cardiac conduction",
        "Coronary insufficiency",
        "Concomitant administration of MAOIs"
      ],
      "precaution_and_warning": [
        "Caution in patients with organic cerebral lesions, convulsions, urinary retention, hyperthyroid, Parkinson’s syndrome, serious myasthenia, advanced hepatic affections, and cardiovascular disorders",
        "Risk of suicide remains in depressive patients during treatment",
        "Risk of nerve sedative syndrome (potentially fatal) and extrapyramidal disorders in rare cases"
      ],
      "side_effects": ["Transient restlessness", "Insomnia"],
      "preparation": {
        "flupenthixol": "10 mg",
        "melitracen": "0.5 mg"
      }
    },
    {
      "name": "Menoral®",
     "img_id":"TEJZBRN.jpeg",
      "image": "menoral_l.jpg",
      "active_ingredients": "Norethisterone",
      "indication": [
        "Dysfunctional Uterine Bleeding (DUB)",
        "PMS (Premenstrual Syndrome)",
        "Endometriosis",
        "Dysmenorrhea",
        "Postponement of menstruation"
      ],
      "dosage_and_administration": {
        "DUB": "1 tablet 3 times a day for 3-4 cycles from day 5 to day 24 of the cycle",
        "PMS": "1 tablet 2 to 3 times a day from day 19 to day 26 of several cycles",
        "Endometriosis": "2-3 tablets daily for 4-6 months",
        "Dysmenorrhea": "1 tablet 3 times a day for 3-4 cycles from day 5 to day 24 of the cycle",
        "Postponement of menstruation": "1 tablet 3 times a day, to be started before expected onset (Menstruation occurs 2-3 days after stopping)"
      },
      "contraindication_and_precaution": [
        "Active thromboembolic processes",
        "Diabetes mellitus with vascular involvement",
        "Presence or history of severe hepatic disease",
        "Presence or history of liver tumors",
        "Known or suspected sex hormone-dependent malignancies",
        "Hypersensitivity to the active substance or any of the excipients"
      ],
      "side_effects": [
        "Visual disturbance",
        "Nausea",
        "Headache",
        "Migraine",
        "Edema",
        "Dyspnea",
        "Hypersensitivity reactions (urticaria, rash)"
      ],
      "drug_interaction": [
        "Phenytoin",
        "Barbiturates",
        "Primidone",
        "Carbamazepine",
        "Rifampicin may decrease therapeutic efficacy",
        "Requirement of oral anti-diabetics or insulin may be changed"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Contraindicated",
        "lactation": "Should not be used"
      },
      "preparation": "5 mg Tablet"
    },
    {
      "name": "Merison™",
     "img_id":"TIxO8j5.jpeg",
      "image": "Merison-tablet.jpg",
      "active_ingredients": "Betahistine Mesilate",
      "indication": [
        "Vertigo and dizziness associated with Meniere’s disease",
        "Meniere’s syndrome",
        "Peripheral vertigo"
      ],
      "dosage_and_administration": {
        "adults": "1 to 2 tablets three times per day after meals"
      },
      "precaution": [
        "History of digestive ulcer",
        "Bronchial asthma",
        "Pheochromocytoma"
      ],
      "adverse_reactions": [
        "Nausea or vomiting",
        "Hypersensitivity reactions such as skin rash"
      ],
      "use_in_pregnancy": "Safety of Betahistine Mesilate during pregnancy has not been established. This drug should be administered to pregnant patients or women suspected of being pregnant only if the expected therapeutic benefit is thought to outweigh any possible risk.",
      "preparation": "6 mg Tablet"
    },
    {
      "name": "Metaspray®",
     "img_id":"fzkYqmt.jpeg",
      "image": "METASPRAY.jpg",
      "form": "Nasal Spray",
      "active_ingredients": "Mometasone Furoate",
      "indication": [
        "Treatment of the nasal symptoms of seasonal and perennial allergic rhinitis in adults and pediatric patients 2 years of age and older",
        "Prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and adolescent patients 12 years and older",
        "Treatment of nasal polyps in patients 18 years and older"
      ],
      "dosage_and_administration": {
        "adults_and_children_12_years_and_older": "Two sprays (50 mcg of Mometasone Furoate in each spray) in each nostril once daily (total daily dose of 100 mcg). Prophylaxis 2 to 4 weeks before the anticipated start of the pollen season with 200 mcg daily.",
        "children_2_to_11_years_of_age": "One spray (50 mcg of Mometasone Furoate in each spray) in each nostril once daily (total daily dose of 100 mcg).",
        "nasal_polyps_adults_18_years_and_older": "Two sprays (50 mcg of Mometasone Furoate in each spray) in each nostril twice daily (total daily dose of 400 mcg). An alternative dose is two sprays once daily (200 mcg daily)."
      },
      "contraindication_and_precaution": [
        "Hypersensitivity to any of the ingredients",
        "Caution is required in patients with active or dormant tuberculous infection, untreated fungal, bacterial, or systemic viral infections, or ocular herpes simplex."
      ],
      "side_effect": [
        "Headache",
        "Viral infection",
        "Sore throat",
        "Nosebleeds",
        "Coughing"
      ],
      "pregnancy_and_lactation": "There are no adequate and well-controlled studies in pregnant women. Mometasone Furoate should be used during pregnancy only if the potential benefits justify the potential risk to the fetus. It is not known if Mometasone Furoate is excreted in human milk. Caution should be used when administering Mometasone to nursing women.",
      "preparation": "120 Nasal Sprays (50 mcg in each spray)"
    },
    {
      "name": "Methicol®",
     "img_id":"KMRT7S5.jpeg",
      "image": "METHICOL.jpg",
      "active_ingredients": "Mecobalamin",
      "indication": [
        "Peripheral neuropathies observed in Diabetic neuropathy, Diabetic retinopathy, Entrapment neuropathy, Amyotrophic lateral sclerosis, Parkinson’s disease, Alzheimer’s disease, Lumbago, Drug induced neuropathy, Multiple sclerosis, Intercostal neuralgia, Vertebral syndrome, Nerve Compression Syndrome",
        "Megaloblastic anemia due to Vitamin B12 deficiency (injection only)"
      ],
      "dosage_and_administration": {
        "tablet": "Adults 3 tablets, equivalent to a total of 1500 mcg of Mecobalamin, administered orally in 3 divided doses."
      },
      "contraindication_and_precaution": [
        "Hypersensitivity to Mecobalamin or to any of the excipients",
        "Mecobalamin should not be administered for extensive periods (months) to patients who do not show clinical response",
        "Prolonged use of larger doses is not recommended for patients whose occupation requires handling mercury or its compounds."
      ],
      "side_effect": [
        "Gastrointestinal symptoms (e.g. anorexia, nausea, diarrhea)",
        "Skin rash"
      ],
      "drug_interaction": "No significant drug interaction reported.",
      "use_in_pregnancy_and_lactation": "Not recommended during pregnancy and lactation.",
      "preparation": "500 mcg Tablet"
    },
    {
      "name": "Mevin™",
     "img_id":"lVubeVA.jpeg",
      "image": "Mevin.jpg",
      "active_ingredients": "Mebeverine Hydrochloride",
      "indication": [
        "Symptomatic treatment of IBS",
        "Chronic irritable colon",
        "Spastic constipation",
        "Mucous colitis",
        "Colicky abdominal pain",
        "Persistent non-specific diarrhoea"
      ],
      "dosage_and_administration": {
        "adults_and_children_over_10_years": "1 tablet three times daily, taken 20 minutes before meals. After several weeks, the dosage may be gradually reduced if the desired effect has been achieved."
      },
      "precaution": [
        "Caution should be exercised in porphyria or allergic reaction to this or any other medicine of this group."
      ],
      "side_effect": ["Skin rash", "Urticaria", "Angioedema"],
      "use_in_pregnancy_and_lactation": "No teratogenicity has been shown in animal experiments. However, the usual precautions concerning the administration of any drug during pregnancy should be exercised. Mebeverine does not excrete in breast milk after administering the therapeutic dose.",
      "use_in_children": "Mebeverine is not recommended in children under 10 years.",
      "preparation": "135 mg Tablet"
    },
    {
      "name": "Mexlo® Eye Drops",
     "img_id":"hzNEb7x.jpeg",
      "image": "Mexlo_l.jpg",
      "active_ingredients": "Lomefloxacin",
      "indication": [
        "Conjunctivitis",
        "Blepharitis",
        "Blepharo-conjunctivitis",
        "Staphylococcus aureus-induced corneal ulcers"
      ],
      "dosage_and_administration": {
        "day_1": "Instill 5 drops into the conjunctival sac within 20 minutes.",
        "days_2_7_9": "Instill 1 drop 2 times daily into the conjunctival sac."
      },
      "contraindication_and_precaution": [
        "Hypersensitivity to Lomefloxacin",
        "Long-term treatment may enhance development of secondary fungal infections",
        "Avoid exposure to sunlight or UV radiation due to phototoxicity"
      ],
      "side_effect": [
        "Slight & transient burning",
        "Allergic reactions (asthma, dyspnoea, urticaria, erythema, pruritus)",
        "Hypersensitization"
      ],
      "drug_interaction": "Preparations containing heavy metals, such as Zinc, should not be used during 15 minutes preceding and following application of Lomefloxacin.",
      "use_in_pregnancy_and_lactation": "The drug should only be used when the benefit outweighs the potential risk for the fetus or infant.",
      "preparation": "0.3% Eye Drops"
    },
    {
      "name": "Migranil®",
     "img_id":"Vd6UEZQ.jpeg",
      "image": "Migranil.jpg",
      "active_ingredients": "Pizotifen",
      "indication": [
        "Prophylactic treatment of recurrent vascular headaches",
        "Classical migraine",
        "Common migraine",
        "Cluster headache"
      ],
      "dosage_and_administration": {
        "dose": "1.5 mg daily at bedtime as a single dose or in three divided doses."
      },
      "contraindication_and_precaution": [
        "Hypersensitivity",
        "Narrow-angle glaucoma",
        "Prostate hypertrophy",
        "Dosage adjustment may be necessary in patients with kidney insufficiency"
      ],
      "side_effect": [
        "Drowsiness",
        "Dizziness",
        "Dry mouth",
        "Nausea",
        "Constipation"
      ],
      "use_in_pregnancy": "Clinical data with Pizotifen in pregnancy are very limited; it should be administered in pregnancy only if the expected benefits outweigh the potential risks.",
      "drug_interaction": [
        "Alcohol",
        "Tranquilizers",
        "Hypnotics",
        "Antidepressants",
        "MAO inhibitors"
      ],
      "preparation": ["0.5 mg Tablet", "1.5 mg Tablet"]
    },
    {
      "name": "Mirakof®",
     "img_id":"DShKZjw.jpeg",
      "image": "Miracof-P-Drop.jpg",
      "active_ingredients": "Butamirate Citrate",
      "indication": [
        "Dry (non-productive) cough",
        "Pre- & post-operative cough sedation"
      ],
      "dosage_and_administration": {
        "tablet": {
          "adolescents_over_12_years": "1-2 tablets daily",
          "adults": "2-3 tablets daily at 8 to 12 hours intervals"
        },
        "syrup": {
          "adults": "15 ml 4 times daily",
          "adolescents": "15 ml 4 times daily",
          "children_6_12_years": "10 ml 3 times daily",
          "children_3_6_years": "5 ml 3 times daily"
        },
        "paediatric_drops": {
          "children_2_months_1_year": "0.50 ml 4 times daily",
          "children_1_3_years": "0.75 ml 4 times daily"
        }
      },
      "contraindication_and_precaution": [
        "Hypersensitivity to the active ingredient"
      ],
      "side_effect": ["Rash", "Nausea", "Diarrhoea", "Vertigo"],
      "use_in_pregnancy_and_lactation": "Butamirate Citrate should not be used during the first trimester of pregnancy. During the remainder of pregnancy, it can be used if indicated by a physician but with caution. The benefits of Butamirate Citrate administration during breast feeding should be carefully weighed against the risks.",
      "preparation": [
        "50 mg Sustained Release Tablet",
        "7.5 mg/ml Syrup (100 ml)",
        "5 mg/ml Paediatric drop (15 ml)"
      ]
    },
    {
      "name": "MiraproTM",
     "img_id":"6WX0Y3D.jpeg",
      "image": "Mirapro.jpg",
      "active_ingredients": "Mirtazapine USP 7.5 mg",
      "indication": ["Treatment of major depressive disorder (MDD)"],
      "dosage_and_administration": {
        "starting_dose": "15 mg/day, administered in a single dose, preferably in the evening prior to sleep",
        "maintenance_dose": "15 to 45 mg/day after 8 to 12 weeks of initial treatment",
        "therapy_duration": "Acute episodes of depression may require several months or longer of sustained pharmacological therapy."
      },
      "contraindication": [
        "Hypersensitivity to mirtazapine or any of the excipients",
        "Concomitant use with Monoamine Oxidase Inhibitors (MAOI)",
        "Mirtazapine should not be used within 14 days of initiating or discontinuing therapy with a MAOI"
      ],
      "side_effect": [
        "Dizziness",
        "Drowsiness",
        "Dry mouth",
        "Increased appetite",
        "Weight gain"
      ],
      "precaution": [
        "Patients should be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, unusual behavior changes, worsening of depression, and suicidal ideation, especially early during treatment and when the dose is adjusted",
        "Risk of agranulocytosis",
        "Mirtazapine may impair judgment, thinking, and motor skills due to its sedative effect",
        "Clinically significant ALT (SGPT) elevations (≥ 3 times the upper limit of the normal range) may occur"
      ],
      "use_in_pregnancy_and_lactation": "Pregnancy Category-C. Patients should notify their physician if they become pregnant or intend to become pregnant during therapy. Patients should also notify their physician if they are breastfeeding.",
      "drug_interaction": [
        "Clinically significant interactions with Monoamine Oxidase Inhibitors (MAOI) and other serotonergic drugs like tryptophan, triptans, linezolid, serotonin reuptake inhibitors, venlafaxine, lithium, tramadol, or St. John’s wort",
        "May interfere with the metabolism or activity of Carbamazepine, Phenytoin, or Cimetidine",
        "Avoid Alcohol & Diazepam while taking Mirtazapine"
      ],
      "preparation": "7.5 mg Tablet"
    },
    {
      "name": "Montene®",
     "img_id":"EAa6idh.jpeg",
      "image": "Montene.jpg",
      "active_ingredients": "Montelukast",
      "indication": [
        "Prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older",
        "Relief of symptoms of allergic rhinitis"
      ],
      "dosage_and_administration": {
        "adults_and_adolescents_15_years_and_older": "One 10 mg tablet daily, to be taken in the evening",
        "children_6_14_years": "5 mg daily, to be taken in the evening",
        "children_2_5_years": "4 mg daily, to be taken in the evening"
      },
      "contraindication_and_precaution": [
        "Hypersensitivity to the active ingredient"
      ],
      "side_effect": [
        "Headache",
        "Rash",
        "Dyspepsia",
        "Dizziness",
        "Abdominal pain",
        "In pediatric patients: Diarrhea, sinusitis, and otitis media"
      ],
      "drug_interaction": [
        "Patients with known aspirin sensitivity should avoid aspirin or nonsteroidal anti-inflammatory agents while taking montelukast"
      ],
      "use_in_pregnancy": "There have been no reports of its use in pregnant women. Caution should be used prior to initiating therapy in nursing mothers.",
      "preparation": [
        "10 mg Tablet",
        "5 mg Chewable Tablet",
        "4 mg Chewable Tablet"
      ]
    },
    {
      "name": "Motigut®",
     "img_id":"QpPzF84.jpeg",
      "image": "Motigut_Tab.jpg",
      "active_ingredients": "Domperidone",
      "indication": [
        "Dyspeptic symptom complex: Associated with delayed gastric emptying, gastroesophageal reflux, and esophagitis. Symptoms include epigastric sense of fullness, abdominal distension, upper abdominal pain, eructation, early satiety, heartburn with or without regurgitation of gastric contents, diabetic gastroparesis, and non-ulcer dyspepsia.",
        "Nausea & vomiting: Acute nausea and vomiting of functional, organic, infectious, dietetic origin or induced by radiotherapy or drug therapy or in migraine.",
        "Parkinson's disease: In dopamine-agonist induced nausea and vomiting.",
        "Radiological studies: Spreading barium transit in follow-through radiological studies."
      ],
      "dosage_and_administration": {
        "adults": "1-2 tablets or 10-20 ml suspension every 6-8 hours daily before meals.",
        "children": "2 ml-4 ml suspension/10 kg or 0.4 ml-0.8 ml paediatric drops/10 kg every 6-8 hours daily."
      },
      "contraindication_and_precaution": [
        "Known hypersensitivity",
        "Gastro-intestinal stimulation",
        "Gastro-intestinal hemorrhage",
        "Mechanical obstruction or perforation",
        "Prolactinoma",
        "Increased risk of extra-pyramidal reactions",
        "Used with caution in patients with hepatic impairment"
      ],
      "side_effect": [
        "Hyperprolactinemia",
        "Galactorrhea",
        "Breast enlargement and soreness",
        "Reduced libido",
        "Dry mouth",
        "Thirst",
        "Headache",
        "Nervousness",
        "Drowsiness",
        "Diarrhea",
        "Skin rash and itching"
      ],
      "drug_interaction": [
        "Bromocriptine",
        "Anti-muscarinics",
        "Opioid analgesics",
        "MAO inhibitors"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Not recommended during pregnancy.",
        "lactation": "It is secreted in breast milk in very small quantities, insufficient to be considered harmful."
      },
      "preparation": [
        "10 mg Tablet",
        "60 ml Suspension",
        "15 ml Paediatric Drops"
      ]
    },
    {
      "name": "Moxacil®",
     "img_id":"UmwfO3X.jpeg",
      "image": "Moxacil-15ml.jpg",
      "active_ingredients": "Amoxicillin",
      "indication": [
        "Infections of the ear, nose & throat, genitourinary tract, skin & skin structure, lower respiratory tract.",
        "Gonorrhea, acute uncomplicated ano-genital & urethral infections.",
        "H. pylori eradication to reduce the risk of duodenal ulcer recurrence in combination with clarithromycin plus lansoprazole as triple therapy.",
        "Prophylactic cover for patients at risk of developing endocarditis when undergoing dental surgery."
      ],
      "dosage_and_administration": {
        "adult": {
          "mild_moderate": "500 mg every 12 hours or 250 mg every 8 hours.",
          "severe": "875 mg every 12 hours or 500 mg every 8 hours."
        },
        "children": {
          "mild_moderate": "25 mg/kg/day in divided doses every 12 hours or 20 mg/kg/day in divided doses every 8 hours.",
          "severe": "45 mg/kg/day in divided doses every 12 hours or 40 mg/kg/day in divided doses every 8 hours.",
          "gonorrhea": "3 g as single oral dose.",
          "prepubertal_children": "50 mg/kg Amoxicillin, combined with 25 mg/kg Probenecid as a single dose."
        }
      },
      "contraindication_and_precaution": [
        "Contraindicated for patients hypersensitive to Penicillin.",
        "In renal impairment, excretion of the antibiotic will be delayed and depending on the degree of impairment, it may be necessary to reduce the total daily dose.",
        "Caution should be exercised in case of erythematous rashes, glandular fever, history of allergy, etc."
      ],
      "adverse_effect": [
        "Mild, rare, and infrequent: Diarrhoea, indigestion, or skin rashes."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Can be used safely throughout pregnancy at the normal adult dose.",
        "lactation": "Can be used safely during lactation in most instances."
      },
      "drug_interaction": [
        "Concurrent administration of Probenecid delays the excretion of Amoxicillin."
      ],
      "preparation": [
        "250 mg & 500 mg Capsule",
        "125 mg/5 ml Suspension",
        "125 mg/1.25 ml Paediatric Drops"
      ]
    },
    {
      "name": "Moxaclav™",
     "img_id":"QMMRLgM.jpeg",
      "image": "Moxaclav.jpg",
      "active_ingredients": "Co-Amoxiclav (Amoxicillin + Clavulanic Acid)",
      "indication": [
        "Upper respiratory tract infections",
        "Lower respiratory tract infections",
        "Genito-urinary tract infections",
        "Skin & soft tissue infections",
        "Bone & joint infections e.g. osteomyelitis",
        "Other infections e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis"
      ],
      "dosage_and_administration": {
        "adults_and_children_over_12_years": "One Moxaclav 375 mg tablet three times a day. In severe infection, one Moxaclav 625 mg tablet three times a day or one Moxaclav 1gm tablet two times a day.",
        "children_6_12_years": "2 teaspoonful of Moxaclav Powder for Suspension every 8 hours.",
        "children_1_6_years": "1 teaspoonful of Moxaclav Powder for Suspension every 8 hours.",
        "children_below_1_year": "25 mg/kg/day in divided doses every 8 hours.",
        "moxaclav_forte_powder_for_suspension": {
          "children_2_12_years": "½ to 2 teaspoonful b.i.d.",
          "children_2_months_to_2_years": "25/3.6 mg/kg/day to 45/6.4 mg/kg/day b.i.d."
        },
        "moxaclav_1.2_iv_injection": {
          "children_up_to_3_months": "30 mg/kg every 8 hours (every 12 hours in the perinatal period & in premature infants)",
          "children_3_months_to_12_years": "30 mg/kg every 6-8 hours"
        }
      },
      "precaution_and_warning": [
        "Co-amoxiclav should be used with care in patients on anti-coagulation therapy or with severe hepatic dysfunction.",
        "In patients with moderate or severe renal impairment, dose should be adjusted."
      ],
      "contraindication": [
        "History of Penicillin hypersensitivity.",
        "Patients with previous history of Co-amoxiclav or penicillin associated cholestatic jaundice."
      ],
      "side_effect": [
        "Mild & transitory nature.",
        "Diarrhoea, pseudomembranous colitis, indigestion, nausea, vomiting & candidiasis."
      ],
      "drug_interaction": ["Oral contraceptives."],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Use of Co-amoxiclav in pregnancy is not recommended unless considered essential by the physician.",
        "lactation": "During lactation, trace quantities of Amoxicillin can be detected in breast milk."
      },
      "preparation": [
        "375 mg Tablet (Amoxicillin 250 mg & Clavulanic Acid 125 mg)",
        "625 mg Tablet (Amoxicillin 500 mg & Clavulanic Acid 125 mg)",
        "1 gm Tablet (Amoxicillin 875 mg & Clavulanic Acid 125 mg)",
        "100 ml Powder for Suspension (Amoxicillin 125 mg & Clavulanic Acid 31.25 mg/5 ml)",
        "50 ml Forte Powder for Suspension (Amoxicillin 400 mg & Clavulanic Acid 57.5 mg/5 ml)",
        "1.2 gm IV Injection (Amoxicillin 1 gm & Clavulanic Acid 0.2 gm)"
      ]
    },
    {
      "name": "Mucospel®",
     "img_id":"5u1RCBB.jpeg",
      "image": "MUCOSPEL-100ML.jpg",
      "active_ingredients": "Bromhexine",
      "indication": "Treatment of respiratory disorders associated with viscid or excessive mucus and/or productive cough.",
      "dosage_and_administration": {
        "adults_and_children_over_10_years": "2 to 4 teaspoonfuls 3 times daily.",
        "children_5_10_years": "1 teaspoonful 3 times daily.",
        "children_2_5_years": "1/2 teaspoonful 3 times daily.",
        "children_below_2_years": "1/4 teaspoonful 3 times daily."
      },
      "contraindication_and_precaution": [
        "Known hypersensitivity or idiosyncratic reaction to Bromhexine Hydrochloride (or any of the other ingredients in the product).",
        "Since mucolytics may disrupt the gastric mucosal barrier, Bromhexine should be used with caution in patients with a history of gastric ulceration."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy_category": "B",
        "pregnancy": "Bromhexine has been taken by a large number of pregnant women & women of childbearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the foetus.",
        "lactation": "It is not recommended for breastfeeding mothers unless the potential benefits to the patient are weighed against the possible risk to the infant."
      },
      "side_effect": [
        "Gastrointestinal side effects",
        "Transient rise in serum aminotransferase values",
        "Headache",
        "Vertigo (dizziness)",
        "Sweating",
        "Allergic reactions"
      ],
      "preparation": "4 mg/5 ml Syrup (100 ml)"
    },
    {
      "name": "Multivit® Plus",
     "img_id":"RSyH1bT.jpeg",
      "image": "MULTIVIT-PLUS.jpg",
      "active_ingredients": [
        "Vitamin A",
        "Vitamin D",
        "Vitamin B1",
        "Vitamin B2",
        "Vitamin B6",
        "Vitamin C",
        "Vitamin E",
        "Nicotinamide",
        "Cyanocobalamin",
        "Folic Acid",
        "Calcium Pantothenate",
        "Iron",
        "Copper",
        "Manganese",
        "Iodine",
        "Potassium",
        "Zinc"
      ],
      "indication": "Vitamin & mineral deficiencies.",
      "dosage_and_administration": "Orally one Multivit Plus tablet daily for adults & children over 5 years of age or as directed by the physicians.",
      "contraindication_and_precaution": [
        "Hypersensitivity",
        "Severe specific deficiencies of vitamins or minerals",
        "Treatment with levodopa as Pyridoxine decreases the efficacy of Levodopa",
        "During the first trimester of pregnancy, larger doses of Vitamin A (more than 10 tablets per day) may be teratogenic",
        "Pernicious anemia or other megaloblastic anemia where vitamin B12 is deficient"
      ],
      "side_effect": "Iron has been associated with gastrointestinal intolerance.",
      "use_in_pregnancy_and_lactation": "During the first trimester of pregnancy, recommended daily dose should not be exceeded.",
      "preparation": "Tablet"
    },
    {
      "name": "Myonil®",
     "img_id":"fMkwA8p.jpeg",
      "image": "Myonil.jpg",
      "active_ingredients": "Eperisone",
      "indication": "Improvement of muscular hypertonic symptoms in the following diseases: Cervical syndrome, periarthritis of the shoulder, lumbago. Spastic paralysis in the following diseases: Cerebrovascular disease, spastic spinal paralysis, cervical spondylosis, postoperative sequelae (including cerebrospinal tumor), sequelae to trauma (spinal trauma, head injury), amyotrophic lateral sclerosis, cerebral palsy, spinocerebellar degeneration, spinal vascular diseases & other encephalomyelopathies.",
      "dosage_and_administration": "For adults: Usually 3 tablets per day in three divided doses after each meal.",
      "contraindication_and_precaution": "In patients with a history of hypersensitivity to Eperisone Hydrochloride.",
      "use_in_pregnancy_and_lactation": "Eperisone Hydrochloride should only be used in pregnant women if the expected therapeutic benefits are evaluated to outweigh the possible risks of treatment. The drug should not be used during lactation.",
      "side_effect": [
        "Excessive relaxation",
        "Stomachache",
        "Nausea",
        "Vertigo",
        "Anorexia",
        "Drowsiness",
        "Skin rashes",
        "Diarrhea",
        "Vomiting",
        "Indigestion",
        "GI disturbances",
        "Insomnia",
        "Headache",
        "Constipation"
      ],
      "preparation": "50 mg Tablet"
    },
    {
      "name": "Nalid®",
     "img_id":"swWrXK9.jpeg",
      "image": "Nalid.jpg",
      "active_ingredients": "Nalidixic Acid",
      "indication": "Urinary tract infection.",
      "dosage_and_administration": {
        "infants_and_children": "Initial: Oral 13.75 mg per kg body weight every six hours for one or two weeks. Maintenance: Oral 8.25 mg per kg body weight every six hours.",
        "adult": "Usual adult dose initially is 1 g every 6 hours for 7 days reducing to 500 mg every 6 hours or as prescribed by the physician."
      },
      "contraindication_and_precaution": "Risk-benefit must be considered during the first trimester of pregnancy & during breastfeeding, impaired renal or hepatic function. Nalidixic acid is contraindicated in the following cases: Infants under 3 months, epilepsy, CNS lesions.",
      "side_effect": [
        "Gastro-intestinal disturbances including nausea, vomiting, diarrhea",
        "Allergic reaction including urticaria, rashes, fever",
        "Arthralgia",
        "Muscle weakness",
        "Phototoxicity"
      ],
      "drug_interaction": "This drug should not be used with the following medications because very serious interactions may occur: certain cancer chemotherapy (alkylating agents such as melphalan).",
      "use_in_pregnancy_and_lactation": "This drug should be used in pregnancy only if clearly needed. Nalidixic acid is excreted into milk in small amounts. It is compatible with breastfeeding.",
      "preparation": "500 mg Tablet & 300 mg/5 ml Powder for Suspension."
    },
    {
      "name": "Naurif®",
     "img_id":"OyxHl4e.jpeg",
      "image": "NAURIF-INJECTION-5AMPLE.jpg",
      "active_ingredients": "Granisetron",
      "indication": {
        "injection": [
          "Prevention of nausea & vomiting associated with initial & repeat courses of emetogenic cancer chemotherapy, therapy including high dose cisplatin.",
          "Prevention & treatment of postoperative nausea & vomiting."
        ],
        "tablet": [
          "Nausea & vomiting associated with initial & repeat courses of emetogenic cancer therapy, including high dose of cisplatin.",
          "Nausea & vomiting associated with radiation, including total body irradiation & fractionated abdominal radiation."
        ]
      },
      "dosage_and_administration": {
        "injection": {
          "chemotherapy_induced_nausea_vomiting": {
            "adults": "10 mcg/kg administered intravenously within 30 minutes before initiation of chemotherapy, & only on the day(s) chemotherapy is given.",
            "paediatric_patients_2_to_16_years": "10 mcg/kg."
          },
          "postoperative_nausea_vomiting": {
            "adults": "Single dose of 1 mg of Naurif should be diluted to 5 ml & administered as a slow intravenous injection (over 30 seconds)."
          }
        },
        "tablet": {
          "emetogenic_chemotherapy": "2 mg once daily or 1 mg twice daily. Administered only on the days(s) chemotherapy is given.",
          "radiation": "2 mg once daily. Two 1 mg tablets are taken within one hour of irradiation."
        }
      },
      "contraindication": "Known hypersensitivity to granisetron.",
      "side_effect": [
        "Headache",
        "Constipation",
        "Asthenia",
        "Diarrhea",
        "Abdominal pain",
        "Dyspepsia",
        "Nausea",
        "Vomiting",
        "Dizziness",
        "Insomnia",
        "Anxiety"
      ],
      "pregnancy": "Pregnancy category B. This drug may be used in pregnancy only if clearly needed.",
      "nursing_mother": "Caution should be exercised when granisetron is administered to a nursing mother.",
      "preparation": "1 mg/ml Injection, 1 mg Tablet."
    },
    {
      "name": "Nebanol®",
     "img_id":"DbMRiHa.jpeg",
      "image": "Nebanol_1.jpg",
      "active_ingredients": "Neomycin Sulphate & Bacitracin Zinc",
      "indication": [
        "Topical bacterial infections",
        "Atopic or contact stasis & infections",
        "Eczematoid dermatitis",
        "Neurodermatitis",
        "Eczema",
        "Anogenital pruritus"
      ],
      "dosage_and_administration": "A thin film to be applied 2 to 4 times daily.",
      "contraindication_and_precaution": [
        "Hypersensitivity",
        "Nephrotoxicity",
        "Overgrowth of non-susceptible organisms including fungi"
      ],
      "adverse_reaction": "Allergic reaction",
      "preparation": [
        "(5 mg + 250 I.U.)/gm Powder",
        "(5 mg + 500 I.U.)/gm Ointment"
      ]
    },
    {
      "name": "Nebanol Plus®",
     "img_id":"A9Sk1LY.jpeg",
      "image": "nebanol_plus_2.jpg",
      "active_ingredients": [
        "Neomycin Sulphate",
        "Bacitracin Zinc",
        "Polymyxin B Sulphate"
      ],
      "indication": [
        "Infected wounds",
        "Burns or skin grafts",
        "Chronic varicose or other indolent ulcers",
        "Furuncles",
        "Carbuncles",
        "Pyoderma",
        "Sycosis barbae",
        "Impetigo and acne",
        "Secondary infected skin lesions of scabies",
        "Pediculosis",
        "Tinea pedis",
        "Contact and allergic dermatitis"
      ],
      "dosage_and_administration": "A thin film to be applied one to three times daily.",
      "contraindication_and_precaution": [
        "Hypersensitivity reaction",
        "Ototoxicity",
        "Not recommended for neonates"
      ],
      "use_in_pregnancy_and_lactation": "Not recommended in pregnancy & lactation.",
      "preparation": "(3.5 mg + 400 I.U. + 5000 I.U.)/gm Ointment"
    },
    {
      "name": "Nebita™",
     "img_id":"IWuwPiY.jpeg",
      "image": "Nebita.jpg",
      "active_ingredients": "Nebivolol HCl",
      "indication": ["Hypertension", "Heart Failure"],
      "dosage_and_administration": {
        "heart_failure": "Initially 1.25 mg once daily, then if tolerated increased at intervals of 1–2 weeks to 2.5 mg once daily, then to 5 mg once daily, then to max. 10 mg once daily.",
        "hypertension": "Starting dose is 5 mg once daily. The dose can be increased at 2 weeks interval up to 40 mg once daily."
      },
      "contraindication_and_precaution": [
        "Severe bradycardia",
        "Heart block greater than first degree",
        "Cardiogenic shock",
        "Decompensated cardiac failure",
        "Sick sinus syndrome",
        "Severe hepatic impairment",
        "Hypersensitivity to any component of this product"
      ],
      "side_effect": ["Headache", "Nausea", "Bradycardia"],
      "drug_interaction": [
        "Use caution when Nebivolol is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.)",
        "Do not use Nebivolol with other β-blockers",
        "Both digitalis glycosides & β-blockers slow atrioventricular conduction & decrease heart rate. Concomitant use can increase the risk of bradycardia.",
        "Nebivolol can exacerbate the effects of myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (verapamil & diltiazem), or antiarrhythmic agents, such as disopyramide."
      ],
      "use_in_pregnancy_and_lactation": "β-blockers may cause intra-uterine growth restriction, neonatal hypoglycaemia, & bradycardia; the risk is greater in severe hypertension. If beta-blockers are used close to delivery, infants should be monitored for signs of β-blockade. Nebivolol is advised to avoid during breast-feeding due to possible risk of toxicity due to β-blockade.",
      "use_in_children": "Safety & effectiveness of Nebivolol in pediatric patients have not been established.",
      "preparation": ["2.5 mg/Tablet", "5 mg/Tablet"]
    },
    {
      "name": "Nebita Plus 5/12.5",
     "img_id":"A6UqYF7.jpeg",
      "image": "Nebita-plus.jpg",
      "active_ingredients": ["Nebivolol", "Hydrochlorothiazide"],
      "indication": "Essential hypertension",
      "dosage_and_administration": "Once daily, preferably at the same time every day.",
      "contraindication_and_precaution": [
        "Hypersensitivity to the active substances",
        "Liver function impairment",
        "Severe renal insufficiency (Creatinine clearance < 30 ml/min.)",
        "Bradycardia",
        "Hypotension",
        "Beta-blockers should not be used in patients with untreated congestive heart failure (CHF) & bradycardia.",
        "In patients with chronic obstructive pulmonary disorders (COPD), beta-blockers should be used with caution as airway constriction may be aggravated.",
        "Thiazides can cause fluid or electrolyte imbalance.",
        "Thiazides may decrease urinary calcium excretion and may cause an intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism."
      ],
      "use_in_pregnancy_and_lactation": "This combination is not recommended during pregnancy. It is not recommended for mothers who are breast-feeding.",
      "side_effect": {
        "nebivolol": [
          "Headache",
          "Dizziness",
          "Tiredness",
          "Diarrhoea",
          "Constipation",
          "Nausea"
        ],
        "hydrochlorothiazide": [
          "Vertigo (spinning sensation)",
          "Convulsions",
          "Itchiness",
          "Rash",
          "Increased sensitivity of your skin to sunlight"
        ]
      },
      "preparation": "5/12.5 Tablet"
    },
    {
      "name": "Neuro-B®",
     "img_id":"RSYq6EE.jpeg",
      "image": "Neuro-B.jpg",
      "active_ingredients": [
        "Thiamine (Vit-B1)",
        "Pyridoxine (Vit-B6)",
        "Cyanocobalamin (Vit-B12)"
      ],
      "indication": [
        "Low back pain",
        "Deficiency of relevant vitamins",
        "Polyneuropathy of any origin (e.g., Diabetic, Alcoholic, Toxic neuropathies)",
        "Neuritis",
        "Neuralgia",
        "Cervical Syndrome",
        "Shoulder-arm syndrome",
        "Lumbago",
        "Sciatica",
        "Mayalgia",
        "Intercostal neuralgia",
        "Herpes Zoster",
        "Trigeminal Neuralgia",
        "Supportive treatment in facial paresis"
      ],
      "dosage_and_administration": {
        "tablet": "1 to 3 tablets daily or as directed by the physician.",
        "injection": "Preferably injected intramuscularly (deep intragluteal). In severe cases 1 ampoule daily until the acute symptoms subside. For milder cases & follow-up therapy, 2 or 3 ampoules per week."
      },
      "contraindication_and_precaution": [
        "Patients on Levodopa therapy",
        "Hypersensitivity to any of the active ingredients",
        "Cyanocobalamin should not be given before a diagnosis has been fully established because of the possibility of masking symptoms of subacute degeneration of the spinal cord",
        "Cyanocobalamin is not a suitable form of Vitamin B12 for the treatment of optic neuropathies associated with raised plasma concentrations of cyanocobalamin"
      ],
      "side_effect": "Well tolerated. Few allergic responses may be seen in rare cases.",
      "use_in_pregnancy_and_lactation": "Sufficient data yet not available in this respect.",
      "drug_interaction": "No drug interactions have yet been reported.",
      "preparation": [
        "(Thiamine Mononitrate 100 mg, Pyridoxine Hydrochloride 200 mg, Cyanocobalamin 200 mcg)/ Tablet",
        "(Thiamine Mononitrate 100 mg, Pyridoxine Hydrochloride 100 mg, Cyanocobalamin 1000 mcg)/ 3 ml Injection"
      ]
    },
    {
      "name": "Neurolep®",
     "img_id":"G0GQEbj.jpeg",
      "image": "Neurolep-tablet.jpg",
      "active_ingredients": "Piracetam",
      "indication": [
        "Cerebral vascular accidents",
        "Cerebral insufficiencies",
        "Mental retardation in children",
        "Behaviour & psychotic problems in old age",
        "Memory deficits"
      ],
      "dosage_and_administration": {
        "adults": "One tablet (800 mg) 3 times a day.",
        "children": "50 mg/kg of body weight in 3 divided doses."
      },
      "contraindication_and_precaution": [
        "Severe renal insufficiency (creatinine clearance < 20 ml/min)",
        "Hepatic impairment",
        "Those under 16 years of age"
      ],
      "side_effect": [
        "Nervousness",
        "Agitation",
        "Irritability",
        "Anxiety",
        "Sleep disturbances",
        "Nausea",
        "Vomiting",
        "Diarrhea",
        "Stomachache",
        "Vertigo",
        "Headache",
        "Trembling",
        "Sexual stimulation"
      ],
      "drug_interaction": [
        "Thyroid extract",
        "Clonazepam",
        "Carbamazepine",
        "Phenyton",
        "Phenobarbitone",
        "Sodium valporate"
      ],
      "preparation": ["800 mg Tablet", "500 mg/5ml Solution"]
    },

    {
      "name": "Nexum®",
     "img_id":"CyPqz9y.jpeg",
      "image": "Nexum-20_l.jpg",
      "active_ingredients": "Esomeprazole",
      "indication": [
        "Gastroesophageal Reflux Disease (GERD)",
        "Healing of Erosive Esophagitis",
        "Maintenance of Healing of Erosive Esophagitis",
        "Symptomatic Gastroesophageal Reflux Disease (GERD)",
        "Risk Reduction of NSAID-associated Gastric Ulcer",
        "H. pylori Eradication (Triple therapy)"
      ],
      "dosage_and_administration": {
        "capsule": {
          "GERD_healing_of_erosive_esophagitis": {
            "dose": "20 mg or 40 mg",
            "frequency": "Once daily for 4 to 8 weeks"
          },
          "GERD_maintenance_of_healing": {
            "dose": "20 mg",
            "frequency": "Once daily"
          },
          "symptomatic_GERD": {
            "dose": "20 mg",
            "frequency": "Once daily for 4 weeks"
          },
          "NSAID_gastric_ulcer_risk_reduction": {
            "dose": "20 mg or 40 mg",
            "frequency": "Once daily for up to 6 months"
          },
          "H_pylori_eradication_triple_therapy": {
            "Esomeprazole": "20 mg twice daily for 10 days",
            "Amoxicillin": "1000 mg twice daily for 10 days",
            "Clarithromycin": "500 mg twice daily for 10 days"
          },
          "paediatric_use": {
            "dose": "20 mg or 40 mg",
            "frequency": "Once daily for up to 8 weeks",
            "additional_notes": "If symptoms do not resolve completely after 4 weeks, an additional 4 weeks of treatment may be considered"
          }
        },
        "injection": {
          "duodenal_ulcer_gastric_ulcer": {
            "dose": "40 mg per day",
            "administration": "Intravenously"
          },
          "reflux_esophagitis": {
            "dose": "20-40 mg per day",
            "administration": "Intravenously"
          },
          "IV_injection_direction": {
            "reconstitution": "Add 5 ml of 0.9% Sodium Chloride Injection to the vial",
            "administration": "Slow intravenous injection over at least 3 minutes",
            "storage": "Room temperature for up to 12 hours"
          },
          "IV_infusion_direction": {
            "reconstitution": "Add 5 ml of 0.9% Sodium Chloride Injection",
            "further_dilution": "Dilute with 5% Dextrose Injection or 0.9% Sodium Chloride or Lactated Ringer’s Injection to a final volume of 50 ml",
            "administration": "Intravenous infusion over 10 to 30 minutes",
            "storage": "Room temperature for up to 12 hours prior to dilution, and 6 hours after dilution with Dextrose"
          }
        }
      },
      "contraindication_and_precaution": [
        "Hypersensitivity to Esomeprazole or any other component of the formulation",
        "Exclude the possibility of malignancy when gastric ulcer is suspected before treatment for dyspepsia"
      ],
      "side_effect": ["Headache", "Diarrhea", "Abdominal pain"],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Use only if clearly needed",
        "lactation": "Esomeprazole is likely to be excreted in human milk. A decision should be made whether to discontinue nursing or the drug based on the importance of the drug to the mother"
      },
      "preparation": ["20 mg Capsule", "40 mg Capsule", "40 mg IV Injection"]
    },
    {
      "name": "Nexum® MUPS Tablet",
     "img_id":"ufXyT1p.jpeg",
      "image": "Nexum-MUPS.jpg",
      "active_ingredients": "Esomeprazole 20 & 40 mg",
      "composition": [
        "Each MUPS tablet contains 20 mg or 40 mg Esomeprazole (as Esomeprazole Magnesium Trihydrate USP)"
      ],
      "MUPS_definition": "MUPS is an abbreviation for Multiple-Unit Pellet System. It refers to tablets prepared by compaction of modified release coated multiparticulates or pellets. This technology combines the advantages of both tablets and pellet-filled capsules in one dosage form.",
      "clinical_advantages": [
        "Greater bioavailability",
        "Uniform emptying of micro pellets from the stomach into the small intestine",
        "Facilitates rapid dissolution of enteric coating and drug release resulting in early tmax and Cmax",
        "Lesser possibility of dose dumping"
      ],
      "indication_and_dosage": {
        "H_pylori_eradication": {
          "dose": "20 mg",
          "frequency": "Twice daily for 7 days",
          "with": ["Amoxicillin", "Clarithromycin"]
        },
        "Zollinger_Ellison_syndrome": {
          "dose": "40 mg to 80 mg",
          "frequency": "Twice daily"
        },
        "GERD": {
          "erosive_esophagitis": {
            "dose": "40 mg",
            "frequency": "Once daily for 4 weeks"
          },
          "maintenance_of_healing": {
            "dose": "20 mg",
            "frequency": "Once daily"
          }
        }
      },
      "paediatric_use": {
        "under_12_years": "Esomeprazole MUPS Tablet is not recommended."
      },
      "administration_instructions": [
        "Swallow the tablet whole or with a glass of water. Do not chew or crush the tablet.",
        "If the patient has trouble swallowing, the tablet can be placed in a glass of water, stirred until disintegrated, and consumed within 30 minutes.",
        "If the patient is unable to swallow, the tablet can be mixed with water and administered via a tube directly into the stomach."
      ],
      "contraindication": [
        "Hypersensitivity to Esomeprazole or any other component of the formulation"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Manufacturer advises caution. No specific information available.",
        "lactation": "It is not known whether Esomeprazole MUPS tablet is excreted in breast milk."
      },
      "side_effect": ["Headache", "Abdominal pain", "Nausea", "Vomiting"],
      "storage": "Store in a cool (below 30°C) and dry place, protected from light and moisture.",
      "preparation": ["20 mg tablet", "40 mg tablet"]
    },
    {
      "name": "Nidipine® SR",
     "img_id":"db06dN9.jpeg",
      "image": "NIDIPIN-SR.jpg",
      "active_ingredients": "Nifedipine",
      "indication": ["Hypertension", "Angina"],
      "dosage_and_administration": {
        "dose": "20 mg",
        "frequency": "Twice daily with food"
      },
      "contraindication_and_precaution": [
        "Cardiogenic shock",
        "Advanced aortic stenosis",
        "Nursing mothers",
        "GI obstruction",
        "Inflammatory bowel disease",
        "Hypotension",
        "Should be swallowed whole, not bitten, chewed, or broken up",
        "Caution in patients with poor cardiac reserve"
      ],
      "side_effect": [
        "Headache",
        "Flushing",
        "Lethargy",
        "Gravitational oedema",
        "Rash",
        "Nausea",
        "Increased frequency of micturition",
        "Eye pain",
        "Gum hyperplasia",
        "Depression",
        "Tremor",
        "Photosensitivity",
        "Few cases of jaundice"
      ],
      "drug_interaction": [
        "ACE inhibitors",
        "Anti-arrhythmics",
        "Anti-bacterials",
        "Anti-epileptics",
        "Antipsychotics",
        "Beta-blockers",
        "Cyclosporin",
        "Muscle relaxants",
        "Ulcer healing drugs"
      ],
      "use_in_pregnancy": "Should be used only if the potential benefit justifies the potential risk to the fetus.",
      "preparation": ["20 mg SR Tablet"]
    },
    {
      "name": "Nimocal®",
     "img_id":"oMcFjzD.png",
      "image": "nimocal_large.png",
      "active_ingredients": "Nimodipine",
      "indication": [
        "Improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms."
      ],
      "dosage_and_administration": {
        "initial_dose": "60 mg",
        "frequency": "Every four hours for 21 consecutive days",
        "start_time": "Within 96 hours of the subarachnoid hemorrhage"
      },
      "side_effect": [
        "Headache",
        "Dizziness",
        "Flushing",
        "Heartburn",
        "Fast heartbeat",
        "Slow heartbeat",
        "Upset stomach",
        "Stomach pain",
        "Constipation",
        "Depression"
      ],
      "precaution": "Blood pressure should be carefully monitored during treatment.",
      "use_in_pregnancy_and_lactation": "Manufacturer advises caution. There is no information available. It is not known whether Nimodipine is excreted in breast milk.",
      "preparation": ["20 mg Tablet", "40 mg Tablet"]
    },

    {
      "name": "Nomi®",
     "img_id":"amsezrR.png",
      "image": "Nomi.png",
      "active_ingredients": "Zolmitriptan",
      "indication": ["Acute treatment of Migraine with or without aura"],
      "dosage_and_administration": {
        "initial_dose": "One tablet",
        "repeat_dose": "After 2 hours if symptoms persist"
      },
      "contraindication": [
        "History of coronary artery disease (CAD) or coronary vasospasm",
        "History of stroke",
        "Transient ischemic attack",
        "Hemiplegic or basilar migraine"
      ],
      "warnings_and_precautions": [
        "Use cautiously in patients with a history of Myocardial Infarction",
        "Prinzmetal Angina",
        "Arrhythmias"
      ],
      "drug_interaction": [
        "Leave at least 6 hours between taking an ergotamine preparation and starting Zolmitriptan",
        "Avoid concomitant administration of other 5HT1D agonists within 12 hours of Zolmitriptan treatment"
      ],
      "side_effect": [
        "Neck/throat/jaw pain/tightness/pressure",
        "Dizziness",
        "Paresthesia",
        "Asthenia",
        "Somnolence",
        "Warm/cold sensation",
        "Nausea",
        "Heaviness sensation",
        "Dry mouth"
      ],
      "precaution_and_warning": [
        "Wolff-Parkinson-White syndrome",
        "Arrhythmias associated with other cardiac accessory conduction pathways"
      ],
      "preparation": ["2.5 mg Tablet"]
    },
    {
      "name": "Normo-KTM",
     "img_id":"r5wd3s7.jpeg",
      "image": "Normo-K_la.jpg",
      "active_ingredients": "Sodium Polystyrene Sulfonate USP",
      "indication": [
        "Treatment of hyperkalemia",
        "Caused by Acute or Chronic Kidney Disease",
        "Other causes may include Liver failure, Adrenal insufficiency, Use of certain drugs like ARB, ACE inhibitors, Beta blockers or Excessive use of Potassium supplements"
      ],
      "dosage_and_administration": {
        "adults": "15 gm to 60 gm daily (1 Sachet 1-4 times daily)",
        "children": "1 gm/kg body weight daily in divided doses for acute hyperkalemia. For maintenance, reduce to 0.5 gm/kg body weight daily",
        "preparation_note": "Suspension should be freshly prepared and not stored beyond 24 hours"
      },
      "contraindication": [
        "Hypokalemia",
        "History of hypersensitivity to polystyrene sulfonate resins",
        "Obstructive bowel disease",
        "Neonates with reduced gut motility (postoperatively or drug-induced)",
        "Oral administration in neonates"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy_category": "C",
        "pregnancy_warning": "Animal reproduction studies have not been conducted. Should be given only if clearly needed",
        "lactation_warning": "It is unknown if excreted in human milk. Caution should be exercised when administered to nursing women"
      },
      "preparation": [
        "Each box contains 10 sachets",
        "Each sachet contains Sodium Polystyrene Sulfonate USP 15 gm",
        "Sodium content is approximately 100 mg per gm of the drug"
      ]
    },
    {
      "name": "Norpill TM1",
     "img_id":"Np3ZDXZ.jpeg",
      "image": "Norpill-1_e.jpg",
      "active_ingredients": "Levonorgestrel",
      "indication": "Emergency contraceptive to prevent pregnancy following unprotected intercourse or contraceptive failure",
      "dosage_and_administration": {
        "instructions": "Take one tablet orally as soon as possible within 72 hours after unprotected intercourse"
      },
      "contraindication_and_precaution": [
        "Should not be given to pregnant women",
        "Does not protect against HIV infection (AIDS) & other sexually transmitted diseases"
      ],
      "side_effect": [
        "Nausea/vomiting",
        "Abdominal pain",
        "Tiredness",
        "Dizziness",
        "Changes in vaginal bleeding",
        "Breast tenderness",
        "Diarrhea",
        "Headache"
      ],
      "drug_interaction": [
        "Barbiturates",
        "Primidone",
        "Phenytoin",
        "Carbamazepine",
        "Herbal medicines containing Hypericum perforatum (St John's Wort)",
        "Rifampicin",
        "Ritonavir",
        "Rifabutin",
        "Griseofulvin",
        "Levonorgestrel may increase the risk of cyclosporin toxicity due to possible inhibition of cyclosporin metabolism"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy_warning": "Should not be given to pregnant women and will not interrupt the pregnancy",
        "lactation_warning": "Levonorgestrel is secreted into breast milk. To reduce infant exposure, take the tablet immediately after feeding and avoid nursing following each tablet administration"
      },
      "preparation": "1.5 mg Tablet"
    },
    {
      "name": "Norvis®",
     "img_id":"W9bFx83.jpeg",
      "image": "NORVIS.jpg",
      "active_ingredients": "Tiemonium Methylsulphate",
      "indication": [
        "Pain in gastrointestinal, biliary, urinary & gynaecological disease",
        "Gastroenteritis",
        "Diarrhoea",
        "Dysentery",
        "Biliary colic",
        "Enterocolitis",
        "Cholecystitis",
        "Colonopathies",
        "Mild cystitis",
        "Spasmodic dysmenorrhoea"
      ],
      "dosage_and_administration": {
        "tablet": "2-6 tablets (100-300 mg) daily in divided doses",
        "injection": "1 ampoule (5 mg) three times daily, through intravenous route slowly or intramuscular route",
        "syrup": "3 mg-6 mg/body weight/day or 1.5 ml-3 ml, 3 times a day"
      },
      "side_effect": "Very rare",
      "contraindication": [
        "Glaucoma or acute pain of eyeball with vision disturbance",
        "Disorder of prostate or urinary bladder"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy_warning": "May be used in pregnancy only if clearly needed, based on risk-benefit ratio",
        "lactation_warning": "May be used in lactating mothers only if clearly needed, based on risk-benefit ratio"
      },
      "preparation": ["50 mg Tablet", "5 mg/2 ml Injection", "10 mg/5 ml Syrup"]
    },
    {
      "name": "Ocubrom™",
     "img_id":"P3WBNEJ.jpeg",
      "image": "Ocubrom.jpg",
      "product_type": "Eye Drops",
      "active_ingredients": "Bromfenac",
      "indication": [
        "Treatment of postoperative inflammation",
        "Reduction of ocular pain in patients who have undergone cataract surgery"
      ],
      "dosage_and_administration": {
        "adults": "One drop should be applied to the affected eye once daily beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 14 days of the postoperative period.",
        "children": "Use and dose must be determined by the doctor"
      },
      "contraindication_and_precaution": [
        "Hypersensitivity to any ingredient in the formulation"
      ],
      "side_effect": [
        "Abnormal sensation in eye",
        "Conjunctival hyperemia",
        "Eye irritation (including burning/stinging)",
        "Eye pain",
        "Eye pruritus",
        "Eye redness",
        "Headache",
        "Iritis"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy_warning": "USFDA Pregnancy Category C. This drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.",
        "lactation_warning": "Caution should be exercised when Bromfenac ophthalmic solution is administered to a nursing woman."
      },
      "use_in_pediatric": "Safety and efficacy in pediatric patients below the age of 18 have not been established yet.",
      "preparation": [
        "Each LDPE container contains 5 ml of Bromfenac 0.07% sterile solution"
      ]
    },
    {
      "name": "Oculant™",
     "img_id":"7ePtOkE.jpeg",
      "image": "Oculant_l.jpg",
      "product_type": "Eye Drops",
      "active_ingredients": [
        "Polyethylene Glycol 400 BP 0.4%",
        "Propylene Glycol BP 0.3%"
      ],
      "indication": [
        "Temporary relief of burning & irritation due to dryness of the eye"
      ],
      "dosage_and_administration": {
        "adults_and_children_over_6": "Instill 1 or 2 drops in the affected eye(s) as needed or as directed by the physician.",
        "children_under_6": "Ask a doctor"
      },
      "contraindication_and_precaution": [
        "Hypersensitivity to any of the components of the medication",
        "May temporarily cause blurred vision right after being placed in the eye(s)",
        "Never touch the tip of the container with any surface to avoid contamination and replace cap after each use"
      ],
      "side_effect": "Generally well tolerated. Should not be used if allergic condition occurs to any ingredients of the product.",
      "use_in_pregnancy_and_lactation": {
        "pregnancy_warning": "Due to the negligible systemic exposure and the lack of pharmacological activity, this medication can be used during pregnancy.",
        "lactation_warning": "It is not known whether this medication is excreted in human milk. Caution should be exercised when this product is applied to a nursing woman."
      },
      "use_in_children": "Safety & efficacy in pediatric patients have not been established.",
      "preparation": [
        "Each plastic dropper bottle contains 10 ml of Polyethylene Glycol 400 BP 0.4% & Propylene Glycol BP 0.3% sterile solution"
      ]
    },
    {
      "name": "Ocof™",
     "img_id":"UWWiUpx.jpeg",
      "image": "Ocof.jpg",
      "active_ingredients": [
        "Dextromethorphan",
        "Phenylephrine",
        "Triprolidine"
      ],
      "indication": [
        "Symptomatic relief of upper respiratory tract disorders accompanied by non-productive cough",
        "Benefits from nasal decongestant, histamine H1-receptor antagonist, and antitussive combination"
      ],
      "dosage_and_administration": {
        "adults_and_children_over_12": "1 teaspoonful 4 times a day",
        "children_6_12_years": "1/2 teaspoonful 4 times a day",
        "children_under_6": "A physician’s advice should be obtained before administering this combination"
      },
      "contraindication": [
        "Known hypersensitivity to Dextromethorphan, Phenylephrine or Triprolidine",
        "Patients under treatment with Monoamine Oxidase Inhibitor within 2 weeks of stopping such treatment"
      ],
      "side_effect": [
        "Drowsiness (rare)",
        "Prostatic enlargement could have been a predisposing factor"
      ],
      "precaution": [
        "May cause drowsiness and impair the ability to drive or use machinery",
        "Avoid concomitant use of alcohol or other centrally acting sedatives",
        "Caution in patients with hypertension, heart disease, diabetes, hyperthyroidism, elevated intraocular pressure, and prostatic enlargement",
        "Should not be used for persistent or chronic cough unless directed by a physician"
      ],
      "use_in_pregnancy_and_lactation": {
        "warning": "There are no specific data on use of this combination during pregnancy & lactation"
      },
      "preparation": ["100 ml syrup"]
    },
    {
      "name": "Ofran®",
     "img_id":"xIF6Xu5.jpeg",
      "image": "OFRAN-50ML.jpg",
      "active_ingredients": "Ondansetron",
      "indication": [
        "Prevention of nausea & vomiting associated with highly emetogenic cancer chemotherapy",
        "Prevention of nausea & vomiting associated with radiotherapy",
        "Prevention of post operative nausea & vomiting"
      ],
      "dosage_and_administration": {
        "chemotherapy_induced_nausea_vomiting": {
          "adult": "24 mg (three 8 mg tablets) in highly emetogenic chemotherapy; one 8 mg tablet or 10 ml of oral solution twice daily for moderately emetogenic chemotherapy",
          "pediatric": "One 4 mg tablet or 5 ml of oral solution 3 times a day for 1 to 2 days after chemotherapy (for 4 to 11 years of age)"
        },
        "radiotherapy_induced_nausea_vomiting": {
          "adult": "One 8 mg tablet or 10 ml of oral solution 3 times daily"
        },
        "post_operational_nausea_vomiting": {
          "adult": "16 mg (two 8 mg tablets or 20 ml of oral solution) 1 hour before induction of anesthesia"
        },
        "dosage_adjustment_hepatic_function": "The total daily dose should not exceed 8 mg"
      },
      "contraindication": [
        "Known hypersensitivity to Ondansetron",
        "Hypersensitivity reactions to other 5-HT3 receptor antagonists",
        "Should not be used instead of nasogastric suction in certain conditions",
        "May mask a progressive ileus and/or gastric distension in certain patients"
      ],
      "precaution": [
        "Should not be used to stimulate gastric or intestinal peristalsis"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy_warning": "Pregnancy category B, should be used only if clearly needed",
        "lactation_warning": "Excreted in milk of lactating animals, caution should be exercised when administered to nursing mothers"
      },
      "preparation": [
        "8 mg Tablet",
        "4 mg/5 ml (50 ml) Solution",
        "8 mg/4 ml Injection"
      ]
    },
    {
      "name": "Olistat™",
     "img_id":"zoryp42.jpeg",
      "image": "Olistat_60.jpg",
      "active_ingredients": "Orlistat",
      "indication": ["Overweight & Obesity management"],
      "dosage_and_administration": {
        "adult": "One capsule 3 times daily with each main meal containing fat before, during, or within 1 hour of the meal"
      },
      "contraindication": [
        "Pregnancy",
        "Chronic malabsorption syndrome",
        "Cholestasis",
        "Known hypersensitivity to Orlistat or any component of the product"
      ],
      "precaution": [
        "Cyclophosphamide should not be taken simultaneously with Orlistat; at least 3 hours gap is required",
        "Patients should take a multivitamin supplement containing fat-soluble vitamins",
        "Monitor liver function tests if any hepatic dysfunction symptoms appear",
        "Patients at risk for renal impairment should be monitored for increased urinary oxalate",
        "Substantial weight loss can increase the risk of cholelithiasis",
        "Organic causes of obesity should be excluded before prescribing Orlistat",
        "Dietary guidelines should be adhered to, with a balanced fat intake"
      ],
      "side_effect": [
        "Oily spotting",
        "Flatus with discharge",
        "Fecal urgency",
        "Fatty/oily stool",
        "Oily evacuation",
        "Increased defecation",
        "Fecal incontinence"
      ],
      "drug_interaction": {
        "cyclosporine": "Reduced plasma levels of cyclosporine when Orlistat is coadministered. Cyclosporine should be taken 3 hours after Orlistat",
        "fat_soluable_vitamins": "Reduced absorption of beta-carotene and vitamin E acetate supplements, effect on vitamin D, A, and K not fully known",
        "levothyroxine": "Monitor thyroid function in patients co-administered with Orlistat, and administer at least 4 hours apart",
        "warfarin": "Monitor closely for changes in coagulation parameters due to reduced vitamin K absorption"
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy_warning": "Pregnancy Category X. Contraindicated during pregnancy as weight loss offers no benefit and may harm the fetus",
        "lactation_warning": "Not known if Orlistat is present in human milk. Caution should be exercised when administered to nursing women"
      },
      "use_in_children": "Safety & effectiveness in pediatric patients below 12 years of age have not been established",
      "preparation": ["60 mg Capsule", "120 mg Capsule"]
    },
    {
      "name": "Olmecar™",
     "img_id":"dEMqLLJ.jpeg",
      "image": "Olmecar-40_l.jpg",
      "active_ingredients": "Olmesartan Medoxomil",
      "indication": [
        "Treatment of hypertension",
        "May be used alone or in combination with other antihypertensive agents"
      ],
      "dosage_and_administration": {
        "starting_dose": "20 mg once daily for patients not volume-contracted",
        "dose_increase": "After 2 weeks, increase to 40 mg if further blood pressure reduction is needed",
        "maximum_dose": "Doses above 40 mg do not show greater effect",
        "dosing_frequency": "Once daily, as twice-daily dosing offers no advantage"
      },
      "contraindication": ["Hypersensitivity to any component of this product"],
      "side_effect": [
        "Back pain",
        "Bronchitis",
        "Increased creatine phosphokinase",
        "Diarrhea",
        "Headache",
        "Hematuria",
        "Hyperglycemia",
        "Hypertriglyceridemia",
        "Influenza-like symptoms",
        "Pharyngitis",
        "Rhinitis",
        "Sinusitis"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy_warning": "Pregnancy Category D. Contraindicated during pregnancy due to potential harm to the fetus",
        "lactation_warning": "Not known if Olmesartan is excreted in human milk. Secreted at low concentrations in lactating rats. Decision to discontinue nursing or the drug should be made, considering the importance of the drug to the mother"
      },
      "use_in_children": "Safety & Effectiveness in pediatric patients have not been established",
      "preparation": ["20 mg Tablet", "40 mg Tablet"]
    },
    {
      "name": "Olmecar™ Plus",
     "img_id":"BXoVPBs.jpeg",
      "image": "Olmecar-Plus_l.jpg",
      "active_ingredients": ["Olmesartan Medoxomil", "Hydrochlorothiazide"],
      "indication": "Indicated for the treatment of hypertension. Not for initial therapy.",
      "dosage_and_administration": {
        "starting_dose": "One tablet once daily",
        "combination_use": "May be administered with other antihypertensive agents",
        "dose_titration": "Dosing should be individualized, with titration at intervals of 2-4 weeks depending on blood pressure response",
        "hydrochlorothiazide_adjustment": "For inadequate control by Olmesartan alone, Hydrochlorothiazide may be added starting with 12.5 mg, later titrated to 25 mg once daily",
        "olmecar_plus_adjustment": "If a patient is on Hydrochlorothiazide, Olmesartan can be added starting with 20 mg once daily, titrated to 40 mg for better control",
        "caution": "Caution should be used in patients with volume depletion or hyponatremia, reducing Hydrochlorothiazide to 12.5 mg before adding Olmesartan"
      },
      "contraindication": [
        "Hypersensitivity to any component of this product",
        "Anuria",
        "Hypersensitivity to other sulfonamide-derived drugs"
      ],
      "side_effect": [
        "Headache",
        "Urinary tract infection",
        "Chest pain",
        "Back pain",
        "Peripheral edema",
        "Vertigo",
        "Abdominal pain",
        "Dyspepsia",
        "Gastroenteritis",
        "Diarrhea",
        "Increased SGOT",
        "Increased GGT",
        "Increased SGPT",
        "Hyperlipidemia",
        "Increased creatine phosphokinase",
        "Hyperglycemia",
        "Arthritis",
        "Arthralgia",
        "Myalgia",
        "Coughing",
        "Rash"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy_warning": "Pregnancy Category D. Should not be used during pregnancy.",
        "lactation_warning": "Olmesartan and Thiazides appear in human milk. Decision to discontinue nursing or the drug should be made based on the drug's importance to the mother."
      },
      "use_in_children": "Safety & Effectiveness in pediatric patients have not been established.",
      "preparation": [
        "Olmesartan Medoxomil 20 mg & Hydrochlorothiazide 12.5 mg"
      ]
    },
    {
      "name": "Oni™",
     "img_id":"ozsZBrb.jpeg",
      "image": "Oni.jpg",
      "active_ingredients": ["Betamethasone Dipropionate", "Clotrimazole"],
      "indication": "Inflammatory dermal infections like tinea pedis, tinea cruris, tinea corporis, etc.",
      "dosage_and_administration": {
        "recommended_dosage": "Twice a day for 2-4 weeks"
      },
      "contraindication": [
        "Hypersensitivity",
        "Facial rosacea",
        "Acne vulgaris",
        "Perioral dermatitis",
        "Perianal & genital pruritus",
        "Napkin eruptions",
        "Bacterial or viral infections"
      ],
      "precaution": [
        "Systemic absorption may lead to HPA axis suppression",
        "Pediatric patients may be more susceptible to systemic toxicity due to their large skin surface to body mass ratios"
      ],
      "side_effect": [
        "Paresthesia",
        "Rash",
        "Edema",
        "Secondary infection",
        "Burning",
        "Dry skin"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy_warning": "Use only if the benefit justifies the potential risk to the fetus",
        "lactation_warning": "Caution should be exercised when treating nursing mothers"
      },
      "use_in_children": "Not recommended for children under 12 years",
      "preparation": ["10 gm Cream"]
    },
    {
      "name": "Orostar™",
     "img_id":"xi9o323.jpeg",
      "image": "Orostar.jpg",
      "active_ingredients": [
        "Menthol",
        "Thymol",
        "Eucalyptol",
        "Methyl Salicylate"
      ],
      "indication": ["Dental Plaque", "Gingivitis", "Bad breath"],
      "dosage_and_administration": {
        "recommended_dosage": "Rinse with 20 ml Orostar Antiseptic Mouthwash for 30 seconds, twice daily (morning & evening). Then rinse with water. Do not swallow."
      },
      "contraindication_and_precaution": [
        "If more than used for rinsing is accidentally swallowed, consult with a doctor."
      ],
      "use_in_children": "Not indicated for children below 12 years of age",
      "preparation": ["Orostar Cool Mint: 120 ml PET container"]
    },
    {
      "name": "Orostar™ Plus",
     "img_id":"8wfuUXS.jpeg",
      "image": "Orostar-Plus_l.jpg",
      "active_ingredients": [
        "Eucalyptol",
        "Menthol",
        "Methyl Salicylate",
        "Thymol",
        "Sodium Fluoride"
      ],
      "indication": [
        "Dental cavities/Tooth decay",
        "Bad breath",
        "Dental plaque",
        "Gingivitis"
      ],
      "dosage_and_administration": {
        "adults_and_children_6_years_and_older": "Use once a day after brushing teeth with toothpaste by vigorously swishing 10ml (as indicated inside cap) or rinse between teeth for 1 minute, then spit out. Do not swallow.",
        "children_under_6_years": "Use according to the consultancy of dentist or physician."
      },
      "precaution": [
        "Should not eat or drink for 30 minutes after rinsing.",
        "Children under 12 years of age should be instructed in good rinsing habits to minimize swallowing.",
        "Children should be supervised in rinsing as necessary until they are capable of using without supervision.",
        "If more than the amount used for rinsing is accidentally swallowed, physicians should be contacted immediately."
      ],
      "drug_interaction": "No drug interaction has been reported.",
      "use_in_pregnancy_and_lactation": "It is safe to use during pregnancy.",
      "use_in_children": "According to the consultancy of dentist or physician.",
      "preparation": [
        "Orostar™ Plus 250 ml: Each PET bottle contains 250 ml mouthwash with a measuring cup.",
        "Orostar™ Plus 120 ml: Each PET bottle contains 120 ml mouthwash with a measuring cup."
      ]
    },
    {
      "name": "Osmolax™",
     "img_id":"aQPdQ3Z.jpeg",
      "image": "Osmolax.jpg",
      "active_ingredients": "Lactulose",
      "indication": ["Constipation", "Hepatic encephalopathy"],
      "dosage_and_administration": {
        "constipation": {
          "adults_and_elders": "15 ml twice daily",
          "children_5_to_10_years": "10 ml twice daily",
          "children_under_5_years": "5 ml twice daily",
          "children_under_1_year": "2.5 ml twice daily"
        },
        "hepatic_encephalopathy": {
          "adults_and_elders": "Initially 30-50 ml three times a day, adjust dose to produce two or three soft stools each day",
          "children": "No dosage recommended"
        },
        "notes": "It may take up to 48 hours before effects are obtained. Clinical experience shows that the medicament may allow gradual dose reduction over time. A maintenance dose of 15 ml per day provides 14 kilocalories and is unlikely to adversely affect diabetic patients."
      },
      "contraindication_and_precaution": [
        "Galactosaemia",
        "Gastro-intestinal obstruction",
        "Lactose intolerance"
      ],
      "side_effect": ["Meteorism and increased flatulence", "Diarrhoea"],
      "use_in_pregnancy": "If laxative therapy is needed in pregnancy, use of this drug is acceptable.",
      "preparation": "3.4 gm/5 ml Solution"
    },
    {
      "name": "OstelTM-D",
     "img_id":"TA5Gb9p.jpeg",
      "image": "AUSTIL-D.jpg",
      "active_ingredients": [
        "Sodium Alendronate",
        "Vitamin D3 (Colecalciferol)"
      ],
      "indications": [
        {
          "condition": "Osteoporosis in Postmenopausal Women",
          "description": "For the treatment of osteoporosis, Ostel-D increases bone mass and reduces the incidence of fractures, including those of the hip and spine."
        },
        {
          "condition": "Increase Bone Mass in Men with Osteoporosis",
          "description": "For the treatment to increase bone mass in men with osteoporosis."
        }
      ],
      "dosage_and_administration": {
        "postmenopausal_women_osteoporosis": [
          {
            "form": "Ostel-D 70/2800 tablet",
            "frequency": "once weekly"
          },
          {
            "form": "Ostel-D 10/400 tablet",
            "frequency": "once daily"
          }
        ],
        "men_osteoporosis": [
          {
            "form": "Ostel-D 70/2800 tablet",
            "frequency": "once weekly"
          },
          {
            "form": "Ostel-D 10/400 tablet",
            "frequency": "once daily"
          }
        ],
        "administration_instructions": {
          "timing": "Take at least 30 minutes before the first food, beverage, or medication of the day with plain water only.",
          "absorption_note": "Other beverages (including mineral water), food, and some medications may reduce Alendronate absorption.",
          "delivery": "Swallow upon rising for the day with a full glass of water to facilitate delivery to the stomach and reduce esophageal irritation.",
          "post_dose_instructions": "Do not lie down for at least 30 minutes after taking until after the first food of the day. Do not chew or suck on the tablet.",
          "restriction": "Do not take at bedtime."
        }
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "Abnormalities of the esophagus which delay esophageal emptying (e.g., stricture or achalasia)",
          "Inability to stand or sit upright for at least 30 minutes",
          "Hypersensitivity to any component of this product",
          "Hypocalcaemia"
        ],
        "precautions": [
          "Correct hypocalcaemia and other mineral metabolism disturbances before starting therapy.",
          "Alendronate may cause local irritation of the upper gastrointestinal mucosa.",
          "Use caution in patients with active upper gastrointestinal problems (e.g., dysphagia, esophageal disease, gastritis, duodenitis, or ulcers).",
          "Stop taking and consult a physician if esophageal diseases develop.",
          "No dosage adjustment needed for elderly or patients with mild-to-moderate renal insufficiency (creatinine clearance 35 to 60 ml/min).",
          "Not recommended for severe renal insufficiency (creatinine clearance < 35 ml/min)."
        ]
      },
      "side_effects": [
        "Esophageal reactions",
        "Abdominal pain and distension",
        "Diarrhoea or constipation",
        "Flatulence",
        "Musculoskeletal pain",
        "Headache",
        "Rash",
        "Erythema",
        "Transient decreases in serum calcium and phosphate"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": {
          "category": "C",
          "warning": "Overdoses of vitamin D have shown teratogenic effects in pregnant animals. Use only if the potential benefit justifies the potential risk to the mother and fetus."
        },
        "lactation": {
          "note": "Colecalciferol and some active metabolites pass into breast milk. Unknown if alendronate is excreted in human milk. Exercise caution when administering to lactating women."
        }
      },
      "preparation": {
        "form": "70/2800 Tablet"
      }
    },
    {
      "name": "Oxapro®",
     "img_id":"NKV5c5H.jpeg",
      "image": "Oxapro-5.jpg",
      "active_ingredients": "Escitalopram",
      "indications": [
        "Major Depressive Disorder (MDD)",
        "Generalized Anxiety Disorder (GAD)"
      ],
      "dosage_and_administration": {
        "population": ["Adults", "Adolescents (12-17 years)"],
        "dosage": "10 mg once daily"
      },
      "contraindications": [
        "Known hypersensitivity to Escitalopram or Citalopram",
        "Concomitant use with Monoamine Oxidase Inhibitors",
        "Concomitant use with Pimozide"
      ],
      "warnings_and_precautions": [
        "Monitor for clinical worsening, suicidality, and unusual changes in behavior during the initial few months of therapy or at times of dose changes.",
        "Prescribe with care in patients with a history of mania and seizure disorder."
      ],
      "side_effects": [
        "Insomnia",
        "Ejaculation disorder (primarily ejaculatory delay)",
        "Nausea",
        "Increased sweating",
        "Fatigue",
        "Somnolence",
        "Decreased libido"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": {
          "category": "C",
          "warning": "Use only if the potential benefit justifies the potential risk to the fetus."
        },
        "lactation": {
          "note": "Escitalopram is excreted in human breast milk. Caution should be exercised when administered to a nursing woman."
        }
      },
      "preparation": ["5 mg Tablet", "10 mg Tablet"]
    },
    {
      "name": "Oxat® 20",
     "img_id":"FOdIcGj.jpeg",
      "image": "Oxat-20.jpg",
      "active_ingredients": "Paroxetine",
      "indications": [
        "Major Depressive Disorder",
        "Obsessive Compulsive Disorder",
        "Panic Disorder",
        "Social Anxiety Disorder",
        "Generalized Anxiety Disorder",
        "Post-traumatic Stress Disorder",
        "Premature Ejaculation"
      ],
      "dosage_and_administration": {
        "recommended_dosage": "20 mg/day"
      },
      "contraindications": [
        "Known hypersensitivity to Paroxetine",
        "Concomitant use with Monoamine Oxidase Inhibitors",
        "Concomitant use with Thioridazine",
        "Concomitant use with Pimozide"
      ],
      "warnings_and_precautions": [
        "Monitor for clinical worsening, suicidality, and unusual changes in behavior during the initial few months of therapy or at times of dose changes.",
        "Prescribe with care in patients with a history of mania and seizure disorder."
      ],
      "drug_interactions": [
        "Serotonergic Drugs",
        "Drugs Metabolized by Cytochrome P450",
        "Tamoxifen",
        "Phenobarbital"
      ],
      "side_effects": [
        "Asthenia",
        "Sweating",
        "Nausea",
        "Decreased appetite",
        "Somnolence",
        "Dizziness",
        "Insomnia",
        "Tremor",
        "Nervousness",
        "Ejaculatory disturbance",
        "Other male genital disorders",
        "Dry mouth",
        "Constipation",
        "Impotence",
        "Female genital disorders"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": {
          "category": "D",
          "warning": "Use with caution as there is evidence of risk to the fetus."
        },
        "lactation": {
          "note": "Paroxetine is excreted in human breast milk. Caution should be exercised when administered to a nursing woman."
        }
      },
      "preparation": ["20 mg Tablet"]
    },
    {
      "name": "Oxifun®",
     "img_id":"rtS107X.jpeg",
      "image": "oxifun_lotion.jpg",
      "active_ingredients": "Oxiconazole 1%",
      "indications": [
        {
          "condition": "Tinea pedis, Tinea cruris, Tinea corporis",
          "causative_organisms": [
            "Trichophyton rubrum",
            "Trichophyton mentagrophytes",
            "Epidermophyton floccosum"
          ]
        },
        {
          "condition": "Tinea (pityriasis) versicolor",
          "causative_organism": "Malassezia furfur"
        }
      ],
      "dosage_and_administration": {
        "application": {
          "Tinea pedis, Tinea corporis, Tinea cruris": {
            "form": ["Lotion", "Cream"],
            "frequency": "once to twice daily",
            "duration": {
              "Tinea corporis": "2 weeks",
              "Tinea cruris": "2 weeks",
              "Tinea pedis": "1 month"
            }
          },
          "Tinea (pityriasis) versicolor": {
            "form": "Cream",
            "frequency": "once daily",
            "duration": "2 weeks"
          }
        },
        "instructions": "Apply to affected and immediate surrounding areas."
      },
      "contraindications_and_precautions": {
        "contraindications": ["Previous hypersensitivity to Oxiconazole"],
        "precautions": []
      },
      "side_effects": [
        "Pruritus",
        "Burning",
        "Irritation",
        "Allergic contact dermatitis",
        "Folliculitis",
        "Erythema",
        "Papules",
        "Fissure",
        "Maceration",
        "Rash",
        "Stinging",
        "Nodules"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": {
          "category": "B",
          "warning": "Use with caution as there are no adequate and well-controlled studies in pregnant women."
        },
        "lactation": {
          "note": "Oxiconazole Nitrate is excreted in human milk. Caution should be exercised when administered to a nursing woman."
        }
      },
      "preparation": ["30 ml Lotion", "10 gm Cream"]
    },
    {
      "name": "Oxifyl® CR",
     "img_id":"Subjvsa.jpeg",
      "image": "OXIFYL-CR.jpg",
      "active_ingredients": "Pentoxifylline",
      "indications": [
        "Peripheral vascular disease evident as intermittent claudication",
        "Venous leg ulcers"
      ],
      "dosage_and_administration": {
        "dosage": "One tablet (400 mg) two to three times a day with meals",
        "duration": "At least 8 weeks"
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "Recent cerebral and/or retinal hemorrhage",
          "Previous intolerance to Pentoxifylline or methylxanthines (e.g., caffeine, theophylline, theobromine)"
        ],
        "precautions": [
          "Patients on warfarin should have frequent monitoring of prothrombin times.",
          "Patients with risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration, cerebral and/or retinal bleeding) should have periodic examinations for bleeding, including hematocrit and/or hemoglobin."
        ]
      },
      "side_effects": [
        "Dyspnea",
        "Edema",
        "Hypotension",
        "Anorexia",
        "Cholecystitis",
        "Constipation",
        "Dry mouth/thirst",
        "Anxiety",
        "Confusion",
        "Depression",
        "Seizures",
        "Epistaxis",
        "Flu-like symptoms",
        "Laryngitis",
        "Nasal congestion",
        "Brittle fingernails",
        "Pruritus",
        "Rash",
        "Urticaria",
        "Angioedema",
        "Blurred vision",
        "Conjunctivitis",
        "Earache",
        "Scotoma",
        "Bad taste",
        "Excessive salivation",
        "Leukopenia",
        "Malaise",
        "Sore throat/swollen neck glands",
        "Weight change"
      ],
      "drug_interactions": ["Warfarin", "Theophylline"],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": {
          "warning": "Use during pregnancy only if the potential benefit justifies the potential risk to the fetus."
        },
        "lactation": {
          "note": "Due to potential tumorigenicity shown in rats, a decision should be made whether to discontinue nursing or discontinue the drug, considering the importance of the drug to the mother."
        }
      },
      "preparation": ["400 mg CR (Controlled Release) Tablet"]
    },
    {
      "name": "PalosetTM",
     "img_id":"qcVMsSh.jpeg",
      "image": "Paloset.jpg",
      "active_ingredients": "Palonosetron",
      "indications": [
        {
          "condition": "Chemotherapy Induced Nausea & Vomiting",
          "details": [
            {
              "type": "Moderately emetogenic cancer chemotherapy",
              "use": "Prevention of acute & delayed nausea & vomiting associated with initial & repeat courses"
            },
            {
              "type": "Highly emetogenic cancer chemotherapy",
              "use": "Prevention of acute nausea & vomiting associated with initial & repeat courses"
            }
          ]
        },
        {
          "condition": "Postoperative Nausea & Vomiting",
          "use": "Prevention of postoperative nausea & vomiting (PONV) for up to 24 hours following surgery"
        }
      ],
      "dosage_and_administration": {
        "chemotherapy_induced_nausea_vomiting": {
          "adults": {
            "dosage": "0.25 mg IV",
            "administration": "Single dose over 30 seconds, approximately 30 minutes before the start of chemotherapy"
          },
          "children": {
            "age_range": "1 month to 17 years",
            "dosage": "20 micrograms/kg IV",
            "administration": "Single dose over 15 minutes, approximately 30 minutes before the start of chemotherapy"
          }
        },
        "postoperative_nausea_vomiting": {
          "adults": {
            "dosage": "0.075 mg IV",
            "administration": "Single dose over 10 seconds, immediately before the induction of anesthesia"
          },
          "children": {
            "age_range": "1 month to 17 years",
            "note": "Not recommended"
          }
        }
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "Known hypersensitivity to Palonosetron or any of its components"
        ],
        "precautions": [
          "Hypersensitivity reactions, including anaphylaxis, have been reported with or without known hypersensitivity to other selective 5-HT3 receptor antagonists"
        ]
      },
      "side_effects": {
        "chemotherapy_induced_nausea_vomiting": ["Headache", "Constipation"],
        "postoperative_nausea_vomiting": ["QT prolongation"]
      },
      "drug_interactions": [
        "No potential or clinically significant drug interactions with Palonosetron were found"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": {
          "category": "B",
          "warning": "No adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed."
        },
        "lactation": {
          "note": "It is not known whether Palonosetron is excreted in human milk."
        }
      },
      "use_in_children": {
        "note": "Can be used in children from 1 month for chemotherapy-induced nausea and vomiting. Not recommended for postoperative nausea and vomiting."
      },
      "preparation": ["0.075 mg IV Injection", "0.5 mg Tablet"]
    },
    {
      "name": "Penrif®",
     "img_id":"LF4M8FY.jpeg",
      "image": "penrif_30_l.jpg",
      "active_ingredients": [
        "Methyl salicylate (Oil of Wintergreen)",
        "Menthol"
      ],
      "indications": [
        "Joint pain and inflammation",
        "Muscle pain",
        "Backache",
        "Minor arthritis"
      ],
      "dosage_and_administration": {
        "application": "Apply to affected areas not more than 3 to 4 times daily"
      },
      "warnings": [
        "For external use only",
        "Do not use with a heating pad",
        "Do not swallow",
        "Do not bandage tightly",
        "Keep away from eyes, mucous membranes, broken or irritated skin",
        "Discontinue use and consult a physician if skin redness or excessive irritation develops, pain lasts for more than 10 days, or with arthritis-like conditions in children under 12"
      ],
      "preparation": [
        "Topical formulation (specific preparation details not fully provided)"
      ]
    },
    {
      "name": "PentadolTM",
     "img_id":"q3c6dDm.jpeg",
      "image": "Pentadol.jpeg",
      "active_ingredients": "Tapentadol, HCl",
      "indication": "Relief of moderate to severe acute pain in patients 18 years of age or older",
      "dosage_and_administration": {
        "dosage": [
          {
            "amount": ["50 mg", "75 mg", "100 mg"],
            "frequency": "Every 4 to 6 hours depending upon pain intensity"
          },
          {
            "first_day": "Second dose may be administered as soon as one hour after the first dose if adequate pain relief is not attained",
            "subsequent_dosing": "50 mg, 75 mg, or 100 mg every 4 to 6 hours, adjusted to maintain adequate analgesia with acceptable tolerability"
          }
        ],
        "maximum_daily_dose": {
          "first_day": "700 mg",
          "subsequent_days": "600 mg",
          "note": "Doses greater than these have not been studied and are not recommended"
        }
      },
      "use_in_special_populations": {
        "renal_disease": {
          "severe_impairment": "Safety and effectiveness of Tapentadol have not been established"
        },
        "hepatic_disease": {
          "moderate_impairment": "Use with caution",
          "severe_impairment": "Not studied, use not recommended"
        }
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "Impaired pulmonary function",
          "Acute or severe bronchial asthma or hypercapnia in unmonitored settings or absence of resuscitative equipment",
          "Patients with or suspected of having paralytic ileus"
        ],
        "precautions": [
          "Use with caution in patients with conditions accompanied by hypoxia, hypercapnia, or respiratory problems such as asthma, chronic obstructive pulmonary disease",
          "Use with caution in patients with sleep apnea syndrome, myxedema, kyphoscoliosis, or CNS depression",
          "Consider alternative non-mu-opioid agonist analgesics or use Tapentadol under careful medical supervision at the lowest effective dose"
        ]
      },
      "side_effects": [
        "Increase/decrease heart rate",
        "Visual disturbance",
        "Abdominal discomfort",
        "Impaired gastric emptying",
        "Irritability",
        "Edema",
        "Drug withdrawal syndrome",
        "Hypersensitivity",
        "Involuntary muscle contractions",
        "Sensation of heaviness",
        "Hypoesthesia",
        "Paresthesia",
        "Disturbance in attention",
        "Sedation",
        "Dysarthria",
        "Memory impairment",
        "Ataxia",
        "Presyncope",
        "Syncope",
        "Coordination abnormal",
        "Seizure",
        "Urticaria",
        "Decreased blood pressure"
      ],
      "drug_interactions": [
        "Mu-opioid agonist analgesics",
        "General anesthetics",
        "Phenothiazines",
        "Tranquilizers",
        "Sedatives",
        "Hypnotics",
        "Other CNS depressants (including alcohol)",
        "Note: May exhibit additive CNS depression"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": {
          "category": "C",
          "warning": "No adequate and well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus.",
          "neonatal_monitoring": "Monitor neonates for respiratory depression if mothers have been taking Tapentadol"
        },
        "lactation": {
          "note": "No information provided on excretion in human milk"
        }
      },
      "preparation": ["50 mg Tablet", "75 mg Tablet", "100 mg Tablet"]
    },
    {
      "name": "Penvik®",
     "img_id":"y4EMV2V.jpeg",
      "image": "Penvik-Forte.jpg",
      "active_ingredients": "Phenoxymethyl Penicillin",
      "indications": [
        "Streptococcal infections",
        "Scarlet fever",
        "Mild erysipelas",
        "Bacterial endocarditis",
        "Lobar pneumonia"
      ],
      "dosage_and_administration": {
        "dosage": "250 to 500 mg every 6 hours"
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "Known hypersensitivity to Phenoxymethyl Penicillin",
          "Severe acute infections"
        ],
        "precautions": []
      },
      "side_effects": [
        "Diarrhoea",
        "Abdominal discomfort",
        "Nausea",
        "Vomiting",
        "Spontaneous petechial hemorrhages",
        "Serum sickness"
      ],
      "drug_interactions": [
        "Zinc oxide",
        "Magnesium oxide",
        "Magnesium carbonate",
        "Calamine",
        "Aspirin",
        "Sulphamethoxypyridazine",
        "Sulphaethidole",
        "Aminoglycosides"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": {
          "note": "No contraindication to the use of penicillin in pregnancy"
        },
        "lactation": {
          "note": "No specific information provided"
        }
      },
      "preparation": [
        "250 mg Tablet",
        "500 mg DS Tablet",
        "100 ml (250 mg/5 ml) Forte Powder for Suspension"
      ]
    },
    {
      "name": "Perkidopa™",
     "img_id":"G6HZoxf.jpeg",
      "image": "Perkidopa.jpg",
      "active_ingredients": ["Levodopa", "Carbidopa"],
      "indications": [
        "Parkinson’s disease",
        "Post-encephalitic Parkinsonism",
        "Symptomatic Parkinsonism following carbon monoxide intoxication",
        "Symptomatic Parkinsonism following manganese intoxication"
      ],
      "dosage_and_administration": {
        "initial_dosage": {
          "form": "Perkidopa™ 110",
          "dosage": "One tablet three or four times a day",
          "titration": "Increase by one tablet every day or every other day until a total of eight tablets (2 tablets q.i.d.) is reached"
        },
        "maintenance_dosage": {
          "note": "Individualize and adjust according to therapeutic response",
          "substitution": {
            "form": "Perkidopa™ 275",
            "condition": "When more levodopa is required",
            "titration": "Increase by one-half or one tablet every day or every other day to a maximum of eight tablets a day"
          },
          "carbidopa_limit": "Experience with total daily dosages of carbidopa greater than 200 mg is limited"
        }
      },
      "contraindications": [
        "Concomitant use with nonselective monoamine oxidase (MAO) inhibitors (discontinue MAO inhibitors at least two weeks prior to initiating therapy)",
        "Known hypersensitivity to any component of the drug",
        "Narrow-angle glaucoma"
      ],
      "precautions": [
        "Associated with dyskinesias, which may require dosage reduction",
        "Administer cautiously to patients with severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic, or endocrine disease"
      ],
      "adverse_reactions": [
        "Dyskinesias (choreiform, dystonic, and other involuntary movements)",
        "Nausea"
      ],
      "use_in_special_populations": {
        "pregnancy": {
          "category": "C",
          "warning": "Use only if the potential benefit justifies the potential risk to the fetus"
        },
        "nursing_mothers": {
          "note": "Levodopa has been detected in human milk. Caution should be exercised when administered to a nursing woman"
        },
        "pediatric_use": {
          "note": "Safety and effectiveness in pediatric patients have not been established. Not recommended for patients below the age of 18"
        }
      },
      "preparation": [
        "Perkidopa™ 110 Tablet: 30 tablets in blister pack",
        "Perkidopa™ 275 Tablet: 30 tablets in blister pack"
      ]
    },
    {
      "name": "Perkinil®",
     "img_id":"oRzLRP9.jpeg",
      "image": "Perkinil.jpg",
      "active_ingredients": "Procyclidine, HCl",
      "indications": [
        "Parkinsonism of arteriosclerotic, idiopathic, and post-encephalitic origin",
        "Control of neuroleptic drug-induced extrapyramidal symptoms (e.g., pseudoparkinsonism, akathisia, acute dystonic reactions)"
      ],
      "dosage_and_administration": {
        "dosage": [
          {
            "initial": "2.5 mg 3 times a day",
            "adjusted": "5 mg 3 times a day",
            "additional": "Occasionally 5 mg at night"
          }
        ]
      },
      "contraindications_and_precautions": {
        "contraindications": [],
        "precautions": [
          "Use with caution in children and geriatric patients",
          "Administer cautiously in patients with diarrhea, cardiovascular disease, glaucoma, urinary retention, hepatic or renal impairment"
        ]
      },
      "side_effects": [
        "Dryness of the mouth",
        "Mydriasis",
        "Blurred vision",
        "Adverse gastrointestinal effects (nausea, vomiting, epigastric distress, constipation)",
        "Allergic reaction (rash)",
        "Muscular weakness",
        "Vertigo",
        "Confusion",
        "Hallucination"
      ],
      "preparation": ["5 mg Tablet", "10 mg/2 ml Injection"]
    },
    {
      "name": "PerkinorTM",
     "img_id":"yMISxmv.jpeg",
      "image": "parkinor.jpg",
      "active_ingredients": "Trihexyphenidyl Hydrochloride",
      "indications": [
        "Adjunct in the treatment of all forms of Parkinsonism (post-encephalitic, arteriosclerotic, idiopathic)",
        "Adjuvant therapy with Levodopa for Parkinsonism",
        "Control of extrapyramidal disorders caused by drugs such as Dibenzoxazepines, Phenothiazines, Thioxanthenes, and Butyrophenones"
      ],
      "dosage_and_administration": {
        "general": {
          "note": "Dosage should be individualized. Start with a low dose, increase gradually, and take with food. Total daily intake is best tolerated in divided doses."
        },
        "idiopathic_parkinsonism": {
          "initial_dose": "1 mg on the first day",
          "titration": "Increase by 2 mg increments every 3 to 5 days until 6 to 10 mg daily"
        },
        "drug_induced_parkinsonism": {
          "initial_dose": "1 mg",
          "total_daily_dose": "Usually ranges between 5 and 15 mg",
          "titration": "Progressively increase until satisfactory control is achieved"
        },
        "concomitant_use_with_levodopa": {
          "note": "Dose of each may need reduction",
          "typical_dose": "3 to 6 mg daily in divided doses"
        },
        "concomitant_use_with_parasympathetic_inhibitors": {
          "dosing": "Divide total daily intake into 3 doses at mealtimes; high doses (10 mg daily) may be divided into 4 doses, with the fourth at bedtime"
        },
        "post_encephalitic_parkinsonism": {
          "typical_dose": "12 to 15 mg daily"
        }
      },
      "contraindications": [
        "Hypersensitivity to Trihexyphenidyl Hydrochloride or any tablet/syrup ingredients",
        "Narrow-angle glaucoma"
      ],
      "adverse_reactions": [
        "Mild nausea",
        "Nervousness",
        "Blurred vision",
        "Dryness of the mouth",
        "Dizziness",
        "Confusion",
        "Memory impairment",
        "Cognitive dysfunctions",
        "Constipation",
        "Weakness",
        "Vomiting",
        "Headache"
      ],
      "drug_interactions": [
        {
          "drugs": ["Cannabinoids", "Barbiturates", "Opiates", "Alcohol"],
          "effect": "Additive effects with Trihexyphenidyl Hydrochloride, potential for abuse"
        },
        {
          "drugs": ["Alcohol", "Other CNS depressants"],
          "effect": "Increased sedative effects"
        }
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": {
          "category": "C",
          "warning": "Use only if clearly needed"
        },
        "lactation": {
          "note": "Caution should be exercised when administered to a nursing woman"
        }
      },
      "preparation": ["2 mg Tablet", "5 mg Tablet", "5 mg/5 ml Syrup"]
    },
    {
      "name": "PerkirolTM",
     "img_id":"fGRxZ6s.jpeg",
      "image": "Perkirol_0.25.jpg",
      "active_ingredients": "Ropinirole",
      "indications": ["Parkinson’s Disease", "Restless Legs Syndrome"],
      "dosage_and_administration": {
        "parkinsons_disease": {
          "starting_dose": "0.25 mg 3 times daily",
          "titration": [
            "After week 4, increase by 1.5 mg/day weekly up to 9 mg/day",
            "Then increase by up to 3 mg/day weekly to a maximum of 24 mg/day"
          ]
        },
        "restless_legs_syndrome": {
          "starting_dose": "0.25 mg once daily, 1 to 3 hours before bedtime",
          "titration": [
            "After 2 days, increase to 0.5 mg once daily",
            "At the end of the first week, increase to 1 mg once daily"
          ]
        }
      },
      "contraindications_and_precautions": {
        "contraindications": ["Hypersensitivity to Ropinirole"],
        "precautions": [
          "Use with caution in patients with severe cardiovascular disease",
          "Caution when given concomitantly with other dopaminergic drugs due to potential for hypotension, bradycardias, or other arrhythmias",
          "Advise patients to exercise caution while driving or operating machines during treatment"
        ]
      },
      "side_effects": [
        "Nausea",
        "Somnolence",
        "Leg edema",
        "Abdominal pain",
        "Vomiting",
        "Syncope",
        "Decreases in systolic blood pressure",
        "Symptomatic hypotension",
        "Bradycardia",
        "Excessive daytime somnolence",
        "Sudden sleep onset episodes"
      ],
      "drug_interactions": [
        "Neuroleptics and centrally acting dopamine antagonists (e.g., sulpiride, metoclopramide)",
        "Theophylline",
        "Ciprofloxacin",
        "Fluvoxamine",
        "Cimetidine",
        "Oestrogens"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": {
          "warning": "Ropinirole should not be used during pregnancy"
        },
        "lactation": {
          "warning": "Ropinirole should not be used in nursing mothers"
        }
      },
      "preparation": ["0.25 mg Tablet", "2 mg Tablet"]
    },
    {
      "name": "Pevitin®",
     "img_id":"i1tjYOF.jpeg",
      "image": "Pevitin-15-gm-pro.jpg",
      "active_ingredients": ["Econazole Nitrate", "Triamcinolone Acetonide"],
      "indications": [
        "Inflammatory dermatomycoses",
        "Inflammatory skin conditions complicated by or threatened by bacterial or fungal skin infection"
      ],
      "dosage_and_administration": {
        "application": "Apply by gently rubbing onto the skin twice daily",
        "duration": "14 days"
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "Tubercular or luetic skin infections",
          "Viral diseases (e.g., herpes, vaccinia, varicella)",
          "Hypersensitivity to imidazoles or corticosteroids"
        ],
        "precautions": [
          "Long-term therapy with corticosteroids can cause skin lesions such as atrophy, telangiectasia, and striae",
          "Risk of adrenal suppression"
        ]
      },
      "side_effects": ["Local mild irritation", "Hypersensitivity"],
      "drug_interactions": ["No information available"],
      "preparation": ["10 gm Cream"]
    },
    {
      "name": "PhylopenTM",
     "img_id":"sbQPjwu.jpeg",
      "image": "Phylopen-250.jpg",
      "active_ingredients": "Flucloxacillin",
      "indications": [
        "Boils, abscesses, carbuncles, furunculosis, cellulitis",
        "Infected skin conditions (e.g., ulcer, eczema, acne)",
        "Infected wounds, infected burns, protection for skin grafts",
        "Otitis media and externa",
        "Impetigo",
        "Pneumonia, lung abscess, empyema",
        "Sinusitis, pharyngitis, tonsillitis, quinsy",
        "Osteomyelitis",
        "Enteritis",
        "Endocarditis",
        "Urinary tract infections",
        "Meningitis",
        "Septicaemia",
        "Prophylactic agent during major surgical procedures (e.g., cardiothoracic and orthopaedic surgery)"
      ],
      "dosage_and_administration": {
        "adult": "500 mg every 6 hours",
        "children_2_to_10_years": "Half of the adult dose",
        "children_under_2_years": "Quarter of the adult dose"
      },
      "contraindications": ["Penicillin hypersensitivity"],
      "side_effects": ["Nausea", "Diarrhoea", "Skin rashes"],
      "drug_interactions": [
        "Gentamicin sulphate",
        "Streptomycin sulphate",
        "Vitamin mixtures",
        "Lipids",
        "Blood products",
        "Protein hydrolysates or other proteinaceous fluids"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": {
          "note": "Use should be reserved for cases considered essential by the clinician"
        },
        "lactation": {
          "note": "No specific information provided"
        }
      },
      "preparation": [
        "250 mg Capsule",
        "500 mg DS Capsule",
        "125 mg/5 ml Powder for Suspension",
        "250 mg/5 ml Forte Powder for Suspension",
        "500 mg Injection"
      ]
    },
    {
      "name": "PrazolokTM",
     "img_id":"24bfBD0.jpeg",
      "image": "Prazolok-ER-2.5.jpg",
      "active_ingredients": "Prazosin",
      "indications": [
        "Hypertension",
        "Raynaud’s phenomenon and Raynaud’s disease",
        "Congestive heart failure",
        "Symptomatic treatment of urinary obstruction due to benign prostatic hyperplasia (BPH)"
      ],
      "dosage_and_administration": {
        "hypertension": {
          "starting_dose": "0.5 mg in the evening, twice or thrice daily for 3 to 7 days",
          "titration": "Increase to 1 mg twice or thrice daily for 3 to 7 days",
          "maximum_dose": "20 mg daily in divided doses"
        },
        "congestive_heart_failure": {
          "starting_dose": "0.5 mg two, three, or four times daily",
          "titration": "Increase to 4 mg in divided doses",
          "maintenance_dose": "4 mg to 20 mg daily in divided doses"
        },
        "raynauds_disease": {
          "starting_dose": "0.5 mg twice daily for 3 to 7 days",
          "maintenance_dose": "1 mg or 2 mg twice daily",
          "note": "Adjust according to clinical response"
        },
        "benign_prostatic_hyperplasia": {
          "starting_dose": "0.5 mg twice daily for 3 to 7 days, initial dose in the evening",
          "maintenance_dose": "2 mg twice daily"
        },
        "special_populations": {
          "renal_impairment": {
            "note": "Initiate at 0.5 mg daily for moderate to severe renal impairment, increase cautiously"
          },
          "hepatic_dysfunction": {
            "note": "Initiate at 0.5 mg daily, increase cautiously"
          },
          "elderly": {
            "note": "Initiate with the lowest possible dose due to susceptibility to hypotension"
          }
        }
      },
      "contraindications": [
        "Known sensitivity to Prazosin, other quinazolines, or any excipients"
      ],
      "side_effects": [
        "Allergic reaction",
        "Depression",
        "Nervousness",
        "Insomnia",
        "Hallucinations",
        "Dizziness",
        "Drowsiness",
        "Headache",
        "Faintness",
        "Syncope",
        "Paraesthesia",
        "Worsening of pre-existing narcolepsy",
        "Blurred vision",
        "Eye pain",
        "Reddened sclera",
        "Vertigo",
        "Tinnitus",
        "Palpitations"
      ],
      "precautions": [
        {
          "condition": "Benign prostatic hyperplasia",
          "note": "Not recommended for patients with a history of micturition syncope or those receiving another alpha-1-antagonist"
        },
        {
          "condition": "Congestive heart failure",
          "note": "Not recommended for congestive cardiac failure due to mechanical obstruction (e.g., aortic valve stenosis, mitral valve stenosis, pulmonary embolism, restrictive pericardial disease)"
        },
        {
          "condition": "Hypertension",
          "note": "Postural hypotension (dizziness, weakness, or rarely loss of consciousness) may occur, particularly at the start of therapy"
        }
      ],
      "drug_interactions": [
        {
          "drugs": "Phosphodiesterase-5 inhibitors (e.g., Sildenafil, Tadalafil, Vardenafil)",
          "effect": "May lead to symptomatic hypotension"
        },
        {
          "drugs": "Beta-adrenergic antagonists, calcium antagonists",
          "effect": "May produce substantial reduction in blood pressure"
        }
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": {
          "category": "C",
          "warning": "Use only if the potential benefit justifies the potential risk to the fetus"
        },
        "lactation": {
          "note": "No specific information provided"
        }
      },
      "preparation": [
        "PrazolokTM 1: 30 tablets in blister pack",
        "PrazolokTM 2: 30 tablets in blister pack"
      ]
    },
    {
      "name": "Prolert®",
     "img_id":"rWjswJR.jpeg",
      "image": "Prolert-01.jpg",
      "active_ingredients": "Fluoxetine",
      "indications": [
        "Depressive illness",
        "Bulimia nervosa",
        "Obsessive compulsive disorders",
        "Pre-menstrual syndrome"
      ],
      "dosage_and_administration": {
        "adult": {
          "major_depressive_disorder": "20 mg/day",
          "obsessive_compulsive_disorder": "20 mg/day",
          "bulimia_nervosa": "60 mg/day",
          "panic_disorder": "10 mg/day"
        },
        "pediatric_7_to_18_years": {
          "major_depressive_disorder": "10-20 mg/day",
          "obsessive_compulsive_disorder": "10 mg/day"
        }
      },
      "contraindications": [
        "Concomitant use with Monoamine Oxidase Inhibitors",
        "Concomitant use with Thioridazine",
        "Concomitant use with Pimozide"
      ],
      "side_effects": [
        "Abnormal dreams",
        "Abnormal ejaculation",
        "Anorexia",
        "Anxiety",
        "Asthenia",
        "Diarrhea",
        "Dry mouth",
        "Insomnia",
        "Nausea",
        "Nervousness",
        "Rash",
        "Somnolence",
        "Sweating"
      ],
      "drug_interactions": [
        "Serotonergic Drugs",
        "Drugs Metabolized by CYP2D6",
        "Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, Warfarin)",
        "Antipsychotics",
        "Anticonvulsants"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": {
          "category": "C",
          "warning": "Use only if the potential benefit justifies the potential risk to the fetus"
        },
        "lactation": {
          "note": "Fluoxetine is excreted in human breast milk. Caution should be exercised when administered to a nursing woman"
        }
      },
      "preparation": ["20 mg Capsule"]
    },
    {
      "name": "Promtil TM",
     "img_id":"wtXs8UJ.jpeg",
      "image": "PROMTIL.jpg",
      "active_ingredients": "Prochlorperazine",
      "indications": [
        "Control of severe nausea and vomiting caused by radiation therapy, cancer chemotherapy, surgery, and other conditions",
        "Relieving nausea, vomiting, and attacks of dizziness or spinning sensations (vertigo) associated with Meniere’s disease and other inner ear disorders",
        "Treatment of psychotic illness such as schizophrenia (hallucinations and hostility)",
        "Acute mania",
        "Short-term treatment of generalized non-psychotic anxiety"
      ],
      "dosage_and_administration": {
        "children": {
          "note": "Not recommended for children <10 kg or <2 years",
          "10_to_14_kg": {
            "dosage": "2.5 mg every 12-24 hours as needed",
            "maximum": "7.5 mg/day"
          },
          "15_to_18_kg": {
            "dosage": "2.5 mg every 8-12 hours as needed",
            "maximum": "10 mg/day"
          },
          "19_to_39_kg": {
            "dosage": "5 mg every 12 hours as needed",
            "maximum": "15 mg/day"
          }
        },
        "adults": {
          "dosage": "5-10 mg 3-4 times/day",
          "usual_maximum": "40 mg/day"
        }
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "Hypersensitivity to prochlorperazine or any component of the formulation",
          "Severe CNS depression",
          "Coma",
          "Use in children <2 years of age or <10 kg"
        ],
        "precautions": [
          "Use with caution in patients with very high or very low blood pressure, liver or heart disease, Reye’s syndrome, alcohol or drug dependencies, nervous system problems, blood disorders, or allergies (especially drug allergies)",
          "Exercise caution during tasks requiring alertness (e.g., driving or using machinery)",
          "Alcohol use may cause extreme drowsiness",
          "May increase sensitivity to sunlight; avoid prolonged sun exposure and use sunscreen and protective clothing",
          "May reduce sweating, increasing susceptibility to heat stroke"
        ]
      },
      "side_effects": [
        "Drowsiness",
        "Jaw, neck, and back muscle spasms",
        "Fine worm-like tongue movements",
        "Rhythmic face, mouth, or jaw movements",
        "Slow or difficult speech",
        "Difficulty swallowing",
        "Restlessness and pacing",
        "Tremors",
        "Shuffling walk",
        "Skin rash",
        "Yellowing of the skin or eyes"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": {
          "note": "No evidence of adverse effects reported during pregnancy"
        },
        "lactation": {
          "note": "No evidence of adverse effects reported during lactation"
        }
      },
      "preparation": ["5 mg Tablet"]
    },
    {
      "name": "Pronor TM",
     "img_id":"rgYB9Bs.jpeg",
      "image": "Pronor.jpg",
      "active_ingredients": "Finasteride",
      "indications": [
        "Treatment and control of Benign Prostatic Hyperplasia (BPH)"
      ],
      "dosage_and_administration": {
        "adults": {
          "dosage": "1 tablet (5 mg) daily",
          "administration": "With or without food"
        }
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "Hypersensitivity to any component of this product",
          "Women who are or may become pregnant",
          "Children",
          "People with severely diminished urinary flow"
        ],
        "precautions": []
      },
      "side_effects": [
        "Impotence (3.7%)",
        "Decreased libido (3.3%)",
        "Decreased volume of ejaculate (2.8%)"
      ],
      "drug_interactions": {
        "note": "No clinically important drug interactions identified",
        "enzyme_system": "Does not significantly affect cytochrome P450-linked drug metabolism",
        "tested_compounds": [
          "Propranolol",
          "Digoxin",
          "Glibenclamide",
          "Warfarin",
          "Theophylline",
          "Antipyrine"
        ],
        "safe_concomitant_use": [
          "ACE inhibitors",
          "Alpha blockers",
          "Beta blockers",
          "Calcium channel blockers",
          "Cardiac nitrates",
          "Diuretics",
          "H2 antagonists",
          "NSAIDs",
          "Quinolones",
          "Benzodiazepines"
        ]
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": {
          "note": "Contraindicated in women who are or may become pregnant"
        },
        "lactation": {
          "note": "Unknown whether Finasteride is excreted in human milk"
        }
      },
      "preparation": ["5 mg Tablet"]
    },
    {
      "name": "Prosalic TM Lotion",
     "img_id":"liejR7k.png",
      "image": "prosalic_large.png",
      "active_ingredients": "Betamethasone + Salicylic Acid",
      "indications": [
        "Treatment of hyperkeratotic and dry corticosteroid-responsive dermatitis where cornified epithelium may resist penetration of the steroid",
        "Salicylic Acid allows access of the dermis more rapidly than by applying steroid alone"
      ],
      "dosage_and_administration": {
        "adults": {
          "dosage": "Apply required quantity of lotion to the affected areas and massage gently and thoroughly",
          "frequency": "Twice daily (morning and night)"
        }
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "Viral diseases including vaccinia, varicella, Herpes simplex",
          "Fungal infections",
          "Tuberculosis of the skin",
          "History of sensitivity to any of the components"
        ],
        "precautions": [
          "Discontinue use if irritation or sensitization develops",
          "Systemic absorption may increase with application to large surface areas",
          "Avoid application to open wounds or damaged skin"
        ]
      },
      "side_effects": [
        "Burning",
        "Itching",
        "Irritation",
        "Dryness",
        "Folliculitis",
        "Hypertrichosis",
        "Hypopigmentation",
        "Perioral dermatitis",
        "Allergic contact dermatitis"
      ],
      "drug_interactions": {
        "note": "May interact with other corticosteroid-containing preparations"
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": {
          "note": "Use only if the potential benefit justifies the potential risk to the fetus; avoid extensive, prolonged use"
        },
        "lactation": {
          "note": "Unknown if absorbed corticosteroids appear in breast milk; decision should weigh importance of drug to the mother"
        }
      },
      "use_in_children": {
        "note": "Children may show greater susceptibility to HPA axis suppression and corticosteroid effects due to higher absorption. Use minimal effective dose. Chronic use may interfere with growth and development."
      },
      "preparation": ["25 ml Lotion"]
    },
    {
      "name": "ProxivirTM",
     "img_id":"OmfvekP.jpeg",
      "image": "Proxivir_e.jpg",
      "active_ingredients": "Tenofovir Disoproxil Fumarate",
      "indications": [
        "Chronic hepatitis B virus infection in adults",
        "HIV infected adults in combination with other antiretroviral agents"
      ],
      "dosage_and_administration": {
        "adults": {
          "dosage": "300 mg once daily with or without food",
          "note": "For adults aged 18 years and older with adequate renal function"
        },
        "renal_impairment": {
          "note": "Dose adjustment needed based on creatinine clearance",
          "adjustments": [
            {
              "creatinine_clearance": "≥50 ml/min",
              "dosing_interval": "Every 24 hours"
            },
            {
              "creatinine_clearance": "30 to 49 ml/min",
              "dosing_interval": "Every 48 hours"
            },
            {
              "creatinine_clearance": "10 to 29 ml/min",
              "dosing_interval": "Every 72 to 96 hours"
            },
            {
              "creatinine_clearance": "Hemodialysis patients",
              "dosing_interval": "Every 7 days or after approximately 12 hours of dialysis"
            }
          ]
        },
        "hepatic_impairment": {
          "note": "No dose adjustment required"
        }
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "Known hypersensitivity to Tenofovir or any component of the product"
        ],
        "precautions": [
          "Do not co-administer with Emtricitabine & Tenofovir combination or Adefovir Dipivoxil",
          "Suspend treatment in patients who develop lactic acidosis or hepatotoxicity",
          "Discontinuation may result in severe acute exacerbation of hepatitis"
        ]
      },
      "side_effects": ["Nausea", "Vomiting", "Diarrhea", "Flatulence"],
      "drug_interactions": {
        "no_significant_interaction": [
          "Antiretroviral drugs",
          "Entecavir",
          "Lamivudine",
          "Methadone",
          "Oral contraceptives",
          "Ribavirin",
          "Tacrolimus"
        ],
        "note": "Effects with drugs that are renally eliminated or affect renal function have not been evaluated"
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": {
          "category": "B",
          "note": "Use only if clearly needed"
        },
        "lactation": {
          "note": "Unknown if excreted in human milk; breastfeeding not recommended while taking Tenofovir"
        }
      },
      "use_in_children": {
        "note": "Safety and effectiveness not established in patients below 18 years"
      },
      "preparation": ["300 mg Tablet"]
    },
    {
      "name": "Pylotrip®",
     "img_id":"Az8litB.jpeg",
      "image": "Pylotrip.jpg",
      "active_ingredients": [
        "Lansoprazole Capsule",
        "Amoxicillin Capsule",
        "Clarithromycin Tablet"
      ],
      "indications": [
        "Eradication of H. pylori in active chronic gastric, duodenal, and gastric ulcers"
      ],
      "dosage_and_administration": {
        "standard_dose": "One strip twice daily for 7–14 days",
        "note": "Or as per physician’s advice"
      },
      "contraindications_and_precautions": {
        "contraindications": ["Hypersensitivity"]
      },
      "side_effects": [
        "Nausea",
        "Vomiting",
        "Diarrhea",
        "Dark stools",
        "Dry mouth",
        "Glossitis",
        "Oral moniliasis",
        "Stomatitis",
        "Tongue discoloration",
        "Myalgia",
        "Confusion",
        "Headache",
        "Dizziness",
        "Skin reactions",
        "Vaginitis",
        "Vaginal moniliasis"
      ],
      "use_in_pregnancy_and_lactation": {
        "note": "Use only if the potential benefit justifies the potential risk to the mother"
      },
      "preparation": ["(30 mg + 1 gm + 500 mg)/Strip"]
    },
    {
      "name": "Pylotrip® R",
     "img_id":"TnsZ0mF.jpeg",
      "image": "Pylotrip-R.jpg",
      "active_ingredients": ["Rabeprazole", "Amoxycillin", "Clarithromycin"],
      "composition": {
        "Rabeprazole": "20 mg tablet",
        "Amoxycillin": "500 mg capsule × 2",
        "Clarithromycin": "500 mg tablet"
      },
      "indications": [
        "Eradication of H. pylori in active chronic gastric, duodenal, and gastric ulcers"
      ],
      "dosage_and_administration": {
        "standard_dose": "One strip twice daily for 7–14 days",
        "note": "Or as per physician’s advice"
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "Known hypersensitivity to any of the components"
        ],
        "pregnancy_and_lactation": {
          "note": "Use only if the potential benefit justifies the potential risk to the mother",
          "amoxycillin_excretion": "Excreted in small amounts in human milk",
          "decision": "Consider discontinuing either nursing or drug therapy"
        },
        "geriatric_use": "Care should be taken due to possible asymptomatic renal and hepatic dysfunction in elderly patients"
      },
      "adverse_reactions": {
        "digestive_system": [
          "Nausea",
          "Vomiting",
          "Diarrhea",
          "Dark stools",
          "Dry mouth",
          "Glossitis",
          "Oral moniliasis",
          "Stomatitis",
          "Tongue discoloration"
        ],
        "musculoskeletal_system": ["Myalgia"],
        "nervous_system": ["Confusion", "Headache", "Dizziness"],
        "skin": ["Skin reactions"],
        "urogenital_system": ["Vaginitis", "Vaginal moniliasis"]
      },
      "preparation": "Box containing 7 Pylotrip R blister strips"
    },
    {
      "name": "Quinivir®",
     "img_id":"GVG5Fef.jpeg",
      "image": "Quinivir-Tablet_l.jpg",
      "active_ingredients": "Hydroxychloroquine Sulfate USP",
      "indications": [
        "Acute and chronic rheumatoid arthritis",
        "Systemic Lupus Erythematosus (SLE)",
        "Malaria"
      ],
      "dosage_and_administration": {
        "route": "Oral, taken with food",
        "rheumatoid_arthritis": {
          "initial_dose": "400 to 600 mg daily",
          "maintenance": "Reduce to 50% of initial dose after 4–8 weeks of good response"
        },
        "sle": {
          "initial_dose": "400 mg once or twice daily for several weeks or months",
          "maintenance_dose": "200 to 400 mg daily"
        },
        "malaria": {
          "adults": {
            "initial_dose": "800 mg",
            "follow_up": "400 mg in 6–8 hours, then 400 mg on each of the next 2 days"
          },
          "children": {
            "total_dose": "25 mg/kg over 3 days",
            "schedule": [
              "1st dose: 10 mg base/kg (max 620 mg)",
              "2nd dose: 5 mg base/kg (max 310 mg) after 6 hours",
              "3rd dose: 5 mg base/kg after 18 hours",
              "4th dose: 5 mg base/kg after 24 hours"
            ]
          },
          "note": "200 mg Hydroxychloroquine Sulfate = 155 mg base"
        }
      },
      "side_effects": [
        "Nausea",
        "Vomiting",
        "Stomach upset",
        "Loss of appetite",
        "Diarrhea",
        "Tiredness",
        "Weakness",
        "Headache",
        "Visual problems"
      ],
      "precautions": [
        "Children are especially sensitive to 4-aminoquinoline compounds",
        "Keep out of reach of children",
        "Ophthalmologic examination every 12 months"
      ],
      "contraindications": [
        "Retinal and visual field changes due to 4-aminoquinoline compounds",
        "Known hypersensitivity to 4-aminoquinoline compounds",
        "Long-term therapy in children"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Use only if clearly needed",
        "lactation": "Consult doctor due to small amounts found in breast milk"
      },
      "preparation": "200 mg Tablet"
    },
    {
      "name": "Rabeca™",
     "img_id":"24TIZCR.jpeg",
      "image": "Rabeca.jpg",
      "active_ingredients": "Rabeprazole Sodium",
      "indications": [
        "Short-term treatment and symptomatic relief of duodenal ulcers and erosive or ulcerative GERD",
        "Maintenance of healing and reducing relapse in GERD patients",
        "Treatment of daytime and nighttime heartburn associated with GERD",
        "Long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison Syndrome",
        "In combination with Amoxicillin and Clarithromycin for eradication of Helicobacter pylori"
      ],
      "dosage_and_administration": {
        "route": "Oral, with or without food",
        "gerd_erosive_ulcerative_healing": {
          "dose": "20 mg once daily for 4 to 8 weeks",
          "note": "An additional 8-week course may be considered if not healed"
        },
        "gerd_maintenance": {
          "dose": "20 mg once daily"
        },
        "gerd_symptomatic": {
          "dose": "20 mg once daily for 4 weeks",
          "note": "Another course may be considered if symptoms persist"
        },
        "duodenal_ulcers": {
          "dose": "20 mg once daily after the morning meal for up to 4 weeks",
          "note": "Some patients may require additional therapy"
        },
        "h_pylori_eradication": {
          "regimen": [
            "Rabeprazole Sodium 20 mg twice daily",
            "Amoxicillin 1000 mg twice daily",
            "Clarithromycin 500 mg twice daily"
          ],
          "duration": "7 days",
          "instructions": "All medications to be taken with morning and evening meals"
        },
        "zollinger_ellison_syndrome": {
          "initial_dose": "60 mg once daily",
          "note": "Doses should be adjusted to individual patient needs; up to 100 mg once daily or 60 mg twice daily possible; can continue as long as clinically indicated"
        }
      },
      "contraindications": [
        "Hypersensitivity to Rabeprazole or any component of the product"
      ],
      "precautions": [
        "Caution in patients with severe hepatic impairment due to increased exposure and decreased elimination"
      ],
      "drug_interactions": [
        "No significant interactions with drugs metabolized by CYP-450 system (e.g., Warfarin, Theophylline, Diazepam, Phenytoin)",
        "30% decrease in bioavailability of Ketoconazole with Rabeprazole 20 mg QD",
        "90% increase in AUC and 29% increase in Cmax of Digoxin"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "USFDA Category C – use only if clearly needed",
        "lactation": "Unknown if excreted in breast milk; consider discontinuing drug or nursing"
      },
      "use_in_children": "Safety and effectiveness in pediatric patients not established",
      "preparation": "20 mg Tablet"
    },
    {
      "name": "Ranolin™ XR",
     "img_id":"05W2UgZ.jpeg",
      "image": "Ranolin-XR.jpg",
      "active_ingredients": "Ranolazine",
      "indications": [
        "Treatment of chronic angina",
        "Can be used with β-blockers, Nitrates, Calcium channel blockers, Anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers",
        "Decreases angina episodes in patients with coronary artery disease on maximal doses of amlodipine",
        "Reserved for patients who have not achieved adequate response with other antianginal drugs",
        "Effect on angina rate or exercise tolerance is smaller in women than in men"
      ],
      "dosage_and_administration": {
        "route": "Oral, with or without food",
        "initial_dose": "500 mg twice daily",
        "maintenance_dose": "Increase to 1 gm twice daily based on clinical symptoms",
        "maximum_dose": "1 gm twice daily",
        "administration_instructions": "Take tablets whole; do not crush, break, or chew",
        "missed_dose": "Take the prescribed dose at the next scheduled time; do not double the next dose"
      },
      "contraindications": [
        "Pre-existing QT prolongation",
        "Hepatic impairment",
        "Taking QT prolonging drugs",
        "Taking potent and moderately potent CYP3A inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin, Nefazodone, Nelfinavir, Ritonavir, Indinavir, Saquinavir, Diltiazem)"
      ],
      "precautions": [
        "Ranolazine blocks Ikr and prolongs the QTc interval in a dose-related manner",
        "Co-administration with Digoxin increases plasma concentrations by 1.5 fold",
        "Caution with co-administration with P-gp inhibitors such as Ritonavir or Cyclosporine"
      ],
      "side_effects": {
        "cardiac_disorders": ["Bradycardia", "Palpitations"],
        "ear_and_labyrinth_disorders": ["Tinnitus", "Vertigo"],
        "gastrointestinal_disorders": [
          "Abdominal pain",
          "Dry mouth",
          "Vomiting"
        ],
        "general_disorders": ["Peripheral edema"],
        "respiratory_disorders": ["Dyspnea"],
        "vascular_disorders": ["Hypotension", "Orthostatic hypotension"]
      },
      "drug_interactions": {
        "CYP3A_inhibitors": "Do not use with strong CYP3A inhibitors. Limit maximum dose to 500 mg twice daily with moderate CYP3A inhibitors (e.g., Diltiazem, Verapamil, Erythromycin)",
        "CYP3A_inducers": "Do not use with CYP3A inducers",
        "P-gp_inhibitors": "May need to reduce the Ranolazine dose based on clinical dose",
        "P-gp_and_CYP2D6_drugs": "May need reduced doses of drugs transported by P-gp or metabolized by CYP2D6 (e.g., Digoxin, TCA)"
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Category C. Use only when the potential benefit justifies the potential risk to the fetus",
        "lactation": "Not known if excreted in breast milk. Discontinue nursing or Ranolazine based on the importance of the drug to the mother"
      },
      "use_in_children": "Safety and effectiveness in pediatric patients not established",
      "preparation": {
        "product": "Ranolin XR 500 tablet",
        "packaging": "20 extended release tablets in PVC blister pack"
      }
    },
    {
      "name": "Rapiflo™",
     "img_id":"VYQjQzP.jpeg",
      "image": "Rapiflo.jpg",
      "active_ingredients": "Silodosin INN 8 mg",
      "dosage_and_administration": {
        "recommended_dose": "8 mg once daily with a meal",
        "renal_impairment": {
          "severe": "Contraindicated in patients with severe renal impairment (CCr < 30 mL/min)",
          "moderate": "Dose should be reduced to 4 mg once daily with a meal in patients with moderate renal impairment (CCr 30-50 mL/min)",
          "mild": "No dosage adjustment is needed in patients with mild renal impairment (CCr 50-80 mL/min)"
        },
        "hepatic_impairment": {
          "severe": "Contraindicated in patients with severe hepatic impairment (Child-Pugh score ≥ 10)",
          "mild_moderate": "No dosage adjustment is needed in patients with mild or moderate hepatic impairment"
        },
        "missed_dose": "If a dose is missed, it can be taken later the same day. If a day is missed, skip the dose and resume the regular schedule. Do not double the dose.",
        "overdose": "Silodosin was evaluated at doses of up to 48 mg/day in healthy male subjects. The dose-limiting adverse event was orthostatic hypotension.",
        "special_populations": {
          "pediatrics": "Not indicated for use in children (< 18 years of age)"
        }
      },
      "contraindications": [
        "Hypersensitivity to Silodosin or any component of the formulation",
        "Concomitant use with potent CYP3A4 inhibitors (e.g., Ketoconazole, Clarithromycin, Itraconazole, Ritonavir)",
        "Use with other α-1 blockers (e.g., Prazosin, Terazosin, Doxazosin)",
        "Intraoperative Floppy Iris Syndrome observed in some patients on α-1 blockers or previously treated with them"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Women of childbearing potential should use adequate contraception while being treated",
        "lactation": "Not known if Silodosin is excreted in human milk. Should not be administered during nursing."
      },
      "adverse_reactions": [
        "Retrograde ejaculation",
        "Dizziness",
        "Retrograde ejaculation is reversible upon discontinuation of the drug"
      ],
      "warnings_and_precautions": [
        "A reduction in blood pressure can occur in individual cases during treatment with Silodosin"
      ],
      "drug_interactions": {
        "CYP3A4_inhibitors": "Silodosin should not be co-administered with potent inhibitors of CYP3A4 (e.g., Ketoconazole, Itraconazole, Clarithromycin, Ritonavir)",
        "moderate_CYP3A4_inhibitors": "Moderate CYP3A4 inhibitors (e.g., Diltiazem) may increase Silodosin AUC by approximately 30%",
        "other_interactions": [
          "Use with α-1 blockers",
          "Herbal remedies (e.g., St. John’s Wort, Milk Thistle)",
          "Grapefruit juice"
        ]
      },
      "preparation": {
        "product": "8 mg Capsule"
      }
    },
    {
      "name": "Rasalet™",
     "img_id":"d8E6TD0.jpeg",
      "image": "rasalet-05.jpg",
      "active_ingredients": "Rasagiline",
      "indication_and_uses": [
        "Treatment of the signs and symptoms of idiopathic Parkinson’s disease as initial monotherapy",
        "As adjunct to other therapies (Levodopa)"
      ],
      "dosage_and_administration": {
        "monotherapy": "1 mg once daily",
        "as_adjunct_without_levodopa": "1 mg once daily",
        "as_adjunct_to_levodopa": "0.5 mg once daily"
      },
      "contraindications": [
        "Use with meperidine",
        "Use with tramadol",
        "Use with methadone",
        "Use with propoxyphene",
        "Use with MAO inhibitors (MAOIs), including other selective MAO-B inhibitors, due to risk of serotonin syndrome"
      ],
      "warnings_and_precautions": [
        "Exacerbation of hypertension may occur during treatment. Medication adjustment may be necessary if elevation of blood pressure is sustained.",
        "Dose should not exceed 0.5 mg once daily for patients with mild hepatic impairment or taking concomitant Ciprofloxacin or other CYP1A2 inhibitors"
      ],
      "side_effects": [
        "Dizziness",
        "Spinning sensation",
        "Joint pain",
        "Headache",
        "Heartburn",
        "Nausea",
        "Muscle pain"
      ],
      "drug_interactions": [
        "Concomitant use with meperidine, dextromethorphan, and antidepressants is not recommended"
      ],
      "use_in_specific_populations": {
        "pregnancy": "Category C. Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.",
        "nursing_mother": "It is not known whether Rasagiline is excreted in human milk. Caution should be exercised when administered to a nursing woman.",
        "pediatrics": "Safety and effectiveness in pediatric patients have not been established"
      },
      "preparation": {
        "tablets": ["0.5 mg", "1 mg"]
      }
    },
    {
      "name": "Rectocare®",
     "img_id":"Oj6Okhp.png",
      "image": "Rectocare_u.png",
      "active_ingredients": "Nitroglycerin",
      "indication_and_uses": [
        "For relief of pain associated with chronic anal fissure"
      ],
      "dosage_and_administration": {
        "general": "Insert the ointment at least 1 cm into the anus using an applicator. The dose is twice daily up to a maximum of 8 weeks."
      },
      "use_in_children": "Not recommended for use in children below 18 years of age.",
      "contraindications_and_precautions": [
        "Contraindicated in patients with known hypersensitivity to Nitroglycerin or other ingredients of the formulation.",
        "Should be used with caution in patients with severe hepatic or renal disease.",
        "Should not be used in patients suffering from severe anemia, glaucoma, hypotension, or increased intracranial pressure."
      ],
      "side_effects": ["Headache", "Dizziness"],
      "use_in_pregnancy_and_lactation": "This ointment should not be used during pregnancy and lactation.",
      "preparation": {
        "ointment": "Each pack contains a tube of 15 gm ointment and an applicator."
      }
    },
    {
      "name": "Remac™",
     "img_id":"OcLcSj7.jpeg",
      "image": "REMAC-500.jpg",
      "active_ingredients": "Clarithromycin",
      "indication_and_uses": [
        "Pharyngitis",
        "Sinusitis",
        "Chronic bronchitis",
        "Pneumonia",
        "Skin & soft tissue infection",
        "Duodenal ulcers for eradication of H. pylori"
      ],
      "dosage_and_administration": {
        "adults": "Remac 250 - 500 mg for 7-14 days.",
        "children": "7.5 mg/kg twice daily."
      },
      "contraindications_and_precautions": [
        "Hypersensitivity to Clarithromycin.",
        "Caution should be taken in administering this antibiotic to patients with impaired hepatic & renal function.",
        "Prolonged or repeated use may result in overgrowth of non-susceptible bacteria or fungi."
      ],
      "drug_interactions": ["Theophylline", "Terfenadine", "Carbamazepine"],
      "use_in_pregnancy_and_lactation": "Clarithromycin is not recommended during pregnancy and lactation.",
      "preparation": {
        "tablet": "500 mg tablet",
        "granules_for_suspension": "125 mg/5 ml granules for suspension"
      }
    },
    {
      "name": "Remus®",
     "img_id":"QMJdmpg.jpeg",
      "image": "Remus-_1.jpg",
      "active_ingredients": "Tacrolimus",
      "indication_and_uses": ["Moderate to severe atopic dermatitis"],
      "dosage_and_administration": {
        "dose": "Twice daily for one week until clearing of signs & symptoms of atopic dermatitis."
      },
      "contraindications_and_precautions": [
        "Hypersensitivity to Tacrolimus",
        "Netherton’s Syndrome",
        "Generalized erythroderma"
      ],
      "side_effects": [
        "Skin burning",
        "Pruritus",
        "Allergic reaction",
        "Anaphylactoid reaction",
        "Angioedema",
        "Anorexia",
        "Anxiety"
      ],
      "drug_interactions": [
        "Erythromycin",
        "Itraconazole",
        "Ketoconazole",
        "Fluconazole",
        "Calcium channel blockers",
        "Cimetidine"
      ],
      "use_in_pregnancy_and_lactation": "Caution should be taken during pregnancy & lactation.",
      "preparation": {
        "ointment": ["0.03%", "0.1%"]
      }
    },
    {
      "name": "Remdinil",
     "img_id":"VuvEene.jpeg",
      "image": "Remdinil_l.jpg",
      "active_ingredients": "Remdesivir",
      "indication_and_uses": [
        "For the treatment of suspected or laboratory confirmed Corona Virus Disease 2019 (COVID-19) in adult and children hospitalized with severe disease.",
        "Severe disease is defined as patients with an oxygen saturation (SpO2) ≤ 94% on room air, or requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).",
        "Remdesivir is authorized for hospitalized adults and pediatric patients for whom use of an intravenous agent is clinically appropriate."
      ],
      "dosage_and_administration": {
        "adults": "200 mg on the first day followed by 9 days of 100 mg once daily via IV infusion in a total volume of up to 250 mL of 0.9% saline over 30 minutes (infusion time may be extended up to 120 minutes).",
        "duration": "10 days total",
        "method_of_administration": "Dilute concentrated solution in intravenous fluids up to 250 mL prior to intravenous administration using 0.9% sodium chloride in water for injection (saline)."
      },
      "side_effects": [
        "Multiple-dose IV administration of Remdesivir 150 mg once-daily for 7 or 14 days was generally well tolerated."
      ],
      "contraindications_and_precautions": {
        "contraindications": [
          "Hypersensitivity to the active substance(s) or to any of the excipients.",
          "Evidence of multiorgan failure.",
          "The use of more than one pressor for septic shock.",
          "ALT > 5 x upper limit of normal (ULN).",
          "Renal failure (eGRF < 30 mL/min), dialysis, or continuous veno-venous hemofiltration.",
          "Participation in any other clinical trial of an experimental agent treatment for other viruses."
        ],
        "precautions": [
          "Transient elevations in ALT and AST have been observed with single doses up to 225 mg and multiple doses of 150 mg for up to 14 days.",
          "Mild, reversible PT prolongation in some subjects but without clinically relevant changes in INR or other evidence of hepatic effects.",
          "Nonclinical animal studies showed dose-dependent and reversible kidney injury and dysfunction, though no evidence of nephrotoxicity was observed in clinical studies."
        ]
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "The use of Remdesivir in pregnant women is not recommended due to the lack of data.",
        "breastfeeding": "It is unknown whether Remdesivir or its metabolites are excreted in human milk.",
        "fertility": "No human data on the effect of Remdesivir on fertility are available."
      },
      "preparation": {
        "concentrate_solution": "100 mg"
      }
    },
    {
      "name": "Renorma",
     "img_id":"1oKUiof.jpeg",
      "image": "RENORMA.jpg",
      "active_ingredients": "Tibolone",
      "indication_and_uses": [
        "Treatment of symptoms resulting from natural or surgical menopause in postmenopausal women.",
        "Prevention of osteoporosis in women who have gone through menopause and are at high risk of fractures but cannot take other medicines used to prevent osteoporosis."
      ],
      "dosage_and_administration": {
        "symptom_treatment": "The recommended dose is 2.5 mg once daily.",
        "bone_density_prevention": "The recommended dose is 2.5 mg once daily. Improvement of symptoms generally occurs within a few weeks, but optimal results are obtained when therapy is continued for at least 3 months.",
        "starting_treatment": "Women experiencing natural menopause should commence treatment with tibolone at least 12 months after their last natural bleed. In case of surgical menopause, treatment may commence immediately."
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "Pregnancy and lactation.",
          "Known, past, or suspected breast cancer.",
          "Known or suspected estrogen-dependent malignant tumors (e.g., endometrial cancer).",
          "Undiagnosed genital bleeding.",
          "Untreated endometrial hyperplasia.",
          "Previous idiopathic or current venous thromboembolism (deep venous thrombosis, pulmonary embolism).",
          "Arterial thromboembolic disease (e.g., angina, myocardial infarction, stroke, or TIA).",
          "Acute liver disease or a history of liver disease as long as liver function tests have failed to return to normal.",
          "Porphyria."
        ],
        "precautions": [
          "Uterine fibroids or endometriosis.",
          "Thromboembolic disorders.",
          "Estrogen-dependent tumors.",
          "Hypertension.",
          "Liver disorders (e.g., liver adenoma).",
          "Diabetes.",
          "Asthma.",
          "Epilepsy."
        ]
      },
      "side_effects": [
        "Gastrointestinal disorders like abdominal pain.",
        "Skin and subcutaneous tissue disorders like abnormal hair growth, acne.",
        "Reproductive system and breast disorders like vaginal discharge, genital pruritus, vaginal candidiasis."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "US-FDA pregnancy category D. Tibolone is contraindicated in pregnancy.",
        "lactation": "Tibolone is contraindicated in lactating women."
      },
      "preparation": {
        "tablet": "2.5 mg"
      }
    },
    {
      "name": "Repres SR",
     "img_id":"GCfLsip.jpeg",
      "image": "Repres_SR_l.jpg",
      "active_ingredients": "Indapamide",
      "indication_and_uses": [
        "Essential hypertension.",
        "Hypertension in patients with renal function impairment.",
        "Salt and fluid retention associated with congestive heart failure."
      ],
      "dosage_and_administration": {
        "general_dosage": "One tablet daily, preferably in the morning."
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "Known allergy to this drug or to sulphonamides.",
          "Renal failure.",
          "Serious liver disease.",
          "Hypokalemia.",
          "Disturbed water/electrolyte balance.",
          "Diabetes.",
          "Gout.",
          "Kidney problems."
        ],
        "precautions": [
          "Monitoring of potassium and uric acid serum levels is recommended."
        ]
      },
      "side_effects": [
        "Dizziness.",
        "Headache.",
        "Anorexia.",
        "Nausea.",
        "Vomiting.",
        "Constipation.",
        "Diarrhea.",
        "Postural hypotension.",
        "Electrolyte imbalances including hypochloremic alkalosis, hyponatremia, hypokalemia, hyperuricemia.",
        "Hypersensitivity reactions including skin rashes, cholestatic jaundice.",
        "Blood dyscrasias including thrombocytopenia, leucopenia, aplastic anemia."
      ],
      "drug_interactions": ["Other antihypertensives.", "Norepinephrine."],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Indapamide is not recommended in pregnant women.",
        "lactation": "Mothers taking Indapamide should not breastfeed."
      },
      "preparation": {
        "tablet": "1.5 mg SR (Sustained Release)"
      }
    },
    {
      "name": "ResQ",
     "img_id":"tH9o1FM.jpeg",
      "image": "ResQ.jpg",
      "active_ingredients": "Coenzyme Q10",
      "indication_and_uses": [
        "HMG CoA reductase inhibitors mediated decreased level of Coenzyme Q10.",
        "Drug-induced myopathy.",
        "Protects body against free radical damage with its antioxidant property.",
        "Adjuvant therapy in cardiovascular disease, especially in angina and congestive heart failure.",
        "Immune system depression.",
        "Cognitive decline.",
        "Useful in the management of periodontal disease."
      ],
      "dosage_and_administration": {
        "general_dosage": "Daily doses of Coenzyme Q10 range from 5 to 300 milligrams. Effectiveness is thought to be obtained with doses of 50 to 200 milligrams daily."
      },
      "side_effects": [
        "Nausea.",
        "Loss of appetite.",
        "Upset stomach.",
        "Diarrhea."
      ],
      "contraindications_and_precautions": {
        "contraindications": [
          "Patients with a known hypersensitivity to any component of this product."
        ],
        "precautions": [
          "Supplemental Coenzyme Q10 may improve beta-cell function and glycemic control in type II diabetics. Therefore, those diabetics who use supplemental Coenzyme Q10 should monitor their diabetic medications accordingly."
        ]
      },
      "drug_interactions": [
        "Warfarin: Supplemental Coenzyme Q10 may decrease the effectiveness of Warfarin.",
        "Statins: Statin drugs are known to decrease Coenzyme Q10 levels in humans.",
        "Doxorubicin: Coenzyme Q10 may help to decrease the cardiotoxicity of doxorubicin.",
        "Antidiabetic medications: Coenzyme Q10 may improve glycemic control in some type II diabetics. If this occurs, anti-diabetic medications might need adjusting."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Due to lack of information on long-term safety, pregnant women should avoid Coenzyme Q10.",
        "lactation": "Nursing mothers should avoid Coenzyme Q10."
      },
      "preparation": {
        "capsule": "30 mg & 60 mg Licap"
      }
    },
    {
      "name": "Retabac™ Ointment",
     "img_id":"BSqcBVp.png",
      "image": "retabac_l.png",
      "active_ingredients": "Retapamulin",
      "indication_and_uses": [
        "Topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adults and pediatric patients aged 9 months and older.",
        "Secondary bacterial skin infections, including infected dermatitis and infected traumatic lesions (e.g., small lacerations, sutured wounds, cuts, abrasions)."
      ],
      "dosage_and_administration": {
        "general_dosage": "Apply a thin layer of Retabac™ to the affected area twice daily for 5 days. The treated area may be covered with a sterile bandage or gauze dressing if desired."
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "Not intended for ingestion or for oral, intranasal, ophthalmic, or intravaginal use."
        ],
        "precautions": [
          "In the event of sensitization or severe local irritation, usage should be discontinued."
        ]
      },
      "side_effects": [
        "Application site irritation (affects less than 2% of patients)."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Pregnancy category B.",
        "lactation": "It is not known whether Retapamulin is excreted in human milk. Caution should be exercised when administered to a nursing woman."
      },
      "preparation": {
        "ointment": "10 gm ointment"
      }
    },
    {
      "name": "Revira®",
     "img_id":"mZztuLB.jpeg",
      "image": "REVIRA-1GM.jpg",
      "active_ingredients": "Valaciclovir",
      "indication_and_uses": [
        "Cold sore (Herpes Labialis) in adults and children.",
        "Genital herpes.",
        "Chickenpox.",
        "Herpes zoster."
      ],
      "dosage_and_administration": {
        "herpes_zoster": "1 gram orally 3 times daily for 7 days. Therapy should start at the earliest sign of herpes zoster and is most effective when started within 48 hours of rash onset.",
        "genital_herpes": {
          "initial_episodes": "1 gram twice daily for 10 days.",
          "recurrent_episodes": "500 mg twice daily for 3 days.",
          "suppressive_therapy": "1 gram once daily for patients with normal immune function. Alternatively, 500 mg once daily for those with 9 or fewer recurrences per year. In HIV-infected patients with CD4 cell count of 100 cells/mm3, 500 mg twice daily.",
          "reduction_of_transmission": "500 mg once daily for the source partner in patients with 9 or fewer recurrences per year."
        },
        "cold_sores": "2 grams twice daily for 1 day, about 12 hours apart.",
        "renal_impairment": "Reduction in dosage is recommended for patients with acute or chronic renal impairment."
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "Known hypersensitivity or intolerance to Valaciclovir, Aciclovir, or any component of the formulation."
        ]
      },
      "side_effects": [
        "Nausea",
        "Headache",
        "Vomiting",
        "Dizziness",
        "Abdominal pain",
        "Facial edema",
        "Hypertension",
        "Tachycardia",
        "Acute hypersensitivity reactions (e.g., anaphylaxis, angioedema, dyspnea, pruritus, rash, urticaria)",
        "CNS symptoms (e.g., aggressive behavior, agitation, ataxia, coma, confusion, dysarthria, encephalopathy, mania, psychosis, seizures, tremors)",
        "Visual abnormalities",
        "Diarrhea",
        "Liver enzyme abnormalities, hepatitis",
        "Renal failure, elevated creatinine",
        "Thrombocytopenia, aplastic anemia, leukocytoclastic vasculitis, TTP/HUS"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Pregnancy Category B. Should be used only if the potential benefit justifies the potential risk to the fetus.",
        "lactation": "Should be administered to a nursing mother with caution and only when indicated."
      },
      "use_in_children": {
        "safety_and_effectiveness": "Safety and effectiveness in prepubertal pediatric patients have not been established."
      },
      "preparation": {
        "tablet": ["500 mg", "1 gm"]
      }
    },
    {
      "name": "Rex®",
     "img_id":"cSl4PxT.jpeg",
      "image": "Rex.jpg",
      "active_ingredients": ["Beta Carotene", "Vitamin C", "Vitamin E"],
      "indication_and_uses": [
        "Reduces risks of cardiovascular diseases",
        "Reduces risks of cataract",
        "Combats infection & chronic diseases",
        "Trend toward decreased age-related degenerative changes",
        "Defense against infection"
      ],
      "dosage_and_administration": {
        "general": "1 tablet daily."
      },
      "contraindications_and_precautions": [
        "Hypersensitivity",
        "Hyperoxaluria"
      ],
      "side_effects": [
        "Loose stools",
        "Yellow discoloration of skin",
        "Chronic overdosage can lead to peeling and redness of the skin",
        "Loss of appetite",
        "Diarrhea and other gastrointestinal disturbances",
        "Abdominal pain",
        "Fatigue",
        "Weakness"
      ],
      "drug_interactions": [
        "Neomycin",
        "Bleomycin",
        "Aminophylline",
        "Nitrofurantoin sodium",
        "Conjugated oestrogens",
        "Sulphafurazole diethanolamine",
        "Chloramphenicol sodium succinate",
        "Chlorothiazide sodium",
        "Hydrocortisone sodium succinate"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "High doses should not be given during pregnancy.",
        "lactation": "High doses should not be given during lactation."
      },
      "preparation": {
        "tablet": "(6 mg + 200 mg + 50 mg)"
      }
    },
    {
      "name": "Rice ORS®",
     "img_id":"twbBjZH.jpeg",
      "image": "Rice-ORS_1_e.jpg",
      "active_ingredients": {
        "500_ml_water": {
          "sodium_chloride": "1.30 gm",
          "potassium_chloride": "0.75 gm",
          "tri_sodium_citrate_dihydrate": "1.45 gm",
          "processed_rice_powder": "25 gm"
        },
        "250_ml_water": {
          "sodium_chloride": "0.650 gm",
          "potassium_chloride": "0.375 gm",
          "tri_sodium_citrate_dihydrate": "0.725 gm",
          "processed_rice_powder": "12.500 gm"
        }
      },
      "indication_and_uses": [
        "Acute fluid & electrolyte loss conditions such as cholera, acute diarrhea & vomiting",
        "Dehydration",
        "Severely low concentrations of salts in the blood (severe electrolyte depletion)"
      ],
      "dosage_and_administration": {
        "guideline": {
          "6_months_to_2_years": "50 ml to 100 ml (10 to 20 Teaspoonfuls) after each watery stool",
          "2_years_to_9_years": "100 ml to 200 ml (20 to 40 teaspoonfuls) after each watery stool",
          "10_years_and_above": "250 ml to 500 ml (1 to 2 glassfuls) after each watery stool"
        }
      },
      "contraindications_and_precautions": {
        "not_to_be_used_in": [
          "Kidney failure resulting in diminished production of urine",
          "Kidney failure preventing production of urine",
          "Obstruction of the stomach or intestines",
          "Reduced blood flow to vital internal organs (shock)",
          "Severe & continuous vomiting (intractable vomiting)",
          "Severe dehydration",
          "Severe diarrhea in infants"
        ],
        "precautions_for_overdose": [
          "Children less than 1 year of age",
          "Patients with imbalance of salt concentrations in the blood (electrolyte imbalance)",
          "Patients with severely decreased kidney function",
          "Patients with severely decreased liver function"
        ]
      },
      "drug_interactions": "There is no known drug interaction reported.",
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Rice ORS® is recommended in pregnancy, as there is no known harmful effect when used.",
        "lactation": "Rice ORS® is recommended during lactation, as there is no known harmful effect when used."
      },
      "use_in_children": "Safety & effectiveness of Rice ORS in pediatric patients below the age of 6 months have not been established.",
      "preparation": {
        "250_ml_water": "Each box contains 10 sachets",
        "500_ml_water": "Each box contains 10 sachets"
      }
    },
    {
      "name": "Robic®",
     "img_id":"a7HiUQ0.jpeg",
      "image": "ROBIC.jpg",
      "active_ingredients": "Ornidazole",
      "indication_and_uses": [
        "Amoebiasis (Intestinal & hepatic)",
        "Giardiasis",
        "Trichomoniasis",
        "Bacterial vaginosis",
        "Treatment of susceptible anaerobic infections"
      ],
      "dosage_and_administration": {
        "amoebiasis": {
          "adults": "500 mg twice a day for 5 days",
          "children": "10-25 mg/kg body weight in 2 divided doses"
        },
        "amoebic_dysentery": {
          "adults": "1.5 gm once a day for 3 days",
          "children": "40 mg/kg body weight once a day for 3 days"
        },
        "giardiasis": {
          "adults": "1.5 gm once daily for 1-2 days",
          "children": "40 mg/kg body weight for 2 days"
        },
        "trichomoniasis": {
          "dosage": "1.5 gm once or 500 mg twice a day for 5 days",
          "note": "Sexual partner should also be treated at the same time"
        },
        "bacterial_vaginosis": {
          "dosage": "3 tablets of 500 mg each as a single dose or one tablet of 500 mg once daily for 5-7 days"
        }
      },
      "contraindications_and_precautions": {
        "contraindications": [
          "Hypersensitivity",
          "Epilepsy",
          "Peripheral neuropathy"
        ],
        "precautions": [
          "In patients with ataxia, vertigo, & mental confusion, Ornidazole should be prescribed with caution"
        ]
      },
      "side_effects": [
        "Nausea",
        "Vomiting",
        "Epigastric pain",
        "Dizziness",
        "Headache",
        "Lassitude",
        "Leukopenia (occasionally)"
      ],
      "drug_interactions": [
        "Disulfiram-like reactions",
        "Concomitant administration of oral anticoagulants may increase the risk of hemorrhage due to diminished hepatic metabolism",
        "Ornidazole has been reported to decrease the clearance of 5-fluorouracil"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Ornidazole should be prescribed only if the potential benefit justifies the potential risk to fetus/neonate",
        "lactation": "Caution is advised"
      },
      "preparation": "500 mg Tablet"
    },
    {
      "name": "RosuvaTM",
     "img_id":"d00bjO9.jpeg",
      "image": "Rosuva-5.jpg",
      "active_ingredients": "Rosuvastatin",
      "indication_and_uses": ["Hypercholesterolemia"],
      "dosage_and_administration": {
        "recommended_dosage": "5-40 mg once daily"
      },
      "contraindications": [
        "Hypersensitivity to Rosuvastatin or any of its components",
        "Active liver disease or unexplained persistent elevations of serum transaminases"
      ],
      "side_effects": [
        "Myalgia",
        "Constipation",
        "Asthenia",
        "Abdominal pain",
        "Nausea"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Not recommended. Should be administered to women of childbearing age only when such patients are highly unlikely to conceive",
        "lactation": "Not recommended"
      },
      "preparation": ["5 mg Tablet", "10 mg Tablet", "20 mg Tablet"]
    },
    {
      "name": "Rutix®",
     "img_id":"tI5Bkww.jpeg",
      "image": "RUTIX-200.jpg",
      "active_ingredients": "Ofloxacin",
      "indication_and_uses": [
        "Chronic bronchitis",
        "Lung abscess",
        "Pneumonia",
        "Enteric fever",
        "Shigellosis",
        "Multi-drug-resistant tuberculosis",
        "Uncomplicated skin and skin structure infections",
        "Acute gonorrhoea",
        "Nongonococcal urethritis and cervicitis",
        "Urinary Tract Infections"
      ],
      "dosage_and_administration": {
        "adults": "200 mg to 800 mg daily for 5-7 days",
        "children": "15 mg/kg/day in two divided doses",
        "acute_or_chronic_prostatitis": "200 mg twice daily for 28 days"
      },
      "contraindications": [
        "Hypersensitivity",
        "Epilepsy",
        "Children or growing adolescents",
        "Pregnant or breastfeeding women"
      ],
      "side_effects": [
        "Nausea",
        "Rash",
        "Vomiting",
        "Abdominal pain",
        "Diarrhoea",
        "Dizziness",
        "Insomnia"
      ],
      "drug_interactions": [
        "Antacids containing magnesium, aluminium, or calcium may decrease absorption of ofloxacin",
        "Iron or Zinc may decrease oral absorption of ofloxacin"
      ],
      "preparation": ["200 mg Tablet", "400 mg Tablet"]
    },
    {
      "name": "Saga®",
     "img_id":"dJtqscR.jpeg",
      "image": "Saga_e.jpg",
      "active_ingredients": "Sparfloxacin",
      "indication_and_uses": [
        "Community acquired pneumonia",
        "Chronic Bronchitis"
      ],
      "dosage_and_administration": {
        "loading_dose": "Two Saga tablets on the first day",
        "maintenance_dose": "One tablet of Saga every 24 hours for a total of 10 days therapy"
      },
      "contraindications_and_precautions": [
        "Hypersensitivity or photosensitivity reactions",
        "Adjustment of the dosage regimen is necessary for patients with impaired renal function (creatinine clearance < 50 ml/min)"
      ],
      "side_effects": [
        "Photosensitivity reaction",
        "Diarrhoea",
        "Nausea",
        "Headache",
        "Dyspepsia",
        "Dizziness",
        "Insomnia",
        "Abdominal pain",
        "QTc interval prolongation"
      ],
      "drug_interactions": ["Antacids & Sucralfate", "Zinc/iron salts"],
      "use_in_pregnancy_and_lactation": [
        "Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus",
        "Safety & effectiveness have not been established in patients below the age of 18 years"
      ],
      "preparation": ["200 mg Tablet"]
    },
    {
      "name": "Salicid™",
     "img_id":"qlMtLB4.jpeg",
      "image": "Salicid-30-gm-Cream_l.jpg",
      "active_ingredients": "Salicylic Acid BP 12%",
      "indication_and_uses": ["Corns and Calluses", "Warts", "Verruca"],
      "dosage_and_administration": {
        "application_instructions": "Apply to the affected area once daily (preferably at night). If possible, hydrate area for 5 minutes to soften prior to application. Occlude the area at night. Wash off in the morning."
      },
      "contraindications_and_precautions": [
        "Should not be used in any patient known to be allergic to Salicylic Acid or any other used ingredients."
      ],
      "side_effects": [
        "An allergic reaction (shortness of breath, closing of the throat, swelling of the lips, face or tongue and hives)",
        "Severe skin irritation may occasionally occur."
      ],
      "use_in_pregnancy_and_lactation": "Pregnancy Category C. If used by nursing mothers, it should not be used on the chest area.",
      "preparation": "30 gm cream"
    },
    {
      "name": "Scabex®",
     "img_id":"MYzBoAv.jpeg",
      "image": "SCABEX-30-gm.jpg",
      "active_ingredients": "Permethrin",
      "indication_and_uses": ["Scabies"],
      "dosage_and_administration": {
        "adults": "One full tube (30 gm)",
        "children": "1/8 (30 gm) of a tube",
        "application_instructions": "Patients >2 months of age can use the dermal cream. It should be applied to the whole body excluding the head."
      },
      "contraindications_and_precautions": ["Hypersensitivity"],
      "side_effects": [
        "Skin discomfort",
        "Burning",
        "Stinging or tingling",
        "Erythema",
        "Edema",
        "Eczema",
        "Rash",
        "Pruritus"
      ],
      "drug_interaction": "The treatment of eczematous-like reactions with corticosteroids should be withheld prior to treatment with Permethrin.",
      "use_in_pregnancy_and_lactation": "Permethrin is suggested not to use during pregnancy & lactation.",
      "preparation": "30 gm Cream"
    },
    {
      "name": "Seclo®",
     "img_id":"XMgDmoF.png",
      "image": "Seclo.png",
      "active_ingredients": "Omeprazole",
      "indication_and_uses": [
        "Gastroesophageal reflux disease including reflux esophagitis",
        "Acid reflux disease",
        "Duodenal & benign gastric ulcers",
        "Helicobacter pylori eradication regimens in peptic ulcer disease",
        "Prophylaxis of acid aspiration",
        "Zollinger-Ellison Syndrome",
        "Treatment of NSAID-associated gastric ulcers, duodenal ulcers or gastroduodenal erosions"
      ],
      "dosage_and_administration": {
        "capsule": {
          "gastroesophageal_reflux_disease": "The usual dosage is 20 mg Omeprazole once daily. For refractory cases, 40 mg once daily. Treatment duration: 4-8 weeks.",
          "acid_reflux_disease": "For long-term management, 10 mg once daily, increasing to 20 mg if symptoms return.",
          "duodenal_benign_gastric_ulcers": "20 mg once daily. Healing occurs within 4-8 weeks. For recurrent cases, 40 mg daily.",
          "helicobacter_pylori": "40 mg once daily or 20 mg twice daily with Amoxicillin 1 g and Clarithromycin 500 mg twice daily for 7-14 days.",
          "prophylaxis_of_acid_aspiration": "40 mg on the evening before surgery and 40 mg 2-6 hours prior to surgery.",
          "zollinger_ellison_syndrome": "60 mg once daily. Adjust dosage as needed with a maximum of 120 mg daily, divided into two doses.",
          "NSAID_associated_gastric_ulcers": "20 mg once daily. Symptom resolution within 4 weeks, with further healing over 4 weeks if necessary."
        },
        "children": {
          "gerd_or_other_acid_related_disorders": [
            {
              "age": ">1 year",
              "body_weight": "10-20 kg",
              "dose": "10 mg once daily, can be increased to 20 mg daily."
            },
            {
              "age": ">2 years",
              "body_weight": ">20 kg",
              "dose": "20 mg once daily, can be increased to 40 mg daily."
            }
          ]
        },
        "IV_injection": {
          "duodenal_ulcer": "40 mg once daily if oral administration is inappropriate.",
          "zollinger_ellison_syndrome": "60 mg daily. Higher doses may be required, with doses exceeding 60 mg split into two doses."
        },
        "IV_direction": {
          "injection": "Reconstitute with 10 ml water for injection. Administer slowly over 2-5 minutes.",
          "infusion": "Reconstitute with 100 ml saline or 5% dextrose. Infuse over 20-30 minutes."
        }
      },
      "contraindications_and_precautions": [
        "No known contraindications.",
        "Exclude malignancy if gastric ulcer is suspected, as symptoms may be alleviated, delaying diagnosis."
      ],
      "side_effects": [
        "Nausea",
        "Diarrhoea",
        "Abdominal colic",
        "Paresthesia",
        "Dizziness",
        "Headache"
      ],
      "use_in_pregnancy_and_lactation": "US FDA pregnancy category C. Omeprazole is excreted in breast milk but is not likely to affect the child when used at therapeutic doses.",
      "preparation": ["20 mg Capsule", "40 mg Capsule", "40 mg IV Injection"]
    },
    {
      "name": "Seclo® MUPS",
     "img_id":"O5bzvmQ.png",
      "image": "Seclo-MUPS_l.png",
      "active_ingredients": "Omeprazole",
      "description": "Seclo® MUPS is a modified release tablet using the Multiple-Unit Pellet System (MUPS) technology. It ensures greater bioavailability, uniform drug release, and better absorption, offering a combination of fast and sustained action with once-daily dosing.",
      "clinical_advantage": [
        "Ensures greater bioavailability",
        "Uniform emptying of micro pellets from the stomach into the small intestine",
        "Minimizes dose dumping",
        "Combination of fast-acting and sustained action",
        "Uniform drug release",
        "Once-daily dosing",
        "Better drug absorption and reduced localized irritation",
        "Better than capsules in reducing esophageal residence time"
      ],
      "pharmacodynamic_advantages": [
        "Ensures rapid and uniform gastric emptying",
        "Larger surface area for more consistent drug dissolution",
        "Reduces inter- and intra-subject variability in absorption and clinical response",
        "Minimizes the possibility of dose dumping and incomplete drug release"
      ],
      "indications": [
        "Duodenal and Gastric ulcers",
        "NSAID-induced gastric and duodenal ulcers",
        "Reflux Esophagitis",
        "GERD (Gastroesophageal Reflux Disease)",
        "Eradication of H. pylori with appropriate antibiotics",
        "Zollinger-Ellison Syndrome"
      ],
      "dosage_and_administration": {
        "adult": {
          "GERD": "20 mg once daily for 4 weeks",
          "gastric_ulcer": "20 mg once daily for 4-8 weeks; in severe cases, twice daily",
          "duodenal_ulcer": "20 mg once daily for 2-4 weeks; in severe cases, twice daily",
          "NSAID_induced_ulceration": "20 mg once daily for 4-8 weeks",
          "reflux_esophagitis": "20 mg once daily for 4-8 weeks; in severe cases, twice daily",
          "h_pylori_eradication": "20 mg twice daily for 1 week with Amoxicillin and Clarithromycin or Metronidazole"
        },
        "children_over_2_years_old": {
          "acid_regurgitation_in_GERD": "20 mg once daily for 2-4 weeks",
          "reflux_esophagitis": "20 mg once daily for 4-8 weeks"
        }
      },
      "contraindication": "Hypersensitivity to any components of the formulation.",
      "precaution": "Use with caution in patients with severe liver dysfunction and severe renal impairment.",
      "use_in_pregnancy_and_lactation": "Not known to be harmful. Can be used during pregnancy. Excreted in breast milk but unlikely to influence the child at therapeutic doses.",
      "drug_interaction": "Omeprazole is metabolized via CYP2C19. Potential interactions with drugs metabolized by CYP2C19 should be considered when starting or stopping treatment.",
      "storage": "Store in a cool (below 30°C) and dry place, protect from light and moisture.",
      "how_supplied": {
        "name": "Seclo® MUPS 20 Tablet",
        "quantity": "30 tablets in Alu-Alu blister pack"
      }
    },
    {
      "name": "Secnid®",
     "img_id":"iFwRNrf.jpeg",
      "image": "SECNID-DS.jpg",
      "active_ingredients": "Secnidazole",
      "indications": [
        "Intestinal Amoebiasis",
        "Hepatic Amoebiasis",
        "Urethritis & Vaginitis due to Trichomonas vaginalis",
        "Giardiasis"
      ],
      "dosage_and_administration": {
        "DS_tablet": {
          "acute_intestinal_amoebiasis": {
            "adults": "2 gm single dose, preferably just before meal",
            "children": "30 mg/kg single dose, preferably just before meal"
          },
          "asymptomatic_amoebiasis": {
            "adults": "2 gm once daily for 3 days, preferably just before meal",
            "children": "30 mg/kg once daily for 3 days, preferably just before meal"
          },
          "hepatic_amoebiasis": {
            "adults": "1.5 gm/day in single or divided doses, just before meal, for 5 days",
            "children": "30 mg/kg/day in single or divided doses, just before meal, for 5 days"
          },
          "giardiasis": {
            "adults": "2 gm single dose, preferably just before meal",
            "children": "35-50 mg/kg single dose, preferably just before meal"
          },
          "trichomoniasis": {
            "adults": "2 gm single dose, preferably just before meal",
            "partner": "The partner should also receive the same treatment concomitantly"
          }
        },
        "secnid_suspension": {
          "children_10_to_15_kg": "1 bottle of Secnid 500 Suspension",
          "children_16_to_25_kg": "1 & 1/2 bottles of Secnid 500 Suspension",
          "children_26_kg_or_more": "2 bottles of Secnid 500 Suspension"
        }
      },
      "contraindication_and_precaution": [
        "Hypersensitivity",
        "Patients should avoid alcohol during treatment",
        "Avoid in patients with a history of blood dyscrasia"
      ],
      "side_effects": [
        "Nausea",
        "Epigastric pain",
        "Metallic taste",
        "Glossitis",
        "Stomatitis",
        "Urticaria",
        "Moderate leukopenia (reversible)"
      ],
      "rare_side_effects": [
        "Vertigo",
        "Ataxia",
        "Motor incoordination",
        "Paresthesia",
        "Peripheral neuropathy"
      ],
      "drug_interaction": ["Disulfiram", "Warfarin"],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Can be prescribed after the first trimester",
        "lactation": "Should not be used during lactation"
      },
      "preparation": "1 gm DS Tablet"
    },
    {
      "name": "Secrin®",
     "img_id":"3rHSxTq.jpeg",
      "image": "Secrin-1_l.jpg",
      "active_ingredients": "Glimepiride",
      "indications": ["Type 2 diabetes"],
      "dosage_and_administration": {
        "initial_dose": "1 mg once daily",
        "dose_adjustment": "If necessary, the daily dose can be increased based on regular blood sugar monitoring, with gradual increments.",
        "maximum_dose": "8 mg daily"
      },
      "contraindication_and_precaution": [
        "Type-I diabetes mellitus",
        "Diabetic precoma or coma",
        "Hypersensitivity to Glimepiride, other sulphonylureas, or sulfonamides",
        "Risk of hypoglycemia during initial weeks of treatment, requiring careful monitoring"
      ],
      "side_effects": [
        "Hypoglycemia",
        "Temporary visual impairment",
        "Nausea",
        "Vomiting",
        "Diarrhea",
        "Abdominal pain",
        "Urticaria",
        "Fall in blood pressure"
      ],
      "drug_interaction": {
        "potentiation_of_blood_sugar_lowering_effect": [
          "Insulin",
          "Other oral antidiabetics",
          "ACE inhibitors",
          "Allopurinol",
          "Anabolic steroids & male sex hormones",
          "Chloramphenicol",
          "Coumarin derivatives",
          "Fluoxetine",
          "MAO inhibitors",
          "Miconazole",
          "Para-aminosalicylic acid",
          "Pentoxifylline",
          "Phenylbutazone",
          "Oxyphenbutazone",
          "Quinolones",
          "Salicylates",
          "Sulfonamides",
          "Tetracyclines",
          "Beta blockers"
        ],
        "weakening_of_blood_sugar_lowering_effect": [
          "Acetazolamide",
          "Barbiturates",
          "Corticosteroids",
          "Diazoxide",
          "Diuretics",
          "Epinephrine & other sympathomimetic agents",
          "Laxatives",
          "Oestrogens & progestogens",
          "Phenothiazines",
          "Phenytoin",
          "Rifampicin",
          "Thyroid hormones",
          "H2-receptor antagonists",
          "Clonidine & reserpine"
        ],
        "alcohol_interaction": "Both acute and chronic alcohol intake may potentiate or weaken the blood-sugar-lowering action of glimepiride unpredictably"
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Glimepiride must not be taken during pregnancy",
        "lactation": "Glimepiride must not be taken by breast-feeding women"
      },
      "preparation": [
        "1 mg tablet",
        "2 mg tablet",
        "3 mg tablet",
        "4 mg tablet"
      ]
    },
    {
      "name": "Secrin® M",
     "img_id":"lBK2USE.jpeg",
      "image": "Secrin-M_l.jpg",
      "active_ingredients": ["Glimepiride", "Metformin Hydrochloride"],
      "indications": [
        "Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Glimepiride and Metformin is appropriate"
      ],
      "dosage_and_administration": {
        "initial_dose": "1 mg Glimepiride & 500 mg Metformin once daily with breakfast or first main meal",
        "starting_dose_for_monotherapy": "Secrin® M 1/500 tablet once daily, gradually titrated after assessing therapeutic response",
        "titration": "The daily dose must be titrated in increments of 1 tablet",
        "maximum_dose": "8 mg Glimepiride and 2000 mg Metformin daily",
        "switching_therapy": "When switching from combination therapy to separate tablets, Glimepiride & Metformin should be administered separately",
        "precautions": "Secrin® M 1/500 tablet must be swallowed whole and not crushed or chewed",
        "combination_with_insulin": "A lower dose of Glimepiride or Insulin may be required to reduce the risk of hypoglycemia"
      },
      "contraindication_and_precaution": {
        "Glimepiride": [
          "Hypersensitivity to Glimepiride, other sulfonylureas, other sulfonamides, or any of the excipients",
          "Pregnancy",
          "Breastfeeding"
        ],
        "Metformin": [
          "Hypersensitivity to Metformin or any of the excipients",
          "Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma",
          "Renal disease or renal dysfunction (serum creatinine levels >1.5 mg/dL [males], >1.4 mg/dL [females] or abnormal creatinine clearance)"
        ]
      },
      "adverse_effects": {
        "Glimepiride": [
          "Hypoglycemia (may be prolonged)",
          "Temporary visual impairment due to blood glucose level changes",
          "Gastrointestinal symptoms: nausea, vomiting, abdominal discomfort, diarrhea",
          "Allergic reactions: itching, urticaria, rashes"
        ],
        "Metformin": [
          "Gastrointestinal symptoms: nausea, vomiting, diarrhea, abdominal pain, loss of appetite"
        ]
      },
      "drug_interaction": {
        "Glimepiride": {
          "potentiation_of_hypoglycemic_action": [
            "NSAIDs",
            "Salicylates",
            "Sulfonamides",
            "Chloramphenicol",
            "Coumarins",
            "Probenecid",
            "MAO inhibitors",
            "Beta adrenergic blocking agents",
            "Clarithromycin"
          ],
          "hyperglycemic_interactions": [
            "Thiazides",
            "Diuretics",
            "Corticosteroids",
            "Phenothiazines",
            "Thyroid products",
            "Estrogens",
            "Oral contraceptives",
            "Phenytoin",
            "Nicotinic acid",
            "Sympathomimetics",
            "Isoniazid"
          ],
          "miconazole_interaction": "Potential severe hypoglycemia with oral miconazole"
        },
        "Metformin": {
          "nifedipine_interaction": "Nifedipine enhances Metformin absorption",
          "cationic_drugs_interaction": "Cationic drugs eliminated by renal tubular secretion may interact with Metformin",
          "hyperglycemic_interactions": [
            "Thiazides",
            "Diuretics",
            "Corticosteroids",
            "Phenothiazines",
            "Thyroid products",
            "Estrogens",
            "Oral contraceptives",
            "Phenytoin",
            "Nicotinic acid",
            "Sympathomimetics",
            "Calcium channel blockers",
            "Isoniazid"
          ]
        }
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Not recommended due to potential harm to the child. Consider insulin therapy instead",
        "lactation": "Not recommended for breastfeeding mothers. Consider insulin therapy if diet alone is inadequate",
        "geriatric_use": "Use with caution in the elderly due to reduced renal function",
        "pediatric_use": "Safety and effectiveness in pediatric patients have not been established"
      },
      "preparation": ["1 mg Glimepiride & 500 mg Metformin tablet"]
    },
    {
      "name": "Sedil®",
     "img_id":"KmihSYL.jpeg",
      "image": "Sedil_large.jpg",
      "active_ingredients": "Diazepam",
      "indications": [
        "Anxiety pain from apprehension & depression",
        "Acute & chronic stress of life",
        "Skeletal muscle spasm",
        "Strychnine poisoning",
        "Premedication for surgical measures (I.M. route recommended)"
      ],
      "dosage_and_administration": {
        "recommended_dose": "15 to 30 mg daily in divided doses"
      },
      "contraindication_and_precaution": [
        "Hypersensitivity to Diazepam",
        "Porphyria or family history of porphyria"
      ],
      "side_effects": [
        "Drowsiness",
        "Headache",
        "Ataxia",
        "Vertigo",
        "Dry mouth",
        "Inattentiveness",
        "Hypotension",
        "Gastrointestinal disturbances",
        "Visual disturbances"
      ],
      "drug_interaction": {
        "intensified_sedation": [
          "Neuroleptics",
          "Tranquillizers",
          "Antidepressants",
          "Hypnotics",
          "Analgesics",
          "Anaesthetics"
        ]
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Category D, use is not recommended due to potential harm",
        "lactation": "Breastfeeding is not recommended during treatment"
      },
      "preparation": ["5 mg Tablet", "10 mg/2 ml Injection"]
    },
    {
      "name": "Sedno®",
     "img_id":"8NaEi1B.jpeg",
      "image": "Sedno-Tab-PRO_l.jpg",
      "active_ingredients": "Desloratadine",
      "indications": ["Allergic Rhinitis", "Chronic Idiopathic Urticaria"],
      "dosage_and_administration": {
        "adults_and_over_12_years": {
          "syrup": "10 ml (2 teaspoonful) once daily",
          "tablet": "One tablet (5 mg) once daily"
        },
        "children_6_11_years": {
          "syrup": "5 ml (1 teaspoonful) daily",
          "tablet": "2.5 mg (half of one 5 mg tablet) once daily"
        },
        "children_1_5_years": {
          "syrup": "2.5 ml (1/2 teaspoonful) daily"
        },
        "children_6_11_months": {
          "syrup": "2 ml (1.0 mg) once daily or as directed by the physician"
        },
        "liver_or_renal_impairment": {
          "starting_dose": "One Sedno® Tablet (Desloratadine 5 mg) every other day"
        }
      },
      "contraindication_and_precaution": [
        "Hypersensitivity to Desloratadine or any of its ingredients",
        "Hypersensitivity to Loratadine",
        "Caution in elderly patients due to possible hepatic, renal, cardiac function decline, and other concurrent disease or therapy"
      ],
      "side_effects": [
        "Dry mouth",
        "Fatigue",
        "Myalgia",
        "Somnolence",
        "Headache",
        "Nausea",
        "Dizziness",
        "Dyspepsia",
        "Pharyngitis"
      ],
      "drug_interaction": {
        "increased_plasma_concentration_of_desloratadine": [
          "Erythromycin",
          "Ketoconazole",
          "Azithromycin",
          "Fluoxetine",
          "Cimetidine"
        ],
        "note": "No clinically relevant changes in the safety profile of Desloratadine"
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Category C, should be used only if clearly needed",
        "lactation": "A decision should be made whether to discontinue nursing or Desloratadine, considering the importance of the drug to the mother"
      },
      "preparation": ["5 mg Tablet", "2.5 mg/5 ml Syrup"]
    },
    {
      "name": "Siglimet™",
     "img_id":"Aewxqo9.jpeg",
      "image": "Siglimet.jpg",
      "active_ingredients": [
        "Sitagliptin Phosphate Monohydrate",
        "Metformin HCl"
      ],
      "indication": [
        "Adjunct to diet & exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Sitagliptin & Metformin is appropriate"
      ],
      "dosage_and_administration": {
        "general_guidelines": "Dose of this combination should be individualized based on the patient's current regimen, effectiveness, and tolerability. Maximum recommended daily dose: 100 mg sitagliptin & 2000 mg metformin.",
        "administration_frequency": "Twice daily with meals, with gradual dose escalation to reduce gastrointestinal side effects.",
        "starting_dose_for_patients_not_on_metformin": "50 mg sitagliptin / 500 mg metformin hydrochloride twice daily.",
        "starting_dose_for_patients_on_metformin": "50 mg sitagliptin / 1000 mg metformin hydrochloride twice daily if already on 850 mg metformin twice daily.",
        "co-administration_with_insulin_or_secretagogues": "Patients on insulin secretagogues or insulin may require lower doses to reduce the risk of hypoglycemia."
      },
      "contraindication_and_precaution": [
        "Renal disease or renal dysfunction (serum creatinine levels ≥1.5 mg/dL for males, ≥1.4 mg/dL for females)",
        "Acute or chronic metabolic acidosis, including diabetic ketoacidosis",
        "History of serious hypersensitivity reactions such as anaphylaxis or angioedema"
      ],
      "side_effects": [
        "Diarrhea",
        "Nausea/vomiting",
        "Flatulence",
        "Abdominal discomfort",
        "Indigestion",
        "Asthenia",
        "Headache"
      ],
      "drug_interaction": {
        "renal_tubular_interaction": "Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) may interact with metformin by competing for common renal tubular transport systems.",
        "digoxin_interaction": "Co-administration of Digoxin and Sitagliptin may slightly increase the mean peak drug concentration of Digoxin, but no dosage adjustment is required."
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Category B. The safety of this combination in pregnant women is not known. It should only be used if clearly needed.",
        "lactation": "It is not known whether sitagliptin is excreted in human milk. Caution should be exercised when administered to a nursing woman."
      },
      "use_in_children": "Safety and effectiveness in pediatric patients under 18 years of age have not been established.",
      "preparation": [
        "Siglimet™ 50/500 Tablet",
        "Siglimet™ 50/1000 Tablet",
        "Siglimet™ XR 50/500 Tablet",
        "Siglimet™ XR 50/1000 Tablet",
        "Siglimet™ XR 100/1000 Tablet"
      ]
    },
    {
      "name": "Siglita™",
     "img_id":"jQKNjRK.jpeg",
      "image": "Siglita-50_l.jpg",
      "active_ingredients": ["Sitagliptin Phosphate Monohydrate"],
      "indication": ["For the Management of Type 2 Diabetes"],
      "dosage_and_administration": {
        "general_guidelines": "The recommended dose of Siglita™ is 100 mg once daily. Siglita™ can be taken with or without food.",
        "renal_insufficiency_guidelines": {
          "mild_renal_insufficiency": "For patients with mild renal insufficiency (CrCl ≥50 mL/min), no dosage adjustment is required.",
          "moderate_renal_insufficiency": "For patients with moderate renal insufficiency (CrCl ≥30 to <50 mL/min), the dose of Siglita™ is 50 mg once daily.",
          "severe_renal_insufficiency_or_esrd": "For patients with severe renal insufficiency (CrCl <30 mL/min) or ESRD requiring hemodialysis or peritoneal dialysis, the dose of Siglita™ is 25 mg once daily. It can be administered without regard to the timing of hemodialysis."
        }
      },
      "contraindication_and_precaution": [
        "History of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema."
      ],
      "side_effects": [
        "Upper respiratory tract infection",
        "Nasopharyngitis",
        "Headache",
        "Hypoglycemia may occur in patients treated with the combination of Sitagliptin & sulfonylurea or add-on to insulin."
      ],
      "drug_interaction": {
        "digoxin_interaction": "Co-administration of Digoxin and Sitagliptin may slightly increase the mean peak drug concentration of Digoxin, but no dosage adjustment is recommended."
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Category B. Safety of Sitagliptin in pregnant women has not been established. Siglita™ should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.",
        "lactation": "It is not known whether sitagliptin is excreted in human milk. Caution should be exercised when Siglita™ is administered to a nursing woman."
      },
      "use_in_children": "Safety and effectiveness in pediatric patients under 18 years of age have not been established.",
      "preparation": ["Siglita™ 50 mg Tablet"]
    },
    {
      "name": "Solider™",
     "img_id":"Y3a9D4z.jpeg",
      "image": "Solider-Pro_l.jpg",
      "active_ingredients": [
        "Solifenacin Succinate INN 5 mg",
        "Solifenacin Succinate INN 10 mg"
      ],
      "indications": [
        "Symptomatic treatment of urge incontinence",
        "Increased urinary frequency and urgency in patients with Overactive Bladder syndrome"
      ],
      "dosage_and_administration": {
        "general_guidelines": "The recommended dose of Solifenacin Succinate is 5 mg once daily. If well tolerated, the dose may be increased to 10 mg once daily. Solifenacin should be taken with liquids and swallowed whole, with or without food.",
        "maximum_effect": "The maximum effect can be determined after 4 weeks at the earliest."
      },
      "contraindications": [
        "Hypersensitivity to Solifenacin",
        "Angioedema",
        "Urinary retention",
        "Dependent on dialysis",
        "Gastroparesis",
        "Uncontrolled narrow angle glaucoma"
      ],
      "adverse_effects": [
        "Dry mouth",
        "Constipation",
        "Blurred vision (accommodation abnormalities)",
        "Urinary retention",
        "Dry eyes"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Category C. There are no adequate studies investigating the effects in pregnant women. Should only be used if the potential benefit justifies the potential risk to the fetus.",
        "lactation": "It is not known whether Solifenacin is excreted in human milk. Should not be administered during nursing."
      },
      "use_in_children": "Safety and efficacy have not been established in children under 18 years of age.",
      "dosing_considerations": {
        "renal_impairment": "For severe renal impairment (CrCl <30 mL/min), a daily dose greater than 5 mg is not recommended. Solifenacin is contraindicated in dialysis-dependent patients.",
        "hepatic_impairment": "For moderate hepatic impairment (Child-Pugh B), a daily dose greater than 5 mg is not recommended. Use in severe hepatic impairment (Child-Pugh C) is not recommended.",
        "cyp450_3a4_inhibitors": "When administered with CYP3A4 inhibitors such as ketoconazole, the daily dose should be maintained at 5 mg."
      },
      "warning": [
        "Use with caution in patients with bladder outlet obstruction at risk of urinary retention, GI obstructive disorders, and risk of decreased GI motility. Should not exceed 5 mg.",
        "Prolongation of QT interval may occur, especially with the 30 mg daily dosage.",
        "Use with caution in patients being treated for angle-closure glaucoma."
      ],
      "drug_drug_interactions": {
        "cytochrome_p450": "Solifenacin is a substrate of CYP3A4, and its pharmacokinetics may be altered by CYP3A4 inhibitors or inducers.",
        "oral_contraceptives": "No significant changes in plasma concentrations of combined oral contraceptives (ethinyl estradiol/levonorgestrel).",
        "warfarin_and_digoxin": "Solifenacin has no significant effect on the pharmacokinetics of R-warfarin or S-warfarin and Digoxin."
      },
      "preparation": ["Solider™ 5 mg Tablet", "Solider™ 10 mg Tablet"]
    },
    {
      "name": "Solo™",
     "img_id":"ic8aVDf.jpeg",
      "image": "Solo_e.jpg",
      "active_ingredients": ["Sodium Chloride 0.9%"],
      "indications": [
        "Moistens dry nasal passages from dry climates or airplane travel",
        "Helps dissolve mucus from stuffy noses",
        "Clears the nose after surgery",
        "Cleanses various parts of the body (wounds, body cavities)",
        "Cleanses medical equipment (bandages, catheters, drainage tubes)",
        "Used as a mixing solution (diluent) for other medications"
      ],
      "dosage_and_administration": {
        "general_guidelines": "Infants, children, and adults: 2-6 drops into each nostril as needed daily."
      },
      "contraindications_and_precautions": [
        "Consult your doctor about your medical history, especially of heart problems (e.g., congestive heart failure), lung problems (pulmonary edema), kidney problems, low levels of potassium (hypokalemia), high levels of sodium (hypernatremia), and any allergies."
      ],
      "adverse_effects": [
        "Stinging",
        "Sneezing",
        "Increased nasal discharge",
        "Salty taste"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Consult with your doctor before use during pregnancy.",
        "lactation": "It is unknown if this medication passes into breast milk. Consult with your doctor before breastfeeding."
      },
      "use_in_children": "Safe for pediatrics.",
      "preparation": "10 ml"
    },
    {
      "name": "Solo™ 0.9% IV",
     "img_id":"L0TNdSH.png",
      "image": "solo1.png",
      "active_ingredients": ["Sodium Chloride BP 0.9% w/v"],
      "indications": [
        "Source of electrolytes and water for hydration in adults and pediatric patients",
        "Extracellular fluid replacement",
        "Treatment of metabolic alkalosis in the presence of fluid loss",
        "Mild sodium depletion",
        "Priming solution in hemodialysis procedures",
        "Pharmaceutical aids and diluents for compatible drug additives"
      ],
      "dosage_and_administration": {
        "general_guidelines": "The concentration and dosage are determined by factors such as age, weight, and clinical condition. Usually, the adult dose is about 1000 ml of 0.9% infusion."
      },
      "contraindications_and_precautions": [
        "Contraindicated where the administration of sodium or chloride could be clinically detrimental.",
        "Careful monitoring of serum electrolyte concentration is necessary.",
        "Administer with caution to patients with congestive heart failure, peripheral or pulmonary edema, impaired renal function, or pre-eclampsia."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Pregnancy Category C. The effects on the fetus and reproduction capacity are not known.",
        "lactation": "It is not known whether this drug is excreted in human milk. Caution should be exercised when administered to a nursing woman."
      },
      "preparation": "500 & 1000 ml intravenous infusion. "
    },
    {
      "name": "Solodex™ IV",
     "img_id":"ZZklFCk.jpeg",
      "image": "Solodex-IV-500-ml.jpg",
      "active_ingredients": [
        "Sodium Chloride BP 0.9% w/v",
        "Dextrose USP 5% w/v"
      ],
      "indications": [
        "Combined water and sodium depletion",
        "Provides dextrose as a nutrient in a sodium chloride medium isotonic to body fluid",
        "Maintenance and replacement of fluid, electrolyte, and carbohydrate in patients unable to take fluids or nutrients by mouth (e.g., due to persistent vomiting, surgery, shock, or accidents)"
      ],
      "dosage_and_administration": {
        "general_guidelines": "The dose is variable and depends on the clinical condition, age, and body surface area of the patient."
      },
      "contraindications_and_precautions": [
        "Should not be used in hyperhydration states, hypotonic dehydration, and hypokalemia.",
        "Contains Sodium Chloride, so it should be used with caution in patients with congestive heart failure, peripheral or pulmonary edema, impaired renal function, or pre-eclampsia."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Pregnancy Category C. The effects on the fetus and reproduction capacity are not known.",
        "lactation": "It is not known whether this drug is excreted in human milk. Caution should be exercised when administered to a nursing woman."
      },
      "preparation": {
        "1000_ml": "Each 1000 ml PP bottle contains a solution of Sodium Chloride BP 0.9% w/v and Dextrose 5% USP w/v.",
        "500_ml": "Each 500 ml PP bottle contains a solution of Sodium Chloride BP 0.9% w/v and Dextrose 5% USP w/v."
      }
    },
    {
      "name": "Solodex™ JR IV",
     "img_id":"IG1k94m.jpeg",
      "image": "Solodex-JR_w.jpg",
      "active_ingredients": [
        "Sodium Chloride BP 0.45% w/v",
        "Dextrose Anhydrous USP 5% w/v"
      ],
      "indications": [
        "Water and sodium depletion",
        "Provides dextrose as a nutrient in a suitable medium of sodium chloride or may be used as a source of sodium chloride",
        "Used for maintenance and replacement of fluid, electrolyte, and carbohydrate in patients, especially children, who are unable to take fluids and nutrients by mouth (e.g., due to persistent vomiting, surgery, shock, or accidents)"
      ],
      "dosage_and_administration": {
        "general_guidelines": "The volume and rate of infusion depend on the clinical condition, age, and body surface area of the patient, and should be determined by the physician."
      },
      "contraindications_and_precautions": [
        "Contraindicated in patients with hypernatremia, acidosis, hypokalemia, and fluid overload."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "It is not known whether Dextrose and Sodium Chloride Infusion can cause fetal harm or affect reproductive capacity when administered to a pregnant woman.",
        "lactation": "It is not known whether this drug is excreted in human milk. Caution should be exercised when administered to a nursing woman."
      },
      "preparation": {
        "500_ml": "Each 500 ml PP bottle contains a solution of Sodium Chloride BP 0.45% w/v and Dextrose Anhydrous USP 5% w/v."
      }
    },
    {
      "name": "Solodex™ Baby IV",
     "img_id":"AlCViiC.jpeg",
      "image": "Solodex-Baby_w.jpg",
      "active_ingredients": [
        "Sodium Chloride BP 0.225% w/v",
        "Dextrose Anhydrous USP 5% w/v"
      ],
      "indications": [
        "Water and sodium depletion",
        "Provides dextrose as a nutrient in a suitable medium of sodium chloride or may be used as a source of sodium chloride",
        "Used for maintenance and replacement of fluid, electrolyte, and carbohydrate in patients, especially neonates and infants, who are unable to take fluids and nutrients by mouth (e.g., due to persistent vomiting, surgery, shock, or accidents)"
      ],
      "dosage_and_administration": {
        "general_guidelines": "The volume and rate of infusion depend on the clinical condition, age, and body surface area of the patient, and should be determined by the physician."
      },
      "contraindications_and_precautions": [
        "Contraindicated in patients with hypernatremia, acidosis, hypokalemia, and fluid overload."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "It is not known whether Dextrose and Sodium Chloride Infusion can cause fetal harm or affect reproductive capacity when administered to a pregnant woman.",
        "lactation": "It is not known whether this drug is excreted in human milk. Caution should be exercised when administered to a nursing woman."
      },
      "preparation": {
        "500_ml": "Each 500 ml PP bottle contains a solution of Sodium Chloride BP 0.225% w/v and Dextrose Anhydrous USP 5% w/v."
      }
    },
    {
      "name": "Sonap®",
     "img_id":"b7HBypj.jpeg",
      "image": "sonap_250.jpg",
      "active_ingredients": "Naproxen Sodium",
      "indications": [
        "Rheumatoid Arthritis",
        "Degenerative Arthritis",
        "Ankylosing Spondylitis",
        "Juvenile Rheumatoid Arthritis",
        "Tendinitis",
        "Bursitis",
        "Acute gout",
        "Acute musculoskeletal disorders (such as sprains, direct trauma & fibrositis)",
        "Migraine",
        "Dysmenorrhoea"
      ],
      "dosage_and_administration": {
        "rheumatoid_arthritis_osteoarthritis_ankylosing_spondylitis": "250 to 500 mg twice daily. May be increased to 1.50 gm for limiting periods.",
        "mild_to_moderate_pain_primary_dysmenorrhoea_acute_tendinitis_bursitis": "500 mg initially, followed by 250 mg every 6 to 8 hours as required. Do not exceed a 1.375 gm total daily dose.",
        "acute_gout": "750 mg, then 250 mg every 6 to 8 hours until attack subsides.",
        "juvenile_arthritis_children_over_5_years": "10 mg/kg daily in two divided doses is recommended."
      },
      "contraindications_and_precautions": [
        "Use with caution in patients with cardiac, hepatic & renal impairment, coagulation defect, & previous history of gastrointestinal ulceration.",
        "Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID, including those in whom attacks of asthma, angioedema, urticaria, or rhinitis have been precipitated by aspirin or any other NSAID."
      ],
      "side_effects": [
        "Nausea",
        "Diarrhoea",
        "Occasionally bleeding & ulceration",
        "Hypersensitivity reactions: bronchospasm, rashes & angioedema",
        "CNS side effects: drowsiness, headache, fluid retention, vertigo, tinnitus, & photosensitivity",
        "A few instances of jaundice, impairment of renal function, thrombocytopenia, & agranulocytosis"
      ],
      "drug_interactions": [
        "ACE inhibitors",
        "Coumarin-type anticoagulants",
        "Sulfonylureas",
        "Propranolol & other beta-blockers",
        "Probenecid",
        "Methotrexate"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "The drug should not be used during pregnancy unless clearly needed.",
        "lactation": "Use in nursing mothers must be avoided."
      },
      "preparation": {
        "250_mg": "250 mg Tablet",
        "500_mg": "500 mg Tablet"
      }
    },
    {
      "name": "Specbac®",
     "img_id":"O5hLnmB.jpeg",
      "image": "Specbac-250mg-inj.jpg",
      "active_ingredients": "Meropenem",
      "indications": [
        "Pneumonias & Nosocomial Pneumonias",
        "Urinary Tract Infections",
        "Intra-abdominal Infections",
        "Gynaecological Infections such as endometritis",
        "Skin & Skin Structure Infections",
        "Meningitis",
        "Septicaemia",
        "Empiric treatment for presumed infections in adult patients with febrile neutropenia & other polymicrobial infections"
      ],
      "dosage_and_administration": {
        "adults": {
          "pneumonia_uti_gynaecological_infections_skin_infections": "500 mg IV every 8 hours",
          "nosocomial_pneumonias_peritonitis_presumed_infections_neutropenic_patients_septicaemia": "1 g IV every 8 hours",
          "cystic_fibrosis": "Doses up to 2 gm every 8 hours",
          "meningitis": "2 gm every 8 hours"
        },
        "children": {
          "over_3_months_to_12_years": "10 to 20 mg/kg every 8 hours",
          "children_over_50_kg": "Adult dosage should be used",
          "4_years_to_18_years_with_cystic_fibrosis": "25 to 40 mg/kg every 8 hours",
          "meningitis": "40 mg/kg every 8 hours"
        }
      },
      "contraindications": ["Hypersensitivity to this product"],
      "adverse_effects": [
        "Inflammation",
        "Thrombophlebitis",
        "Pain at the site of injection",
        "Skin reactions: rash, pruritus, urticaria",
        "Abdominal pain",
        "Nausea",
        "Vomiting",
        "Diarrhoea",
        "Headache",
        "Paraesthesiae"
      ],
      "precautions": [
        "As with all beta-lactam antibiotics, rare hypersensitivity reactions have been reported.",
        "Before initiating therapy with meropenem, careful inquiry should be made concerning previous hypersensitivity reactions to beta-lactam antibiotics.",
        "The co-administration of Specbac with potentially nephrotoxic drugs should be considered with caution."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Specbac should not be used in pregnancy unless the potential benefit justifies the potential risk to the fetus.",
        "lactation": "Specbac should not be used in breastfeeding women unless the potential benefit justifies the potential risk to the baby."
      },
      "preparation": {
        "250_mg": "250 mg IV Injection",
        "500_mg": "500 mg IV Injection",
        "1_gm": "1 gm IV Injection"
      }
    },
    {
      "name": "Splendora™",
     "img_id":"AF6LQD3.png",
      "image": "SPlendora_large.png",
      "active_ingredients": "Minoxidil",
      "indications": [
        "For the treatment of alopecia androgenetica (hair loss) in males & females between 18 to 65 years of age"
      ],
      "dosage_and_administration": {
        "application": "Apply 1 ml (7 sprays) of Splendora™ topical solution twice daily at 12-hour intervals to the scalp, beginning at the centre of the affected area & spreading the solution out to cover the entire affected area.",
        "max_dose": "The total daily application dose should not exceed 2 ml.",
        "dry_time": "Splendora™ topical solution should be allowed to remain on the scalp for about 4 hours before washing. The night-time application should be done 2–4 hours before going to bed to allow the solution to dry out.",
        "application_instructions": "Do not massage the solution into the scalp. A hair dryer should not be used to speed up drying. Do not mix with any hair oil.",
        "missed_application": "If a daily application is missed, continue with the next application.",
        "washing_instructions": "Hands should be washed immediately if Minoxidil topical solution is applied with the fingertips.",
        "results_timing": "Twice-daily applications for 4 months or more may be required for hair growth evidence. To arrest hair fall, use for not less than 45 days."
      },
      "contraindications": [
        "Patients with cardiac abnormalities",
        "Children below 18 years of age",
        "Patients using occlusive dressings or other medicines on the scalp",
        "Patients with red, inflamed, infected, irritated, or painful scalp (including psoriasis & sunburn)"
      ],
      "side_effects": [
        "Dermatitis",
        "Hypertrichosis (occurs in 0.1–5% of patients)"
      ],
      "drug_interactions": [
        "Do not use with topical agents that alter the stratum corneum barrier (e.g., tretinoin or dithranol) as it enhances absorption of Minoxidil.",
        "Theoretical possibility of potentiating orthostatic hypotension when combined with peripheral vasodilators."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Minoxidil topical solution should not be used during pregnancy.",
        "lactation": "Minoxidil topical solution should not be used during lactation."
      },
      "preparation": {
        "topical_solution": "5% topical solution"
      }
    },
    {
      "name": "SQ-Mycetin® Eye/Ear Drops",
     "img_id":"8ZRT8CT.jpeg",
      "image": "SQ-Mycetin_l.jpg",
      "active_ingredients": "Chloramphenicol",
      "indications": [
        "Bacterial infection involving conjunctiva or cornea",
        "Otitis externa"
      ],
      "dosage_and_administration": {
        "eye": "2 drops every 1-4 hours depending upon the severity.",
        "ear": "2-3 drops every 3-4 hours."
      },
      "contraindications_and_precautions": [
        "Hypersensitivity or toxic reactions.",
        "Blood dyscrasias (granulocytopenia, thrombocytopenia & moderate anaemia) may occur after prolonged ophthalmic use."
      ],
      "side_effects": [
        "Bone marrow hypoplasia",
        "Rarely optic atrophy in children",
        "Stinging & burning of the eye",
        "Vesicular or maculopapular dermatitis",
        "Sore throat",
        "Angioedema"
      ],
      "drug_interactions": [
        "Chymotrypsin will be inhibited if given simultaneously with Chloramphenicol."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Use only when considered essential by the physicians.",
        "lactation": "Use only when considered essential by the physicians."
      },
      "preparation": {
        "eye_ear_drops": "0.5% Eye/Ear Drops"
      }
    },
    {
      "name": "Square Zinc®",
     "img_id":"9JT8T0u.jpeg",
      "image": "Square-zinc.jpg",
      "active_ingredients": "Zinc Sulphate Monohydrate USP",
      "indications": [
        "Treatment of diarrhea in children from 2 months to 5 years of age in connection with Oral Rehydration Salts (ORS)",
        "Treatment of other zinc deficiency conditions such as loss of appetite, severe growth retardation, deformed bone formation, impaired immunological response, recurrent respiratory tract infections, acrodermatitis enteropathica, parakeratotic skin lesions, defective and delayed wound healing, anemia, night blindness, and mental disturbances"
      ],
      "dosage_and_administration": {
        "diarrhea_treatment": {
          "2_to_6_months": "10 mg elemental zinc once daily for 10-14 days",
          "6_months_to_5_years": "20 mg elemental zinc once daily for 10-14 days"
        },
        "other_indications": {
          "under_10_kg": "10 mg elemental zinc 2 times daily",
          "10_to_30_kg": "20 mg elemental zinc 1-3 times daily",
          "over_30_kg": "40 mg elemental zinc 1-3 times daily"
        }
      },
      "contraindications": ["Hypersensitivity to zinc"],
      "precautions_and_warnings": [
        "Concurrent administration of Zinc salt with penicillamine might diminish the effect of penicillamine.",
        "Absorption of Zinc may be decreased by various compounds, including some foods.",
        "Chelation may occur with tetracyclines."
      ],
      "drug_interactions": [
        "Zinc may inhibit the absorption of concurrently administered tetracyclines. When both are being given, an interval of at least 3 hours should be allowed."
      ],
      "overdose": {
        "symptoms": [
          "Corrosion and inflammation of the mucous membrane of the mouth and stomach",
          "Ulceration of the stomach followed by perforation"
        ],
        "management": [
          "Gastric lavage and emesis should be avoided",
          "Demulcents such as milk should be given",
          "Chelating agents such as sodium edetate may be useful"
        ]
      },
      "preparation": {
        "tablet": "20 mg tablet"
      }
    },
    {
      "name": "Sulprex™ HFA Inhaler",
     "img_id":"4Qr3lU6.jpeg",
      "image": "sulprex_large.jpg",
      "active_ingredients": ["Ipratropium", "Salbutamol"],
      "indications": [
        "For patients with chronic obstructive pulmonary disease (COPD) and asthma who continue to have bronchospasm and require a second bronchodilator."
      ],
      "dosage_and_administration": {
        "recommended_dose": "Two inhalations four times a day.",
        "maximum_dose": "The total number of inhalations should not exceed 12 in 24 hours.",
        "additional_dose": "Patients may take additional inhalations as required."
      },
      "contraindications_and_precautions": [
        "Contraindicated in patients with a history of hypersensitivity to soya lecithin or related food products such as soybean and peanut."
      ],
      "side_effects": [
        "Edema",
        "Fatigue",
        "Hypertension",
        "Dizziness",
        "Nervousness",
        "Paresthesia",
        "Tremor",
        "Dysphonia",
        "Insomnia",
        "Diarrhea",
        "Dry mouth",
        "Dyspepsia",
        "Vomiting",
        "Arrhythmia",
        "Palpitation",
        "Tachycardia",
        "Arthralgia",
        "Angina",
        "Increased sputum",
        "Taste perversion",
        "Urinary tract infection/dysuria"
      ],
      "preparation": {
        "inhaler": "Each puff delivers 20 mcg of Ipratropium bromide & 100 mcg of Salbutamol, 200 puffs."
      }
    },
    {
      "name": "Sulprex™ Nebuliser Solution",
     "img_id":"ctU7IIn.jpeg",
      "image": "SULPREX-NEBULIZER-2.5ML.jpg",
      "active_ingredients": ["Ipratropium", "Salbutamol"],
      "indications": [
        "For the management of bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD)."
      ],
      "dosage_and_administration": {
        "recommended_dose": "1 ampoule three or four times daily.",
        "administration_method": "May be administered from a suitable nebulizer or an intermittent positive pressure ventilator.",
        "age_group": "Adults (including elderly patients) and children over 12 years."
      },
      "contraindications_and_precautions": [
        "Contraindicated in patients with hypertrophic obstructive cardiomyopathy or tachyarrhythmia.",
        "Contraindicated in patients with hypersensitivity to ipratropium bromide, salbutamol sulfate, or to atropine or its derivatives."
      ],
      "side_effects": [
        "Dry mouth",
        "Nervousness",
        "Dizziness",
        "Tremor",
        "Headache",
        "Palpitations",
        "Tachycardia",
        "Cough",
        "Dysphonia",
        "Nausea",
        "Arrhythmia",
        "Atrial fibrillation",
        "Myocardial ischaemia"
      ],
      "use_in_pregnancy_and_lactation": [
        "Should not be used in pregnancy, especially the first trimester, unless the expected benefit outweighs any possible risk to the fetus.",
        "Should not be administered to breastfeeding mothers unless the expected benefit outweighs any possible risk to the neonate."
      ],
      "preparation": {
        "solution": "(Ipratropium 500 mcg + Salbutamol 2.5 mg)/2.5 ml, 10 ampoules."
      }
    },
    {
      "name": "Sultolin®",
     "img_id":"7NXHVa6.jpeg",
      "image": "Sultolin-cozycap_l.jpg",
      "active_ingredients": "Salbutamol",
      "indications": ["Bronchial asthma", "Chronic bronchitis", "Emphysema"],
      "dosage_and_administration": {
        "Sultolin_SR_tablet": "8 mg tablet twice daily",
        "Sultolin_syrup": "1-2 mg 3 to 4 times daily. Not recommended below 2 years of age.",
        "Sultolin_100_HFA_Inhaler": "2 puffs 3-4 times daily",
        "Sultolin_Cozycap": "1-2 Cozycap may be administered as a single dosage. The usual recommended dosage for adults is the contents of one 200 mg capsule every 4 to 6 hours using a revolizer device."
      },
      "contraindications_and_precautions": [
        "Hypersensitivity to the active ingredient"
      ],
      "side_effects": [
        "Nervousness",
        "Tremor",
        "Headache",
        "Tachycardia",
        "Palpitation",
        "Less frequent adverse reactions: Muscle cramps, insomnia, nausea, weakness, dizziness, chest discomfort"
      ],
      "drug_interaction": [
        "Other oral sympathomimetic agents should not be used concomitantly.",
        "Cautions to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants."
      ],
      "preparation": {
        "Sultolin_SR_tablet": "8 mg SR Tablet",
        "Sultolin_syrup": "2 mg/5 ml Syrup",
        "Sultolin_100_HFA_Inhaler": "100 µg/puff",
        "Sultolin_Cozycap": "200 µg DPI Capsule"
      }
    },
    {
      "name": "Sultolin® Respirator Solution",
     "img_id":"hpNBr7L.jpeg",
      "image": "SULTOLIN-SOLUTION-20ML.jpg",
      "active_ingredients": "Salbutamol",
      "indications": [
        "Treatment of severe acute asthma (status asthmaticus)",
        "Bronchospasm in adults and children",
        "Effective in children >18 months"
      ],
      "dosage_and_administration": {
        "intermittent_administration": {
          "adult": "Sultolin Respirator Solution 0.5-1.0 ml should be diluted to final volume of 2.0-4.0 ml with normal saline for injection. The resulting solution is inhaled from a suitably driven nebulizer until aerosol generation ceases (about 10 minutes).",
          "undiluted": "For undiluted use, 2.0 ml of the solution is placed in the nebulizer and inhaled until bronchodilatation is achieved (usually 3-5 minutes).",
          "children_under_12": "Children under 12 years of age: 0.5 ml of the solution diluted to 2.0-4.0 ml with normal saline. Intermittent treatment may be repeated four times a day."
        },
        "continuous_administration": "Sultolin Respirator Solution is diluted with normal saline for injection, 1-2 ml solution made up to 100 ml with diluent. The diluted solution is administered as an aerosol by a suitably driven nebulizer at a rate of 1-2 mg/hour."
      },
      "contraindications_and_precautions": [
        "History of hypersensitivity to any of its components",
        "Use with care in patients known to have received large doses of other sympathomimetic drugs",
        "Use with care in patients with thyrotoxicosis"
      ],
      "side_effects": [
        "Small increase in heart rate",
        "Peripheral vasodilation",
        "Fine tremor of skeletal muscle"
      ],
      "use_in_pregnancy": "Unnecessary administration of drugs during the first trimester of pregnancy is undesirable.",
      "preparation": {
        "Sultolin_Respirator_Solution": "5 mg Salbutamol/ml, 20 ml Respirator Solution"
      }
    },
    {
      "name": "Susten™",
     "img_id":"YXGPpDR.jpeg",
      "image": "Susten.jpg",
      "active_ingredients": "Dapoxetine Hydrochloride",
      "indications": [
        "Premature ejaculation (PE) in men 18 to 64 years of age, who have:",
        "Persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the patient wishes.",
        "Marked personal distress or interpersonal difficulty as a consequence of PE and poor control over ejaculation."
      ],
      "dosage_and_administration": {
        "adult_men_18_to_64_years": {
          "starting_dose": "30 mg, taken as needed approximately 1 to 3 hours prior to sexual activity.",
          "maximum_dose": "If the effect of 30 mg is insufficient and side effects are acceptable, the dose may be increased to 60 mg.",
          "maximum_dosing_frequency": "One dose every 24 hours."
        }
      },
      "overdose": {
        "symptoms": [
          "Somnolence",
          "Gastrointestinal disturbances such as nausea and vomiting",
          "Tachycardia",
          "Tremor",
          "Agitation",
          "Dizziness"
        ],
        "management": "In cases of overdose, standard supportive measures should be adopted as required."
      },
      "side_effects": [
        "Dizziness",
        "Headache",
        "Somnolence",
        "Tremor",
        "Blurred vision",
        "Tinnitus",
        "Sinus congestion",
        "Nausea",
        "Diarrhea",
        "Abdominal pain",
        "Dry mouth",
        "Fatigue",
        "Insomnia",
        "Hypertension"
      ],
      "contraindications": [
        "Hypersensitivity to dapoxetine hydrochloride",
        "Significant pathological cardiac conditions such as heart failure (NYHA class II-IV), conduction abnormalities (second or third degree AV block or sick sinus syndrome) not treated with a permanent pacemaker, significant ischemic heart disease or significant valvular disease",
        "Concomitant treatment with monoamine oxidase inhibitors (MAOIs), thioridazine, or within 7 days after dapoxetine has been discontinued",
        "Concomitant treatment with serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), or other medicinal/herbal products with serotonergic effects, or within 14 days of discontinuing these treatments."
      ],
      "drug_interactions": {
        "CNS_active_medicinal_products": "Caution is advised if dapoxetine is administered with CNS active medicinal products.",
        "PDE5_inhibitors": {
          "tadalafil": "No significant effect on dapoxetine pharmacokinetics.",
          "sildenafil": "Slight changes in dapoxetine pharmacokinetics, not expected to be clinically significant, but caution is advised due to possible reduced orthostatic tolerance."
        },
        "Tamsulosin": "No changes in the pharmacokinetics of tamsulosin with dapoxetine, but caution is advised due to possible reduced orthostatic tolerance.",
        "Warfarin": "Caution is advised when dapoxetine is used in patients taking warfarin chronically.",
        "Ethanol": "Avoid alcohol while taking dapoxetine as it may increase the chance of dizziness, drowsiness, slow reflexes, altered judgment, and enhance neurocardiogenic adverse events such as syncope."
      },
      "use_in_pregnancy_and_lactation": "Dapoxetine is not indicated for use by women.",
      "preparation": "30 mg tablets"
    },
    {
      "name": "Suvotol",
     "img_id":"GWcC3zr.jpeg",
      "image": "suvotol-pack_l.jpg",
      "active_ingredients": "Suvorexant",
      "indications": [
        "Insomnia, characterized by difficulties with sleep onset and/or sleep maintenance."
      ],
      "dosage_and_administration": {
        "recommended_dose": "10 mg, no more than once per night, taken before 30 minutes of going to bed, with at least 7 hours remaining before the planned time of awakening.",
        "time_to_effect": "Time to effect may be delayed if taken with or soon after a meal."
      },
      "contraindications": ["Do not use in patients with narcolepsy."],
      "special_warnings_and_precautions": [
        "Daytime somnolence: Risk of impaired alertness and motor coordination, including impaired driving; risk increases with dose.",
        "Caution patients taking 20 mg against next-day driving and other activities requiring complete mental alertness.",
        "Need to evaluate for co-morbid diagnoses: Reevaluate if insomnia persists after 7 to 10 days of treatment."
      ],
      "side_effects": [
        "Sleepiness during the day",
        "Not thinking clearly",
        "Act strangely, confused, or upset",
        "Sleep-walking"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy_category": "C",
        "note": "There are no adequate and well-controlled studies in pregnant women."
      },
      "preparation": "10 mg Tablet"
    },
    {
      "name": "Suzyme®",
     "img_id":"YhbTBVh.png",
      "image": "Suzyme.png",
      "active_ingredients": "Pancreatin",
      "indications": {
        "children": [
          "Reduced or absence of pancreatic exocrine secretion",
          "Cystic fibrosis"
        ],
        "adults": [
          "In the conditions with deficient pancreatic exocrine function such as:",
          "Following pancreatectomy",
          "Following total gastrectomy",
          "Chronic pancreatitis",
          "Steatorrhea",
          "Somatostatinoma",
          "Celiac disease"
        ]
      },
      "dosage_and_administration": "1-3 tablets daily with a meal or as per the direction of the physician.",
      "contraindications_and_precautions": [
        "A proper balance between fat, protein, and starch intake must be maintained to avoid temporary indigestion."
      ],
      "side_effects": [
        "Pancreatin may cause buccal and perianal soreness, particularly in infants.",
        "Hypersensitivity reactions may include sneezing, lacrimation, or skin rashes."
      ],
      "drug_interactions": [
        "Alkaline media will rupture the enteric coating. To prevent bursting out of the content in the stomach, Pancreatin should not be used concurrently with antacids."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy_category": "C",
        "note": "Not known whether Pancreatin is distributed into milk. Caution advised if Pancreatin is used."
      },
      "preparation": "325 mg tablet"
    },
    {
      "name": "Tazid®",
     "img_id":"yxl5PDo.jpeg",
      "image": "TAZID-1GM-INJECTION.jpg",
      "active_ingredients": "Ceftazidime",
      "indications": [
        "Single infections",
        "Mixed infections",
        "Severe infections in general",
        "Respiratory tract infections",
        "Ear, nose & throat infections",
        "Skin & soft tissue infections",
        "Gastrointestinal, biliary & abdominal infections",
        "Bone & joint infections",
        "Infections associated with hemo & peritoneal dialysis & with continuous ambulatory peritoneal dialysis (CAPD)"
      ],
      "dosage_and_administration": {
        "adults": "1 to 6 gram per day 8 or 12 hourly (IM/IV) in the majority of infections.",
        "children": {
          "over_two_months": "The usual dosage range for children aged over two months is 30 to 100 mg/kg/day, given as two or three divided doses.",
          "neonates_and_up_to_two_months": "The usual dosage range is 25 to 60 mg/kg/day as two divided doses."
        }
      },
      "pregnancy_and_lactation": {
        "pregnancy_category": "B",
        "note": "Ceftazidime is excreted in human breast milk & caution should be exercised when administered to a nursing woman."
      },
      "side_effects": [
        "Local: phlebitis or thrombophlebitis with IV administration; pain and/or inflammation after IM injection.",
        "Hypersensitivity: Urticarial rash, fever, pruritus, & very rarely angioedema & anaphylaxis (bronchospasm and/or hypotension).",
        "Diarrhea, nausea, vomiting, abdominal pain, & very rarely oral thrush or colitis, candidiasis, vaginitis.",
        "Headache, dizziness, paraesthesia & bad taste."
      ],
      "contraindications": [
        "Known hypersensitivity to Cephalosporin antibiotics."
      ],
      "drug_interactions": [
        "Increased nephrotoxicity has been reported following concomitant administration of cephalosporins & aminoglycoside antibiotics."
      ],
      "preparation": [
        "250 mg IM/IV Injection",
        "500 mg IM/IV Injection",
        "1 gm IM/IV Injection"
      ]
    },
    {
      "name": "Tazocilin™ 4.5 IV Infusion",
     "img_id":"uVV6EV4.jpeg",
      "image": "Tazocilin-4.5.jpg",
      "active_ingredients": "Piperacillin & Tazobactam",
      "indications": [
        "Nosocomial pneumonia (moderate to severe)",
        "Community-acquired pneumonia (moderate severity only)",
        "Uncomplicated & complicated skin & skin structure infections including cellulitis, cutaneous abscesses & ischemic/diabetic foot infections",
        "Postpartum endometritis or pelvic inflammatory disease",
        "Appendicitis (complicated by rupture or abscess) & peritonitis",
        "Management of neutropenic patients (adults, adolescents & children) with fever suspected to be due to bacterial infections"
      ],
      "dosage_and_administration": {
        "adults_and_children_over_12_years": "The usual dosage is Tazocilin 4.5 IV infusion given every eight hourly. The total daily dose of Piperacillin/Tazobactam depends on the severity & localization of the infection & can vary from 2.25 gm to 4.50 gm administered every six or eight hourly.",
        "neutropenia": "The recommended dose is Piperacillin/Tazobactam 4.5 gm every six hours in combination with an aminoglycoside.",
        "administration": "Piperacillin/Tazobactam may be given by slow intravenous infusion (over 20-30 minutes)."
      },
      "contraindications_and_precautions": [
        "Hypersensitivity to Piperacillin or any of the beta-lactam antibiotics & to Tazobactam or any other beta-lactamase inhibitor."
      ],
      "side_effects": [
        "Nausea, vomiting, diarrhoea",
        "Less commonly: stomatitis, dyspepsia, constipation, jaundice, hypotension, headache, insomnia, injection-site reactions",
        "Rarely: abdominal pain, hepatitis, oedema, fatigue, eosinophilia",
        "Very rarely: hypoglycemia, hypokalemia, pancytopenia, Stevens-Johnson syndrome, toxic epidermal necrolysis"
      ],
      "drug_interactions": [
        "Probenecid",
        "Anticoagulants",
        "Vecuronium",
        "Methotrexate"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Piperacillin/Tazobactam should only be used during pregnancy if clearly indicated.",
        "lactation": "Piperacillin is excreted in low concentrations in breast milk. Women who are breast-feeding should be treated only if clearly indicated."
      },
      "use_in_children": {
        "under_2_years": "Piperacillin/Tazobactam is not recommended for use in children below 2 years old due to insufficient data on safety."
      },
      "hepatic_impairment": "No dose adjustment is necessary.",
      "preparation": "4.5 gm IV Infusion"
    },
    {
      "name": "Tebast™",
     "img_id":"LL3NGox.jpeg",
      "image": "Tebast-Tab-PRO_l.jpg",
      "active_ingredients": "Ebastine",
      "indications": [
        "Seasonal & perennial allergic rhinitis",
        "Chronic Idiopathic Urticaria",
        "Allergic skin disorders"
      ],
      "dosage_and_administration": {
        "adults_over_12_years": "10 mg (one tablet) once daily",
        "children_6_to_12_years": "5 mg (half tablet) once daily",
        "food": "Ebastine may be taken with or without food."
      },
      "contraindications": [
        "Patients with a known hypersensitivity to Ebastine or any of its ingredients."
      ],
      "side_effects": [
        "Headache",
        "Dry mouth",
        "Drowsiness",
        "Less commonly: abdominal pain, dyspepsia, nausea, insomnia"
      ],
      "drug_interactions": [
        "Concomitant use of Ketoconazole, Itraconazole, Clarithromycin, or Erythromycin may increase plasma levels of Ebastine & cause QTc interval prolongation."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "The safety of Ebastine during pregnancy has not been established.",
        "lactation": "The safety of Ebastine during lactation has not been established."
      },
      "preparation": "10 mg tablet"
    },
    {
      "name": "Terminex™",
     "img_id":"htr1woQ.jpeg",
      "image": "terminex_large.jpg",
      "active_ingredients": ["Mifepristone", "Misoprostol"],
      "indications": [
        "Termination of early unwanted pregnancy up to 63 days (9 weeks)"
      ],
      "dosage_and_administration": {
        "step_1": "Patient will take 1 (one) Mifovent (Mifepristone) tablet orally.",
        "step_2": "After 24 hours, patient will take 4 (four) Isovent (Misoprostol) tablets sublingually.",
        "step_3": "After 10-14 days, patient will confirm her termination of pregnancy by ultrasonography."
      },
      "contraindications": [
        "Confirmed or suspected ectopic pregnancy",
        "IUD in place",
        "Chronic adrenal failure",
        "History of allergy to Mifepristone, Misoprostol, or other prostaglandins",
        "Hemorrhagic disorders or concurrent anticoagulant therapy"
      ],
      "side_effects": [
        "Commonly reported side effects: nausea, vomiting, diarrhea."
      ],
      "drug_interactions": {
        "mifepristone": "Although specific drug or food interactions with Mifepristone have not been studied, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism, increasing serum levels of Mifepristone.",
        "misoprostol": "Misoprostol has not been shown to interfere with the beneficial effects of aspirin on signs & symptoms of rheumatoid arthritis. Misoprostol does not exert clinically significant effects on the absorption, blood levels, and antiplatelet effects of therapeutic doses of aspirin."
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Terminex is indicated for use in the termination of pregnancy (through 63 days' pregnancy) and has no other approved indication for use during pregnancy.",
        "lactation": "It is not known whether Mifepristone is excreted in human milk. Since the effects of Mifepristone on infants are unknown, breast-feeding women should consult with their health care provider to decide if they should discard their breast milk for a few days following administration of the medications."
      },
      "preparation": [
        "One Mifepristone 200 mg tablet in one blister",
        "Four Misoprostol tablets of 200 mcg each in another blister"
      ]
    },
    {
      "name": "Tetrax®",
     "img_id":"IEwjqPi.jpeg",
      "image": "Tetrax-500.jpg",
      "active_ingredients": "Tetracycline",
      "indications": [
        "Rickettsial infection",
        "Mycoplasma pneumoniae infections",
        "Chlamydial Infections",
        "Nongonococcal or non-specific urethritis",
        "Lyme disease",
        "Brucellosis",
        "Miscellaneous infections including granuloma inguinale, cholera, glanders, relapsing fever & V. vulnifians",
        "Urinary tract infections",
        "Bronchitis",
        "PID",
        "STD",
        "Travelers diarrhea",
        "Acne vulgaris",
        "Prostatitis",
        "Syphilis",
        "Anaerobic infections"
      ],
      "dosage_and_administration": {
        "adults": "1-2 g daily given in 2-4 divided doses",
        "children": "25-50 mg/kg daily"
      },
      "contraindications_and_precautions": [
        "Hypersensitivity",
        "Systemic lupus erythematosus",
        "Renal impairment",
        "In impaired liver function, high doses should be avoided",
        "Potentially hepatotoxic drugs (including erythromycin, chloramphenicol, isoniazid & sulphonamides) should not be given concomitantly"
      ],
      "side_effects": [
        "Depression of bone growth",
        "Discoloration of the teeth when given during tooth development (i.e., during the later half of pregnancy, during infancy & in childhood)",
        "Anaphylaxis",
        "Urticaria & rashes are uncommon",
        "Photosensitivity reactions",
        "Epigastric distress & nausea",
        "Vomiting",
        "Appears to aggravate pre-existing renal failure",
        "Candidiasis",
        "Esophageal ulcerations"
      ],
      "use_in_pregnancy_and_lactation_and_children": {
        "pregnancy": "Tetracycline should not be used during pregnancy",
        "lactation": "Tetracycline should not be used during lactation",
        "children": "Tetracycline should not be used in children"
      },
      "preparation": "500 mg Capsule"
    },
    {
      "name": "Thyrin®",
     "img_id":"QKSqsiu.jpeg",
      "image": "Thyrin-25-Tablet_l.jpg",
      "active_ingredients": "Levothyroxine Sodium",
      "indications": [
        "Hypothyroidism - Primary (thyroidal)",
        "Secondary (pituitary) hypothyroidism",
        "Tertiary (hypothalamic) hypothyroidism",
        "Subclinical hypothyroidism",
        "Pituitary TSH suppression"
      ],
      "dosage_and_administration": {
        "adult_dosage": {
          "initial_starting_dose": "25-50 mcg/day",
          "adjustments": "Gradual increments in dose at 6-8 week intervals",
          "dose_range": "12.5-25 mcg increments until clinically euthyroid and serum TSH normal",
          "severe_hypothyroidism": "12.5-25 mcg/day with gradual increments of 25 mcg/day every 2-4 weeks",
          "secondary_or_tertiary_hypothyroidism": "Titration until clinically euthyroid and serum free-T4 restored to upper half of normal range",
          "elderly_or_cardio_patients": "1.7 mcg/kg/day"
        },
        "pediatric_dosage": {
          "newborns": "10-15 mcg/kg/day, or 50 mcg/day if serum T4 is very low or undetectable",
          "infants_children": "Initial dose 25 mcg/day with increments of 25 mcg every 2-4 weeks",
          "age_based_dosing": {
            "0-3_months": "10-15 mcg/kg/day",
            "3-6_months": "8-10 mcg/kg/day",
            "6-12_months": "6-8 mcg/kg/day",
            "1-5_years": "5-6 mcg/kg/day",
            "6-12_years": "4-5 mcg/kg/day",
            "over_12_years_incomplete_growth_puberty": "2-3 mcg/kg/day",
            "complete_growth_puberty": "1.7 mcg/kg/day"
          }
        }
      },
      "contraindications_and_precautions": [
        "Untreated subclinical or overt thyrotoxicosis of any etiology",
        "Acute myocardial infarction",
        "Uncorrected adrenal insufficiency",
        "Levothyroxine has a narrow therapeutic index, careful dosage titration is necessary to avoid over- or under-treatment"
      ],
      "side_effects": [
        "Fatigue",
        "Increased appetite",
        "Weight loss",
        "Heat intolerance",
        "Fever",
        "Excessive sweating",
        "Headache",
        "Nervousness",
        "Anxiety",
        "Irritability",
        "Tremors",
        "Muscle weakness",
        "Palpitations"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "US FDA Pregnancy Category A. Pregnancy may increase Levothyroxine requirements.",
        "lactation": "Thyroid hormones are excreted minimally in human milk; caution should be exercised when administered to a nursing woman."
      },
      "use_in_children": "Can be used",
      "preparation": "25 mcg & 50 mcg Tablet"
    },
    {
      "name": "Ticamet® Cozycap",
     "img_id":"aStcQZn.jpeg",
      "image": "Ticamet_11.jpg",
      "active_ingredients": ["Salmeterol", "Fluticasone Propionate"],
      "indications": [
        "Long term maintenance treatment of asthma",
        "Chronic Obstructive Pulmonary Disease (COPD)",
        "For patients 12 years of age and older"
      ],
      "dosage_and_administration": {
        "administration": "One dry powder capsule inhalation twice daily, approximately 12 hours apart"
      },
      "contraindications_and_precautions": [
        "Contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive measures",
        "CVS & CNS effects seen with all sympathomimetic drugs (e.g., increased blood pressure, heart rate, excitement)",
        "Significant hypokalemia in some patients",
        "Systemic eosinophilic conditions and vasculitis (Churg-Strauss syndrome)",
        "Be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy"
      ],
      "side_effects": [
        "Respiratory tract infection",
        "Pharyngitis",
        "Sinusitis",
        "Hoarseness/dysphonia",
        "Oral candidiasis",
        "Bronchitis",
        "Headache",
        "Nausea & vomiting",
        "GI discomfort & pain",
        "Diarrhoea",
        "Musculoskeletal pain",
        "Hypersensitivity reactions, including rash, angioedema & bronchospasm"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus"
      },
      "preparation": [
        "100 Cozycap (50 mcg + 100 mcg)",
        "250 Cozycap (50 mcg + 250 mcg)",
        "500 Cozycap (50 mcg + 500 mcg)"
      ]
    },
    {
      "name": "Ticamet® HFA Inhaler",
     "img_id":"3FGwXgr.jpeg",
      "image": "TICAMET-HFA-CFC.jpg",
      "active_ingredients": ["Salmeterol", "Fluticasone Propionate"],
      "indications": [
        "Regular treatment of asthma where the combination of LABA + Steroid is appropriate",
        "Effective for COPD patients"
      ],
      "dosage_and_administration": {
        "adults_and_adolescents": "2 puffs twice daily for patients 12 years and older"
      },
      "contraindications_and_precautions": {
        "contraindications": ["Hypersensitivity to any of the ingredients"],
        "precautions": [
          "Should not be used to treat acute asthma symptoms where a fast-acting bronchodilator (e.g., Salbutamol) is required"
        ]
      },
      "side_effects": [
        "Tremor",
        "Palpitations",
        "Headache",
        "Hoarseness",
        "Candidiasis (thrush) of the mouth and throat"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Should be used only if the expected benefit to the mother is greater than the possible risk to the fetus"
      },
      "preparation": [
        "125 HFA Inhaler (25 mcg of Salmeterol & 125 mcg of Fluticasone Propionate per puff, 120 puffs)",
        "250 HFA Inhaler (25 mcg of Salmeterol & 250 mcg of Fluticasone Propionate per puff, 120 puffs)"
      ]
    },
    {
      "name": "Ticalog TM 90",
     "img_id":"aSgDqRY.jpeg",
      "image": "ticalog_large.jpg",
      "active_ingredients": "Ticagrelor (Antiplatelet)",
      "indications": [
        "Prevention of Atherothrombotic events in adult patients with ACS (STEMI, Non-STEMI, Unstable Angina)",
        "PCI management"
      ],
      "dosage_and_administration": {
        "initial_dose": "180 mg loading dose (two tablets of 90 mg)",
        "maintenance_dose": "90 mg twice daily",
        "aspirin": "Take aspirin daily, usually 325 mg initially, followed by a maintenance dose of 75-100 mg"
      },
      "contraindications": [
        "Hypersensitivity to Ticagrelor or any of the excipients",
        "Active pathological bleeding (peptic ulcer)",
        "History of intracranial haemorrhage",
        "Moderate to severe hepatic impairment",
        "Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, nefazodone, ritonavir, atazanavir)"
      ],
      "drug_interactions": {
        "CYP3A_inhibitors": [
          "Avoid use with strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, telithromycin)"
        ],
        "CYP3A_inducers": [
          "Avoid use with potent inducers of CYP3A (e.g., rifampin, dexamethasone, phenytoin, carbamazepine, phenobarbital)"
        ],
        "aspirin": "Use of Ticagrelor with aspirin maintenance doses above 100 mg reduced the effectiveness of Ticagrelor",
        "simvastatin_lovastatin": "Avoid doses greater than 40 mg due to higher serum concentrations of these drugs",
        "digoxin": "Monitor digoxin levels when initiating or changing ticagrelor therapy",
        "other_concomitant_therapy": "Can be administered with unfractionated or low-molecular-weight heparin, GPIIb/IIIa inhibitors, proton pump inhibitors, beta-blockers, ACE inhibitors, and angiotensin receptor blockers"
      },
      "overdose": {
        "treatment": "No known antidote. Treatment should follow local standard medical practice. Prolonged bleeding risk expected."
      },
      "side_effects": [
        "Dyspnea",
        "Bleeding",
        "Headache",
        "Cough",
        "Dizziness",
        "Nausea",
        "Atrial fibrillation",
        "Hypertension",
        "Non-cardiac chest pain",
        "Diarrhea",
        "Back pain",
        "Hypotension",
        "Fatigue",
        "Chest pain"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Category C. Not recommended during pregnancy due to limited data.",
        "nursing_mothers": "Ticagrelor is excreted in milk. A decision should be made whether to discontinue breastfeeding or therapy, considering the risks."
      },
      "use_in_children": "Safety and efficacy in children below the age of 18 have not been established for the approved adult indications.",
      "preparation": "10 tablets in Alu-PVDC blister pack"
    },
    {
      "name": "Ticas®",
     "img_id":"4Vm7c0T.jpeg",
      "image": "ticas_small.jpg",
      "active_ingredients": "Fluticasone Propionate",
      "indications": [
        "Inflammatory and pruritic manifestations of corticosteroid-responsive eczema/dermatitis"
      ],
      "dosage_and_administration": {
        "frequency": "Once or twice daily"
      },
      "contraindications_and_precautions": [
        "Rosacea",
        "Acne vulgaris",
        "Peri-oral dermatitis",
        "Primary cutaneous viral infections (e.g., Herpes Simplex, chicken pox)",
        "Perianal and genital pruritus",
        "Fluticasone Propionate is not indicated for primarily infected skin lesions caused by fungal or bacterial infections",
        "Dermatoses in children under one year of age, including dermatitis and napkin eruptions"
      ],
      "side_effects": [
        "Local burning and pruritus",
        "Hypersensitivity reactions",
        "Atrophic changes in the skin such as thinning, striae, dilatation of the superficial blood vessels",
        "Hypertrichosis",
        "Hypopigmentation",
        "Secondary infection",
        "Hypercorticism"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Should only be considered if the expected benefit to the mother outweighs any potential risk to the fetus.",
        "lactation": "Should only be used if the expected benefit to the mother outweighs any potential risk to the infant."
      },
      "preparation": "10 gm Cream"
    },
    {
      "name": "Tilex® Max",
     "img_id":"3bo2v33.jpeg",
      "image": "Tilex-max.jpg",
      "active_ingredients": ["Glucosamine Sulfate", "Diacerein"],
      "indications": [
        "Osteoarthritis",
        "Rheumatoid arthritis",
        "Joint injuries"
      ],
      "dosage_and_administration": {
        "adults_and_children_over_12_years": "1 tablet twice daily (12-hourly) with food for 4-12 weeks"
      },
      "contraindications_and_precautions": [
        "Hypersensitivity to Glucosamine",
        "Diabetics should monitor blood glucose levels regularly",
        "No special studies were conducted in patients with renal or hepatic insufficiency, but administration should be under appropriate medical supervision for severe cases",
        "Children should not be supplemented with Glucosamine",
        "Contraindicated in patients allergic to shellfish (e.g., shrimp, crab), those with diabetes, asthma, alcohol dependence, or liver disease",
        "Complete blood count, liver function, and urinalysis should be monitored regularly",
        "Diacerein is contraindicated in pregnancy, lactation, and hypersensitivity to anthraquinone derivatives"
      ],
      "side_effects": [
        "Diarrhea",
        "Constipation",
        "Epigastric pain",
        "Heartburn",
        "Nausea",
        "Vomiting",
        "Headache",
        "Skin rashes",
        "Drowsiness",
        "Intense yellow coloring of urine"
      ],
      "drug_interactions": [
        "No significant drug interactions with antibiotics, antidepressants, antihypertensive agents, nitrates, antiarrhythmics, anxiolytics, hypoglycemic agents, or antisecretives",
        "Decreased absorption of Diacerein with aluminum and/or magnesium hydroxide antacids",
        "Increased risk of diarrhea with laxatives and antibiotics",
        "Avoid co-administration with fibers and phytic acids"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Glucosamine and Diacerein are contraindicated during pregnancy",
        "lactation": "Glucosamine and Diacerein are contraindicated during breastfeeding"
      },
      "preparation": "750 mg Glucosamine Sulfate & 50 mg Diacerein Tablet"
    },
    {
      "name": "Timotor™",
     "img_id":"RLSfS1z.jpeg",
      "image": "TIMOTOR-100MG.jpg",
      "active_ingredients": "Trimebutine Maleate",
      "indications": [
        "Treatment and relief of symptoms associated with irritable bowel syndrome (spastic colon)",
        "Postoperative paralytic ileus to accelerate the resumption of intestinal transit following abdominal surgery"
      ],
      "dosage_and_administration": {
        "adults": "100mg-200mg, 3 times per day before meals"
      },
      "adverse_reactions": [
        "Dry mouth",
        "Foul taste",
        "Diarrhea",
        "Dyspepsia",
        "Epigastric pain",
        "Nausea",
        "Constipation",
        "Drowsiness",
        "Fatigue",
        "Dizziness",
        "Hot/cold sensations",
        "Headache"
      ],
      "contraindications": [
        "Patients with known hypersensitivity to trimebutine maleate or any excipient"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "The use of trimebutine maleate in pregnant women is recommended",
        "lactation": "It is not known if trimebutine maleate passes into breast milk. This medication should be used while breastfeeding only if the potential benefits outweigh risks to the nursing infants"
      },
      "drug_interactions": [
        "Trimebutine maleate increases the duration of d-tubocurarine-induced curarization",
        "No other drug interactions have been observed during clinical trials or otherwise reported"
      ],
      "preparation": "100 mg Tablet"
    },
    {
      "name": "Tofator™",
     "img_id":"YFCTDXe.jpeg",
      "image": "tofator_l.jpg",
      "active_ingredients": "Tofacitinib Citrate INN",
      "indications": {
        "rheumatoid_arthritis": "Treatment of adult patients with moderately to severely active Rheumatoid Arthritis who have had an inadequate response or intolerance to Methotrexate. It may be used as monotherapy or in combination with Methotrexate or other nonbiologic Disease-Modifying Antirheumatic Drugs (DMARDs).",
        "psoriatic_arthritis": "Treatment of adult patients with active Psoriatic Arthritis who have had an inadequate response or intolerance to Methotrexate or other Disease-Modifying Antirheumatic Drugs (DMARDs).",
        "ulcerative_colitis": "Treatment of adult patients with moderately to severely active Ulcerative Colitis (UC)."
      },
      "dosage_and_administration": {
        "general": "Do not initiate Tofacitinib if absolute lymphocyte count <500 cells/mm3, an absolute neutrophil count (ANC) <1000 cells/mm3, or hemoglobin <9 g/dL.",
        "rheumatoid_arthritis": "Tofacitinib 5 mg twice daily.",
        "psoriatic_arthritis": "Tofacitinib 5 mg twice daily (in combination with nonbiologic DMARDs).",
        "ulcerative_colitis": "Tofacitinib 10 mg twice daily for at least 8 weeks; then 5 or 10 mg twice daily. Discontinue after 16 weeks of 10 mg twice daily if adequate therapeutic benefit is not achieved.",
        "renal_hepatic_impairment": "For patients with moderate and severe renal or hepatic impairment, Tofacitinib 5 mg once daily.",
        "limitations_of_use": "Use in combination with biologic DMARDs or potent immunosuppressants such as Azathioprine and Cyclosporine is not recommended."
      },
      "side_effects": {
        "rheumatoid_and_psoriatic_arthritis": [
          "Upper respiratory tract infection",
          "Nasopharyngitis",
          "Diarrhea",
          "Headache"
        ],
        "ulcerative_colitis": [
          "Nasopharyngitis",
          "Elevated cholesterol levels",
          "Headache",
          "Upper respiratory tract infection",
          "Increased blood creatine phosphokinase",
          "Rash",
          "Diarrhea",
          "Herpes zoster"
        ]
      },
      "precautions": [
        "Serious Infections: Avoid use during active serious infections, including localized infections.",
        "Gastrointestinal Perforations: Caution in patients at increased risk.",
        "Laboratory Monitoring: Regular monitoring of lymphocytes, neutrophils, hemoglobin, liver enzymes, and lipids is recommended.",
        "Immunizations: Avoid live vaccines while using Tofacitinib."
      ],
      "contraindications": ["None."],
      "use_in_specific_population": {
        "pregnancy": "Category C. No adequate and well-controlled studies in pregnant women.",
        "lactation": "No data on the use of Tofacitinib during breastfeeding.",
        "pediatric_use": "Safety and effectiveness in pediatric patients have not been established.",
        "geriatric_use": "Caution in elderly patients (65 years and older) due to higher incidence of infections."
      },
      "preparation": "5 mg Tablet"
    },
    {
      "name": "Togent®",
     "img_id":"ZibVH5O.jpeg",
      "image": "TOGENT.jpg",
      "active_ingredients": ["Diphenhydramine HCl", "Zinc acetate"],
      "indications": [
        "Temporarily relieves pain and itching associated with insect bites",
        "Minor burns",
        "Sunburn",
        "Minor skin irritations",
        "Minor cuts and scrapes",
        "Rashes due to poison ivy, poison oak, and poison sumac",
        "Dries the oozing and weeping of poison ivy, poison oak, and poison sumac"
      ],
      "dosage_and_administration": {
        "general": "Adults and children above 2 years: Apply to the affected area 3 to 4 times daily. The skin should be clean, cool, and dry before application. Avoid hot showers or baths before applying. Apply lightly until the cream disappears, covering all skin surfaces (e.g., between fingers and toes, under nails, on soles of the feet)."
      },
      "contraindications_and_precautions": [
        "Contraindicated in individuals with known allergy to its components, other pyrethroids or pyrethrins.",
        "Do not use on large areas of the body with any other product containing diphenhydramine, even if taken orally.",
        "Consult with a physician before use on chickenpox or measles.",
        "Avoid contact with eyes while using the product."
      ],
      "side_effects": [
        "Contact dermatitis with mild erythematous vesicular lesions and papules (occasionally reported)."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Use during pregnancy should only follow medical advice due to the absence of specific studies. Teratogenic effects are not anticipated.",
        "lactation": "Caution should be exercised in administering diphenhydramine to nursing mothers, but levels in breast milk following topical application are likely to be very low."
      },
      "preparation": "10 gm Cream"
    },
    {
      "name": "Topicort®",
     "img_id":"tBEBeO2.jpeg",
      "image": "TOPICORT.jpg",
      "active_ingredients": ["Hydrocortisone Acetate"],
      "indications": [
        "Irritant dermatitis",
        "Allergic dermatitis",
        "Eczema",
        "Seborrheic dermatitis",
        "Lichen simplex",
        "Pruritus ani",
        "Flexural psoriasis",
        "Itching and rashes caused by insect bites",
        "Minor thermal burns",
        "Sunburn"
      ],
      "dosage_and_administration": {
        "general": "Apply 2 or 3 times daily as directed."
      },
      "contraindications_and_precautions": [
        "Do not use in the presence of infections (bacterial, viral, fungal).",
        "Avoid use on skin ulcers.",
        "Hypersensitivity to any component of the formulation.",
        "In infants and children, long-term topical therapy should be avoided to prevent adrenal suppression."
      ],
      "side_effects": ["Hypersensitivity reactions may occur."],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "It is recommended that topical corticosteroids should not be used extensively during pregnancy.",
        "lactation": "Consult a physician before use during lactation."
      },
      "preparation": "10 gm Cream"
    },
    {
      "name": "Torax TM",
     "img_id":"y8hLYEY.jpeg",
      "image": "Torax-10.jpg",
      "active_ingredients": ["Ketorolac Tromethamine"],
      "indications": [
        "Short-term management of moderate to severe acute post-operative pain",
        "Acute pain of other origins"
      ],
      "dosage_and_administration": {
        "injection": {
          "adults": {
            "initial_dose": "60 mg IM (Single)",
            "maintenance_dose": "30 mg IM/IV every 6 hours",
            "maximum_dose": "120 mg/day"
          },
          "elderly_patients": {
            "initial_dose": "30 mg IM",
            "maintenance_dose": "10-15 mg IM/IV every 6 hours",
            "maximum_dose": "60 mg/day"
          },
          "duration": "Maximum duration of treatment should not exceed two days."
        },
        "tablets": {
          "dosage": "10 mg every 6 hours as required up to 7 days."
        }
      },
      "contraindications": [
        "Hypersensitivity to this drug or other NSAIDs.",
        "Patients in whom aspirin or other prostaglandin synthesis inhibitors induce allergic reactions.",
        "History of peptic ulcer or gastrointestinal bleeding.",
        "Moderate or severe renal impairment.",
        "History of asthma."
      ],
      "drug_interactions": [
        "NSAIDs",
        "Aspirin",
        "Anti-coagulants",
        "Methotrexate",
        "Probenecid"
      ],
      "side_effects": [
        "Nausea",
        "Vomiting",
        "Gastrointestinal bleeding",
        "Melaena",
        "Peptic ulcer",
        "Pancreatitis",
        "Anxiety",
        "Drowsiness",
        "Dizziness",
        "Headache",
        "Hallucinations",
        "Excessive thirst",
        "Inability to concentrate",
        "Insomnia",
        "Malaise",
        "Fatigue",
        "Pruritus",
        "Urticaria",
        "Skin photosensitivity",
        "Lyell’s syndrome",
        "Stevens-Johnson syndrome",
        "Flushing",
        "Bradycardia",
        "Hypertension",
        "Palpitations",
        "Chest pain",
        "Infertility in females",
        "Dyspnoea",
        "Asthma",
        "Pulmonary oedema",
        "Fever",
        "Injection site pain"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Contraindicated during pregnancy, labour or delivery.",
        "lactation": "Contraindicated in mothers who are breastfeeding."
      },
      "preparation": [
        "10 mg Tablet",
        "30 mg/1 ml Injection",
        "60 mg/2 ml Injection"
      ]
    },
    {
      "name": "Tory®",
     "img_id":"RF7Ji7z.png",
      "image": "TOry_60.png",
      "active_ingredients": ["Etoricoxib"],
      "indications": [
        "Relief of pain and inflammation in osteoarthritis",
        "Rheumatoid arthritis",
        "Other chronic musculoskeletal disorders",
        "Acute gout",
        "Dysmenorrhoea",
        "Following dental surgery"
      ],
      "dosage_and_administration": {
        "adults_and_adolescents_over_16_years": {
          "osteoarthritis": "60 mg once daily",
          "chronic_musculoskeletal_disorders": "60 mg once daily",
          "dysmenorrhoea": "60 mg once daily",
          "rheumatoid_arthritis": "90 mg once daily",
          "pain_following_dental_surgery": "120 mg once daily",
          "acute_gout": "120 mg once daily"
        }
      },
      "contraindications_and_precautions": [
        "Known hypersensitivity to Etoricoxib",
        "Active peptic ulceration or gastrointestinal (GI) bleeding",
        "Signs of asthma, acute rhinitis, nasal polyps, angioneurotic oedema, or urticaria following administration of acetylsalicylic acid or other NSAIDs",
        "Inflammatory bowel disease",
        "Severe congestive heart failure",
        "Children and adolescents under 16 years of age"
      ],
      "side_effects": [
        "Dry mouth",
        "Taste disturbance",
        "Mouth ulcers",
        "Flatulence",
        "Constipation",
        "Appetite and weight changes",
        "Chest pain",
        "Fatigue",
        "Paraesthesia",
        "Influenza-like syndrome",
        "Myalgia"
      ],
      "drug_interactions": [
        "Oral anticoagulants",
        "Diuretics",
        "ACE inhibitors",
        "Acetylsalicylic acid",
        "Cyclosporin",
        "Tacrolimus",
        "Lithium",
        "Methotrexate",
        "Oral contraceptives",
        "Prednisone/Prednisolone",
        "Digoxin",
        "Drugs metabolized by sulfotransferases (e.g., Ethinyl Estradiol)",
        "Drugs metabolized by CYP isoenzymes",
        "Ketoconazole",
        "Rifampicin",
        "Antacids"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Should be avoided in late pregnancy due to the risk of premature closure of the ductus arteriosus. Use during the first two trimesters only if the potential benefit justifies the potential risk to the fetus.",
        "lactation": "It is not known whether this drug is excreted in human milk."
      },
      "preparation": ["60 mg Tablet", "90 mg Tablet", "120 mg Tablet"]
    },
    {
      "name": "Travolar™ Eye Drops",
     "img_id":"oYRWLqZ.jpeg",
      "image": "Travolar-IC_l.jpg",
      "active_ingredients": ["Travoprost"],
      "indications": [
        "Reduction of intraocular pressure in adult patients with open-angle glaucoma",
        "Ocular hypertension"
      ],
      "dosage_and_administration": {
        "general": "The recommended dose is one drop in the affected eye(s) once daily. Optimal effect is observed with evening dosing."
      },
      "contraindications_and_precautions": [
        "Contraindicated in patients with known hypersensitivity to any ingredient of this formulation."
      ],
      "drug_interactions": [
        "Concomitant ocular medications should be administered at least 5 minutes apart from the instillations to avoid washout effects."
      ],
      "side_effects": [
        "Ocular hyperemia",
        "Decreased visual acuity",
        "Eye discomfort",
        "Foreign body sensation",
        "Pain and pruritus",
        "Redness may be seen in a few cases"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Pregnancy Category C. This drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.",
        "lactation": "It is not known whether this drug or its metabolites are excreted in human milk. Caution should be exercised when Travolar is administered to a nursing woman."
      },
      "preparation": "3 ml solution in LDPE container"
    },
    {
      "name": "Trevox®",
     "img_id":"o3GKwFF.jpeg",
      "image": "TREVOX.jpg",
      "active_ingredients": ["Levofloxacin"],
      "indications": [
        "Acute maxillary sinusitis",
        "Acute bacterial exacerbation of chronic bronchitis",
        "Community-acquired pneumonia",
        "Nosocomial pneumonia",
        "Complicated urinary tract infections",
        "Uncomplicated urinary tract infections",
        "Acute pyelonephritis",
        "Chronic bacterial prostatitis",
        "Uncomplicated and complicated skin and soft tissue infections including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections",
        "Inhalation anthrax (post-exposure) to prevent the development of inhalational anthrax following exposure to Bacillus anthracis"
      ],
      "dosage_and_administration": {
        "acute_sinusitis": "500 mg once daily for 10-14 days",
        "exacerbation_of_chronic_bronchitis": "250-500 mg once daily for 7 days",
        "community_acquired_pneumonia": {
          "standard": "500 mg once daily for 7-14 days",
          "alternative": "750 mg once daily for 5 days"
        },
        "nosocomial_pneumonia": "750 mg once daily for 7-14 days",
        "complicated_urinary_tract_infections": "250 mg daily for 7-10 days",
        "uncomplicated_UTI": "250 mg once daily for 3 days",
        "acute_pyelonephritis": "250 mg once daily for 10 days",
        "chronic_bacterial_prostatitis": "500 mg once daily for 28 days",
        "uncomplicated_skin_and_soft_tissue_infections": "500 mg once daily for 7-10 days",
        "complicated_skin_and_soft_tissue_infections": "750 mg once daily for 7-14 days",
        "inhalation_anthrax_post_exposure": "500 mg once daily for 60 days"
      },
      "contraindications_and_precautions": [
        "Hypersensitivity to Levofloxacin",
        "Adequate hydration should be maintained to avoid concentrated urine",
        "Dose adjustment should be exercised in the presence of renal insufficiency"
      ],
      "side_effects": [
        "Nausea",
        "Vomiting",
        "Diarrhea",
        "Abdominal pain",
        "Flatulence",
        "Phototoxicity",
        "Tremors",
        "Depression",
        "Confusion"
      ],
      "drug_interactions": ["Antacids", "Iron", "NSAIDs", "Warfarin"],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Not recommended for use during pregnancy as the effects on the unborn child are unknown.",
        "lactation": "Not recommended for use during nursing as the effects on the infant are unknown."
      },
      "preparation": "500 mg Tablet"
    },
    {
      "name": "Trevox® 500 IV",
     "img_id":"SxrGro4.jpeg",
      "image": "Trevox-Infusion_l.jpg",
      "active_ingredients": [
        "Levofloxacin 500 mg as Levofloxacin Hemihydrate INN"
      ],
      "indications": [
        "Mild, moderate, and severe infections caused by susceptible strains of designated microorganisms, including:",
        "Nosocomial pneumonia",
        "Community-acquired pneumonia",
        "Acute bacterial sinusitis",
        "Acute bacterial exacerbation of chronic bronchitis",
        "Complicated and uncomplicated skin and skin structure infections",
        "Chronic bacterial prostatitis",
        "Complicated and uncomplicated urinary tract infections",
        "Acute pyelonephritis",
        "Inhalational anthrax (post-exposure)"
      ],
      "dosage_and_administration": {
        "general": "The usual dose of Levofloxacin infusion is 250 mg or 500 mg administered by slow intravenous infusion over 60 minutes every 24 hours, or 750 mg administered by slow infusion over 90 minutes every 24 hours.",
        "specific_dosages": {
          "nosocomial_pneumonia": {
            "dose": "750 mg",
            "duration": "7-14 days"
          },
          "community_acquired_pneumonia": {
            "dose": "500 mg or 750 mg",
            "duration": "7-14 days or 5 days"
          },
          "acute_bacterial_sinusitis": {
            "dose": "500 mg or 750 mg",
            "duration": "7-14 days or 5 days"
          },
          "acute_bacterial_exacerbation_of_chronic_bronchitis": {
            "dose": "500 mg",
            "duration": "7 days"
          },
          "complicated_skin_and_skin_structure_infections": {
            "dose": "750 mg",
            "duration": "7-14 days"
          },
          "uncomplicated_skin_and_skin_structure_infections": {
            "dose": "500 mg",
            "duration": "7-10 days"
          },
          "chronic_bacterial_prostatitis": {
            "dose": "500 mg",
            "duration": "28 days"
          },
          "complicated_urinary_tract_infections_or_acute_pyelonephritis": {
            "dose": "250 mg or 750 mg",
            "duration": "10 days or 5 days"
          },
          "uncomplicated_urinary_tract_infection": {
            "dose": "250 mg",
            "duration": "3 days"
          },
          "inhalation_anthrax_post_exposure": {
            "dose": "500 mg",
            "duration": "once daily for 60 days"
          }
        }
      },
      "contraindications_and_precautions": [
        "Contraindicated in persons with known hypersensitivity to levofloxacin or other quinolone antibacterials.",
        "Adequate hydration should be maintained to avoid concentrated urine.",
        "Dose adjustment should be exercised in the presence of renal insufficiency."
      ],
      "side_effects": [
        "Headache",
        "Nausea",
        "Vomiting",
        "Diarrhea",
        "Constipation",
        "Abdominal pain",
        "Dyspepsia",
        "Edema",
        "Injection site reaction",
        "Less common side effects (0.1 to 1%) include allergic reactions, hyperglycemia, hypoglycemia, anxiety, agitation, tremor, palpitation, abnormal hepatic function, tendonitis"
      ],
      "drug_interactions": [
        "No data concerning interaction with oral antacids, sucralfate, multivitamins, didanosine, or metal cations.",
        "No fluoroquinolone should be co-administered with any solution containing multivalent cations (e.g., magnesium) through the same intravenous line.",
        "Levofloxacin may enhance the effect of warfarin, leading to elevated prothrombin time."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Not recommended for use during pregnancy unless the potential benefit justifies the potential risk to the fetus.",
        "lactation": "Levofloxacin may be excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue the drug, considering the importance of the drug to the mother."
      },
      "preparation": "500 mg/100 ml solution of Levofloxacin for intravenous infusion"
    },
    {
      "name": "Trispray®",
     "img_id":"yvgRor0.jpeg",
      "image": "TRISPRAY.jpg",
      "active_ingredients": ["Triamcinolone Acetonide"],
      "indications": [
        "Treatment and prophylaxis of the nasal symptoms of seasonal and perennial allergic rhinitis in patients aged 6 years and older."
      ],
      "dosage_and_administration": {
        "adults_and_children_12_years_and_older": "2 sprays in each nostril once daily.",
        "children_6_to_12_years": "1 spray in each nostril once daily.",
        "children_below_6_years": "Not recommended."
      },
      "contraindications": ["No contraindications."],
      "adverse_reactions": [
        "Rhinitis",
        "Headache",
        "Pharyngitis",
        "Epistaxis",
        "Nasal irritation",
        "Dry mucous membrane",
        "Naso-sinus congestion",
        "Sneezing",
        "Nasal septal perforation"
      ],
      "drug_interactions": ["None known."],
      "precautions": [
        "If there is any reason to suppose that adrenal function is impaired, care must be taken while transferring patients from systemic steroid treatment to Triamcinolone."
      ],
      "preparation": "55 mcg/spray, Nasal Spray"
    },

    {
      "name": "Trupan®",
     "img_id":"i6cEap1.jpeg",
      "image": "Trupan-20.jpg",
      "active_ingredients": ["Pantoprazole"],
      "indications": [
        "Benign gastric ulcer",
        "Duodenal ulcer",
        "Gastroesophageal reflux disease (GERD)",
        "NSAID-induced peptic ulcer",
        "Acid hypersecretory conditions including Zollinger-Ellison Syndrome",
        "Eradication of Helicobacter pylori (in combination with antibiotics)",
        "Ulcers resistant to H2 receptor antagonists"
      ],
      "dosage_and_administration": {
        "oral": {
          "benign_gastric_ulcer": "40 mg daily in the morning for 4 weeks, continued for further 4 weeks if not fully healed.",
          "duodenal_ulcer": "40 mg daily in the morning for 2 weeks, continued for further 2 weeks if not fully healed.",
          "GERD": "20-40 mg daily in the morning for 4 weeks, continued for further 4 weeks if not fully healed.",
          "NSAID_induced_peptic_ulcer": "20 mg daily.",
          "acid_hypersecretory_conditions": "Initially 80 mg once daily adjusted according to response (Elderly - maximum 40 mg daily).",
          "H_pylori_eradication": "40 mg twice daily with antibiotics.",
          "H2_resistant_ulcers": "40 mg once daily for 8 weeks; maintenance 20 mg daily."
        },
        "injection": {
          "ulcers": "40 mg once daily for 7-10 days.",
          "GERD_with_esophagitis": "40 mg once daily for 7-10 days.",
          "peptic_ulcer_rebleeding": "80 mg IV bolus + 8 mg/hour infusion for 72 hours.",
          "acid_aspiration_prophylaxis": "80 mg IV every 12 hours for 24 hours, then 40 mg every 12 hours.",
          "Zollinger_Ellison_Syndrome": "80 mg IV every 12 hours (may increase to every 8 hours)."
        }
      },
      "contraindications": [
        "Hypersensitivity to pantoprazole or formulation components."
      ],
      "precautions": [
        "Tablets must not be split, crushed, or chewed.",
        "Monitor for magnesium deficiency in long-term use.",
        "May increase risk of Clostridium difficile infection."
      ],
      "side_effects": [
        "Headache",
        "Diarrhea",
        "Abdominal pain",
        "Flatulence",
        "Rash",
        "Insomnia",
        "Hyperglycemia"
      ],
      "drug_interactions": [
        "May reduce absorption of ketoconazole, itraconazole, atazanavir.",
        "Increased INR with warfarin (monitor PT/INR)."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "USFDA Pregnancy Category B. Use only if clearly needed.",
        "lactation": "Discontinue nursing or drug based on risk-benefit assessment."
      },
      "preparation": ["20 mg Tablet", "40 mg Tablet", "40 mg IV Injection"]
    },
    {
      "name": "Tusca Plus™",
     "img_id":"KqfbGlH.jpeg",
      "image": "Tusca-Plus.jpg",
      "active_ingredients": [
        "Guaifenesin",
        "Levomenthol",
        "Diphenhydramine HCl"
      ],
      "indications": [
        "Symptomatic relief of upper respiratory tract disorders with productive cough"
      ],
      "dosage_and_administration": {
        "age_12_and_above": "10 mL 4 times daily"
      },
      "contraindications": [
        "Hypersensitivity to Guaifenesin, Levomenthol, or Diphenhydramine",
        "Concurrent use or recent (2 weeks) MAO inhibitor therapy",
        "Children under 12 years of age"
      ],
      "precautions": [
        "Liver, kidney, or prostate disorders",
        "Avoid alcohol",
        "Caution with CNS depressants (tranquilizers, barbiturates, codeine)",
        "May impair driving/operating machinery",
        "Elderly patients (increased sensitivity to anticholinergic effects)"
      ],
      "side_effects": [
        "Angioedema (face/lips/tongue swelling)",
        "Allergic reactions",
        "Numbness",
        "Drowsiness",
        "Dizziness",
        "Blurred vision",
        "Dry mouth/nose/throat",
        "Nausea/vomiting"
      ],
      "drug_interactions": [
        "MAO inhibitors (contraindicated)",
        "CNS depressants (alcohol, barbiturates, opioids)",
        "Anticholinergic drugs (additive effects)"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "No specific data available - use only if potential benefit justifies risk",
        "lactation": "Avoid (Diphenhydramine may pass into breast milk)"
      },
      "preparations": ["100 mL Syrup"]
    },
    {
      "name": "Tylace™",
     "img_id":"3d3jfE0.jpeg",
      "image": "tylace_l.jpg",
      "active_ingredients": ["Acetylcysteine"],
      "indications": [
        "Adjunctive treatment for abnormal/viscid mucus secretions in:",
        {
          "respiratory_conditions": [
            "Acute/chronic bronchopulmonary disorders (pneumonia, bronchitis, emphysema, tracheobronchitis)",
            "Chronic asthmatic bronchitis",
            "Tuberculosis",
            "Bronchiectasis",
            "Primary amyloidosis of the lung",
            "Atelectasis from mucus obstruction",
            "Pulmonary complications of cystic fibrosis",
            "Post-thoracic/cardiovascular surgery",
            "Post-traumatic chest conditions"
          ]
        },
        {
          "other_uses": [
            "Paracetamol overdose (optimal if given within 8 hours of ingestion)"
          ]
        }
      ],
      "dosage_and_administration": {
        "respiratory_conditions": {
          "adults_and_children_above_6": "1 effervescent tablet (600 mg) daily (preferably in evening) for 5-10 days",
          "administration_note": "Dissolve 1 tablet in 200 mL water before drinking"
        },
        "paracetamol_overdose": {
          "initial_dose": "140 mg/kg",
          "maintenance_dose": "70 mg/kg every 4 hours for 17 additional doses"
        }
      },
      "contraindications": [
        "Hypersensitivity to acetylcysteine",
        "Phenylketonuria",
        "Active peptic ulcer"
      ],
      "precautions": [
        "Asthma patients (risk of bronchospasm)",
        "Elderly patients",
        "Renal/hepatic impairment"
      ],
      "side_effects": {
        "common": ["Heartburn", "Nausea", "Vomiting", "Diarrhea"],
        "rare": ["Bronchospasm", "Shortness of breath", "Upset stomach"],
        "very_rare": ["Severe skin reactions", "Immune reactions"]
      },
      "drug_interactions": [
        "Increased bioavailability of Amoxicillin",
        "Reduced absorption of Cefalexin",
        "Potentiated effects of Nitroglycerin",
        "No interaction with Doxycycline"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Category B - Use with caution",
        "lactation": "Caution advised (limited data)"
      },
      "preparation": ["600 mg Effervescent Tablet"]
    },
    {
      "name": "Ucol™ 2",
     "img_id":"zeYZ2DQ.jpeg",
      "image": "UCOL-2.jpg",
      "active_ingredients": ["Tolterodine Tartrate"],
      "indications": [
        "Treatment of Overactive Bladder (urinary urgency, frequency, urge incontinence)",
        "Nocturnal enuresis (bedwetting) in children"
      ],
      "dosage_and_administration": {
        "adults": "2 mg twice daily (may reduce to 1 mg twice daily if needed)",
        "administration_notes": [
          "Dose adjustment may be required for patients with hepatic/renal impairment",
          "Take with or without food"
        ]
      },
      "contraindications": [
        "Urinary retention",
        "Uncontrolled narrow-angle glaucoma",
        "Hypersensitivity to tolterodine or components"
      ],
      "precautions": [
        "Decreased gastrointestinal motility",
        "Renal impairment",
        "Hepatic impairment",
        "Autonomic neuropathy",
        "Hiatal hernia with reflux esophagitis",
        "Elderly patients (increased sensitivity to anticholinergic effects)"
      ],
      "side_effects": [
        "Dry mouth (very common)",
        "Dyspepsia",
        "Reduced lacrimation",
        "Headache",
        "Constipation",
        "Dry eyes",
        "Dizziness",
        "Fatigue"
      ],
      "drug_interactions": {
        "potent_inhibitors": ["Ketoconazole (increases tolterodine levels)"],
        "other_interactions": [
          "Warfarin (monitor INR)",
          "Oral contraceptives (potential interaction)"
        ]
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Use only if potential benefit justifies fetal risk",
        "lactation": "Avoid (excretion in breast milk likely)"
      },
      "preparation": ["2 mg film-coated tablet"]
    },
    {
      "name": "Uriset™",
     "img_id":"IpVJJx3.jpeg",
      "image": "uriset_large.jpg",
      "active_ingredients": ["Potassium Citrate", "Citric Acid Monohydrate"],
      "indications": [
        "Burning urination (due to acidic urine)",
        "Prevention of uric acid kidney stones (with/without calcium stones)",
        "Adjuvant therapy in gout (with uricosuric agents)",
        "Correction of metabolic acidosis in kidney disease"
      ],
      "dosage_and_administration": {
        "burning_urination": {
          "adults_and_children_over_6": "10 mL 3 times daily (diluted in 1 glass water)",
          "children_1_6_years": "5 mL 3 times daily (diluted in ½ glass water)"
        },
        "kidney_stones_acidosis": {
          "adults_and_children_over_6": "10-15 mL 4 times daily (diluted in 1 glass water)",
          "children_1_6_years": "5-10 mL 4 times daily (diluted in ½ glass water)"
        },
        "gout_therapy": {
          "adults_and_children_over_6": "10-15 mL 4 times daily (diluted in 1 glass water)",
          "children_1_6_years": "5-10 mL 4 times daily (diluted in ½ glass water)"
        },
        "administration_notes": [
          "Always dilute before ingestion",
          "Preferably take after meals",
          "Use provided measuring cup"
        ]
      },
      "contraindications": [
        "Hypersensitivity to ingredients",
        "Severe renal impairment with oliguria/azotemia",
        "Untreated Addison's disease",
        "Adynamia episodica hereditaria",
        "Acute dehydration",
        "Heat cramps",
        "Anuria",
        "Severe myocardial damage",
        "Hyperkalemia"
      ],
      "precautions": [
        "Renal impairment (monitor potassium levels)",
        "Cardiac disease",
        "Hypertension",
        "Avoid concurrent potassium supplements",
        "Risk of hyperkalemia and alkalosis",
        "Take with food to reduce GI irritation",
        "Ensure adequate water intake"
      ],
      "side_effects": [
        "Hyperkalemia (muscle weakness, irregular heartbeat)",
        "Metabolic alkalosis",
        "GI irritation/nausea",
        "Diarrhea (saline laxative effect)"
      ],
      "drug_interactions": {
        "potassium_related": [
          "Potassium-sparing diuretics (spironolactone, triamterene)",
          "ACE inhibitors (lisinopril)",
          "Angiotensin II receptor blockers (losartan)",
          "Potassium supplements"
        ],
        "other_interactions": [
          "Antacids containing aluminum",
          "Aspirin/salicylates",
          "Digoxin",
          "Lithium",
          "Drospirenone/eplerenone"
        ]
      },
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Contraindicated unless benefit outweighs risk",
        "lactation": "Unknown excretion in breast milk - consult physician"
      },
      "preparation": {
        "form": "Oral solution",
        "packaging": "200 mL PET bottle with measuring cup"
      }
    },
    {
      "name": "Urocure™",
     "img_id":"cQ1IvtF.jpeg",
      "image": "Urocure-100-SR.jpeg",
      "active_ingredients": ["Nitrofurantoin USP"],
      "indications": [
        "Treatment of uncomplicated urinary tract infections (UTIs)",
        "Genitourinary surgical prophylaxis"
      ],
      "dosage_and_administration": {
        "capsule": {
          "adults_and_children_over_12": {
            "UTI_treatment": "1 capsule (100 mg) every 12 hours for 7 days",
            "surgical_prophylaxis": "1 capsule twice daily (day of procedure + 3 days)"
          }
        },
        "suspension": {
          "adults": {
            "standard_dose": "50-100 mg 4 times daily",
            "note": "Lower dose for uncomplicated UTIs"
          },
          "pediatric": {
            "dose": "5-7 mg/kg/day in 4 divided doses",
            "contraindication": "Not for infants <1 month"
          }
        }
      },
      "contraindications": [
        "Anuria/oliguria",
        "Renal impairment (CrCl <60 mL/min or elevated creatinine)",
        "History of nitrofurantoin-associated cholestatic jaundice/hepatic dysfunction",
        "Hypersensitivity to nitrofurantoin",
        "Infants <1 month old"
      ],
      "precautions": [
        "Complete full course of therapy",
        "Monitor for pulmonary/hepatic reactions",
        "Avoid magnesium trisilicate antacids",
        "Use caution in patients with G6PD deficiency",
        "May cause false-positive urine glucose tests"
      ],
      "side_effects": {
        "common": ["Nausea", "Headache", "Flatulence"],
        "less_common": [
          "Diarrhea",
          "Dyspepsia",
          "Abdominal pain",
          "Constipation",
          "Vomiting",
          "Dizziness",
          "Drowsiness"
        ],
        "serious": [
          "Pulmonary fibrosis (with long-term use)",
          "Hepatotoxicity",
          "Peripheral neuropathy"
        ]
      },
      "drug_interactions": [
        {
          "interactant": "Magnesium trisilicate antacids",
          "effect": "Reduces absorption"
        },
        {
          "interactant": "Uricosurics (probenecid, sulfinpyrazone)",
          "effect": "Inhibits renal secretion"
        }
      ],
      "special_populations": {
        "pregnancy": {
          "category": "B",
          "recommendation": "Use only if clearly needed"
        },
        "lactation": {
          "excretion": "Trace amounts in breast milk",
          "recommendation": "Avoid in infants <1 month"
        },
        "pediatrics": {
          "safety": "Not established for neonates <1 month"
        }
      },
      "preparation": [
        "100 mg sustained-release capsule",
        "Oral suspension (exact concentration not specified)"
      ]
    },
    {
      "name": "Urso™",
     "img_id":"EpzTgHr.jpeg",
      "image": "urso_150.jpg",
      "active_ingredients": "Ursodeoxycholic Acid",
      "indications": [
        "Alcoholic Fatty Liver Disease",
        "Dissolution of cholesterol gallstones",
        "Primary Biliary Cholangitis (PBC)",
        "Primary Sclerosing Cholangitis (PSC)",
        "Non-alcoholic steatohepatitis (NASH)",
        "Cholestasis",
        "Viral hepatitis"
      ],
      "dosage_and_administration": {
        "dissolution_of_gallstones": "8-12 mg/kg/day (single nighttime dose or divided doses)",
        "primary_biliary_cholangitis": "10-15 mg/kg/day in 2-4 divided doses",
        "alcoholic_fatty_liver": "300 mg/day",
        "acute_viral_hepatitis": "600 mg/day",
        "primary_sclerosing_cholangitis": "25-30 mg/kg/day",
        "nash": "13-15 mg/kg/day",
        "administration_notes": "Take with food for better absorption"
      },
      "contraindications": [
        "Non-functioning gallbladder",
        "Calcified gallstones",
        "Pigmented gallstones",
        "Inflammatory bowel disease"
      ],
      "precautions": [
        "Liver disease (monitor liver enzymes)",
        "Peptic ulcer disease",
        "Obesity (may reduce efficacy for gallstone dissolution)"
      ],
      "side_effects": [
        "Nausea",
        "Vomiting",
        "Diarrhea",
        "Gallstone calcification",
        "Pruritus",
        "Dyspepsia",
        "Constipation"
      ],
      "drug_interactions": [
        {
          "interactant": "Estrogenic hormones",
          "effect": "Reduces efficacy (increases bile cholesterol)"
        },
        {
          "interactant": "Bile-acid binders (cholestyramine, antacids, charcoal)",
          "effect": "Reduces absorption"
        },
        {
          "interactant": "Ciclosporin",
          "effect": "May increase absorption"
        }
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": {
          "category": "B",
          "note": "Used safely in cholestasis of pregnancy (3rd trimester)"
        },
        "lactation": {
          "safety": "No documented problems in breastfeeding"
        }
      },
      "monitoring_parameters": [
        "Liver function tests (ALT, AST, GGT)",
        "Gallstone characteristics (ultrasound monitoring)",
        "Lipid profile (with long-term use)"
      ],
      "preparation": ["150 mg tablet", "300 mg tablet"]
    },
    {
      "name": "Utal™",
     "img_id":"UWy9mGK.jpeg",
      "image": "Utal-Tablet.jpg",
      "active_ingredients": {
        "name": "Ulipristal Acetate",
        "strength": "5 mg"
      },
      "indications": ["Treatment of uterine fibroids"],
      "dosage_and_administration": {
        "standard_regimen": "1 tablet (5 mg) once daily for 3 months",
        "repeat_cycle": "May repeat treatment after 8-week medication-free interval",
        "administration_notes": [
          "Take at the same time each day",
          "May be taken with or without food"
        ]
      },
      "contraindications": [
        "Hypersensitivity to ulipristal or excipients",
        "Undiagnosed genital bleeding",
        "Non-fibroid related uterine conditions",
        "Uterine/cervical/ovarian/breast cancer"
      ],
      "precautions": [
        "Monitoring of endometrial thickness required",
        "Hepatic impairment (risk of liver injury)",
        "Asthma patients (may exacerbate symptoms)",
        "Severe renal impairment"
      ],
      "side_effects": {
        "common": [
          "Endometrial thickening",
          "Hot flushes",
          "Headache",
          "Abdominal pain"
        ],
        "less_common": [
          "Uterine hemorrhage",
          "Nausea",
          "Fatigue",
          "Breast tenderness"
        ],
        "serious": [
          "Liver injury (monitor transaminases)",
          "Severe vaginal bleeding"
        ]
      },
      "drug_interactions": [
        {
          "interactant": "Strong CYP3A4 inducers (rifampicin, carbamazepine)",
          "effect": "May reduce efficacy"
        },
        {
          "interactant": "Progesterone-containing products",
          "effect": "Theoretical antagonism"
        }
      ],
      "use_in_special_populations": {
        "pregnancy": {
          "category": "X",
          "note": "Contraindicated in pregnancy"
        },
        "lactation": {
          "recommendation": "Avoid breastfeeding during treatment"
        },
        "fertility": {
          "note": "Restores fertility after discontinuation"
        }
      },
      "monitoring_requirements": [
        "Pelvic ultrasound (baseline and post-treatment)",
        "Liver function tests (before and during treatment)",
        "Endometrial assessment"
      ],
      "preparation": [
        "form : Film-coated tablet",
        "strength : 5 mg",
        "packaging : 28 tablets per pack"
      ]
    },
    {
      "name": "Valoate®",
     "img_id":"NVaDwVN.jpeg",
      "image": "VALOATE-100ML.jpg",
      "active_ingredients": ["Sodium Valproate"],
      "indications": [
        "Epilepsy (all seizure types)",
        "Mania (bipolar disorder)",
        "Chronic headache/migraine prophylaxis"
      ],
      "dosage_and_administration": {
        "adults": {
          "initial": "600 mg/day in 2 divided doses (with food)",
          "titration": "Increase by 200 mg every 3 days",
          "maximum": "2.5 g/day in divided doses",
          "maintenance": "1-2 g/day (20-30 mg/kg/day)"
        },
        "pediatric": {
          "under_20kg": {
            "initial": "20 mg/kg/day in divided doses",
            "note": "Monitor plasma concentrations"
          },
          "over_20kg": {
            "initial": "400 mg/day (weight-independent)",
            "titration": "Increase by 20-30 mg/kg as needed"
          }
        },
        "administration_notes": [
          "Take with food to reduce GI irritation",
          "Do not crush/extended-release tablets",
          "Maintain consistent dosing schedule"
        ]
      },
      "contraindications": [
        "Hypersensitivity to valproate",
        "Active liver disease or hepatic dysfunction",
        "Porphyria",
        "Urea cycle disorders",
        "Mitochondrial disorders"
      ],
      "black_box_warnings": [
        "Hepatotoxicity (especially in children <2 years)",
        "Fetal risk (teratogenicity)",
        "Pancreatitis"
      ],
      "precautions": [
        "Monitor liver enzymes and platelets",
        "Assess ammonia levels if encephalopathy suspected",
        "Weight monitoring (risk of significant gain)",
        "Suicidal ideation risk",
        "Elderly patients (increased sedation risk)"
      ],
      "side_effects": {
        "common": [
          "Nausea/vomiting",
          "Tremor",
          "Weight gain",
          "Alopecia (usually reversible)",
          "Sedation"
        ],
        "serious": {
          "hepatic": ["Hyperammonemia", "Hepatotoxicity"],
          "hematologic": ["Thrombocytopenia", "Pancytopenia"],
          "metabolic": ["Pancreatitis", "Carnitine deficiency"],
          "dermatologic": [
            "Stevens-Johnson syndrome",
            "Toxic epidermal necrolysis"
          ],
          "reproductive": ["PCOS-like symptoms", "Amenorrhea"]
        }
      },
      "drug_interactions": {
        "pharmacokinetic": [
          {
            "drug": "Phenobarbital/Phenytoin",
            "effect": "Mutual metabolism alteration"
          },
          {
            "drug": "Lamotrigine",
            "effect": "Increased lamotrigine toxicity risk"
          }
        ],
        "pharmacodynamic": [
          {
            "drug": "Warfarin",
            "effect": "Increased bleeding risk"
          },
          {
            "drug": "Aspirin",
            "effect": "Increased valproate levels"
          },
          {
            "drug": "CNS depressants",
            "effect": "Additive sedation"
          }
        ]
      },
      "use_in_special_populations": {
        "pregnancy": {
          "category": "D",
          "risks": [
            "Neural tube defects (1-2%)",
            "Cognitive deficits",
            "Autism spectrum disorder risk"
          ],
          "recommendation": "Absolute contraindication in pregnancy unless no alternatives"
        },
        "lactation": {
          "excretion": "Present in breast milk",
          "recommendation": "Generally avoided (neurodevelopmental concerns)"
        },
        "pediatrics": {
          "hepatic_risk": "Higher in children <2 years",
          "monitoring": "Requires frequent LFTs and clinical monitoring"
        }
      },
      "monitoring_requirements": [
        "Baseline and periodic LFTs",
        "CBC with platelets",
        "Valproate levels (therapeutic range: 50-100 mcg/mL)",
        "Ammonia levels if symptomatic",
        "Pregnancy testing in women of childbearing potential"
      ],
      "preparations": [
        {
          "form": "CR Tablet",
          "strengths": ["200 mg", "300 mg", "500 mg"]
        },
        {
          "form": "Syrup",
          "strength": "200 mg/5 mL"
        }
      ]
    },
    {
      "name": "Vanprox TM",
     "img_id":"V2uOMxh.jpeg",
      "image": "Vanprox.jpg",
      "active_ingredients": "Cefpodoxime",
      "indications": [
        "Lower respiratory tract infections",
        "Upper respiratory tract infections",
        "Urinary tract infections including gonorrhoea, cystitis",
        "Skin and soft tissue infections",
        "Gynecological infections",
        "Acute otitis media",
        "Childhood infections"
      ],
      "dosage_and_administration": {
        "adults": {
          "acute_community_acquired_pneumonia": "400 mg / 200 mg 12 hourly for 14 days",
          "acute_bacterial_exacerbation_of_chronic_bronchitis": "400 mg / 200 mg 12 hourly for 10 days",
          "uncomplicated_gonorrhoea": "200 mg Single dose",
          "rectal_gonococcal_infection_in_women": "200 mg Single dose",
          "skin_soft_tissue_infections": "200 mg twice daily",
          "pharyngitis_tonsillitis": "200 mg 12 hourly for 5-10 days",
          "uncomplicated_urinary_tract_infection": "200 mg 12 hourly for 7 days",
          "acute_maxillary_sinusitis": "400 mg / 200 mg 12 hourly for 10 days"
        },
        "children": {
          "15_days_to_6_months": "4 mg/kg every 12 hours",
          "6_months_to_2_years": "40 mg every 12 hours",
          "3_to_8_years": "80 mg every 12 hours",
          "over_9_years": "100 mg every 12 hours"
        }
      },
      "contraindications_and_precautions": [
        "Known allergy to the cephalosporin class of antibiotics",
        "In patients with transient or persistent reduction in urinary output due to renal insufficiency, reduce the total daily dose of Cefpodoxime to avoid high and prolonged serum antibiotic concentration",
        "Prolonged use may result in overgrowth of nonsusceptible organisms. If superinfection occurs, take appropriate measures"
      ],
      "side_effects": [
        "Gastrointestinal disorders (diarrhoea, nausea, vomiting, abdominal pain)",
        "Rash",
        "Urticaria and itching"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Pregnancy Category B. Cefpodoxime has no known teratogenic effects",
        "lactation": "Excreted in breast milk. Caution should be exercised when administering to nursing women"
      },
      "drug_interactions": [
        "Antacids",
        "H2-blockers",
        "Probenecid",
        "Nephrotoxic drugs"
      ],
      "preparation": ["40 mg/5 ml Suspension", "20 mg/ml Paediatric Drops"]
    },
    {
      "name": "Vertina® D",
     "img_id":"h8M7rso.png",
      "image": "Vertina_D.png",
      "active_ingredients": [
        "Doxylamine Succinate",
        "Pyridoxine Hydrochloride"
      ],
      "indication": "Nausea and Vomiting of Pregnancy (NVP)",
      "dosage_and_administration": {
        "recommended_dosage": "Take two tablets daily at bedtime, maximum 4 tablets daily",
        "administration_instructions": "Take on an empty stomach with a glass of water"
      },
      "contraindications": [
        "Known hypersensitivity to Doxylamine Succinate, other ethanolamine derivative antihistamines, Pyridoxine Hydrochloride, monoamine oxidase inhibitors (MAO), or any inactive ingredient in the formulation"
      ],
      "special_warnings_and_precautions": [
        "Use is not recommended if concurrently using central nervous system (CNS) depressants including alcohol, as it may result in severe drowsiness leading to falls or accidents"
      ],
      "side_effects": ["Somnolence"],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Pregnancy Category A",
        "lactation": "Women should not breastfeed while using Vertina-D"
      },
      "preparation": "Tablet"
    },
    {
      "name": "Vertina® Plus",
     "img_id":"k9HelyW.png",
      "image": "Vertina_Plus.png",
      "active_ingredients": ["Meclizine", "Pyridoxine"],
      "indication": [
        "Prophylaxis and symptomatic relief of nausea, vomiting, dizziness, motion sickness, radiation sickness, and vertigo associated with diseases of the vestibular system (e.g., Meniere’s syndrome, labyrinthitis, and other vestibular disturbances)",
        "Morning sickness during pregnancy"
      ],
      "dosage_and_administration": {
        "nausea_and_vomiting": "One tablet 1-2 times daily or as directed by physician",
        "motion_sickness": "One or two tablets daily, taken one hour prior to journey for protection, with the dose possibly repeated every 24 hours for the duration of the journey",
        "vertigo": "One tablet two times daily or as directed by physician",
        "labyrinthine_and_vestibular_disturbances": "Meclizine HCl 25-100 mg daily in divided doses, depending on clinical response",
        "radiation_sickness": "50 mg Meclizine HCl administered 2-12 hours prior to radiation treatment; Pyridoxine (vitamin B6) 50-200 mg per day"
      },
      "contraindications_and_precautions": [
        "Contraindicated in individuals with hypersensitivity to these ingredients",
        "Caution in patients with asthma, bronchitis, emphysema, enlarged prostate, glaucoma, or urinary tract blockage due to potential anticholinergic action"
      ],
      "side_effects": [
        "Drowsiness",
        "Dry mouth",
        "Urinary retention",
        "Blurred vision (rare)",
        "Sensory neuropathy with high doses of Pyridoxine hydrochloride over extended periods"
      ],
      "use_in_pregnancy_and_lactation": "Indicated",
      "preparation": "Meclizine HCl 25 mg & Pyridoxine HCl 50 mg film-coated tablet"
    },
    {
      "name": "Viglimet™",
     "img_id":"anEp0tL.jpeg",
      "image": "Viglime.jpg",
      "active_ingredients": ["Vildagliptin", "Metformin HCl"],
      "indication": "Viglimet is indicated in patients with type 2 diabetes who are unable to achieve sufficient glycemic control at their maximally tolerated dose of oral Metformin alone or who are already treated with the combination of Vildagliptin & Metformin as separate tablets.",
      "dosage_and_administration": {
        "adults": {
          "initial_dose": [
            "50 mg Vildagliptin / 500 mg Metformin twice daily",
            "50 mg Vildagliptin / 850 mg Metformin twice daily"
          ],
          "recommended_dose": "100 mg Vildagliptin + 2000 mg Metformin HCl daily",
          "food_instructions": "Taking the combination with or just after food may reduce gastrointestinal symptoms associated with Metformin",
          "dose_adjustments": "Doses higher than 100 mg of Vildagliptin are not recommended. There is no clinical experience in triple combination with other antidiabetic agents."
        }
      },
      "contraindications_and_precautions": [
        "Hypersensitivity to the active substance or excipients",
        "Renal Impairment: Creatinine clearance <60 mL/min",
        "Hepatic Impairment: ALT or AST >2.5 times the upper limit of normal (ULN)",
        "Type 1 diabetes"
      ],
      "side_effects": [
        "Lactic acidosis due to Metformin",
        "Rare cases of hepatic dysfunction",
        "Common side effects: tremor, headache, dizziness, nausea, hypoglycemia, fatigue"
      ],
      "drug_interactions": [
        "No interactions with pioglitazone, Metformin, glibenclamide, digoxin, warfarin, amlodipine, ramipril, valsartan, or simvastatin",
        "Glucose-lowering effect may be reduced by thiazides, corticosteroids, thyroid products, and sympathomimetics",
        "Close monitoring of glycemic control is required when cationic drugs are co-administered",
        "Glucocorticoids, beta 2-agonists, diuretics & ACE inhibitors may alter blood glucose"
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "There are no adequate data on the use of Vildagliptin & Metformin in pregnant women; the potential risk is unknown.",
        "nursing_mothers": "It is not known whether Vildagliptin is excreted in human milk. Due to lack of human data, Vildagliptin & Metformin should not be used during lactation."
      },
      "use_in_children": "Not recommended for patients under 18 years of age.",
      "preparation": "Viglimet 50/500 Tablet"
    },
    {
      "name": "Viglita™",
     "img_id":"8WBgA9P.jpeg",
      "image": "Viglita-50_e.jpg",
      "active_ingredients": "Vildagliptin",
      "indication": "Viglita is indicated as an adjunct to diet & exercise to improve glycemic control in patients with type 2 diabetes mellitus, or as monotherapy in dual combination with Metformin, a sulphonylurea, a thiazolidinedione, or insulin when diet, exercise, and a single antidiabetic agent do not result in adequate glycemic control.",
      "dosage_and_administration": {
        "monotherapy": ["50 mg daily", "100 mg daily"],
        "dual_combination_metformin_or_thiazolidinedione": "50 mg twice daily (morning & evening)",
        "dual_combination_sulphonylurea": "50 mg once daily in the morning",
        "meal_instructions": "Viglita may be taken with or without a meal.",
        "dose_adjustments": "No dosage adjustment is required in the elderly or in patients with mild renal impairment."
      },
      "contraindications_and_precautions": [
        "Hypersensitivity to the active substance or any excipients",
        "Moderate to severe renal impairment",
        "Hepatic impairment: ALT or AST >3 times the upper limit of normal (ULN)",
        "Type 1 diabetes"
      ],
      "side_effects": [
        "The majority of adverse reactions were mild & transient, not requiring treatment discontinuations.",
        "Rare cases of hepatic dysfunction.",
        "Clinical trials of up to & more than 2 years did not show any additional safety signals or unforeseen risks."
      ],
      "drug_interactions": [
        "No interactions with pioglitazone, Metformin, glibenclamide, digoxin, warfarin, amlodipine, ramipril, valsartan, or simvastatin.",
        "The glucose-lowering effect may be reduced by thiazides, corticosteroids, thyroid products, and sympathomimetics."
      ],
      "use_in_pregnancy_and_lactation": {
        "pregnancy": "Vildagliptin should not be used in pregnancy.",
        "nursing_mothers": "Vildagliptin should not be used during lactation."
      },
      "use_in_children": "Vildagliptin is not recommended for patients under 18 years of age.",
      "preparation": "Each tablet contains Vildagliptin INN 50 mg."
    },
    {
      "name": "Vigorex™",
     "img_id":"R16NRVb.jpeg",
      "image": "Vigorex-25.jpg",
      "active_ingredients": "Sildenafil",
      "indication": "Erectile Dysfunction",
      "dosage_and_administration": {
        "starting_dose": "50 mg once daily",
        "timing": "Taken before 30-40 minutes of intercourse",
        "dose_adjustments": "The dose may be increased to a maximum of 100 mg or decreased to 25 mg depending on effectiveness & tolerance.",
        "maximum_frequency": "Once per day",
        "food_instructions": "Takes longer to work if taken with a heavy meal."
      },
      "contraindications": [
        "Sildenafil potentiates the hypotensive effects of nitrates.",
        "Contraindicated in patients using organic nitrates in any form."
      ],
      "side_effects": {
        "common": [
          "Headache",
          "Facial flushing",
          "Indigestion",
          "Effects on vision (light sensitivity, blurred vision)",
          "Stuffy nose",
          "Dizziness"
        ],
        "uncommon": [
          "Vomiting",
          "Skin rash",
          "Bleeding at the back of the eye",
          "Red eyes",
          "Eye pain",
          "Double vision",
          "Irregular or rapid heartbeat",
          "Muscle pain",
          "Feeling sleepy",
          "Reduced sense of touch",
          "Vertigo",
          "Ringing in the ears",
          "Nausea",
          "Dry mouth",
          "Chest pain",
          "Feeling tired"
        ],
        "serious": [
          "Sudden wheeziness",
          "Difficulty in breathing",
          "Swelling of the eyelids, face, lips, or throat"
        ]
      },
      "warnings": [
        "Potential risk in sexual activity for patients with preexisting cardiovascular disease.",
        "Not recommended for men for whom sexual activity is inadvisable due to cardiovascular status.",
        "No controlled clinical data for patients who have suffered myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months.",
        "Caution in patients with resting hypotension (BP <90/50), hypertension (BP >170/110), cardiac failure, or coronary artery disease causing unstable angina.",
        "Risk of prolonged erection >4 hours & priapism (painful erection >6 hours)."
      ],
      "precautions": [
        "May interact with medications, especially those used to treat chest pain.",
        "Do not take with nitrates or nitric oxide donors (e.g., amyl nitrite) due to a risk of dangerously low blood pressure.",
        "Caution with alpha-blockers, protease inhibitors, and those with hypotension or a recent stroke.",
        "Avoid excessive alcohol consumption as it may impair ability to achieve an erection."
      ],
      "pregnancy_lactation_and_paediatric_use": [
        "Not indicated for use in newborns, children, or women."
      ],
      "preparation": ["25 mg tablet", "50 mg tablet", "100 mg tablet"]
    },
    {
      "name": "Vigosol™ IV",
     "img_id":"LoaLA7g.jpeg",
      "image": "Vigosol_1.jpg",
      "active_ingredients": "Solution of 5% Composite Amino Acid with Electrolytes & D-Sorbitol",
      "indication": [
        "Source of amino acids for protein synthesis in patients needing intravenous nutrition.",
        "Particularly suitable for patients with basal amino acid requirements.",
        "Indicated in faster recovery in surgery, burns, renal insufficiency, hepatic insufficiency, and effective management of cancer."
      ],
      "dosage_and_administration": {
        "nitrogen_requirement": {
          "normal_nutritional_state": "0.10-0.15 g nitrogen/kg/day (no or minor metabolic stress)",
          "moderate_metabolic_stress": "0.15-0.20 g nitrogen/kg/day (moderate metabolic stress with or without malnutrition)",
          "severe_catabolism": "0.20-0.25 g nitrogen/kg/day (severe catabolism as in burns, sepsis, and trauma)"
        },
        "dose_range": "0.10-0.25 g nitrogen/kg/day",
        "obese_patients": "Dose based on estimated ideal weight.",
        "infusion_dosage": "1000-2000 ml per 24 hours depending on patient’s requirements.",
        "infusion_rate": "Infused slowly at 1.4-2.8 ml (30-60 drops) per minute."
      },
      "contraindications_and_precautions": [
        "Contraindicated in patients with inborn errors of amino acids metabolism.",
        "Contraindicated in patients with irreversible liver damage and severe uremia when dialysis facilities are not available."
      ],
      "use_in_pregnancy_and_lactation": [
        "Successful and safe administration during pregnancy in humans has been reported.",
        "Animal reproduction studies have not been carried out with amino acids."
      ],
      "preparation": "Each box contains sterile solution of 5% composite Amino Acid with electrolytes."
    },
    {
      "name": "VOLINAC™",
     "img_id":"FlQOMov.jpeg",
      "image": "volinac_large.jpg",
      "active_ingredients": "Diclofenac Sodium",
      "composition": "Each gram of VOLINAC gel contains Diclofenac Diethylamine BP equivalent to Diclofenac Sodium BP 10 mg.",
      "pharmacology": {
        "diclofenac_diethylamine": "Systemically absorbed through the skin, inhibits the enzyme cyclooxygenase, reducing the formation of PGE2.",
        "menthol": "A vasodilator that dilates blood vessels, produces a feeling of coolness, and provides analgesia.",
        "methyl_salicylate": "A known anti-inflammatory agent."
      },
      "indication": "Indicated for the quick relief from pain, swelling, and inflammation due to musculoskeletal disorders such as sprains, strains, tendinitis, bursitis, neck & shoulder pain, sciatica, muscle stiffness, joint pain, back ache, and lumbago.",
      "dosage_and_administration": {
        "recommended_application": "Approximately one-inch band of gel should be applied to the affected site three to four times daily with rubbing until the film disappears."
      },
      "contraindications": [
        "Known hypersensitivity to any part of the preparation."
      ],
      "precautions": [
        "For external use only.",
        "Avoid contact with the eyes.",
        "Stop use and ask a doctor if the condition worsens or does not improve within 7 days.",
        "Keep out of the reach of children.",
        "If swallowed, get medical help or contact a poison control center right away."
      ],
      "side_effects": [
        "Usually well tolerated.",
        "Extremely low frequency of hypersensitivity reactions."
      ],
      "use_in_pregnancy_and_lactation": "The safety of VOLINAC Gel has not been established during pregnancy. There are no well-controlled studies of diclofenac in pregnant women.",
      "use_in_pediatric_patients": "Safety and effectiveness in pediatric patients have not been established.",
      "storage": "Store in a cool and dry place, protected from light.",
      "how_supplied": "50 gm tube"
    },
    {
      "name": "Viodin®",
     "img_id":"MxmAWoo.jpeg",
      "image": "Viodin15ml_l.jpg",
      "active_ingredients": "Povidone-Iodine",
      "indication": [
        "Primary or secondary topical infections.",
        "Infected surgical incisions, infected decubitus or stasis ulcers, pyodermas.",
        "Secondarily infected dermatoses, infected traumatic lesions, burns, incisions & other topical lesions.",
        "Viodin ointment can cure abrasions, minor cuts & wounds.",
        "Mouth-wash is indicated for acute mucosal infection for mouth & pharynx."
      ],
      "dosage_and_administration": {
        "ointment_5_percent": "For infection treatment, apply once or twice daily or at dressing changes for a maximum of 14 days. For prevention, apply once or twice a week as necessary. Clean and dry affected skin, may be covered with a dressing.",
        "mouthwash_1_percent": "For adults and children over 6 years: Use undiluted or diluted with warm water. Gargle or rinse with up to 10 ml for up to 30 seconds without swallowing. Repeat up to four times daily for up to 14 days.",
        "solution_10_percent": "Apply full strength as an antiseptic skin cleanser."
      },
      "contraindications_and_precautions": [
        "Contraindicated in known or suspected iodine hypersensitivity.",
        "Contraindicated in patients or users with thyroid disorders.",
        "Not recommended for regular use in neonates.",
        "Special caution is needed when applying regularly to broken skin in patients with pre-existing renal insufficiency.",
        "Avoid regular use in patients on concurrent lithium therapy.",
        "Not for use in children under 6 years of age.",
        "Do not use for more than 14 days."
      ],
      "side_effects": [
        "Local skin reactions.",
        "Severe burns may cause systemic adverse effects like metabolic acidosis, hypernatraemia, and renal function impairment."
      ],
      "preparation": [
        "1% (50 mg/5 ml) Mouthwash/Gargle",
        "10% (500 mg/5 ml) Solution",
        "5% (50 mg/gm) Ointment"
      ]
    },
    {
      "name": "Virux®",
     "img_id":"fqt6wOL.png",
      "image": "Virux-Sup.png",
      "active_ingredients": "Aciclovir",
      "indication": [
        "Treatment of viral infections due to Herpes simplex virus (type I & II) and Varicella zoster virus (herpes zoster & chickenpox).",
        "Treatment of Herpes simplex virus infections of the skin and mucous membranes, including initial and recurrent genital herpes.",
        "Prophylaxis of herpes simplex infections in immunocompromised patients."
      ],
      "dosage_and_administration": {
        "herpes_simplex_initial": "200 mg 5 times daily for 5 days. For immunocompromised patients, 400 mg 5 times daily for 5 days. Increase to 800 mg 5 times daily if healing is incomplete or new lesions appear.",
        "children_under_2_years": "Half of the adult dose.",
        "children_over_2_years": "Adult dose.",
        "prevention_of_recurrence": "200 mg 4 times daily or 400 mg twice daily, possibly reduced to 200 mg 2-3 times daily with interruptions every 6-12 months.",
        "prophylactic_treatment_immunocompromised": "200 to 400 mg 4 times daily.",
        "varicella_chickenpox_adults_and_children_over_40kg": "800 mg 4 times daily for 5 days.",
        "varicella_chickenpox_children_under_40kg": "20 mg/kg (max 800 mg) per dose 4 times daily for 5 days.",
        "varicella_chickenpox_children_under_2_years": "200 mg 4 times daily.",
        "varicella_chickenpox_children_2_5_years": "400 mg 4 times daily.",
        "varicella_chickenpox_children_over_6_years": "800 mg 4 times daily.",
        "herpes_zoster_shingles": "800 mg 5 times daily for 7 days.",
        "rectal_proctitis_herpes": "400 mg 5 times daily for 10 days or until clinical resolution.",
        "virux_cream": "Apply to lesions or impending lesions 5 times daily (omitting the night-time dose). Continue for 5 days, extend up to 10 days if needed."
      },
      "virux_iv_inj_dosage": {
        "herpes_simplex_infection": "5 mg/kg every 8 hours (normal or immunocompromised).",
        "very_severe_herpes_zoster_infection": "5 mg/kg every 8 hours (normal).",
        "varicella_zoster_infection_immunocompromised": "10 mg/kg every 8 hours.",
        "herpes_simplex_encephalitis": "10 mg/kg every 8 hours (normal or immunocompromised)."
      },
      "contraindications_and_precautions": [
        "Known hypersensitivity to Aciclovir.",
        "Virux® cream is not recommended for application to mucous membranes such as the eye, mouth, or vagina."
      ],
      "side_effects": [
        "Skin rashes, nausea, vomiting, diarrhea, headache, and abdominal pain."
      ],
      "drug_interactions": ["Probenecid, Amphotericin B, Ketoconazole."],
      "use_in_pregnancy_and_lactation": [
        "Should be used during pregnancy only when the potential benefits justify the possible risks to the fetus.",
        "Consider the potential for chromosomal damage at high concentrations.",
        "Due to potential serious adverse reactions to aciclovir in nursing infants, a decision should be made whether to discontinue nursing or the drug."
      ],
      "preparation": [
        "200 & 400 mg Tablet",
        "200 mg/5 ml Suspension",
        "50 mg/gm Cream",
        "500 mg IV Inj"
      ]
    },
    {
      "name": "Virux® HC",
     "img_id":"ohE9EO0.jpeg",
      "image": "virux_hc_l.jpg",
      "active_ingredients": ["Aciclovir", "Hydrocortisone"],
      "indication": [
        "Virux® HC Cream is indicated for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and shorten the lesion healing time in adults and children (6 years of age and older)."
      ],
      "dosage_and_administration": {
        "general_usage": "Apply the cream topically 5 times per day for 5 days. Therapy should be initiated as early as possible after the first signs and symptoms."
      },
      "contraindications": ["No known contraindications."],
      "precautions": [
        "Aciclovir and Hydrocortisone should not be used in the eye, inside the mouth or nose, or on the genitals.",
        "Patients should seek medical advice when a cold sore fails to heal within 2 weeks."
      ],
      "side_effects": [
        "Local skin reactions like drying or flaking of the skin, burning or tingling, erythema, pigmentation changes, and application site reactions including signs and symptoms of inflammation."
      ],
      "use_in_pregnancy_and_lactation": [
        "Pregnancy Category B. No adequate and well-controlled studies of systemic Aciclovir in pregnant women.",
        "Systemic exposure of Aciclovir and Hydrocortisone following topical administration of this cream is minimal."
      ],
      "drug_interactions": [
        "No drug interaction studies have been performed with Aciclovir and Hydrocortisone."
      ],
      "preparation": "(50mg + 10mg)/gm Cream"
    },
    {
      "name": "Xenole®",
     "img_id":"yX1N8M8.png",
      "image": "Xenole_u.png",
      "active_ingredients": ["Naproxen", "Esomeprazole"],
      "indication": [
        "For the relief of signs & symptoms of Osteoarthritis, Rheumatoid Arthritis & Ankylosing Spondylitis.",
        "To decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers."
      ],
      "dosage_and_administration": {
        "general_usage": "One Xenole 375 or Xenole 500 tablet twice daily, at least 30 minutes before a meal."
      },
      "contraindications_and_precautions": [
        "Known hypersensitivity.",
        "History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.",
        "During the perioperative period in the setting of coronary artery bypass graft (CABG) surgery.",
        "Late pregnancy."
      ],
      "side_effects": [
        "Most common side effects are erosive gastritis, dyspepsia, gastritis, diarrhea, gastric ulcer, upper abdominal pain, nausea, etc."
      ],
      "drug_interactions": [
        "Concomitant use of NSAIDs may reduce the antihypertensive effect of ACE inhibitors, diuretics, and beta-blockers."
      ],
      "use_in_pregnancy_and_lactation": ["Pregnancy category C."],
      "use_in_children": [
        "Use in children less than 18 years has not been established."
      ],
      "preparation": [
        "Naproxen 375 mg + Esomeprazole 20 mg Tablet",
        "Naproxen 500 mg + Esomeprazole 20 mg Tablet"
      ]
    },
    {
      "name": "Xfin",
     "img_id":"OZX9Ds4.jpeg",
      "image": "Xfin.jpg",
      "active_ingredients": "Terbinafine HCL",
      "indication": [
        "Fungal infections of the skin caused by dermatophytes such as Trichophyton rubrum, Trichophyton mentagrophytes, Microsporum canis, and Epidermophyton floccosum.",
        "Xfin™ Tablet: Onychomycosis of the toenail or fingernail due to dermatophytes.",
        "Ringworm (Tinea corporis, Tinea cruris, and Tinea pedis) where oral therapy is considered appropriate due to the site, severity or extent of the infection.",
        "Xfin™ Cream: Yeast infections of the skin principally caused by the genus Candida (e.g., Candida albicans).",
        "Pityriasis (tinea) versicolor due to Pityrosporum orbiculare (also known as Malassezia furfur)."
      ],
      "dosage_and_administration": {
        "tablet": "250 mg once daily for each indication.",
        "cream": "Cream can be applied once or twice daily. Duration of treatment varies according to the indication and the severity of infections."
      },
      "preparation": ["250 mg Tablet", "10 gm Cream"]
    },
    {
      "name": "Xflam™",
     "img_id":"rvftRX2.jpeg",
      "image": "xflam-tablet.jpg",
      "active_ingredients": "Dexibuprofen",
      "indication": [
        "Management of pain & inflammation associated with Osteoarthritis & other musculoskeletal disorders.",
        "Symptomatic treatment of mild to moderate pain & inflammation including dysmenorrhoea & dental pain."
      ],
      "dosage_and_administration": {
        "recommended_dosage": "600-900 mg Dexibuprofen per day, at 2-3 divided doses.",
        "maximum_single_dose": "400 mg",
        "maximum_daily_dosage": "Can be raised temporarily up to 1200 mg Dexibuprofen per day in patients with acute disorders or exacerbations.",
        "elderly_patient_dosage": "Lowest effective dose is recommended. The dosage can be raised to adult dosage if well tolerated."
      },
      "contraindication_and_precaution": [
        "Contraindicated in patients with previous history of hypersensitivity to Dexibuprofen or other NSAIDs.",
        "Contraindicated in patients who experience attack of asthma, bronchospasm, acute rhinitis, urticaria or edema after use of similar drugs (e.g., aspirin or other NSAIDs).",
        "Contraindicated in patients with active or suspected hemorrhage, Crohn’s disease or Ulcerative Colitis, serious heart diseases, kidney function impairment (GFR < 30 ml/min), and severe liver function impairment."
      ],
      "side_effect": [
        "Dyspepsia, diarrhea, fatigue, headache, nausea, vomiting, abdominal pain.",
        "Less common side effects: Flatulence, urticaria, pruritus, purpura, rhinitis, bronchospasm, insomnia, tinnitus."
      ],
      "use_in_pregnancy_and_lactation": [
        "Avoid use during pregnancy.",
        "Use with caution in nursing mothers."
      ],
      "use_in_children": "Not established for patients below 18 years of age.",
      "preparation": ["400 mg Tablet"]
    },
    {
      "name": "Xten™",
     "img_id":"vQ1L7hM.jpeg",
      "image": "XTEN.jpg",
      "active_ingredients": "Tenoxicam",
      "indication": [
        "Rheumatoid Arthritis",
        "Osteoarthritis",
        "Ankylosing Spondylitis",
        "Post-operative pain",
        "Acute gout",
        "Primary dysmenorrhoea"
      ],
      "dosage_and_administration": {
        "general_dosage": "20 mg daily at the same time of day for all indications except primary dysmenorrhoea, post-operative pain & acute gout.",
        "primary_dysmenorrhoea_dosage": "20 to 40 mg once daily.",
        "post_operartive_pain_dosage": "40 mg once daily up to five days.",
        "acute_gout_dosage": "40 mg once daily for two days, followed by 20 mg once daily for the next five days."
      },
      "contraindication_and_precaution": [
        "Hypersensitivity to Tenoxicam or any component of the product or other NSAIDs.",
        "Salicylates or other NSAIDs inducing symptoms of asthma, rhinitis, or urticaria.",
        "Suffering from gastritis, gastric & duodenal ulcers."
      ],
      "side_effect": [
        "Gastrointestinal tract: gastric, epigastric & abdominal discomfort, dyspepsia, heartburn, nausea.",
        "Central nervous system: dizziness, headache."
      ],
      "drug_interaction": [
        "Salicylates increase the clearance & volume of distribution of NSAIDs including Tenoxicam.",
        "Increased risk of gastrointestinal bleeding when antiplatelet agents & selective serotonin-reuptake inhibitors (SSRIs) are combined with NSAIDs.",
        "No clinically significant interaction with Frusemide, but Tenoxicam attenuates the blood pressure lowering effect of Hydrochlorothiazide.",
        "Tenoxicam might attenuate the antihypertensive effects of alpha-adrenergic blockers & ACE-inhibitors.",
        "No interactions with centrally acting alpha agonists or calcium channel blockers.",
        "No clinically relevant interaction with Atenolol."
      ],
      "use_in_pregnancy_and_lactation": [
        "Avoid treatment during the third trimester of pregnancy.",
        "No evidence of adverse reactions in breast-fed infants of mothers taking Tenoxicam."
      ],
      "use_in_children": "Not yet established.",
      "preparation": ["20 mg Tablet"]
    },
    {
      "name": "Xylocon®",
     "img_id":"yKMxuYv.jpeg",
      "image": "Xylocon-0.05_l.jpg",
      "active_ingredients": "Oxymetazoline",
      "indication": [
        "Relief of nasal congestion associated with acute & chronic rhinitis",
        "Common cold",
        "Sinusitis"
      ],
      "dosage_and_administration": {
        "adults_and_children_6_years_and_older": "2 to 3 drops of Xylocon® 0.05% in each nostril twice daily, in the morning & evening.",
        "children_2_to_5_years": "2 to 3 drops of Xylocon® 0.025% in each nostril twice daily in the morning & evening.",
        "duration_of_use": "Oxymetazoline HCl should generally be used for no longer than 3-5 days."
      },
      "contraindication_and_precaution": [
        "MAO inhibitors",
        "Tricyclic antidepressants",
        "Patients sensitive to other nasal decongestants may be sensitive to this medication."
      ],
      "side_effect": [
        "Stinging",
        "Burning",
        "Sneezing",
        "Increased nasal discharge",
        "Drying of the nostrils",
        "Altered taste"
      ],
      "drug_interaction": [
        "Causes hypertensive crisis if used simultaneously with MAO inhibitors or Tricyclic antidepressants."
      ],
      "use_in_pregnancy_and_lactation": [
        "Safe in the third trimester of a normal pregnancy.",
        "Caution should be exercised when administering to a nursing mother."
      ],
      "preparation": [
        "0.05% Nasal Drops for adults",
        "0.025% Paediatric Nasal Drops for children"
      ]
    },
    {
      "name": "Zanthin™",
     "img_id":"NP7wZCd.jpeg",
      "image": "Zanthin.jpg",
      "active_ingredients": "Astaxanthin",
      "indication": [
        "Strong antioxidant",
        "Internal beautification & skin improvement",
        "Improvement of cardiovascular health",
        "Improvement of brain & central nervous system health",
        "Healthy immune system"
      ],
      "dosage_and_administration": {
        "recommended_daily_dosage": "4 mg per day",
        "dosage_table": {
          "2-4 mg": "Antioxidant, Cardiovascular Health, Immune System Enhancer",
          "4-8 mg": "Internal Beauty & Skin Improvement, Strength & Endurance, Brain & Central Nervous System Health, Eye Health",
          "4-12 mg": "Arthritis, Silent Inflammation (C-reactive protein), Internal Sunscreen"
        }
      },
      "contraindication_and_precaution": [
        "Hypersensitive to any component of an Astaxanthin containing supplement.",
        "Pregnant women & nursing mothers should avoid Astaxanthin containing supplements."
      ],
      "side_effect": ["No reports have been found regarding Astaxanthin."],
      "drug_interaction": [
        "There are no known adverse reactions when taken in conjunction with medications."
      ],
      "use_in_pregnancy_and_lactation": [
        "Both pregnant women & lactating mothers should avoid Astaxanthin containing supplements."
      ],
      "preparation": ["2 mg tablet", "4 mg tablet"]
    },
    {
      "name": "Zesup®",
     "img_id":"Bct5xuN.jpeg",
      "image": "ZESUP-SYRUP.jpg",
      "active_ingredients": "Zinc Sulphate",
      "indication": [
        "Zinc deficiency and/or zinc losing conditions",
        "Recurrent Respiratory Tract Infections",
        "Diarrhoea",
        "Loss of appetite",
        "Severe growth retardation",
        "Deformed bone formation",
        "Impaired immunological response",
        "Acrodermatitis enteropathica",
        "Parakeratotic skin lesions",
        "Defective & delayed wound healing",
        "Anaemia",
        "Night blindness",
        "Mental disturbances"
      ],
      "dosage_and_administration": {
        "syrup": {
          "child_under_10_kg": "5 ml (1 teaspoonful) 2 times daily",
          "child_between_10_and_30_kg": "10 ml (2 teaspoonful) 1-3 times daily",
          "adults_and_children_over_30_kg": "20 ml (4 teaspoonful) 1-3 times daily"
        },
        "instructions": "This drug is most effective if taken at least 1 hour before or 2 hours after meals. If it causes stomach upset, it may be taken with a meal. Regular use is recommended to get the most benefit."
      },
      "contraindication_and_precaution": [
        "Contraindicated in those who are hypersensitive to any component of the ingredient of this zinc-containing supplement.",
        "In acute renal failure, zinc accumulation may occur; dose adjustment required if needed."
      ],
      "side_effect": [
        "Nausea",
        "Vomiting",
        "Diarrhoea",
        "Stomach upset",
        "Heartburn",
        "Gastritis"
      ],
      "use_in_pregnancy_and_lactation": [
        "Zinc is used during pregnancy & lactation at a dose of 20 mg per day.",
        "Zinc crosses the placenta & is present in breast milk."
      ],
      "drug_interaction": [
        "Concomitant intake of a Tetracycline & Zinc may decrease the absorption of both.",
        "Concomitant administration of Zinc & Quinolone may also decrease the absorption of both.",
        "Concomitant intake of Penicillamine & Zinc may depress absorption of Zinc."
      ],
      "preparation": ["100 ml Syrup"]
    },
    {
      "name": "Zif®",
     "img_id":"TthlRzm.jpeg",
      "image": "Zif.jpg",
      "active_ingredients": ["Ferrous Sulphate", "Zinc Sulphate", "Folic Acid"],
      "indication": [
        "Treatment & prophylaxis of Iron, Folic Acid & Zinc deficiency, especially during pregnancy & lactation."
      ],
      "dosage_and_administration": {
        "capsules": "1 capsule daily. 2 capsules may be required in more severe cases."
      },
      "contraindication_and_precaution": [
        "Hypersensitivity",
        "Care should be taken in haemochromatosis, haemolytic anaemia, or red cell aplasia."
      ],
      "drug_interaction": [
        "Tetracycline",
        "Penicillamine",
        "Antacids",
        "Zinc accumulation could exist."
      ],
      "use_in_pregnancy": [
        "Should be avoided during the first trimester of pregnancy."
      ],
      "side_effect": [
        "Dark stools",
        "Nausea",
        "Gastrointestinal irritation",
        "Anorexia",
        "Vomiting",
        "Discomfort",
        "Constipation",
        "Diarrhoea",
        "Allergic reactions"
      ],
      "preparation": [
        "Each timed-release capsule contains dried Ferrous Sulphate 150 mg, Folic Acid 500 mcg, and Zinc Sulphate Monohydrate 61.80 mg."
      ]
    },
    {
      "name": "Zif-CI TM",
     "img_id":"bVbvf7i.jpeg",
      "image": "ZIF-CL.jpg",
      "active_ingredients": ["Carbonyl Iron", "Folic Acid", "Zinc"],
      "indication": [
        "Treatment & prophylaxis of Iron, Folic Acid & Zinc deficiency, especially during pregnancy & lactation."
      ],
      "dosage_and_administration": {
        "adults": "One capsule daily before food or as directed by the physician."
      },
      "contraindication_and_precaution": [
        "Known hypersensitivity to any of its components or those with Iron overload.",
        "Special care should be taken in patients with Iron overload states, such as haemochromatosis, haemolytic anaemia, or red cell aplasia.",
        "In patients with renal failure, there may be the risk of Zinc accumulation."
      ],
      "side_effect": [
        "Nausea",
        "Anorexia",
        "Vomiting",
        "Discomfort",
        "Constipation",
        "Diarrhoea",
        "Dark stool",
        "Rare allergic reactions"
      ],
      "drug_interaction": {
        "carbonyl_iron": [
          "Tetracycline antibiotics",
          "Quinolone antibiotics",
          "Levodopa",
          "Levothyroxine",
          "Methyldopa",
          "Penicillamine"
        ],
        "folic_acid": ["Phenobarbital", "Phenytoin", "Primidone"]
      },
      "use_in_pregnancy_and_lactation": [
        "Use of any drug during the first trimester of pregnancy should be avoided if possible.",
        "Administration of Iron during the first trimester requires definite evidence of Iron deficiency.",
        "Prophylaxis of Iron deficiency where inadequate diet calls for supplementary Zinc & Folic Acid is justified during the remainder of pregnancy."
      ],
      "preparation": [
        "Each TR capsule contains Elemental Iron 50 mg as Carbonyl Iron, Folic Acid 0.50 mg & Zinc Sulphate Monohydrate 61.80 mg."
      ]
    },
    {
      "name": "Zif® Forte",
     "img_id":"40jl0nX.jpeg",
      "image": "Zif-Forte_n.jpg",
      "active_ingredients": [
        "Carbonyl Iron",
        "Folic Acid",
        "Vitamin B-Complex",
        "Vitamin C (as Ascorbic Acid)",
        "Zinc Sulphate Monohydrate"
      ],
      "indication": [
        "Treatment & prophylaxis of Iron, Folic Acid, Vitamin B-Complex, Vitamin C & Zinc deficiency, especially during pregnancy & lactation.",
        "Indicated for geriatric patients with generalized weakness due to vitamins & minerals deficiency."
      ],
      "dosage_and_administration": {
        "adults": "One capsule daily before food or as directed by the physician."
      },
      "contraindication_and_precaution": [
        "Contraindicated in patients with known hypersensitivity to any of its components or those with Iron overload.",
        "Special care should be taken in patients with Iron overload states, such as haemochromatosis, haemolytic anaemia, or red blood cell aplasia.",
        "Failure to respond to the treatment requires further investigations to exclude other causes of anaemia.",
        "In patients with renal failure, there may be the risk of Zinc accumulation."
      ],
      "side_effect": [
        "Gastrointestinal irritations such as nausea",
        "Anorexia",
        "Vomiting",
        "Discomfort",
        "Constipation",
        "Diarrhoea",
        "Dark stool",
        "Rare allergic reactions"
      ],
      "use_in_pregnancy_and_lactation": [
        "Use of any drug during the first trimester of pregnancy should be avoided if possible.",
        "Administration of Iron during the first trimester requires definite evidence of Iron deficiency.",
        "Prophylaxis of Iron deficiency where inadequate diet calls for supplementary Zinc & Folic Acid is justified during the remainder of pregnancy."
      ],
      "drug_interaction": {
        "carbonyl_iron": [
          "Decreases the absorption of tetracycline antibiotics",
          "Quinolone antibiotics",
          "Levodopa",
          "Levothyroxine",
          "Methyldopa",
          "Penicillamine"
        ],
        "folic_acid": [
          "Interacts with antiepileptics, possibly reducing plasma concentrations of phenobarbital, phenytoin, and primidone."
        ]
      },
      "preparation": [
        "Each capsule contains Elemental Iron 50 mg (as Carbonyl Iron INN), Folic Acid BP 0.50 mg, Thiamine Mononitrate USP 2 mg, Riboflavin USP 2 mg, Pyridoxine Hydrochloride BP 1 mg, Nicotinamide USP 10 mg, Vitamin C (as Ascorbic Acid) USP 50 mg & Zinc Sulphate Monohydrate USP 61.80 mg."
      ]
    },
    {
      "name": "ZifoletTM",
     "img_id":"TilRHpc.jpeg",
      "image": "ZIFOLET.jpg",
      "active_ingredients": ["Folic Acid", "Zinc"],
      "indication": [
        "Prophylaxis & prevention of Zinc & Folic Acid deficiencies."
      ],
      "dosage_and_administration": {
        "adults": "One tablet daily or as recommended by the physician."
      },
      "contraindication": [
        "Zinc is contraindicated in patients having hypersensitivity to Zinc.",
        "Folic Acid is contraindicated in untreated cobalamine deficiency."
      ],
      "side_effect": [
        "Abdominal pain",
        "Dyspepsia",
        "Nausea",
        "Vomiting",
        "Fever",
        "Respiratory distress"
      ],
      "drug_interaction": [
        "Large amounts of Calcium decrease the absorption of Zinc."
      ],
      "use_in_pregnancy_and_lactation": ["Recommended."],
      "preparation": [
        "Each film-coated tablet contains Folic Acid 5 mg & Zinc 20 mg."
      ]
    },
    {
      "name": "Ziliron-B®",
     "img_id":"OyZxEub.jpeg",
      "image": "ZILIRON-B.jpg",
      "active_ingredients": [
        "Iron (III) Hydroxide Polymaltose Complex",
        "Folic Acid",
        "Vitamin B-complex",
        "Zinc Sulphate Monohydrate"
      ],
      "indication": [
        "Prevention & treatment of Iron, Folic Acid, Zinc & Vitamin B-Complex deficiencies."
      ],
      "dosage_and_administration": {
        "adults": "One capsule daily. Two capsules may be required a day in severe cases or as directed by the physician."
      },
      "contraindication_and_precaution": [
        "Contraindicated in patients with a known hypersensitivity to any of the ingredients of this product.",
        "As with all Iron preparations, a dark coloration of the stool may occur, which is without clinical significance."
      ],
      "side_effect": [
        "Generally well tolerated.",
        "Very few allergic reactions may be seen."
      ],
      "use_in_pregnancy": [
        "Use of any drug during the first trimester of pregnancy should be avoided if possible.",
        "Thus, administration of Iron during the first trimester requires definite evidence of Iron deficiency.",
        "Prophylaxis of Iron deficiency where inadequate diet calls for supplementary Zinc & Folic Acid is justified during the remainder of pregnancy."
      ],
      "drug_interaction": [
        "No interactions have been observed.",
        "Since the Iron is complex bound, ionic interaction with foodstuff components (phytates, oxalates, tannin, etc.) & concomitant administrations of medicaments (tetracyclines, antacids) are unlikely to occur."
      ],
      "preparation": [
        "Each capsule contains Iron (III) Hydroxide Polymaltose Complex INN 188 mg equivalent to elemental Iron 47 mg, Folic Acid BP 0.5 mg, Thiamine Hydrochloride BP 5 mg, Riboflavin BP 2 mg, Pyridoxine Hydrochloride BP 2 mg, Nicotinamide BP 20 mg & Zinc Sulphate Monohydrate USP 61.80 mg."
      ]
    },
    {
      "name": "Zimax®",
     "img_id":"tyYRP8R.jpeg",
      "image": "Zimax-250.jpg",
      "active_ingredients": "Azithromycin",
      "indication": [
        "Bronchitis & pneumonia",
        "Sinusitis & pharyngitis/tonsillitis",
        "Otitis media",
        "Skin & soft tissue infections",
        "Sexually transmitted diseases"
      ],
      "dosage_and_administration": {
        "adults": "500 mg once daily for 3 days.",
        "children": "10 mg/kg body weight once daily for 3 days."
      },
      "contraindication_and_precaution": [
        "Known hypersensitivity",
        "Should not be used in patients with hepatic disease",
        "Avoid concomitant administration with terfenadine or astemizole",
        "Precaution should be taken in patients with more severe renal impairment"
      ],
      "side_effect": [
        "Nausea",
        "Vomiting",
        "Abdominal discomfort (pain/cramps)",
        "Flatulence",
        "Diarrhoea",
        "Headache",
        "Dizziness",
        "Skin rashes",
        "Reversible elevations in liver transaminases"
      ],
      "drug_interaction": [
        "Antacids",
        "Ergot Derivatives",
        "Digoxin & Cyclosporin",
        "Anti-histamines"
      ],
      "use_in_pregnancy_and_lactation": [
        "The initial treatment of chlamydial cervicitis in pregnancy",
        "In other infections, Azithromycin should be used only when clearly needed",
        "Exercise caution when administering to a nursing woman"
      ],
      "preparation": [
        "500 mg Tablet",
        "250 mg Capsule",
        "200 mg/5 ml Suspension",
        "500 mg IV Infusion"
      ]
    },
    {
      "name": "Zolibac™",
     "img_id":"ibcwz4r.jpeg",
      "image": "ziloback_large.jpg",
      "active_ingredients": "Cefazolin as Cefazolin Sodium USP",
      "indication": [
        "Respiratory Tract Infections",
        "Urinary Tract Infections",
        "Skin and Skin Structure Infections",
        "Biliary Tract Infections",
        "Bone and Joint Infections",
        "Genital Infections",
        "Septicemia",
        "Endocarditis",
        "Perioperative Prophylaxis"
      ],
      "dosage_and_administration": {
        "usual_adult_dosage": {
          "perioperative_prophylactic_use": [
            "1 gram IV or IM administered ½ hour to 1 hour prior to the start of surgery",
            "For lengthy operative procedures (e.g. 2 hours or more), 500 mg to 1 gram IV or IM during surgery",
            "500 mg to 1 gram IV or IM every 6 to 8 hours for 24 hours postoperatively",
            "In surgery where the occurrence of infection may be particularly devastating (e.g. open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Zolibac™ may be continued for 3 to 5 days following the completion of surgery"
          ]
        }
      },
      "contraindication_and_precaution": [
        "Cefazolin is contraindicated in patients with known allergy to the Cephalosporin group of Antibiotics"
      ],
      "side_effect": [
        "Injection site reactions (pain, swelling, skin rash, or a hard lump)",
        "Diarrhea",
        "Stomach pain",
        "Stomach cramps",
        "Nausea",
        "Vomiting",
        "Loss of appetite",
        "Skin rash or itching",
        "Hives",
        "White patches or sores inside the mouth or on the lips",
        "Vaginal itching or discharge",
        "Heartburn",
        "Gas",
        "Rectal itching",
        "Confusion",
        "Weakness",
        "Hypotension",
        "Drowsiness",
        "Headache",
        "Allergic reactions"
      ],
      "use_in_pregnancy_and_lactation": [
        "Pregnancy Category B",
        "Cefazolin is present in very low concentrations in the milk of nursing mothers. Caution should be exercised when Cefazolin is administered to a nursing woman"
      ],
      "drug_interaction": [
        "Probenecid may decrease renal tubular secretion of Cephalosporins when used concurrently, resulting in increased and more prolonged Cephalosporin blood levels"
      ],
      "preparation": ["1 gm & 500 mg IM/IV Injection"]
    },
    {
      "name": "Zox®",
     "img_id":"Xr5skbc.jpeg",
      "image": "ZOX-30ML.jpg",
      "active_ingredients": "Nitazoxanide",
      "indication": [
        "Diarrhoea caused by Cryptosporidium parvum & Giardia lamblia",
        "Amoebiasis",
        "Helminth infections"
      ],
      "dosage_and_administration": {
        "age_1_3_years": "5 ml (100 mg) twice daily for 3 days",
        "age_4_11_years": "10 ml (200 mg) twice daily for 3 days",
        "age_12_years_and_above": "25 ml or 1 tablet (500 mg) twice daily for 3 days"
      },
      "contraindication_and_precaution": [
        "Known hypersensitivity to Nitazoxanide or any other ingredient in the formulations",
        "Should be administrated with caution to patients with hepatic, renal & biliary disease"
      ],
      "side_effect": [
        "Abdominal pain",
        "Diarrhoea",
        "Vomiting",
        "Headache (reported rarely)"
      ],
      "use_in_pregnancy_and_lactation": [
        "Pregnancy category B. This drug should be used during pregnancy only if clearly needed",
        "Caution should be exercised when Nitazoxanide is administrated to a nursing woman"
      ],
      "drug_interaction": [
        "Caution should be taken when administering Nitazoxanide concurrently with other highly plasma-protein bound drugs"
      ],
      "preparation": ["500 mg Tablet", "30 ml & 60 ml Suspension (100 mg/5 ml)"]
    },
    {
      "name": "Adovas®",
     "img_id":"yA9NUF3.jpeg",
      "image": "Adovas-100.jpg",
      "active_ingredients": "Basak (Adhatoda Vasica) with some other herbs",
      "indication": [
        "All kinds of cough",
        "Dry irritable cough",
        "Allergic & smoker’s cough",
        "Effective in throat irritation & hoarseness"
      ],
      "dosage_and_administration": {
        "adults": "3 teaspoonfuls (15 ml) 2 - 3 times a day. In acute cough, warm water can be added for better result.",
        "children_under_12_years": "1-2 teaspoonfuls (5 - 10 ml) 3 times a day"
      },
      "contraindication_and_precaution": [
        "There is no evidence available on contraindication but it may happen in patients who are hypersensitive to any of its ingredients"
      ],
      "side_effect": "No known side effects",
      "use_in_pregnancy_and_lactation": "The safety of Adovas syrup in pregnancy has not been established. Therefore, it should be used during pregnancy only under the supervision of a physician.",
      "preparation": ["100 ml syrup", "200 ml syrup"]
    },
    {
      "name": "AmCivit®",
     "img_id":"jp6jedG.jpeg",
      "image": "AMCIVIT-SYRUP-100ML_.jpg",
      "active_ingredients": "Amlaki (Emblica officinalis)",
      "indication": ["Vitamin C deficiency", "Scurvy", "Anemia in children"],
      "dosage_and_administration": {
        "children": "½ teaspoonful - 1 teaspoonful (2.5 ml - 5 ml) 2 times daily",
        "adult": "2 - 3 teaspoonful (10 - 15 ml) 2 - 3 times daily or as directed by the physician"
      },
      "contraindication_and_precaution": [
        "There is no evidence available on contraindication. Precaution should be taken in patients who are hypersensitive to any of its ingredients."
      ],
      "side_effect": "There is no known significant side effect.",
      "use_in_pregnancy_and_lactation": "No adverse effect of Amcivit syrup has been reported.",
      "preparation": ["100 ml syrup"]
    },
    {
      "name": "Arubin®",
     "img_id":"17PlhC8.png",
      "image": "Arubin_.png",
      "active_ingredients": [
        "Ferrous fumarate",
        "Emblica officinalis",
        "Terminalia chebula",
        "Other herbs"
      ],
      "indication": [
        "Iron deficiency anemia",
        "Anemia due to malnutrition",
        "Loss of appetite"
      ],
      "dosage_and_administration": {
        "adults": "1 or 2 capsule to be taken 2 times daily with water",
        "children": "Not recommended under 12 years of age"
      },
      "contraindication_and_precaution": [
        "There is no evidence available on contraindication but it may happen in patients who are hypersensitive to any of its ingredients.",
        "Caution should be taken with concomitant use of antacid, calcium supplements & tannin-containing herbal preparations. Iron supplements should not be taken within 1 hour before or 2 hours after ingestion of any of the above."
      ],
      "side_effect": "Arubin capsules are not known to have any side effects if taken as per prescribed dosage.",
      "use_in_pregnancy_and_lactation": [
        "In the first trimester of pregnancy, adequate iron intake is usually obtained from a proper diet; however, in the second & third trimesters, when iron deficiency is more prevalent due to greatly increased requirements, iron supplements may be recommended.",
        "Some clinicians prefer to evaluate the patient before giving routine iron supplementation.",
        "Problems in humans have not been documented with intake of normal daily recommended amounts."
      ],
      "preparation": ["500 mg Capsule"]
    },
    {
      "name": "Cardi QTM",
     "img_id":"aHSvlU7.jpeg",
      "image": "Cardi-Q-100.jpg",
      "active_ingredients": "Ubidecarenone (Coenzyme Q10)",
      "indications": [
        "Neurological Disorders",
        "Myopathy",
        "Muscular Dystrophy",
        "Ataxia",
        "Parkinson’s disease",
        "Genetic Neuromuscular Disease",
        "Alzheimer’s disease",
        "Migraine",
        "Cardiovascular Disease",
        "Congestive Heart Failure (CHF)",
        "Cardiomyopathy",
        "Hypertension",
        "Heart Protection during Surgery",
        "Angina",
        "Periodontal Gum Disease",
        "Exercise Performance",
        "Diabetes",
        "Cancer",
        "Asthma",
        "Thyroid Disorder"
      ],
      "dosage_and_administration": "1 - 3 capsules daily after meal or as directed by physician.",
      "contraindications": "None known.",
      "pregnancy_and_lactation": "There is a lack of long-term safety data to support the safe use of Ubidecarenone during pregnancy and lactation.",
      "side_effects": [
        "Occasionally gastrointestinal discomfort",
        "Dizziness",
        "Skin rash (mostly with higher doses)"
      ],
      "drug_interactions": [
        "Statins: May increase Ubidecarenone levels without affecting statin efficacy.",
        "Warfarin: May reduce the effectiveness of warfarin.",
        "Thyroid drugs: May alter the effect of thyroid drugs.",
        "Beta blockers (particularly propranolol): May inhibit Ubidecarenone dependent enzymes.",
        "Antidiabetic medications: May improve glycemic control in some type II diabetics, requiring dose adjustment.",
        "Doxorubicin: May reduce cardiotoxicity caused by doxorubicin."
      ],
      "storage": "Store at cool and dry place below 30°C, away from direct sunlight & moisture. Keep out of the reach of children. Do not freeze.",
      "composition": [
        "Cardi-QTM 50 mg soft gel Capsule: Each capsule contains Ubidecarenone (coenzyme Q10) 50 mg.",
        "Cardi-QTM 100 mg soft gel Capsule: Each capsule contains Ubidecarenone (coenzyme Q10) 100 mg."
      ]
    },
    {
      "name": "ColmintTM",
     "img_id":"G8DwquX.jpeg",
      "image": "Colmint_l.jpg",
      "active_ingredients": "Peppermint oil (Mentha x piperita)",
      "indications": [
        "Irritable bowel syndrome",
        "Abdominal pain & spasm",
        "Abdominal distension/bloating"
      ],
      "dosage_and_administration": {
        "adults": "1 capsule 3 times daily 30 to 60 minutes before meal with a glass of water. The dose may be increased to a maximum of 2 capsules 3 times daily or as directed by a physician.",
        "children": "1 capsule 3 times daily or as directed by a physician (for children 8 years & above)."
      },
      "contraindications_and_precautions": [
        "Contraindicated in patients with achlorhydria.",
        "Contraindicated for infants & small children due to the potential risk of spasm of the tongue or respiratory tract.",
        "Should not be taken with food or immediately after meals. It should be taken 30 to 60 minutes before meals.",
        "Capsules must not be chewed or crushed, must be swallowed whole with a little liquid."
      ],
      "side_effects": "No known side effects according to Commission E.",
      "pregnancy_and_lactation": "No known restrictions.",
      "preparation": "187 mg (0.2 ml) Softgel Capsule."
    },
    {
      "name": "DubarelTM",
     "img_id":"Zyexvy6.jpeg",
      "image": "Dubarel-200-ml_l.jpg",
      "active_ingredients": "Saraca indica with some other herbs",
      "indications": [
        "Metrorrhagia",
        "Secondary amenorrhea",
        "Anovulatory infertility",
        "Polycystic ovarian syndrome (PCOS)"
      ],
      "dosage_and_administration": {
        "children_under_12": "Not applicable.",
        "above_12_and_adults": "2 - 3 teaspoonfuls (10 - 15 ml) 2 - 3 times daily after meal for 3 – 6 months or as directed by the physician."
      },
      "contraindications_and_precautions": "No known.",
      "side_effects": "No health hazards or side effects are known in conjunction with the proper administration of designated therapeutic dosages.",
      "preparation": "100 ml syrup"
    },
    {
      "name": "Enerton®",
     "img_id":"dGdVTze.jpeg",
      "image": "Enerton.jpg",
      "active_ingredients": "Extract of Sida cordifolia",
      "indications": [
        "General weakness",
        "Strength & energy booster",
        "Superb sports tonic",
        "Tonic for asthmatic patients"
      ],
      "dosage_and_administration": {
        "children_under_12": "Not recommended.",
        "adults": "2 - 3 teaspoonfuls (10 - 15 ml) 2 - 3 times daily or as directed by the physician."
      },
      "contraindications_and_precautions": "Caution should be taken in hypertension, DM & others CNS stimulants.",
      "side_effects": "When used within the recommended dosage range, it is well tolerated.",
      "use_in_pregnancy_and_lactation": "It is not recommended during pregnancy.",
      "preparation": "200 ml syrup"
    },
    {
      "name": "Eprim®",
     "img_id":"kGtuyc5.jpeg",
      "image": "Eprim_l1.jpg",
      "active_ingredients": "Evening primrose oil",
      "indications": [
        "Dysmenorrhea",
        "Cyclical mastalgia",
        "Low breastmilk supply",
        "Acne vulgaris",
        "Atopic dermatitis & Eczema",
        "Pregnancy mask"
      ],
      "dosage_and_administration": "One or two capsules two to three times daily or as advised by the physician.",
      "side_effects": "Adverse effects are rare at recommended dosages. Overdose may cause loose stool and abdominal pain.",
      "contraindications_and_precautions": "Previously it was not recommended for patients diagnosed with schizophrenia or those already receiving epileptogenic drugs such as phenothiazines. However, a recently published analysis of clinical trials involving polyunsaturated fatty acids in the treatment of schizophrenia did not indicate a clear therapeutic or adverse effect of evening primrose oil supplements on schizophrenic patients.",
      "use_in_pregnancy_and_lactation": "No known restrictions. Non-teratogenic, based on animal studies. LA, GLA, and DGLA are important components of human breast milk, so it is reasonable to assume that evening primrose oil may be taken while nursing. According to World Health Organization (WHO), pregnant or lactating women should get 5% of their total daily caloric intake from EFAs.",
      "preparation": "500 mg & 1000 mg Softgel Capsule"
    },
    {
      "name": "Eprim® Plus",
     "img_id":"RF5PkPy.jpeg",
      "image": "eprim-plus.jpg",
      "active_ingredients": "Evening primrose oil",
      "indications": [
        "Dysmenorrhea",
        "Cyclical mastalgia",
        "Low breastmilk supply",
        "Acne vulgaris",
        "Atopic dermatitis & Eczema",
        "Pregnancy mask"
      ],
      "dosage_and_administration": "One or two capsules two to three times daily or as advised by the physician.",
      "side_effects": "Adverse effects are rare at recommended dosages. Overdose may cause loose stool and abdominal pain.",
      "contraindications_and_precautions": "Previously it was not recommended for patients diagnosed with schizophrenia or those already receiving epileptogenic drugs such as phenothiazines. However, a recently published analysis of clinical trials involving polyunsaturated fatty acids in the treatment of schizophrenia did not indicate a clear therapeutic or adverse effect of evening primrose oil supplements on schizophrenic patients.",
      "use_in_pregnancy_and_lactation": "No known restrictions. Non-teratogenic, based on animal studies. LA, GLA, and DGLA are important components of human breast milk, so it is reasonable to assume that evening primrose oil may be taken while nursing. According to World Health Organization (WHO), pregnant or lactating women should get 5% of their total daily caloric intake from EFAs.",
      "preparation": "500 mg & 1000 mg Softgel Capsule"
    },
    {
      "name": "EredexTM",
     "img_id":"U1utjwe.jpeg",
      "image": "Eredex_l.jpg",
      "active_ingredients": "Yohimbe (Pausinystalia yohimbe)",
      "indications": [
        "Erectile dysfunction (Male impotence)",
        "Loss of libido",
        "Exhaustion"
      ],
      "dosage_and_administration": "Adult: 1 tablet 3 times daily or as advised by the physician.",
      "contraindications_and_precautions": "The drug should not be used by patients with liver & kidney diseases, chronic inflammation of the sexual organs or prostate gland, or with a history of gastric or duodenal ulcers.",
      "side_effects": [
        "Anxiety states",
        "Elevated blood pressure",
        "Exanthema",
        "Nausea",
        "Insomnia",
        "Tachycardia",
        "Tremor",
        "Mania",
        "Vomiting"
      ],
      "drug_interaction": "Theoretically, Yohimbe may counteract the hypotensive effect of antihypertensive medications, resulting in inadequate blood pressure control. It may potentiate pharmaceutical MAO-inhibitors.",
      "preparation": "5.4 mg capsule"
    },
    {
      "name": "FlemoTM",
     "img_id":"V8YHH1w.jpeg",
      "image": "Flemo_.jpg",
      "active_ingredients": "Undenatured Type II Collagen",
      "indications": [
        "Osteoarthritis",
        "Rheumatoid arthritis",
        "Joint pain & inflammation",
        "Difficulties in flexibility & mobility",
        "Joint discomfort & stiffness (knee extension)",
        "Impaired joint function",
        "Strenuous exercise & sports"
      ],
      "dosage_and_administration": "Orally 1 capsule daily with water or as directed by the physician.",
      "contraindications": "Contraindicated in patients with known hypersensitivity to chicken or egg.",
      "side_effects": [
        "Undenatured Type II Collagen is generally well tolerated in recommended dose.",
        "Overdose may cause constipation and headache."
      ],
      "drug_interaction": "Not known.",
      "use_in_pregnancy_and_lactation": "Lack of scientific evidence on the use of Undenatured Type II Collagen during pregnancy or lactation.",
      "preparation": "40 mg Capsule"
    },
    {
      "name": "GarlinTM",
     "img_id":"9Y3SYAN.jpeg",
      "image": "garlin-10-mg.jpg",
      "active_ingredients": "Garlic oil (standardized)",
      "indications": ["Hyperlipidemia", "Atherosclerosis", "Mild Hypertension"],
      "dosage_and_administration": "1 - 2 capsules daily for 8 – 18 weeks or as advised by the physician.",
      "contraindications": [
        "None known.",
        "The World Health Organization cautions against the use of garlic by patients with a known allergy to garlic and those taking Warfarin."
      ],
      "side_effects": [
        "Gastro-intestinal symptoms",
        "Changes to the flora of the intestine",
        "Allergic reactions (rare)"
      ],
      "use_in_pregnancy_and_lactation": "None known. Major sulfur containing volatiles from garlic are transmitted to breast milk leading to improved drinking habits of infants.",
      "preparation": "10 mg Softgel Capsule"
    },
    {
      "name": "GelaseedTM",
     "img_id":"UlpDMJ8.jpeg",
      "image": "Gelaseed.jpg",
      "active_ingredients": "Flaxseed oil (Linum usitatissimum)",
      "indications": ["Hyperlipidemia", "Constipation"],
      "dosage_and_administration": "One softgel capsule two to three times daily, with a meal. For easier swallowing, take with water before and during ingestion.",
      "adverse_effects": [
        "Adverse effects are rare at recommended dosages.",
        "Overdose may cause loose stool and abdominal pain."
      ],
      "contraindications": [
        "Flaxseed Oil should be used with caution when combined with blood thinning medication (i.e. Warfarin, Coumadin)."
      ],
      "use_in_pregnancy_and_lactation": "Flaxseed oil is possibly unsafe when taken by mouth during pregnancy. Some research suggests that flaxseed oil might increase the chance of premature birth when taken during the second or third trimesters of pregnancy.",
      "children": "Flaxseed is possibly safe for children in short-term use.",
      "preparation": "Softgel capsule 1000 mg"
    },
    {
      "name": "Giloba®",
     "img_id":"tuKJVCa.jpeg",
      "image": "GILOBA.jpg",
      "active_ingredients": "Ginkgo biloba",
      "indications": [
        "Cerebral insufficiency",
        "Demential syndromes: memory deficit, poor concentration, depression, dizziness & headache",
        "Vertigo & tinnitus",
        "Peripheral vascular diseases",
        "Sexual dysfunction secondary to SSRI use",
        "Acute cochlear deafness"
      ],
      "dosage_and_administration": "Giloba 60 mg 1 or 2 capsules 2 to 3 times daily or as advised by the physician.",
      "contraindications_and_precaution": [
        "Ginkgo should always be used with caution in patients taking anticoagulants or antiplatelet agents i.e. warfarin, heparin & aspirin.",
        "It is also contraindicated in bleeding disorders due to increased bleeding potential associated with chronic use (6 - 12 months) or before elective surgery.",
        "Contraindicated in patients with known risk factors for intracranial hemorrhage."
      ],
      "side_effects": "No side effects following proper administration of designated therapeutic dosages.",
      "use_in_pregnancy_and_lactation": "There is no known restriction on the use of ginkgo in pregnancy & lactation.",
      "preparation": "60 & 120 mg Capsule"
    },
    {
      "name": "Gintex®",
     "img_id":"Z6DkGq9.jpeg",
      "image": "GINTEX.jpg",
      "active_ingredients": "Panax ginseng",
      "indications": [
        "General weakness & tiredness",
        "Infertility in men",
        "Type 2 diabetes mellitus",
        "Cognitive function & mental performance enhancement"
      ],
      "dosage_and_administration": "One Gintex capsule 1 or 2 times a day or as advised by the physician.",
      "contraindications_and_precaution": [
        "Ginseng can be taken with any other vitamin, minerals or herbal supplement.",
        "No known contraindications according to the German E Commission & World Health Organization (WHO).",
        "Overstimulation & insomnia have also been reported with Ginseng.",
        "Anecdotal evidence suggests that excessive doses may mildly elevate blood pressure and/or cause hypersexuality."
      ],
      "side_effects": "Over Ginseng’s many years of use, no serious side effects or drug interactions have been reported.",
      "use_in_pregnancy_and_lactation": "No known restriction according to the American Herbal Product Association & German Commission E.",
      "preparation": "500 mg Capsule"
    },
    {
      "name": "Ispergul®",
     "img_id":"xAmIH9x.jpeg",
      "image": "Ispergul-02.jpg",
      "active_ingredients": "Plantago ovata husk",
      "indications": [
        "Constipation",
        "Hemorrhoids",
        "Ulcerative colitis",
        "Hyperlipidemia"
      ],
      "dosage_and_administration": {
        "adults": "3.5 gm (1 sachet) 2 to 3 times daily with a glass of water.",
        "children_6_to_12_years": "2 gm to 3.5 gm (½ to 1 sachet) 2 to 3 times daily with a glass of water."
      },
      "contraindications_and_precaution": [
        "Psyllium is contraindicated in patients who have pathological narrowing in the GIT, intestinal obstruction, fecal impaction, difficulty in swallowing or esophageal narrowing, difficulties in regulating diabetes mellitus."
      ],
      "side_effects": "Incorrect administration procedure (with too little fluid) can cause the product to swell & lead to obstruction of the esophagus or intestine, particularly with older people. Patients with exocrine pancreatic insufficiency should avoid use of psyllium due to its inhibitory actions on pancreatic lipase.",
      "drug_interaction": [
        "Concurrent use of licorice, laxatives & antidiabetic agents may result in increased risk of hypokalemia & hypoglycemia.",
        "Carbamazepine bio-availability may reduce during concomitant administration of psyllium seed."
      ],
      "use_in_pregnancy_and_lactation": "No adverse effects of Ispergul have been reported.",
      "preparation": ["3.5 gm Sachet", "120 gm Container"]
    },
    {
      "name": "Jorvan™",
     "img_id":"swG0jIs.jpeg",
      "image": "jorvan_large.jpg",
      "active_ingredients": "Commiphora mukul (Guggulu) with other herbs",
      "indications": [
        "Rheumatoid arthritis",
        "Osteoarthritis",
        "Neuralgia",
        "Myalgia",
        "Spondylitis",
        "Backache",
        "Joint pain/Arthralgia",
        "Muscle sprain",
        "Joint stiffness"
      ],
      "dosage_and_administration": "1 capsule 2-3 times a day after meal or as advised by the physician.",
      "contraindications_and_precaution": [
        "Contraindicated in known allergy to plants or guggulu.",
        "Use with precaution in hyperthyroidism, diarrhea, or while using antihypertensive, anti-fungal, and lipid-lowering medication."
      ],
      "side_effects": "Generally well tolerated. High doses may rarely cause stomach irritation, diarrhea, stomatitis, and urticaria.",
      "pregnancy_and_lactation": "Should not be used during pregnancy or lactation.",
      "preparation": "500 mg Capsule"
    },
    {
      "name": "Lecor™",
     "img_id":"e6ysvCF.jpeg",
      "image": "Lecor_l.jpg",
      "active_ingredients": "Extract of Caesalpinia sappan & Woodfordia fruticosa (Patrangasav)",
      "indications": [
        "Leucorrhea",
        "Cervicitis",
        "Non-specific vaginitis",
        "Pelvic inflammatory disease"
      ],
      "dosage_and_administration": "Above 12 years & Adult: 3 teaspoonfuls (15 ml) 3 times daily after meal for 15 days.",
      "contraindications_and_precaution": "Not known.",
      "side_effects": "No known side effects in proper dosage. Rarely, high dose may cause burning sensation, diarrhea, or increased urine output.",
      "drug_interaction": "Not known.",
      "pregnancy_and_lactation": "Should not be taken during pregnancy. No reported adverse effects on fetal development or breast-fed infants.",
      "use_in_children": "Not known.",
      "preparation": "200 ml syrup"
    },
    {
      "name": "Livolite®",
     "img_id":"SGjb90t.jpeg",
      "image": "LIVOLITE.jpg",
      "active_ingredients": "Andrographis (Andrographis paniculata)",
      "indications": [
        "Viral fever",
        "Flu",
        "Common cold",
        "Sinusitis",
        "Viral hepatitis"
      ],
      "dosage_and_administration": "1 capsule 3 times daily between meals for 5 to 10 days or as directed by the physician.",
      "contraindications_and_precaution": "Contraindicated in cases of known allergy to plants of the Acanthaceae family.",
      "side_effects": "Large oral doses may cause gastric discomfort, vomiting, and loss of appetite.",
      "drug_interaction": "May have a synergistic effect with Isoniazid.",
      "pregnancy_and_lactation": "Should not be used during pregnancy or lactation.",
      "preparation": "200 mg Capsule"
    },
    {
      "name": "Monera®",
     "img_id":"PihY9gd.png",
      "image": "monera_large.png",
      "active_ingredients": "Bacopa monnieri (Brammi) with other ingredients as per BNAF",
      "indications": [
        "Memory loss",
        "Attention Deficit Disorder (ADD)",
        "Attention Deficit Hyperactivity Disorder (ADHD)",
        "Dementia",
        "Alzheimer’s disease",
        "Autistic Spectrum Disorder (ASD)"
      ],
      "dosage_and_administration": {
        "2-5 years": "1/2 teaspoonful (2.5 ml) 2 - 3 times daily after meal for 3 months",
        "6-12 years": "1 teaspoonful (5 ml) 2 - 3 times daily after meal for 3 months",
        "Above 12 years & Adult": "2 – 3 teaspoonfuls (10 - 15 ml) 3 times daily after meal for 3 months"
      },
      "contraindications_and_precaution": "Generally well tolerated, but caution in hyperthyroidism, fever & acute infection. Patients with medical conditions should consult a doctor.",
      "side_effects": "No side effects at recommended therapeutic doses.",
      "drug_interaction": "May potentiate thyroid-stimulating drugs or reduce effects of anti-thyroid drugs. May reduce toxicity of morphine and other opiates. Shown to reduce cognitive decline from phenytoin.",
      "pregnancy_and_lactation": "Consult a physician before use. No reported adverse effects on fetal development or breast-fed infants.",
      "preparation": "100 ml Syrup"
    },
    {
      "name": "Navit®",
     "img_id":"wYlvErV.jpeg",
      "image": "Navit_11.jpg",
      "active_ingredients": "Spirulina (Arthrospira platensis)",
      "indications": [
        "Malnutrition",
        "Immune deficiency",
        "High Cholesterol",
        "Allergic reaction",
        "Skin disorders & hair loss",
        "Decreased milk supply in lactating mothers"
      ],
      "dosage_and_administration": "4 to 6 Capsules (500 mg each) per day or as per the instruction of a healthcare provider",
      "contraindications_and_precaution": "Contraindicated in individuals hypersensitive to any component of a Spirulina-containing supplement",
      "side_effects": "Occasional gastrointestinal symptoms such as nausea; rare reports of allergic reactions",
      "pregnancy_and_lactation": "Safe as per clinical study",
      "preparation": "500 mg Capsule"
    },
    {
      "name": "Ocubil™",
     "img_id":"ekfR2YK.jpeg",
      "image": "Ocubil_large.jpg",
      "active_ingredients": "Bilberry (Vaccinium myrtillus L)",
      "indications": [
        "Retinopathy (hypertensive & diabetic)",
        "Night blindness",
        "Cataracts",
        "Macular degeneration",
        "Retinitis pigmentosa",
        "Hemorrhagic retinopathy"
      ],
      "dosage_and_administration": "1 capsule should be taken 2-3 times daily or as per the instruction of physician",
      "contraindications_and_precaution": "None known",
      "side_effects": "None known",
      "drug_interaction": "None known",
      "pregnancy_and_lactation": "No known restriction",
      "preparation": "160 mg Capsule"
    },
    {
      "name": "Nilagel™",
     "img_id":"UrFYw0H.jpeg",
      "image": "nilagel_large.jpg",
      "active_ingredients": "Nigella Sativa",
      "indications": [
        "Common cold",
        "Cough",
        "Asthma",
        "Bronchitis",
        "Muscle spasm",
        "Fever",
        "Dyspepsia",
        "Vomiting",
        "Gout",
        "Insufficient breast milk",
        "Eczema",
        "Wound healing",
        "Improves immune system",
        "Reduces blood sugar",
        "Reduces blood pressure",
        "Prevents hair loss"
      ],
      "dosage_and_administration": "1 capsule 2-3 times daily or as directed by the registered physician",
      "side_effects": "No side effects have been reported",
      "contraindications_and_precaution": "There is no known precaution & contraindication",
      "drug_interaction": "It can be taken with any other vitamins, minerals or herbal supplement",
      "pregnancy_and_lactation": "Not recommended during pregnancy. In lactating mothers, it may be taken to increase breast milk",
      "preparation": "500 mg Softgel Capsule"
    },
    {
      "name": "Pepnor®",
     "img_id":"yNom09M.jpeg",
      "image": "Pepnor_100.jpg",
      "active_ingredients": "Extract of Cumin",
      "indications": [
        "Dyspepsia or indigestion",
        "Abdominal gas or flatulence",
        "Nausea",
        "Vomiting",
        "Anorexia",
        "Abdominal colic"
      ],
      "dosage_and_administration": {
        "children_under_12": "1-2 teaspoonfuls (5-10 ml) 2 to 3 times daily",
        "adult": "2-3 teaspoonfuls (10-15 ml) 3 times daily or as directed by the physician"
      },
      "contraindications_and_precaution": "May occur in hypersensitive individuals. Caution advised in patients with gallstones or obstructive jaundice due to bile-stimulating properties of ginger.",
      "side_effects": "No known significant side effect",
      "pregnancy_and_lactation": "Safe and beneficial for pregnant and lactating women",
      "preparation": "100 ml Syrup"
    },
    {
      "name": "Probio™",
     "img_id":"YhJ0ajI.jpeg",
      "image": "probio_large.jpg",
      "active_ingredients": "A Probiotic combination (Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium bifidum & fructooligosaccharides)",
      "indications": [
        "Diarrhea",
        "Lactose intolerance",
        "Vaginal infection",
        "Antibiotic related illness"
      ],
      "dosage_and_administration": {
        "adult": "1–2 capsules 1–2 times daily or as directed by the physician",
        "children_6_months_or_above": "1 sachet daily with 3–4 tablespoons of milk, water, or other suitable liquid, or as directed by the physician"
      },
      "contraindications_and_precaution": "Not known",
      "side_effects": "No side effects following proper administration of designated therapeutic dosages",
      "pregnancy_and_lactation": "No known restriction during pregnancy and lactation",
      "preparation": "4 billion probiotics in capsule and sachet"
    },
    {
      "name": "Redclov™",
     "img_id":"tRQkN2k.jpeg",
      "image": "red_clov_l.jpg",
      "active_ingredients": "Standardized extract of Red clover Isoflavones",
      "indications": [
        "Relief of menopause symptoms such as hot flushes and night sweats",
        "Menopause-related osteoporosis and bone density loss",
        "Maintenance of cholesterol level"
      ],
      "dosage_and_administration": "1–2 capsules per day depending on body weight and severity of symptoms, taken with a meal and at approximately the same time each day",
      "contraindications_and_precaution": "Diet should not be supplemented with Isoflavonoid phytoestrogens during therapy with reproductive hormones due to risk of competitive inhibition",
      "drug_interaction": "May decrease efficacy of Tamoxifen; caution advised when used with anticoagulants, contraceptives, estrogen, and progesterone-like drugs",
      "adverse_reaction": "No known adverse reactions at recommended dosage; excessive intake in animals may reduce fertility",
      "use_in_pregnancy_and_lactation": "Not recommended during pregnancy or lactation due to secretion of isoflavones in breast milk",
      "preparation": "30 Capsules"
    },
    {
      "name": "Reli Balm™",
     "img_id":"gmCiffn.jpeg",
      "image": "Ralibalm-Lit-_l.jpg",
      "active_ingredients": {
        "mentha_spp": "l-Menthol 80 mg",
        "cinnamomum_camphora": "d-Camphor 45 mg",
        "eucalyptus_oil": "180 mg",
        "mint_oil": "10 mg"
      },
      "indications": [
        "Pain in neck and shoulder",
        "Pains in muscles and joints",
        "Relief of minor aches"
      ],
      "dosage_and_administration": "For adults and children over 12, rub well on the affected area. Repeat 3 to 4 times daily. Consult a healthcare professional before use for children under 12.",
      "contraindications": "Not recommended for infants and young children.",
      "use_in_pregnancy_and_lactation": "Should be used with caution or seek the advice of a healthcare professional before use.",
      "drug_interaction": "Not known.",
      "precaution": "For external use only.",
      "warnings": [
        "Use only as directed.",
        "Avoid contact with eyes and mucous membranes.",
        "Do not apply to wounds, damaged or irritated skin.",
        "Do not bandage or cover with wrap or use heating pad.",
        "Do not use 1 hour prior to bathing or within 30 minutes after bathing."
      ],
      "preparation": "25 gm cream"
    },
    {
      "name": "Revatol™",
     "img_id":"fq8FVTr.png",
      "image": "large_revatol.png",
      "active_ingredients": "Grape extract",
      "indications": [
        "Chronic Obstructive Pulmonary Disease (COPD)",
        "Asthma",
        "Pulmonary fibrosis"
      ],
      "dosage_and_administration": {
        "children_under_12": "1 - 2 teaspoonfuls (5 - 10 ml) 2-3 times daily after meal.",
        "above_12_and_adults": "3 - 4 teaspoonfuls (15 - 20 ml) 2 times daily after meal for 4-8 weeks or as directed by the physician."
      },
      "contraindications_precautions": "Caution should be taken in hypertension, liver disease, alcohol dependence & diabetes. Patients with medical conditions should talk to their doctors before taking Revatol. Lactobacillus products (e.g., Probiotics) should be taken 2 or more hours apart.",
      "side_effects": "No side effects in the mentioned therapeutic doses. Rare cases of stomach pain, headache, & allergic reaction have been reported.",
      "use_in_pregnancy_and_lactation": "Consult a physician prior to use. It should be used only when clearly needed.",
      "preparation": "200 ml syrup"
    },
    {
      "name": "Silybin®",
     "img_id":"kdVGDc2.jpeg",
      "image": "SILYBIN-70.jpg",
      "active_ingredients": "Silymarin (Silybum marianum)",
      "indications": [
        "Acute viral hepatitis",
        "Toxic liver damage (supportive treatment in jaundice)",
        "Toxic hepatitis caused by psychotropic agents",
        "Alcohol-related liver disease including cirrhosis",
        "Poisoning by A. phalloides"
      ],
      "dosage_and_administration": {
        "normal": "1 capsule 3 times daily; maintenance dose of 1 capsule 2 times daily as advised by the physician."
      },
      "contraindications_precautions": "No information available regarding contraindications.",
      "side_effects": "Mild laxative effect has occasionally been observed.",
      "use_in_pregnancy_and_lactation": "Use under the supervision of a physician due to lack of available information.",
      "preparation": "140 mg capsules"
    },
    {
      "name": "Torel™",
     "img_id":"wygWqqi.png",
      "image": "Product_Torel_lar.png",
      "active_ingredients": "l-Menthol, d-Camphor, methyl salicylate & Oleoresin capsicum",
      "indications": [
        "Muscle pain sprains",
        "Headache",
        "Joint pain & stiffness",
        "Sprains, strains & sports injuries",
        "Bruising",
        "Fibrositis",
        "Osteoarthritis"
      ],
      "dosage_and_administration": {
        "children_over_6_years_and_adults": "Clean the affected area. Apply a small amount (equal to the surface area of the tip of a finger) 3 to 4 times daily or as directed by the physician.",
        "children_under_6_years": "Not to be used."
      },
      "contraindications_precautions": "Capsicum preparations are contraindicated for application on injured skin, allergies to aspirin, allergic inflammation of skin, eczema, itchy rash & near the eyes.",
      "side_effects": "In rare cases, hypersensitivity reactions may occur. Inhalation may cause bronchoconstriction.",
      "use_in_pregnancy_and_lactation": "No available information on restriction during pregnancy & lactation. May be safely used if benefits outweigh risks.",
      "preparation": "20 mg cream"
    },
    {
      "name": "Ulpep™",
     "img_id":"sI2b6M9.jpeg",
      "image": "Ulpep.jpeg",
      "active_ingredients": "Ferula assafoetida (Hing) with other herbs",
      "indications": [
        "Gastritis (Wound in lining of the stomach)",
        "Hyperacidity",
        "Gastric Ulcer & Duodenal Ulcer",
        "Dyspepsia",
        "Indigestion"
      ],
      "dosage_and_administration": {
        "normal": "One Ulpep capsule 2 times a day just before meal or as directed by the physician."
      },
      "contraindications": "Hingastak churna is contraindicated in cases of known allergy to plants. Caution is advised in moderate to severe hypertension & edema due to its salt content (12.3%).",
      "side_effects": "When used within the recommended dosage range, Hingastak Churna is well tolerated. Very high doses may lead to stomach irritation, diarrhea, stomatitis, and urticaria. Best used under medical supervision.",
      "use_in_pregnancy_and_lactation": "Should not be used during pregnancy or lactation.",
      "preparation": "500 mg Capsule"
    },
    {
      "name": "Uripam™",
     "img_id":"0xyCsAP.png",
      "image": "uripam_large.png",
      "active_ingredients": "Saw Palmetto Oil, Pygeum Bark Oil, Korean Ginseng, Zinc Sulphate Monohydrate, and Copper Gluconate",
      "indications": [
        "An advanced blend of minerals & herbs for a proactive approach to prostate health.",
        "Saw Palmetto supports normal prostate function and healthy urinary flow.",
        "Contains Zinc which is required for normal reproductive function."
      ],
      "dosage_and_administration": {
        "adult": "1-2 capsules daily or as advised by the physician."
      },
      "side_effects": [
        "Rare cases of gastrointestinal disturbance.",
        "Ingestion on an empty stomach may cause nausea.",
        "Hypertension reported in 3.1% of patients taking Saw Palmetto extract."
      ],
      "contraindications": "Not indicated for advanced BPH with severe urinary retention. Should not be used without first ruling out prostate cancer.",
      "precautions": [
        "Saw Palmetto might slow blood clotting, increasing the risk of bleeding during and after surgery.",
        "Stop using Saw Palmetto at least 2 weeks before scheduled surgery."
      ],
      "pediatric_use": "Safety and effectiveness in the pediatric population have not been established.",
      "drug_interactions": "Saw Palmetto might slow blood clotting. Taking it with medications that also slow clotting (e.g., Aspirin, Clopidogrel, Enoxaparin, Heparin, Warfarin) may increase bruising and bleeding risk.",
      "preparation": "160 mg Softgel Capsule"
    }
  ]
}
